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The present decades have witnessed major advances in the development and applications of 
Computational Intelligence Techniques (CITs), which are commonly associated with 
metabolomics and omics analyses related to diseases diagnosis. This includes, amongst others, 
research work performed on Niemann-Pick class 1 and 2 diseases (NPC1 and NPC2 
respectively), the severest form of which may involve liver dysfunction. Some of the main 
reasons for the high frequency of CITs use in metabolomics studies are also related to the 
development of techniques to detect major discriminatory metabolite variables for the purpose 
of disease diagnosis and progression. Alongside this, is the major demanding requirement to 
further understand potential metabolic pathways involved in order to improve our 
understanding of the molecular mechanisms underlying NPC1 disease. 
 
NPC1 is a rare neurodegenerative disorder attributable to NPC1 gene function loss, which 
causes adverse fat storage at the lysosomal levels (Mathieson, 2013; Xu et al., 2010). However, 
plasma metabolite profiling can provide insights into disease diagnosis and prognosis, while 
providing a clear ‘picture’ of the underlying metabolites altered during disease processes, 
including their early stages. Currently, biomarker discovery appears as the most effective 
solution to employ regarding the monitoring of disease progression (Mathieson, 2013; Ruiz-
Rodado et al., 2014). 
 
In the present thesis, the intelligent tri-modelling techniques (ITMTs) which are combination 
of CITs applied to the multivariate (MV) analysis of biofluid datasets is proposed. The ITMTs 
serves as a combination of the scalar visualisation algorithm (SVA) for data visualisation and 
high-dimensional data representation into bi or tri-dimensional spaces. The optimum super 
support vector machine (OSVM) is also employed for the MV classification of metabolic 




probabilistic classification and regression purposes. This was followed by investigations of 
correlations between these biomolecular diseases features. Furthermore, the tri-ranking 
techniques (TRTs) was developed in order to establish a ranking between the NPC1 disease 
features, in addition to those available for the NPC1 liver dysfunction disease features in a 
mouse model system to determine their importance in the further development of these 
diseases.    
  
High-resolution proton nuclear magnetic resonance (1H NMR) is used as high-throughput 
multicomponent analytical technique to generate very large quantities of metabolic data, which 
hold essential and useful information regarding the metabolites analysed. Prior to the 
performance of MV metabolomics analysis, a robust data handling technique based on 
balancing the dataset, feature selection, and stratified cross-validation of datasets is involved. 
Furthermore, the intelligent task technology fit theory has been proposed here, enabling a swift, 
consistent and rational model development through threshold settings for model validations.  
 
 Application of the intelligent tri-modelling techniques (ITMTs) using SVA, OSVM and PCR, 
combined with the tri-ranking techniques (TRTs) have allowed the discovery of major 
discriminatory variables for NPC1 disease. Hence, using the blood plasma dataset the scalar 
visualisation algorithm could diagnose NPC1 disease through the following potential 
biomarkers: hexacosanoate acid, (R)-3-hydroxybutyrate, L-fucose, lactate, 3-
hydroxyisovalerate, Citrate, N-acetyl-4-O-acetylneuraminate, methionine, and glutamine. 
Additionally, the SVA strategy highlighted the following major biomarkers in the 1H NMR 
NPC liver dysfunction dataset, including glycogen, glutamate, glutamine, taurine, 
glycerophosphocholine, acetoacetate, taurine, myo-inositol, lactate, leucine, isoleucine, and 
alanine.  
 
However, the PCR approach established a significant correlation between biomarker features 
for NPC1 disease, in addition to the mouse model of NPC liver dysfunction progression. 
Moreover, the OSVM technique could clearly segregate between the two classes of 
patients/animals in both disease pathogenesis studies.   
 
This thesis presents the Intelligent Tri-Model Techniques (ITMTs), using 1H NMR-linked 
metabolite profiling, new biomarkers for NPC1 disease diagnosis, and the NPC1-based liver 




This may represent a major advance regarding the diagnosis of NPC1 disease and its 
pathological sequelae. Such biomarkers may serve as valuable assets for monitoring the 
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Research in general has always progressed incrementally, especially when new researchers 
generate new methods and techniques as improvements over existing ones, and or developing 
new ways of solving existing issues. This incremental development has seen tremendous 
changes occurring in different areas where researchers have been very active. This includes 
those such as mathematics, physics, robotics, computer sciences, medicine, pharmacy, etc.   
                           
The last three areas noted above are the ones especially featured in this research investigation, 
with many applications of metabolomics analysis techniques. These research fields include 
cancer, type 1 and 2 diabetes, Alzheimer’s and Parkinson’s diseases, NPC and further 
lysosomal storage diseases, etc., (Beger et al., 2010; Yun et al., 2016; Daniel and Forbes, 2015). 
However, the differing sets of biomarkers discovered have not really met the level of 
expectations sought. Indeed, such research findings have fallen short to provide ultimate 
diagnostic and prognostic biomarkers or to suggest appropriate treatments via subsequent drug 
targeting strategies. To date, no particular effective, disease-specific treatment is available for 
NPC1 disease (National Institute of Neurological Disorder and Stroke, 2016; Niemann-Pick 
UK, 2012).     
 
This research work proposes CITs based on the intelligent tri-modelling techniques (ITMTs) 
approach in biomarkers discovery. The reason of such development is to employ three 
complementary techniques for dataset dimensional reduction, data visualisation, data 
classification, and finally a regression by establishing a correlation between disease features 





The introductory component of this thesis encompasses the research background providing 
essential information on this metabolomics research, followed by the research motivations 
stating the reasons for conducting this study, and the research objectives highlighting the main 
questions supporting this investigation. Further research aims and objectives highlighting the 
main achievable tasks performed are given, followed by the contribution of this work to 
research, which presents the research achievements and successes. Finally, the different stages 
of this introductory chapter are detailed for clarity purposes.  
 
1.2. Research Background 
 
For a very long time in the history of humanity, research performed on human diseases have 
been a very daunting task for researchers, especially in the disease diagnosis fields of study 
where more support in terms of funding is needed. Research and development (R&D) for top 
neglected diseases was $2.956 billion in 2008, and $3.189 billion in 2009; while funding on 
the same diseases were $1.873 billion in 2008 and $2.121 billion in 2009. Further investment, 
such as total public funding (high income countries and multilaterals) on disease was $1.78 
billion in 2008, and $2.049 billion in 2009; showing a drop in investment in the R&D 
2008/2009 (Ngo et al., 2013).  
 
In addition, it should be mentioned that diseases control, cure and eradication can be very 
difficult objectives to achieve, without sustained investments in the research areas. This meant 
that more effort needed to be done in this regard. Thus, investment in research related to 
neglected diseases, has constantly been above the US $3 billion from 2009 to 2014; while in 
2014 there was an increase of US $150 million to reach US $3.37 billion due to the Ebola 
epidemic outbreak in the west African region (Sanderson, 2015).  
 
Furthermore, researches showed that in some specific cases diseases genes have the potential 
of changing their structure through alteration, mutation, etc., which can be very challenging in 
terms of finding adequate treatments and appropriate remedies. This is valid for diseases like 
Niemann-Pick disease, which is rare progressive genetic disorder, with different forms, such 
as the Niemann-Pick type A, B, and C (National Institute of Neurological Disorder and Stroke, 





Type C Niemann-Pick disease is an autosomal recessive inherited condition that is both rare 
and fatal. The Niemann-Pick class C (NPC) disease is present in the following ratios; class 1 
or NPC1 (95%), and class 2 or NPC2 (5%) of the total infected population, i.e., with an 
incidence of approximately 500 cases diagnosed worldwide. The figure may be higher due to 
difficulties in diagnosing this medical condition (Blom, 2003; Maue et al., 2012; “Niemann-
Pick Disease Overview,” 2013). Research findings established that NPC1 patients carry the 
mutated NPC1 genes that encodes the protein NPC1, whilst their parents, also known as 
heterozygotes or carriers, have one functional NPC1 gene and one non-functional one. For 
NPC2 disease, this case is very rare, and shows no clearly observable signs or symptoms (Akst, 
2014;  Balch et al., 2008).  
 
NPC1 disease can affect individuals before birth, but may not be apparent until late childhood. 
In fact, there is no clear age when certain manifestations become visible, including the first 
appearance of the symptoms, the disease’s progression and its neurological manifestations 
(Maue et al., 2012; Yang, 2005). In addition, there are limited options concerning the NPC1 
disease treatments and this lack of appropriate therapeutic method at early stages can lead to a 
more severe form of the disease (Fan et al., 2013). In fact, in view of the disease’s link to gene 
mutation, NPC1 gene mutation screening has been applied, but failed to provide the necessary  
information regarding  disease diagnosis and progression (Maue et al., 2012; Yang, 2005). 
Therefore, there is an urgent requirement for the proposal of appropriate treatment methods for 
this debilitating condition.    
 
Consequently, the usage of computational intelligence techniques (CITs) in metabolomics 
multivariate analysis, for NPC1 patients’ metabolites scrutiny appeared to have the potential to 
handle this challenge, especially through the detection of new biomarkers or the improvement 
of existing ones (Duarte et al., 2014; Ruiz-Rodado et al., 2014; Turkoglu et al., 2016 ; Wang 
et al., 2013). The need of using the computational intelligence techniques to produce efficient 
models in biomarkers discovery, especially in relation to finding effective and efficient 
treatments for the NPC 1 disease and the related liver dysfunction and associated disease is 
real.  
 
Subsequently, the overview of the research background would ultimately lead to several 
motivating factors for the current study. These motivating elements supporting and sustaining 





 1.3. Research Motivation 
 
Living organisms produce different type of biofluids such as saliva, blood plasma, urine, 
synovial fluids, etc., for several reasons including functionalities. In this case, the production 
is said to be functionally driven (MedicineNet, 2016; Novak et al., 2010; Rettner et al., 2016). 
Thus, most or all the secretions released by glands and cells are function specific substances. 
For example, urine is considered as the body system cleaner from all its impurities, whilst blood 
has different functions including carrying nutrients, and gases such as oxygen (O2), and dioxide 
carbon (CO2), protection, and regulation (MedicineNet, 2016; Novak et al., 2010; Oxford 
Dictionaries, 2016; Rettner et al., 2016).   
 
Biofluids can act as indicator of the physical, mental, and psychical ability of a living being to 
adapt to its environment, because metabolites generated can be used to measure the degree of 
fitness, state of illness, infection level, etc., of the individual (s) under study, and its (their) 
suitability to live as normal being. Hence, how to tackle the disease diagnosis, progression, and 
improve the individual (s)’ living condition could be investigated through biofluids 
metabolomics analysis.  
 
Indeed, previous studies focused on diseases classifications using more conventional methods 
such as LC/MS, GC/MS, etc., combined with data analysis techniques such as principal 
components analysis (PCA), principal component regression (PCR), partial least squared 
discriminant analysis (PLS-DA), etc., have so far shown their limitations in terms of their 
efficacies in finding relevant biomarkers for diseases diagnosis (Amathieu, 2016; Becker et al., 
2012). 
 
The use of high-throughput techniques, including 1H NMR spectroscopy has made it easy for 
researchers to generate large amount of data that carry countless information related to disease 
diagnosis, progression. In this respect, the scrutiny of this large amount of data through 
metabolomic multivariate analysis of biofluids, using CITs is an opportunity to grab the 
maximum knowledge on living organisms, and to examine their properties at molecular and or 




to the disease diagnosis and progression from an early stage, while designing ways for new 
biomarkers detecting and or improving existing ones.  
 
This presentation of the different motivations sustaining the present study would be incomplete 
if some fundamental questions were not raised, giving clear orientation for future investigations 
to take place.  
 
1.4. Research Questions 
 
The research questions allow the research to be focussed, have a direction, set boundaries and 
they act as a frame of reference for assessing the work undertaken (O’Leary, 2013). The 
research questions help to achieve the research aims and objectives, while creating ways and 
platforms for arguments presentation (Duke, 2014). The main research questions that arose 
from this study are outlined below:  
 
1. Can the use of CITs help in improving biomarkers discovery in the NPC1 disease and the 
severe form of the disease diagnosis and progression? 
 
2. Can the use of CITs be an answer to diseases early diagnosis through metabolomics 
multivariate analysis of biofluids datasets?  
 
3. Can the use of CITs help in establishing correlation between the NPC1 disease and the 
disease features on the one hand, and the NPC liver dysfunction disease (NPC LDD) and its 
features on the other hand?  
 
4. Can the use of CITs help in establishing the interaction between a set of features and the 
NPC1 diseases at different stages of progression? 
 
5. Can the biomarkers detection help in the understanding of the pathway followed and the 
diseases progression?  
 






1.5. Research Aims 
 
Artificial Intelligence as one of the fastest-growing field in research, especially in the area of 
computer sciences has had many applications in various scientific and technological fields such 
as computational intelligence, bioinformatics, pharmacy, chemistry, engineering, etc. The 
application of CITs in the present study, has several aims which are outlined below.   
 
Going through the different research questions highlighted above, it comes clearly that the 
aforementioned issues have not been properly addressed or not been addressed to a higher 
standard level. Indeed, in several studies conducted researchers while working toward 
biomarkers discovery, have not found the biomarker (s) that would have revolutionised the 
research area. Mostly, the biomarkers discovered would need further research to be conducted,  
in order to confirm the findings (Qi et al., 2012; Qiu et al., 2008).  Nevertheless, the author of 
this thesis believes that this initial stage is as important as the final stage of definite validation 
of the biomarker discovered, because this is where the importance of the main discriminants is 
first established allowing further work to be carried out.  
 
Therefore, although biomarker discovery offers much promise in the field of disease diagnosis, 
it has not yet attained and met the level of expectation the research community has placed on 
it; hence, it has not yet been employed to its full potential (Qi et al., 2012; Rocha et al., 2011; 
Wang et al., 2012). The following algorithms could be used as intelligent tools to address the 
issue, since their combination will enable the researcher to view the internal data structure, 
segregate between healthy and disease subjects, and finally, correlate disease features and 
disease diagnosis and progression.   
 
The first among these algorithms is the scalar visualisation algorithm (SVA), developed as tool 
that converts scalar value to image. The 1H NMR-detectable metabolite levels are 
transformed/assigned to index values. Hence, using a colour lookup table, a given index value 
is attributed and mapped to a colour in the colour lookup table (Johnson, 2015; Johnsona, 2012; 
Komura, 2016). In this manner, researchers can gain insight into more complex phenomenon 




molecular level which can, in turn, be visualised and understood (Johnsona, 2012; Kuhn and 
Johnson, 2013). 
 
The second algorithm, the support vector machine (SVM), is a supervised learning algorithm 
used either for regression or classification purposes; but usually associated with classification 
problems. Thus, data points are plotted in an n-dimension space where n correspond to the 
number of features, with a hyperplane used for discriminating between diseased individuals 
and non-diseased ones (Ray, 2015).  
 
Finally, principal component regression (PCR) is a statistical strategy that analyses datasets 
containing linear combinations of independent variables (principal components), which in turn 
generate outcomes in the form of binary or dichotomous variables. The possible outcomes 
might include; true or false, diseased or non-diseased, yes or no, 1 or 0 etc. The main reasons 
behind the model development is to establish the level of association of the independent 
variables with the outcome using the coefficient of regression r, or alternatively determine the 
strength of the relationship between two variables using α2 the square of the coefficient of 
correlation. Finally determining the equation of a best fit relationship that best describes the 
cloud of data points in the data space. The defined equation can be used as a mean value for 
predicting the outcomes of the measurements performed (Larose, 2006; McDonald, 2015; 
Schoonjans, 2016). Therefore, the aims of the current research are: 
 
1. The application and development of CITs through metabolomics multivariate analysis, for 
the detection and or improvement of existing biomarkers for NPC1 diseases diagnosis.  
  
2. The application of CITs such as tri-modelling techniques in the detection of new biomarkers, 
and understand related pathways in NPC1 diseases diagnosis, through the metabolite profiling 
of biofluids datasets.   
 
These research aims are presented as large sets of tasks; these will be delineated in the 
following section into more manageable detailed sets of achievable tasks that constitute the 





1.6. Research Objectives 
 
Given the above research aims, the main research objectives may be further sub-divided into 
more simple and clearer measurable outcomes that are provided below:  
 
1. To employ CITs such as the novel intelligent tri-modelling techniques (ITMTs) for the 
detection of new biomarkers, and the improvement of existing ones through the metabolomics 
multivariate analysis of NPC1 diseases diagnosis. 
 
2. To use the scalar visualisation algorithm (SVA) for data visualisation and representation 
purposes. 
 
3. To use support vector machine (SVM) transformed to the optimal support vector machine 
(OSVM) for data classification purposes, in the view of improving the identification of existing 
or new biomarkers in NPC 1 disease diagnosis.  
 
4. To use principal component regression (PCR) models for regression analysis, establishing 
correlations between disease features and NPC1 disease diagnosis and progression.  
 
5. To use the tri-ranking techniques (TRTs) as effective features ranking for biomarker 
detection.  
 
6. To finally use the intelligent technology task fit model (ITTFM) to improve metabolomics 
multivariate analysis processes.  
 
The aforementioned objectives highlighted allow researchers to present the main contributions 
made to the present research field in the next session. 
 
1.7. Contribution to Knowledge  
 
This research overall aimed at employing Computational Intelligence Techniques (CITs), in 
particular the intelligent tri-modelling techniques (ITMTs), in NMR-linked metabolomics 




In this respect, the findings of this study will become part of the literature in this research field 
by demonstrating that;  
 
1. Application of CITs, especially the ITMTs has improved biomarker discovery in NPC1 
diseases and the NPC1 disease-assoCITaed liver damage.  
   
2. Applying ITMTs has led to potential new biomarker discovery via metabolomics 
multivariate analysis for the benefit of NPC1 diseases diagnosis. 
 
3. Using ITMTs has allowed and improved the prediction and the correlation between NPC1 
diseases features and the NPC1 disease severity and  progression.  
 
4. Applying tri-ranking techniques (TRTs) has allowed and improved biomarker detection. 
 
5. Applying the intelligent technology task fit model (ITTFM) has improved the application of 
CITs in metabolomics multivariate analysis processes generally. 
 
The above highlighted contributions were achieved based on the structure of the different 
chapters presented below. 
 
1.8. Research Outline  
 
The current thesis encompasses seven chapters establishing a logical structure for it, and the 
clarity in the arguments used throughout the whole research process. These chapters are 
outlined in detail below:  
 
Chapter one is the introductory chapter that outlines the study background in relation to 
previous and recent research in the field of metabolomics multivariate analysis research, 
especially with respect to biomarker discovery. Research motivations and research questions 
were then addressed, by attempting to understand the reasons for them, whilst making 
connections to the different questions arising within this study. Responding to these questions 





This research programme’s aims and objectives were deducted from the research questions, 
with the second term being a more detailed and achievable outcome of the first one. 
Furthermore, research contributions including achievements made have been presented in 
terms of how they will be integrated to the current literature in this field of research. Finally, 
the different chapters, alongside their specific contributions, have been presented in this 
research outline.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
 
Chapter two encompasses a literature review, and provides a comprehensive overview of 
research and literature available in the area of metabolomics multivariate analysis, especially 
those related to diseases diagnosis studies. It commences with some clarifications concerning 
the main terms related to metabolomics research. This includes metabolism, metabolites, 
metabolomes, etc., and the manner in which they are understood and employed in this research.  
Means of avoiding confusing terminologies, leading to common misunderstandings and mis-
interpretations, has also been clarified. This chapter then introduces some recent research work 
involving metabolomics multivariate analysis, metabolite profiling, and the main CITs used in 
this research. Finally, research validation techniques were then reviewed, ensuring that the 
proposed research project follows standard validation techniques. 
    
Chapter three describes the methodology adopted in this research, and begins with an 
introductory part, and then the research paradigms and research approaches involved are 
reviewed, with more emphasis placed on quantitative methods, given that the datasets 
employed and the methods utilised are exclusively quantitative ones. Moreover, the intelligent 
technology task fit model (ITTFM) was developed. Therefore, differing algorithms and 
functions were written to ease and support the current research project. 
                                                                                                                                                
Chapter four, however, highlights the research design adopted to plan the present research as 
a whole, so that all the steps are coordinated. In addition, the tools involved in the data analysis 
stages were scrutinised and properly chosen, ensuring that they are in line with the research 
questions and the expected outcomes. Furthermore, the research validation models applied 
were visited to ascertain that they facilitate meeting the assigned objectives.  
 
Chapter five focuses on data analysis and the results of the process stages. This is related to the 




based on existing biomarkers. New biomarkers discovered were biochemically identified, and 
the overall classifier performances and ranking results are provided. Data were analysed by 
applying various techniques, the results obtained related to the disease diagnosis, and the 
biomarkers detected by the employment of differing models and ranking techniques are 
displayed. A comparison was made in order to validate these techniques, models and findings. 
 
Chapter six presents the discussion part of the study. The critical discussion conducted focuses 
on the results generated and the major findings. The suggested pathways related to the disease 
diagnosis were established. The pathway analysis firstly focuses on the NPC1 disease diagnosis 
in terms of statistical results generated, and finally the pathways detected in relation to the 
major biomarkers present in that pathway.  Secondly, the same analysis is conducted in 
connection to the more severe form of the NPC disease that gives rise to liver dysfunction and 
damage in the case of NPC mouse model. Finally, more emphasis is placed on the biomarkers 
discovered.   
 
Chapter seven is a closing chapter outlining the contribution of the present research in terms 
of classifier performances, and metrics improvements when compared to precedent research 
conducted. In addition, the new biomarkers discovered and their wider implication in disease 
diagnosis are highlighted. In addition, the areas where further research could be performed are 
outlined, ensuring that research on metabolomics multivariate analysis for biomarker discovery 








“You cannot open a book without learning something”  
 
  Confucius 
 
 
2. LITERATURE REVIEW  
 
2.1. Introduction  
This Chapter reviews the most recent and relevant literature in the field of metabolomics 
multivariate analysis of biofluids, using Computational Intelligence Techniques (CITs). The 
use of computer technologies for the purpose of disease diagnosis and especially in biomarker 
discovery is a thrilling and very exciting research area, in which much has been conducted to 
improve decision-making processes for clinicians and supporting research tasks (Beger, 2013).   
 
Thus, research on disease diagnosis process is a critical research area, mostly because it 
involves and directly impact on human life. Typically, when diagnosing a patient, clinicians 
making the wrong diagnosis may become a life-threatening issue. This is one of the main 
reasons why it was particularly important to use animals to measure drugs’ efficacies, 
toxiCITies, etc., in laboratory evaluations prior to administration to humans. In this respect, the 
research methods and findings involving new biomarkers discoveries have to be approved 
through the cumbersome but necessary route of validation processes (Beger, 2013).  
 
However, the complexity of human diseases which involve critical interactions between 
molecular and cellular systems, and which impact on disease development processes, require 
the use of different approaches. Therefore, animal and non-animal models are necessary for a 
wider understanding of the mode of operation of the disease, and most importantly the disease 
aetiology, physiopathology and pathogenesis. In addition, using experimental animals in 
research investigations is believed to be one of the most efficient ways of understanding the 
complex relationship between molecules, cells and organs with respect to disease development 





Nevertheless, the detection of the main causes of the disease can be achieved through the 
discovery of major biomarkers.  Indeed, in the research areas related to disease diagnosis, the 
use of biomarkers has been welcomed by researchers for a range of reasons. This includes the 
fact that it may assist the development of more effective and efficient treatments for the 
diseases under investigation, while easing the developmental steps towards and effective drug 
design and evaluations (Beger, 2013; Chau et al., 2008).  
 
For the reasons noted above, reviewing other researchers’ work could be equally important for 
this researcher, since it has enabled him to have a wider overview of what has been performed 
to date in this field, together with the techniques utilised in the data collection and analysis 
steps. It also enabled the author to learn what was achieved in terms of findings and discoveries, 
the differing limitations of other researchers’ works, and also gaps in knowledge that would 
help to plan and design the present research project, via the solution of existing issues (Beger, 
2013). Based on these precedents, the current literature review encompasses the following 
sections: 
 
Section 1 - Chapter introduction;  
Section 2 - Metabolomics and the definition of important terms such as metabolites, 
metabolism, etc.; 
Section 3 - Computational Intelligence Techniques (CITs) and their use in the empirical work;  
Section 4 - An introduction to the notion of nuclear magnetic resonance (NMR) spectroscopy 
and the related spectra acquisition;  
Section 5 - Metabolomics multivariate analysis of biofluids, with details also provided on the 
Niemann-Pick Type C1 disease and its associated liver dysfunction; 







In this section the term metabolomics is defined, starting with all the related notions, including 
metabolites, metabolisms, metabolomes, etc. In this manner, the author has clarified how the 
terms were understood and used by other researchers. Below are given these series of 
definitions.  
 
 2.2.2. Definitions: Metabolites, Metabolism, and Metabolomes 
Metabolites are considered to be the end-products of cellular regulatory processes, and as such 
their levels are regarded as the ultimate response of biological systems to generic 
environmental changes (Fiehn, 2002). They also serve as chemical entities that can be analysed 
using standard chemical analysis techniques such as molecular spectroscopy and mass 
spectroscopy (MS) (Goodacre et al., 2004). However, the use of further analysis techniques 
could prove to be means of improving the analysis quality; this includes coupling MS to gas 
chromatographic (GC) or liquid chromatographic (LC) techniques. Moreover, new techniques 
such as NMR spectroscopy with a very high-throughput capability could help in handling a 
large quantity of data, whilst allowing the extraction of a large amount of biomolecular 
information, especially when combined with tools such as SVM (Salazar et al., 2012).  
 
The term metabolome was introduced several decades ago and it is not a neologism. In fact, it 
was used for the first time in 1998 in a paper dealing with yeast genome; all the other “omics” 
terms such as proteome, and transcriptome were already in use (Fiehn et al., 2002; Schripsema, 
2010).  In this respect, metabolomes are said to describe the complete set of all the native small 
molecules which are non-polymeric compounds, participating in the general metabolic 
reaction, with the specificity that they are required mainly for maintenance, growth and normal 
function of all cells. This view is compatible with these other definitions, which affirmed that 
metabolomes represented the complete set of all small molecules, or low-molecular-mass (< 1 
kDa) components in a biological sample participating in general metabolic reactions, or the set 
of metabolites synthesised by an organism (Beecher, 2003; Fiehn, 2002; Kosmides et al., 
2013). However, some researchers have used metabolomes to express different 
reality/phenomenon. For instance, Goodacre et al., (2004) affirmed that metabolomes 





As far as this research work is concerned, the term metabolomes representing a set of 
metabolites and is not synonymous with metabolite profiling (defined in 2.2.3.), i.e. associated 
with data analysis techniques. After these first series of definitions, the other terms involved in 




 Definition of Metabolomics  
The term metabolomics appeared in 1990 and 2000 respectively, broadly defining the study of 
metabolomes. The main and more comprehensive definitions of this term so far given are the 
ones mentioned on Xenobiotica 1999; where the term metabolomics is related to the study of 
the quantitative complement of metabolites in a biological system, the changes in metabolite 
concentrations or fluxes related to genetic or environmental perturbation. However, since then 
several complementary definitions have been provided in relations to this term, but the focus 
in this research will be on three main points that are keys to it.  
 
1) Firstly, Nicholson et al. (2003) affirmed that metabolomics is the systematic investigation 
of the metabolic response of living systems to any environmental stimuli. Going deeper into 
this definition, researchers emphasised that metabolomics was a new research technology 
concerned with the systematic study of small molecules found in organisms, cells and tissues, 
in addition to biofluids such as saliva, urine, blood plasma, etc., (Lau et al., 2016;  Shiryaeva, 
2006; Sun et al., 2013). It was also suggested that large amounts of data can be generated, 
gathered and then analysed using various methods including mass spectroscopy (Harrigan and 
Goodacre, 2003; Nicholson et al., 1999; Suberu et al., 2016; Tomita and Nishioka, 2006; 
Vuckovic, 2012). However, NMR spectroscopy using high-throughput capabilities that 
required a small level of data preparation, amongst other advantages, appears to be the first 
choice in metabolomics research (Goodacre et al., 2004). Furthermore, Goodacre et al. (2004) 
argued that amongst these larger amounts of data available, only a handful will be necessary to 





2) Indeed, by applying data visualisation, dimensionality reduction techniques such as feature 
selections, by the means of CITs, e.g. SVA and PCA in the PCR model, high-dimensional 
datasets are transformed to low dimensional ones to develop these models. The models (SVA, 
SVM, and PCR) will be used to support the thorough body fluid analyses necessary for 
understanding the underlying changes in the metabolomes at the precise molecular level. 
 
3) Moreover, Fiehn (2002, 2006) suggested that metabolomics is more related to the unbiased 
quantitative and qualitative analysis of samples containing biochemical intermediates. This 
researcher added that because there was no single technology that could carry out a thorough 
comprehensive analysis, metabolomics was dealt with by multiple analysis techniques 
supported by unbiased software. Therefore, metabolomics should not be restricted to the 
metabolites’ physiochemical properties that include the molecular mass, chemical structure, 
etc. Hence, tools such as scalar visualisation algorithm (SVA), support vector machines 
(SVM), principal components regression (PCR), etc., have been used in metabolomics 
research, and could even be combined in a single study for a multi-dimensional analysis of a 
given dataset (Zhang et al., 2014). Indeed, the use of different analytical techniques provides 
the opportunity to develop robust models leading to the detection of more relevant biomarkers 
for the research analysis ahead.  
 
4) Finally, presented as a new powerful technology, metabolomics can be used to successfully 
perform biofluid-based metabolite profiling, in order to segregate between diseased and healthy 
control individuals (He et al., 2009; Wang et al., 2007; Zhang et al., 2014). Consequently, 
metabolomics has been identified as the comprehensive analytical approach that would provide 
complementary information compared to other omics research, such as genomics, 
transcriptomics, and proteomics, throughout low-molecular-mass biomolecule analysis and 
which is applicable to biofluids and their  metabolites therein (S. Qi et al., 2012).  
 
 These major points and definitions are regarded as core to this project, and should be used for 
monitoring the overall research work.  However, differential analysis techniques have been 
employed and have also been defined in the present study. 
 
 Metabolite Profiling  
Shulaev (2006) reported that metabolite profiling is related to the measurement of metabolite 




in the assessment of patients’ health conditions. Therefore, the term metabolite profiling refers 
to the quantitative analysis of a set of metabolites in a set of biochemical pathways, or, 
alternatively, a specific class of compounds. 
 
In this regard, Fiehn (2006) stated that metabolite profiling has confined itself only in the 
scrutiny of a certain range, or a pre-determined number of compound classes. Therefore, as far 
as data analysis is concerned, a single analytical platform should be sufficient for this analysis 
model.  Suberu et al. (2016) added that metabolic profiling provides a microscopic view of 
metabolite analysis, based on a targeted analysis approach using mass spectroscopy. 
Consequently, Bartel et al. (2013) believed that this term should be regarded as the functional 
signature of physiological state, affecting both genetic regulation and  environmental factors. 
 
Hence, in the current study, the term metabolic profiling is related to the quantitative analysis 
of a set of biochemical metabolites. Following these definitions of metabolic profiling, there 
remains a requirement to define the next important terms in the following metabolic 
fingerprinting sub-section highlighted below.    
 
 Metabolic Fingerprinting  
 Dettmer et al. (2007) defined the term metabolic fingerprinting as a full screening approach, 
allowing an unbiased classification of samples based on metabolite patterns, also known as 
fingerprinting. In addition, the genetic perturbations that the whole biological systems undergo 
as a response to the transformations in a disease environment, and the possible identification 
of discriminating metabolites which can follow, is referred to as metabolic fingerprinting.  
 
Based on the precedent definition, some researchers termed metabolic fingerprinting as a 
method allowing the discrimination between samples based on the growth condition, 
developmental stages, their origin, or on their biological relevance. Further, the same 
researchers related the term metabolomics to metabolite fingerprinting, with the former being 
the measurement of the latter (Goodacre et al., 2004; Kruger et al., 2008). However, some 
researchers questioned two main points, which were the relationship between metabolic 
fingerprinting and the sample origin (Mussap et al., 2013); and whether metabolite 
fingerprinting is related to the whole metabolomes or part of it (Dettmer et al., 2007; Scholz et 




refers to the analysis of biological samples based on their origin; however, it does not concern 
the whole system metabolomes involved.  
 
After this series of definitions, the next focus is the review of the CITs involved in the 
metabolomics research. 
 
2.3. Computational Intelligence Techniques (CITs)  
 
Different computational intelligence techniques (CITs) are available, and based on the 
objectives defined, different combinations of these techniques could help in answering many 
research questions. Below are presented the three main CITs that will be supporting this 
research. These include the scalar visualisation algorithm (SVA) using the technique of the 
‘look-up’ table to convert indexes into ‘colours’ stored in the look-up table. On the other hand, 
the support vector machine (SVM) is an algorithm based on supervised learning techniques to 
produce a deterministic classification of the input variables. Finally, the principal components 
regression (PCR) strategy uses algorithms to correlate one nominal (dependent) variable which 
is a dichotomous or binary outcome variable in the form of 1 and 0 or diseased and healthy 
control, etc., and several independent or non-independent predictive variables (Schoonjans, 
2016). 
 
2.3.1. Scalar Visualisation Algorithm (SVA)  
 Principle 
The word ‘visualisation’ in the field of computer science, engineering, etc., relates to an area 
in which researchers can explore, measure and stimulate, while mining into data in order to get 
insight into the underlying relationship within the data structures (Johnsona, 2012). Three main 
visualisation algorithms exist, including the scalar algorithm, the vector algorithm and the 
tensor algorithm. The main focus in this study is on the first algorithm mentioned. The scalar 
visualisation algorithm (SVA) is used in producing images of the different diseases datasets 
showing the importance and interconnection between features in disease diagnosis. Using the 
colour mapping technique to display features in such a manner that changes in the features’ 




deals with generating images that convey salient information, while improving our 
understanding of underlying processes. Therefore, Johnsona (2012) stated that data 
visualisation carries such important value in terms of the understanding of the large amount of 
data and information flowing in various fields of research, including biomedical and medical 
science, bio-informatics, pharmacy, particle physics, engineering, etc. 
 
The scalar visualisation algorithm is based on the principle of creating a relationship between 
the spectrum peak value considered as index and the colour look-up table. In this manner, a 
spectrum peak will correspond to a colour and the underlying changes at molecular level can 
be visualised by changes in the colour in the map hence generated. SVA changes the data 
structure, like changing or mapping the scalar data into colour. Subsequently, some 
applications of the scalar visualisation algorithm are presented. 
 
 Model Applications 
The scalar visualisation algorithm has been applied in different field of research. In the 
following research, the model has been applied to map the additional scalar values to the output 
in order to make the contrast more apparent. Indeed, some data type carries too many different 
kind of information in such a way that even colour is not enough to represent them all in the 
output. The image process and the texture mapping are combined to map scalar values to the 
local image contrast (Pan et al., 2004). In this other study cerebral spatial structure of the 
cerebral vessels were visualised in three dimensions allowing an effective disease diagnosis.  
The combination of distance colour blending, a spectroscopic technique and the CUDA-based 
volume representation and the related transfer function have helped the team of researchers to 
make it possible for surgical team to observe from different angles the vascular areas. This 
technique has enabled to improve the cerebrovascular structure, while revealing adjacent areas 
that can make a massive difference during surgical intervention  (Luo, 2013).  
 
In addition to visualising the disease features relationships, segregating diseased group from 
healthy control individuals is another way of having more insight into the disease underlying 
structure. The support vector machine is a classification algorithm that can help in this respect 
and is next studied in this research.  
 






Support vector machine (SVM) is a classification algorithm based on a heuristic process, 
allowing the development of a prediction method. As a classifier, SVM was developed in the 
1990’s by Vapnik and his research team. The rationale behind this method is to find the best 
fit hyperplane allowing through input variables a separation between two different categories. 
This could be used for example on a binary classification that requires the segregation between 
diseased and healthy control individuals in a disease dataset. However, when this is not 
possible, a kernel function φ can be applied that transforms the input variables, such as in 
increasing the dimensionality of the input space, to find a separation boundary between the two 
classes (Salazar et al., 2012). Thus, by applying φ to the original dataset    𝐷0,   a new dataset 
is generated  𝐷𝑖,  such that: 
 
∀ 𝑥𝑖 ∈ 𝐷0, ∃𝜙/𝜙: 𝑥𝑖  ⟼ 𝑦𝑖 =  𝜙 (𝑥𝑖  ): (𝟏)     
 
𝐻𝑒𝑛𝑐𝑒, 𝑎𝑛𝑦  𝑥𝑖 𝑏𝑒𝑙𝑜𝑛𝑔𝑖𝑛𝑔 𝑡𝑜 𝐷0 𝑡ℎ𝑒𝑟𝑒 𝑖𝑠 𝜙 𝑠𝑢𝑐ℎ 𝑡ℎ𝑎𝑡 𝑦𝑖 =  𝜙 (𝑥𝑖  ).  𝐹𝑢𝑟𝑡ℎ𝑒𝑟, 




 𝑤𝑖𝑡ℎ  𝑦𝑖 = {1,0}, 𝑖𝑛𝑑𝑖𝑐𝑎𝑡𝑖𝑛𝑔 𝑏𝑖𝑛𝑎𝑟𝑦 𝑐𝑙𝑎𝑠𝑠𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛, 𝑡ℎ𝑒𝑟𝑒𝑓𝑜𝑟𝑒 
 
𝑡ℎ𝑒 𝑐𝑙𝑜𝑠𝑒𝑠𝑡 ℎ𝑦𝑝𝑒𝑟𝑝𝑙𝑎𝑛𝑒 𝑡𝑜 𝑡ℎ𝑒 𝑑𝑎𝑡𝑎 𝑝𝑜𝑖𝑛𝑡𝑠 𝑓𝑟𝑜𝑚 𝑒𝑎𝑐ℎ 𝑜𝑓 𝑡ℎ𝑒 𝑡𝑤𝑜 𝑐𝑙𝑎𝑠𝑠𝑒𝑠, ℎ𝑎𝑠 𝑡ℎ𝑒 
 
𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛:𝑊𝑇𝜙 (𝑥 ) + 𝑏 = 0: (2′) 𝑡ℎ𝑎𝑡 𝑖𝑠 𝑙𝑖𝑛𝑒𝑎𝑟, 𝑎𝑛𝑑 𝑙𝑖𝑛𝑒𝑎𝑟 𝑠𝑒𝑝𝑎𝑟𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑖𝑛𝑣𝑜𝑙𝑣𝑒𝑠 
 ∃ 𝑊, 𝑏 / 𝑊𝑇𝜙(𝑥 ) + 𝑏 = 1 ∶ (𝟐) (Salazar et al. , 2012; Verplancke et al. , 2008).  
  
  𝐵𝑦 𝑎𝑝𝑝𝑙𝑦𝑖𝑛𝑔 𝑡ℎ𝑖𝑠 𝑎𝑠𝑠𝑢𝑚𝑝𝑡𝑖𝑜𝑛, 𝑖𝑡 𝑖𝑠 𝑑𝑒𝑟𝑖𝑣𝑒𝑑 𝑡ℎ𝑎𝑡:  
 
𝑊𝑇𝜙 (𝑥 ) + 𝑏 {
≥ 1,    𝑖𝑓  𝑦𝑖 = 1
≤ −1, 𝑖𝑓 𝑦𝑖 = −1 
 ,   𝑖 = 1, 2, … . , 𝑛 ∶ (𝟑)     
 





𝑎𝑛𝑑 𝑡ℎ𝑒 ℎ𝑦𝑝𝑒𝑟𝑝𝑙𝑎𝑛𝑒, 𝑎𝑛𝑑 𝑖𝑠:  
2
‖𝑤‖
. 𝑇ℎ𝑒𝑟𝑒𝑓𝑜𝑟𝑒 𝑚𝑎𝑥𝑖𝑚𝑖𝑠𝑖𝑛𝑔 𝑡ℎ𝑒 𝑚𝑎𝑟𝑔𝑖𝑛 𝑖𝑠 𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡: 
 
𝑡𝑜 𝑠𝑜𝑙𝑣𝑖𝑛𝑔:  min
𝑤,𝑏
‖𝑤‖2 , 𝑤𝑖𝑡ℎ 𝑦𝑖 (𝑊
𝑇𝜙 (𝑥) + 𝑏) ≥ 1 , 𝑓𝑜𝑟  𝑖 = 1, 2, … . . , 𝑛 ∶ (𝟒) 
 
𝐼𝑓  𝑤∗ 𝑎𝑛𝑑  𝑏∗ 𝑟𝑒𝑝𝑟𝑒𝑠𝑒𝑛𝑡 𝑎 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑡𝑜  𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛  (4), 𝑡ℎ𝑒 ℎ𝑦𝑝𝑒𝑟𝑝𝑙𝑎𝑛𝑒 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛: 
 
𝑏𝑒𝑐𝑜𝑚𝑒𝑠: 𝐷∗(𝑥) = (𝑊∗)𝑇  𝜙 (𝑥 ) + 𝑏∗) = 0.  𝐴𝑙𝑙 𝑡ℎ𝑒 𝑣𝑎𝑙𝑢𝑒𝑠 𝜙 (𝑥𝑖) 𝑠𝑎𝑡𝑖𝑠𝑓𝑦𝑖𝑛𝑔  
 
𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛 (4) 𝑎𝑟𝑒 𝑘𝑛𝑜𝑤𝑛 𝑎𝑠 𝑎 𝑠𝑢𝑝𝑝𝑜𝑟𝑡 𝑣𝑒𝑐𝑡𝑜𝑟𝑠.  𝐻𝑒𝑛𝑐𝑒, 𝑆𝑉𝑀 𝑎𝑠 𝑑𝑒𝑡𝑒𝑟𝑚𝑖𝑛𝑖𝑠𝑡𝑖𝑐  
 
𝑐𝑙𝑎𝑠𝑠𝑖𝑓𝑖𝑒𝑟 𝑐𝑎𝑛 𝑏𝑒 𝑎 𝑝𝑜𝑤𝑒𝑟𝑓𝑢𝑙 𝑡𝑜𝑜𝑙 𝑓𝑜𝑟 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑛𝑔 𝑢𝑠𝑒𝑓𝑢𝑙 𝑖𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 𝑓𝑟𝑜𝑚 
 
𝑙𝑎𝑟𝑔𝑒 𝑑𝑎𝑡𝑎𝑠𝑒𝑡, 𝑒𝑠𝑝𝑒𝑐𝑖𝑎𝑙𝑙𝑦 𝑤ℎ𝑒𝑛 𝑡ℎ𝑒𝑟𝑒 𝑎𝑟𝑒 𝑚𝑜𝑟𝑒 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒𝑠 𝑡ℎ𝑎𝑛 𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛𝑠  
 
(Salazar et al. , 2012;  Verplancke et al. , 2008).  
 
 Model Applications 
The support vector machine (SVM) serves as a deterministic classification algorithm using a 
heuristic method for prediction purposes. SVM is based on the principle of detecting a 
hyperplane that is used as a separation n-dimensional plane between two different classes 
(Verplancke et al., 2008). The process of defining a hyperplane can be achieved through a 
straightforward process or through a transformation using a linear kernel function, especially 
when it is not possible to find such hyperplane in a lower dimensional input space, by mapping 
the dataset into a higher dimensional features space. In this manner, such a transformation can 
allow the detection of the separation hyperplane (Grootveld, 2014; Salazar et al., 2012; Zhang 
et al., 2006). 
 
In the specific case of binary classifications, the SVM has been employed in order to 
discriminate between diseased individuals and healthy control ones in relation to two 





However, in this research project, the SVM approach applied employed the recursive features 
elimination technique to remove the less significant features in this binary classification 
process (Guyon et al., 2002), combined with the k folds stratified cross-validation technique, 
in which the dataset is divided into a total of 5, 10 or 15 groups or folds. During the modelling 
process, one fold is purposely omitted, also known as leave-one-out, and this process is 
repeated n times. The technique is used to validate the whole modelling process (Grootveld, 
2014). In this research, the classification of the patients into two groups is insufficient, since 
one of the main aims is to connect the diseases features to the disease progression. A regression 
analysis would help in this regard, and therefore the principal components regression strategy 
described below was applied. 
 
2.3.3. Principal Component Regression (PCR)  
 
 The Principle  
The technique of principal components regression (PCR) is mainly the regression analysis of 
Y upon a series of principal components, and has been mainly used to address collinearity 
issues in the dataset, especially amongst variables or predictors (Cook, 2007; Massy, 1965). 
Researchers support that when many variables are potential explanatory ones, it becomes more 
complicated to select the variable(s) responsible for the variability observed in the dataset 
examined  (Massy, 1965; Puelz et al., 2017). However, the conversion of these potential 
explanatory variables to one or several main explanatory variable(s) reduces the variable space, 
a process easing the explanation and the overall understanding of the modifications sought. 
Finally, the nominal dependent variable can be regressed upon the principal components. 
Hence, when the inter-relations between variables are not clearly understood, and when too 
many variables are candidates for the variability explanation, then it becomes necessary to use 
the principal components for more visibility in the explanatory variability of the disease 
diagnosis and progression. PCR in this research has been applied as a combination of the 
principal components analysis (PCA) and the multiple logistic regression (MLR) approach. 
   






PCA is a statistical procedure developed in 1901 by Karl Pearson, who based his technique on 
the famous theorem of the principal axis in geometry, related to the major and minor axes of a 
hyperbola (for generality). It is considered as one of the oldest technique for reducing the data 
dimensionality in the area of multivariate data analysis (Cook, 2007).  
 
As an exploratory method, principal components analysis involves orthogonal transformation 
of the original features into a new reference of features, also known as factors or principal 
components (PCs) that are a linear combination of the original features (Anton, 1987;  
Manfredi, 2013). In view of the fact that the PCs are orthogonal to each other, they therefore 
carry independent information. The first principal component accounts for the main variance 
in the original dataset, which corresponds to the main independent information; however, the 
other principal components carry the residual information (Manfredi, 2013). 
 
PCA provides important information on the principal axes for data analysis, including the 
factor scores and loadings. The first corresponding to the sample coordinates in the principal 
component reference, whilst the second gives the coefficients of the linear combination of the 
original features on a given PC. The gathered information can be interpreted with regards to 
the potential and most relevant biomarkers present in such datasets (Manfredi, 2013). Some 
applications of principal component analysis are examined below. 
 
 Applications of PCA  
Different cases have been reported in the literature in relation to the application of PCA as a 
visualisation tool to determine whether there is total separation between classes in the new 
features that is the PCs’ space. In respect to the understanding of the likelihood of a patient 
developing diseases such as NPC1 disease, PCA can provide very useful information  for the 
detection of candidate biomarkers (Manfredi, 2013).  
 
PCA was employed for the identification of blood plasma biomarkers for NPC1 disease. 
Indeed, this study aimed to identify the pathological mechanisms that underlines NPC1 disease, 
in order to detect biomarkers. In this regard, the change in liver expression in the NPC1 mouse 
model at different steps of disease progression was also studied. PCA was able to identify  three 
different expression groups, including 1-week-old control and mutant mice, 3- to 11-week-old 




of statistical techniques such as PCA in the interpretation of metabolomic, genomic, etc., 
datasets allows the extraction of biomarker(s) that can inform us in disease diagnosis and 
prognosis (Wang, 2008).  
 
One example of the applications of PCA is another “omics” strategy focused on the potential 
effects of pollutants on fish. Fish plasma samples were collected and analysed using a surface 
enhanced laser desorption ionization – time of flight mass spectroscopy (SELDI-TOF MS) that 
is a gel-free proteomic technique. Hence, the protein expression in fish and the transformations 
at organism level were investigated (Nilsen et al., 2011). The results showed a strong 
correlation between the first principal component PC1 (explaining 23.6% variability) and the 
gonadosomatic index (GSI) value. Further analysis of PC2 and PC3 explained respectively 
18.6% and 9.1% variability respectively, and highlighted an additional relationship related to 
alkylphenol exposure. This, in turn, confirmed the ability of the PCA to distinguish between 
females exposed to alkylphenols from those unexposed, which could disclose potential 
biomarker candidates specific to such exposure (Nilsen et al., 2011).  
 
Principal component analysis can be used to separate different groups of individuals or patients 
in relation to disease studies. Additionally, it can be combined with other algorithms while 
trying to understand features involved in disease progression. This includes the multiple 
logistic regression (MLR) approach, which is described in the sub-section below.  
 
Multiple Logistic Regression (MLR)  
 
 The Principle 
Schoonjans, (2016) defines multiple logistic regression (MLR) as a statistic model used in data 
analysis, which features one dependent nominal variable that has two values. In such cases, the 
dependent variable is a dichotomous or binary coded value of 1 for (diseased, male, yes, etc.), 
and 0 for (healthy, female, no, etc.), and two or more measurements which could be 
independent, or non-independent and correlated. He added that MLR allows use of variation in 
the measurements to predict the value of the dependent variable.  
 
Indeed, he also noted that applying MLR aimed at finding the best fitting model describing the 




i.e. an outcome variable), and a set of independent predictors or explanatory variables. The 
probability of predicting an outcome is given by the formula:  
 
𝑌′ = 𝑌0 + α1𝑋1 +  α2𝑋2 + α3𝑋3 …+ α𝑛𝑋𝑛 ∶  (𝟓) 
 
𝐻𝑖𝑔𝑔𝑖𝑛𝑠, (2005)𝑠ℎ𝑜𝑤𝑒𝑑 𝑡ℎ𝑎𝑡 𝑌0 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 𝑜𝑓 𝑌′, 𝑎𝑛𝑑 𝑡ℎ𝑒 𝑣𝑎𝑙𝑢𝑒𝑠 α𝑖  𝑡ℎ𝑒 𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛  
 
𝑌′𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 1 𝑖𝑛𝑐𝑟𝑒𝑚𝑒𝑛𝑡 𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑋𝑖 𝑐𝑎𝑛 𝑏𝑒 𝑑𝑒𝑡𝑒𝑟𝑚𝑖𝑛𝑒𝑑. 𝐹𝑜𝑟 𝑡ℎ𝑒 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑖𝑜𝑛,  
 
𝑟𝑒𝑓𝑒𝑟 𝑡𝑜 (𝐻𝑖𝑔𝑔𝑖𝑛𝑠, 2005).  
 
Moreover, the logistic regression generates the regression coefficients and their associated 
standard errors, with a formula to predict the logit transformation of the probability of the 
presence of the response or the outcome as mentioned below: 
 
𝑙𝑜𝑔𝑖𝑡 (𝑝) =  𝑌′ = 𝑌0 + α1𝑋1 +  α2𝑋2 + α3𝑋3 …+ α𝑛𝑋𝑛 ∶  (𝟔),  
 
𝑤ℎ𝑒𝑟𝑒 𝑝 𝑖𝑠 𝑡ℎ𝑒 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑝𝑟𝑒𝑠𝑒𝑛𝑐𝑒 𝑜𝑓 𝑎 𝑔𝑖𝑣𝑒𝑛 𝑜𝑢𝑡𝑐𝑜𝑚𝑒. 
 






 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑝𝑟𝑒𝑠𝑒𝑛𝑐𝑒 𝑜𝑓 𝑐ℎ𝑎𝑟𝑎𝑐𝑡𝑒𝑟𝑖𝑠𝑡𝑖𝑐
𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑎𝑏𝑠𝑒𝑛𝑐𝑒 𝑜𝑓 𝑐ℎ𝑎𝑟𝑎𝑐𝑡𝑒𝑟𝑖𝑠𝑡𝑖𝑐
 
 
𝑙𝑜𝑔𝑖𝑡 (𝑝) = 𝑙𝑛 
𝑝
1−𝑝
          (Schoonjans, 2016). 
 
The estimation in logistic regression chooses parameters that maximise the likelihood of 
observing the sample values, rather than choosing the parameters that minimise the sum of 
square errors (Higgins, 2005; Schoonjans, 2016). Managing high-dimensional variables with 
only a few samples is highly complex in regression analysis; however, regressing Y on the 
principal components seems to be effective, providing acceptable results which are explored 






 Applications of the MLR Model 
Different applications of MLR have been reported to predict the likelihood of a patient 
developing a given disease (Abbott and Carroll, 1984; Schoonjans, 2016; Taooka et al., 2014). 
In a biomedical research study, the binary nominal dependent variable Y will take the binary 
values corresponding to either diseased or healthy individuals. Similarly, MLR is used in the 
current thesis to predict the likelihood of an individual being correctly identified as an NPC1 
disease patient, which corresponds to the individual being likely to develop the disease at an 
early stage or being at risk of sudden death (Taooka et al., 2014).  
 
 Equally, MLR has been used in the analysis of prolonged QTc interval in the treatment of 
pneumonia patients. In the heart electrical cycle related to the ventricle depolarisation and 
repolarisation, the QTc corresponds to the time elapsed between the start of the Q wave and 
the end of the T wave. The datasets analysed in the record of clinical and laboratory data, and 
contained information such as ECG findings, blood chemistry data, etc. The multiple logistic 
regression (MLR) model was used to compare the datasets (Taooka et al., 2014). 
 
The investigation of QTc as one of the risk factors in elderly pneumonia patients was performed 
by a team of researchers. The results acquired showed that the prolonged interval of the heart 
depolarisation and repolarisation, that represents a risk factor for ventricular dysrhythmia 
(causing sudden death) of QTc > 0.44 seconds is a potential prognosis factor for pneumonia in 
elderly patients. In fact, MLR analysis showed that the QTc prolonged interval also featured 
as a predictive factor of increased mortality in pneumonia patients  (Taooka et al., 2014; World 
Wide Antimalarial Resistance Network, 2012).  
 
Following the presentation of certain applications of MLR, and with the two steps (i.e. PCA 
and MLR) combined together, the principal component regression model has hence been 
further developed. Some applications of the PCR model are provided below.  
 
 
 PCR Model Applications  
Several applications of PCR model have been mentioned in different literature. For example, 
PCR was utilised to understand the traits variance related to underlying genetic 




on single nucleotide polymorphisms (SNPs) can be detrimental to the selection of a given gene 
as main biomarkers for trait variance (Shen and Zhu, 2009). Similar studies have shown the 
importance of the interaction between different loci within a gene, which can generate more 
information and finally improve the detection power (Schaid et al, 2002).  
 
However, determination of the number of PCs upon which to regress the dependent variable 
Y’ is not rationally established, but the common suggestion and applied technique is to use 
several PCs among the first that account for 80 to 90 % of the variability, also considering that 
these may just not be strongly related or even unrelated to the outcome (Gauderman et al., 
2007; Wang and Abbott, 2008). Nevertheless, the author of this thesis believes that it is worth 
expanding the variability space in an attempt to involve more PCs in the understanding of the 
phenomenon under investigation. Indeed, involving more principal components in the 
explanation of the maximum variability within the dataset (80% and 90% variability), is more 
likely to traduce the whole reality of the changes happening at genes level.   
 
The combination PCA and logistic regression was applied to develop a model that will facilitate 
the construction of a valid coronary heart disease risk score in comparison to the traditional 
clinical risk one. For this purpose, the researchers generated the genetics risk scores (GRS) of 
a cohort of 49,310 SNPs based on the cardiogram meta-analysis of coronary heart disease 
(CHD) of the cohort of individuals recruited to the study. Different tests were performed on 5 
different types of population at risk. Clinical scores such as the Framingham risk score (FRS) 
was also considered in this research. The results showed that integrating the GSR and FRS 
values improved the risk prediction for those aged 60 years, and plus for more than 10 years. 
Notwithstanding, the GRS detected different risk patterns with men being more at risk, which 
was between 12 to 18 years earlier than those less at risk (Abraham et al., 2016).  
 
These studies highlight the importance of the application of PCR to correlate disease features 
and the diagnostic. Nevertheless, metabolomics multivariate analysis implies also the use of 
1H NMR spectroscopic technique that has been used to convert the blood and liver extract 





2.4. Nuclear Magnetic Resonance (NMR) and Data Acquisition  
     
2.4.1. Introduction 
Nuclear magnetic resonance (NMR) spectroscopy is now a widely used analytical technique 
with a wide variety of research applications, including pharmaceutical and biotechnology 
analysis, clinical research, etc. The technique is also applicable to  physicians’ use as magnetic 
resonance imaging (MRI), since the principle is the same (Amathieu, 2016; Bruker 
Corporation, 2013). NMR spectroscopic analysis of biofluids, however, it is a more 
reproducible technique that requires little sample preparation, is able to provide a fast, 
comprehensive information regarding the biomolecular composition of metabolites therein, 
together with a thorough and full structural elucidation  (Joshi, 2012). 
 
2.4.2. Theory and Principles 
The main concept of nuclear magnetic resonance is based on the phenomenon of nuclear spin. 
Indeed, atoms in molecules have discrete energy levels characterised by electronic, vibrational, 
and rotational or spin states. When placed in an electromagnetic field (B0) generating 
electromagnetic radiation, atoms present in chemical compounds will absorb and emit photons, 
in such a manner that the energy of the photon will correspond to one of the energy levels of 
the atoms. The different types of spectroscopy are linked to the frequency involved since the 
energy level is proportional to the frequency according to the equation:  
 
𝐸 = ℎ𝜇: (𝟕);  ℎ = 6.62 . 10−34 𝑚2 𝑘𝑔 𝑠−1  𝑖𝑠 𝑡ℎ𝑒 𝑝𝑙𝑎𝑛𝑐𝑘 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡;  𝜇 𝑡ℎ𝑒 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦    
 
NMR spectra are obtained throughout a range of frequencies (10-800 MHz), which correspond 
to the resonance frequencies of certain spectrometers. Therefore, NMR is viewed as the study 
of the magnetic properties and the energy of atomic nuclei when placed in a powerful external 
magnetic field, B. Thus, when a nucleus of mass m and charge q = e is rotating with a constant 
veloCITy v at a constant distance r from the rotational axis, the momentum µ can be expressed 








 𝜇 = 𝑚𝑣𝑟 = (
𝑒
2𝑚
) 𝐿 = 𝛾. 𝐿 ∶ (𝟖) 
𝐴 𝑟𝑜𝑡𝑎𝑡𝑖𝑛𝑔 𝑛𝑢𝑐𝑙𝑒𝑢𝑠 𝑜𝑟 𝑜𝑏𝑗𝑒𝑐𝑡 𝑝𝑙𝑎𝑐𝑒𝑑 𝑖𝑛 𝑎 𝑚𝑎𝑔𝑛𝑒𝑡𝑖𝑐 𝑓𝑖𝑒𝑙𝑑 𝐵0, 𝑤𝑖𝑙𝑙 𝑏𝑒 𝑒𝑥𝑝𝑜𝑠𝑒𝑑 𝑡𝑜  
𝑎 𝑡𝑜𝑟𝑞𝑢𝑒: 𝑇 = 𝜇𝐵0 , 𝑤𝑖𝑡ℎ  (
𝑑𝜇
𝑑𝑡
) =  𝛾𝜇. 𝐵0  =  𝜇. 𝛾𝐵0 ∶ (𝟗)  
𝐴 𝑝𝑟𝑒𝑐𝑒𝑠𝑠𝑖𝑜𝑛 𝑜𝑓 𝜇 𝑎𝑏𝑜𝑢𝑡 𝐵0 𝑐𝑎𝑛 𝑏𝑒 𝑑𝑒𝑠𝑐𝑟𝑖𝑏𝑒𝑑 𝑏𝑦 (
𝑑𝜇
𝑑𝑡
) =  𝜇. 𝜔0 ∶ (𝟏𝟎)  
 
𝑇ℎ𝑒 𝐿𝑎𝑟𝑚𝑜𝑟 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛 𝑒𝑠𝑡𝑎𝑏𝑙𝑖𝑠ℎ𝑒𝑠 𝑡ℎ𝑎𝑡: 𝜔0 =  𝛾𝐵0 ∶ (𝟏𝟏) (De Graaf, 2007). 
 
Further information regarding the theory and principles of the 1H NMR spectroscopic 
technique can be found in (De Graaf, 2007). 
 
2.4.3. Generation on NMR Free Induction Decay (FID) File  
When biofluids or tissue samples extracts are subjected to high-resolution NMR analysis, an 
FID file containing all the information in the form of excitation frequency or amplitude of 
signal emitted is provided. Thus, when the RF emitted by the magnetic field is equal to the 
frequency of the nucleus, there is absorption followed by an emission of a signal. The frequency 
(ppm, known as chemical shift) values for each nucleus studied are critically dependent on its 
magnetic and therefore chemical environment within a particular molecule. Therefore, the FID 
file contains information related to the excitation amplitude given the ppm value of the 
chemical shift. Finally, the raw spectra information contained in the FID files are converted 
into Excel files, before they undergo further processing, including baseline correction, zero-
filling, Fourier-Transform, etc. 
 
2.4.4. Zero-Filling 
The technique of zero-filling has the objective of improving the spectral resolution of the NMR 
spectra generated. However, spectral resolution is usually too low; hence, resolving the 
problem is more related to knowledge of the spectral amplitude and the intermediate 
frequencies. De Graaf (2007) argued that decreasing spectral width or increasing the 
acquisition time appears to serve as the best options for solving this issue.  However, the latter 
solution increases the data storage, resulting in an increase of the noise contribution. 
Furthermore, extending the acquired FID automatically increases the acquisition time, a 




Transformation, a string of points of zero amplitude are added to the FID files, a technique 
known as zero-filling.  
 
2.4.5. Fourier-Transformation Process 
During Fourier Transformation, the RF excitation creates a complete excitation state of the 
nucleus, while the magnetisation is precessing about B0 and inducing an electromagnetic field 
(emf) within the receiving coil. Additionally, spins can exchange energy between themselves, 
hence the spin-spin relaxation time T2 causes the emf to behave like a decreasing function of 
time. However, a local distribution of B0 is created across samples, followed by a subsequent 
distribution of the Larmor frequencies. The frequency distribution causes a rapid loss of  
magnetisation, which is more profound than the loss of  magnetisation experienced/sustained 
during the T2 relaxation time (De Graaf, 2007). The Larmor Frequency for proton spin is given 





 (𝟏𝟐)  
 
Therefore, the signal generated in an inhomogeneous magnetic field for a sample, with uniform 
proton density and a relaxation time T2 given by: 
𝑀𝑥𝑦(𝑡) =  𝑀𝑥𝑦(0)𝑒
−
𝑡
𝑇2  ∫ 𝑒+𝑖𝛾∆ B0(𝑟)𝑡
∞
𝑟
𝑑𝑟 =  𝑀𝑥𝑦(0)𝑒
−
𝑡
𝑇∗2 ,   𝑤𝑖𝑡ℎ ∆ B0 𝑏𝑒𝑖𝑛𝑔 𝑖𝑛𝑑𝑖𝑐𝑎𝑡𝑖𝑣𝑒  
𝑜𝑓  B0 𝑖𝑛ℎ𝑜𝑚𝑜𝑔𝑒𝑛𝑒𝑖𝑡𝑦 𝑎𝑛𝑑  ∆ B0 = B0(𝑟) − ∆ B0,𝑛𝑜𝑚 ;  𝑤𝑖𝑡ℎ B0(𝑟) 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝑡ℎ𝑒 
 
 𝑚𝑎𝑔𝑛𝑒𝑡𝑖𝑐 𝑓𝑖𝑒𝑙𝑑 𝑎𝑡 𝑝𝑜𝑠𝑖𝑡𝑖𝑜𝑛 𝑟, 𝑎𝑛𝑑  B0,𝑛𝑜𝑚 𝑡ℎ𝑒 𝑛𝑜𝑚𝑖𝑛𝑎𝑙 𝑚𝑎𝑔𝑛𝑒𝑡𝑖𝑐 𝑓𝑖𝑒𝑙𝑑 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ. 
 
The electromagnetic signal sent to the receiver in the transverse plane precessing at the Larmor 
frequency, and exponentially decaying at a characteristic time constant T*2, is represented as a 
complex function:    
𝑀𝑥𝑦 (𝑡), 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑒𝑑 𝑎𝑠: 
 𝑀𝑥𝑦 (𝑡) =  𝑀𝑥(𝑡) + 𝑖𝑀𝑦(𝑡);  𝑐𝑜𝑚𝑝𝑙𝑒𝑥 𝑡𝑟𝑎𝑛𝑠𝑣𝑒𝑟𝑠𝑒 𝑚𝑎𝑔𝑛𝑒𝑡𝑖𝑠𝑎𝑡𝑖𝑜𝑛 𝑤𝑖𝑡ℎ  
 





𝑀𝑥 (𝑡) =  𝑀0 cos[(𝑤0 − 𝑤)𝑡 +  ∅]𝑒
−
𝑡
𝑇∗2  ∶ (𝟏𝟑)  
 
 𝑀𝑦 (𝑡) =  𝑀0 sin[(𝑤0 − 𝑤)𝑡 +  ∅]𝑒
−
𝑡
𝑇∗2 ∶ (𝟏𝟒) 𝑤𝑖𝑡ℎ ∅ 𝑡ℎ𝑒 𝑝ℎ𝑎𝑠𝑒 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑜𝑟𝑖𝑔𝑖𝑛 𝑡 = 0  
 
NMR is therefore able to detect the x and y components of this complex motion. The time-
dependent emf (signal amplitude) is known as free induction decay (FID). Mx (t) and My (t) are 
known as real and imaginary FIDs respectively, with sinusoidal representations. Further, Mx 
(t) and My  (t) correspond to the spectra acquired during NMR spectroscopy (De Graaf, 2007). 
Indeed, although containing the most relevant information on the nuclear spin, the time-domain 
data (FID) is converted into a frequency domain (spectra) using the Fourier Transform 
function, which is provided below; 
 
     f(t)   − −−→  F(ω), transforming   FID − − − − > 𝑠𝑝𝑒𝑐𝑡𝑟𝑎 
 
𝐹(𝜔) =  ∫ 𝑓(𝑡)𝑒−𝑖𝜔𝑡
+∞
−∞
𝑑𝑡 ∶ (𝟏𝟓)  
or 
𝐹(𝜈) =  ∫ 𝑓(𝑡)𝑒−𝑖2𝜋𝜈𝑡
+∞
−∞
𝑑𝑡 ∶ (𝟏𝟔) 
 
Based on the Fourier Transform, the values of the complex transverse magnetisation function 
can be determined (De Graaf, 2007). 
 
2.4.6. Chemical Shift 
The notion of chemical shift is applied based on the assumption that the resonance frequency    
𝜔     depends on the magnetic field     𝐵0,     the gyromagnetic ratio    𝛾,    and the chemical 
environment of the nuclei studied. This latter effect is known as chemical shift. Indeed, nuclei 
are shielded by electrons surrounding them to the external magnetic field B0. Therefore, the 
effect of these electrons will be to reduce the overall effect of the external magnetic field 
received by every single nucleus. The resulting intensity of the magnetic field B received by a 
given nucleus is given by the formula below, where B0 is the external magnetic field value, and 





 𝐵 = (1 − 𝜎)𝐵0 : (𝟏𝟕)        (De Graaf, 2007). 
 
Data acquired in this manner finally go through the data processing stages, in order to remove 
noise prior to the analysis stage. Some applications of the NMR spectroscopy to the analysis 
of metabolomics biofluids are highlighted below.   
 
2.5. Metabolomics Multivariate Analysis of Biofluids – Application to the 
Study of Niemann-Pick Disease Type C1 (NPC1) 
 
2.5.1. Introduction  
Major research publications focused on metabolomics research related to NPC1 disease are 
investigated in this study. The manner in which the research was carried out, what techniques 
were used, what the findings were, and finally how to relate all these different steps to the 
current research questions. To answer each of these different questions, the following are 
included in this subsection: (1) an introductory component presenting the importance and the 
scope of this review; (2) an overview of Niemann-Pick type C1 disease; and finally (3) 
metabolomics multivariate analysis of the disease is discussed, with the underlying pathways 
related to the disease progression, together with research limitations and the gap(s) in 
knowledge, which are all scrutinised.  
 
 2.5.2. Niemann-Pick Diseases Types C1 and C2 
Niemann-Pick disease type C is a rare neurodegenerative lysosomal storage disorder which 
arises from functional losses of either NPC1 or NPC2 genes. Indeed, the NPC disease is caused 
by the mutation of NPC1 (95%) and NPC2 genes (5%) (Vanier, 2010). This altered storage at 
lysosomal and endosomal levels, coupled with the cellular trafficking of cholesterol and 
sphingolipids to degradation, causes unesterified cholesterol accumulation in the lysosomes 
and late endosomes, and 80% of the patients experiencing pronounced abnormalities. In infant 
years and childhood, the neurological symptoms vary from delay in the sensorimotor 




(Vanier, 2010). Although to date there is no fully effective treatment for NPC1 disease, 
miglustat (MGS) is the only alternative therapy approved by the Food and Drug Administration 
(FDA) in the USA (Fan et al., 2013). 1H NMR-based metabolomics could indeed provide 
insights into NPC1 disease prognosis and diagnosis while presenting a clear picture of the 
underlying metabolic alterations in this disease’s early stages, and this analysis is reviewed 
below.  
 
2.5.3. Metabolomics Multivariate Analysis of NPC1 Disease  
Metabolomics analysis and metabolite profiling of the NPC1 diseases, and the more severe 
form of the disease related to the liver dysfunction are being investigated in order to  achieve 
deep insights at the biomolecular level. This, in turn, can help us to attain a clear understanding 
of the disease’s aetiology. This scrutiny will provide readers with a clear picture of the changes 
occuring at molecular level, and the related pathways associated with disease progression.  
In this regard, a team of researchers conducted a study on NPC1 disease in order to detect 
biomarkers that will help to clarify disease progression. Their main objective was to detect 
biomarkers that would provide valuable information regarding defects in metabolic pathways, 
information of much relevance to the development of effective treatments for NPC1 disease 
(Fan et al., 2013).  
Their work focused on studying lipid storage at a lysosomal level in mouse tissue, and human 
cerebrospinal fluid, to which they applied targeted metabolomics profiling. They found that the 
following lipids, including sphingoid bases, monohexosylceramides (MC), and the GM2 
gangliosides were highly concentrated in the liver. Additionally, high levels of GM2 and GM3 
gangliosides were present in the brain (Fan et al., 2013). They decided, with the help of an 
animal cohort, to treat this high lysosomal concentration of sphingolipids with miglustat and 
2-hydroxypropyl- β-cyclodextrin (HP- β -CD). The results of both treatments showed a 
decrease of the sphingolipids at lysosome level.  Based on the success of this animal-based 
study, the same researchers extended their technique, but this time by applying similar 
treatments to human subjects.    
 
They also analysed blood plasma and cerebrospinal fluid (CSF) of NPC1 patients through 




responded to the therapeutic intervention. They applied MGS as drug in the treatment of the 
NPC1 disease and obtained a significante reduction of the level of the GM1 and GM3 
gangliosides in the NPC1 subjects blood plasma. However, CSF increased MCs sphingolipids. 
This highlighted the fact that the sphingolipidosis during NPC1 disease was attributable to the 
trapping of unesterified cholesterol in the lysosome, which in turn does not permit recycling of 
the sphingolipids. Moreover, MGS treatment in NPC1 patients provoked profound alterations 
in plasma and cerebrospinal fluid sphingolipids. HP-β–CD treatment caused a similar alteration 
in CSF to that observed in NPC1 mouse cohorts. Furthermore, researchers noted a reduction in 
lipid content in liver, spleen and brain tissue after single or combined therapy of MGS with 
HP-β–CD. These researchers also discovered that HP-β–CD, and combined treatments were 
equally effective, but more effective in reducing lipid storage than MGS administered alone; 
this signified that HP-β–CD treatment was more effective and efficient than the MGS alone.   
 
(Fan et al., 2013) postulated that NPC1 gene mutation was causing a severe perturbation such 
as intercellular cholesterol trafficking, a process resulting in a huge and uncontrolled 
accumulation of lipids within the lysosome. The temporary solution was the application of a 
therapy that provided some relief in terms of controlling the excess of lipid accumulation. 
Finally, the FDA in the US approved the therapies based on MGS, the glycosphingolipid 
inhibitor that gained approval for the treatment of NPC1 disease.  
 
In another research investigation, Yang, (2005) showed that sterol homoeostasis dysfunction 
caused cholesterol accumulation, and the provocation of neuronal apoptosis was one of the 
main causes of NPC1 disease. Typically, blockage of cholesterol transport between the 
lysosome and the sterol regulatory machinery was responsible for the cholesterol homoeostasis 
defect.    
 
The same researcher further investigated this disease, and followed five different Chinese 
patients and their family. The neurological manifestation of the disease encompassed the 
following signs, amongst others, specifically cerebral atrophy with psychomotor retardation, 
speech, and mental function deterioration, etc. Indeed, it was shown that there was a variation 
in the age at which the first disease symptoms appeared, and the later the appearance, the slower 
the disease progression. Moreover, the earlier the disease symptoms manifested, the more 





However, the validation of these findings was insufficient. Therefore, its acceptance was 
weakened in view of several reasons, including the limited number of NPC1 subjects, 
combined with the fact that the reliance on the clinical trial outcomes indicated that the long-
term observation of patients, and the difficulties associated with the measurement of variance 
in outcomes. These reasons were sufficient to affect the therapies’ reliabilities. Consequently, 
the FDA was sceptical about the findings and related techniques, despite being one of the rare 
therapies currently applied. This leaves the door open to more effective NPC1 treatment 
regimens to be developed. 
   
Typically, the determination of NPC1 disease biomarkers allow a non-invasive, non-
destructive, quantification of disease progression, and this development will be welcomed by 
all stakeholders involved in this orphan disease research. Moreover, researchers affirmed that 
oxysterols have been already discovered as specific biomarker for NPC1 disease; therefore, the 
discovery of more powerful and discriminatory biomarkers is required (Fan et al., 2013). 
 
Following their study and discoveries, (Fan et al., 2013) suggested that it was valuable to use 
sphingoid base monohexosylceramides (MCs), i.e. the GM2 and GM3 gangliosides, as 
biomarkers for determining treatment efficacy, especially during clinical trials in monitoring 
NPC1 disease progression based on drug administration. They added that the sphingolipids 
detected fulfilled the required biomarkers discovery criteria. This included ease of detectability 
in CSF, and their quantification through MS/MS, etc. 
 
However, Yang (2005) believed that in view of NPC1 disease pathogenesis complexity, 
including proteostasis, liquid trafficking, inflammatory, oxidative stress, and pro-apoptotic 
pathways, it is unlikely that a biomarker or class of biomarkers will be found that would help 
to define a quantifiable measure for the diagnosis, monitoring, and assessment of responses to 
intervention in NPC1 disease. Moreover, the latter researcher sustained that the main problem 
related to cholesterol homoeostasis defect triggers neuronal apoptosis. However, he added that 
NPC1 gene mutation and the different functional implications remained unknown (Bi and Liao, 
2010, Wang, 2011, Yang, 2005).  
 
Despite the fact that these researchers, main focus was based on the finding of new biomarkers 
for NPC1 disease diagnosis, they proposed further research towards the development of 




or to all other lysosomal storage diseases (Fan et al., 2013a). Thus, these researchers gave 
another orientation to the research, potentially ascribable to several explanations. Nevertheless, 
this research is keeping the current orientation with the option of finding new biomarkers in 
order to improve NPC1 disease and the NPC-associated liver disease treatment regimens.   
 
After scrutinising the research on NPC1 disease, and even finding gaps in knowledge, the focus 
of this research area can be placed on other types of NPC1-related diseases that are investigated 
using metabolomics and metabolite profiling. One major aspect of this work was focused on 
liver dysfunction associated with this disease, as well as on the research methods applied, the 
data analysis techniques used and their relevance to the research questions.   
 
In this regard, the following study concerning liver disease revealed that blood serum 
metabolomics could be used as a research analysis technique to differentiate between patients 
with liver cirrhosis, and that the application of multiple classification methods could ultimately 
separate patients with low, mild or severe chronic liver failure (CLF).  However, in this 
particular case, the research was conducted by applying metabolomics using 1H NMR analysis 
for the identification and quantification of metabolites. The detection of glutamine could help 
in this study for the prediction of an unfavourable outcome for patients with fulminant CLF 
(Amathieu, 2016).   
 
In another study, Qi et al. (2012) focused their work on serum metabolite profiling of 
individuals with liver cirrhosis (LC), especially when it reaches the advanced stage of liver 
failure, where the liver is unable to compensate changes related to bridging fibrosis. The above 
researchers believed that detecting this disease in its early stages could serve to provide patients 
with the necessary care and also to make accurate decisions regarding the treatment to be 
administered, whilst ensuring the detection of efficient biomarkers related to LC. 
 
Furthermore, the above researchers demonstrated the importance of hepatitis B virus (HBV), 
with a higher impact on patients developing LC. For this reason, their study was reoriented 
toward the analysis of the HBV-liver cirrhosis patients. They discovered that the distinction 
between patients in the early stage and those at the later stage of the disease could clearly be 
established. Furthering their study, they also found that serum metabolites could be used to 




with the advantage of detecting the molecules responsible for the difference; including creatine, 
acetoacetate, glutamine and glutamate viewed as significant biomarkers.    
 
This shows the enormous potential offered by metabolomics in the study of human diseases. 
Indeed, the use of CITs provides newly, rich and diverse research and investigation platforms 
in relation to enhancing our understanding of disease aetiology and diagnosis, and other 
opportunities to follow (Duarte et al., 2014). Nonetheless, research related to liver dysfunction 
disease has not yet detected relevant biomarkers that will help in the diagnosis of the disease 
advancement. Therefore, there is more work to be done on NPC1 disease diagnosis, in order to 
provide practitioners with new biomarkers that will be a breakthrough in its diagnosis and 
therapeutic monitoring.  
 
 
2.6. Chapter Summary 
 
This chapter provided the author with an opportunity to review the state-of-the-art of 
metabolomics multivariate analysis in disease diagnosis. Throughout this journey, several 
terms were reviewed, in such a manner that differing interpretations and understandings were 
unified and clarified. Moreover, different CITs were visited to give a clear picture of how they 
could be supporting the present research project in order to meet the research aims and 
objectives. Furthermore, NMR theory and principle were investigated to provide a wider 
understanding of the phenomenon behind it, including the way data is generated, especially 
NMR spectral profiles used to explain the underlying transformation at the molecular level 
with respect to disturbances in metabolism.  
 













“I cannot articulate enough to express my dislike to people who think that understanding 
spoils your experience… How would they know?” 
 
Marvin Minsky  
 
  




Methodology is related to learning and adopting several common approaches involved in 
researching, and it usually leads to designing the research and finishing with data gathering and 
data analysis.  Moreover, it is a form of thinking impeding on the design and all the changes in 
the research organisational plan (Jonker and Pennink, 2009). Whilst other considered it as the 
strategy or plan of action linking the methods to the research outcomes (Creswell, 2003). 
 
However, different combinations can be applied when it becomes a methodological choice. 
Depending on the type of research carried out, researchers chose the research approach that 
best suit their work in order to meet the research aims and objectives (Sarantakos, 2005; 
Wahyuni, 2012). In the present thesis, a quantitative research approach was chosen, while the 
intelligent technology task fit model was developed to support the whole research project.  
  
This chapter is structured as follows. Section (1) contains the introduction with an overview of 
the chapter, whereas section (2) highlights the research methodology, which describes the 
approach, and also the theory selected. In section (3), the research method is visited, and in 
section (4) the samples and feature selection techniques are respectively investigated. In section 
(5), the research project challenges are identified. In section (6), the possible outcomes of the 
research work conducted are forecasted, and finally in section (7) a summary of the chapter is 





3.2. Research Methodology  
 
In this research methodology section, a brief description and justification of the choice of 
quantitative research approach used to support this metabolomics multivariate analysis 
research is included. This is followed by the presentation of the intelligent technology task fit 
model (ITTFM) developed as an extension of the task technology fit theory (TTFT) by 
Goodhue and Thompson (1995), followed by a highlight of the reasons for this choice.   
 
3.2.1. Quantitative Research Approach  
 
  Quantitative Research Approach Notion  
 
There are two main research approaches, including quantitative and qualitative research 
approaches. Different opinions exist regarding the use of these research approaches in science 
in general. Some are of the opinion that both approaches should be considered and applied 
together, while others take the view that they are quite different and as such should not be 
mixed, but rather should be considered separately. A third approach is that involving the 
combination of these two main approaches. This is referred to as the mixed research approach. 
Both approaches can utilise knowledge, techniques, etc., from each other, since the two main 
approaches are useful and equally valid for research purposes (Bell, 2014; Bryman, 1988; 
Hughes, 2012). In this research work, the inductive approach to quantitative study is been used 
and is related to the fact that the research starts with research questions, aims, and objectives 
that need to be achieved throughout the research (Dudovsky, 2011). Moreover, quantitative 
research is referred to empirical research studies, where researchers are more interested in 
understanding general principles of behaviours related to humans and animals, whilst 
attempting to estimate the average performance throughout the study. In addition, a thorough 
quantitative research protocol involving the collection of numerical data, usually on a smaller 
and more manageable scale (Blaxter, Hughes, and Tight, 1996; Bryman, 1997; McGregor and 






  Reasons for Choosing a Quantitative Research Approach  
 
The quantitative research approach was selected for this study for a number of reasons, which 
are highlighted below. This approach provides researchers with more reliable measurements, 
and experimental control through sampling and design, with the possibility of generating causal 
statement and replicable processes. Furthermore, it allows the implementation of stronger 
analytical tests for validation purposes via statistical methods, implementing stratified cross-
validation and logistic regression, and establishing feature correlations, deterministic and 
probabilistic predictions, etc., (Everitt and Hay, 1992; Hughes, 2012). However, Burns (2000) 
and  Hughes (2012) questioned the fact that in the quantitative research approach, researchers 
are subjectively involved in the research process, which is regarded as a source of bias of the 
research results. This position is arguable in the sense that a researcher using a quantitative 
research will for sure collect data and process them using techniques such as AI techniques. 
The results always include the minimum intervention of the researcher. In addition, techniques 
are even employed to minimise the unwanted source of bias, including cross-validation 
techniques, balancing the dataset to avoid that the classifier identifies all the data points as 
belonging to the majority class, etc.  
 
Nevertheless, this journey towards disease diagnosis has to be supported by a strong theory. 
The following sub-section proposes the Intelligent Technology Task Fit Model (ITTFM).  
 
3.2.2. The Intelligent Technology Task Fit Model (ITTFM)   
This sub-section outlines the development of the intelligent technology task fit model (ITTFM), 
which is an extension of the task technology fit theory (TTFT).  
 
  Intelligent Technology Task Fit Model (ITTFM)  
 
The ITTFM is a strategy developed to create an adequacy between the intelligent technology 




that is of paramount importance to the current research project outcomes. Hence, matching the 
SVA data visualisation performances and the dimensionality reduction, or the optimum support 
vector OSVM (optimisation of the support vector machine) classifier algorithm for improving 
biomarker discoveries in disease diagnosis. The ITTFM model can also be used to assess the 
potential of the multiple logistic regression (MLR) software predictive approach. This includes 
the probability to develop the NPC1 disease and the NPC liver dysfunction datasets, based on 
biomarkers detected.  
 
The ITTFM model offers the possibility to use different experimental processes in order to 
assess and measure model performances using the looping processes, and a threshold value r0. 
For example, NPC1 disease classification rates  𝒓 ≥ 𝒓𝟎   could be used as valid assessment 
criteria. Where loop 1 is related to the OSVM classification, and loop 2 is related to the MLR 
probabilistic classification. The ITTFM model is presented below in Figure 1.   
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Figure 1. Different components of the Intelligent Technology Task Fit Model (ITTFM) with 




characteristics, and the performance impact. The looping options to improve the system 
performance is defined by the stages 1 and 2. 
  
 ITTFM as an Extension of the TTFM 
ITTFM is an adopted model from the task-technology fit model (TTFM) developed by 
Goodhue and Thompson (1995). The model aims to apply intelligent technologies to IT/IS, for 
aligning intelligent technologies and the tasks to be performed intelligently. The intelligent 
technology is designed to fit the task performed, hence the descriptor intelligent technology 
task fit model. ITTFM supports the current research project development, and includes the 
following characteristics:  
 
1. The looping processes 1 – 4 (as follows), allowing the researcher to go back as far as sample 
and feature selections involved in this research work, in order to perform an iterative and 
incremental assessment and gradually improving the model performance. Hence, when this 
criteria  𝒓 ≥ 𝒓𝟎 is not met, the researcher can re-conduct the NMR data analysis process, change the 
sampling technique, or the features selection technique applied, etc. This means in clear that a trade-off 
has to be found between the quality of the tasks performed, and the intelligent technology model 
applied.         
 
2. Implementation of a threshold r0 allowing the researcher to validate the research overall 
process by comparing the performance rate r to r0. For example, the threshold value depends 
on the type of model developed, and the kind of assessment carried out.  Hence;  
 A model developed to assess a critical system should have a higher threshold:  
    𝑟 ≥  𝑟0 = 𝒂 =  1 ∶ 𝑡ℎ𝑢𝑠 𝑡ℎ𝑒 𝑎𝑙𝑖𝑔𝑛𝑚𝑒𝑛𝑡 𝑠ℎ𝑜𝑢𝑙𝑑 𝑏𝑒 𝑝𝑒𝑟𝑓𝑒𝑐𝑡 𝑡𝑜 ℎ𝑎𝑛𝑑𝑙𝑒 𝑡ℎ𝑒 𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙𝑖𝑡𝑦   
 A model developed to assess a normal system such as the classification of datasets to 
segregate between NPC1 disease patients and healthy control individuals can have a 
threshold set as follows: 
   𝑟 ≥  𝑟0 = 𝒂 =  0.8 ∶ 𝑡ℎ𝑢𝑠 𝑡ℎ𝑒 𝑎𝑙𝑖𝑔𝑛𝑚𝑒𝑛𝑡 𝑖𝑠 𝑠𝑒𝑡 ℎ𝑖𝑔ℎ            
3. Self-assessment option for the final result improvement is another particularity of this model, 
which is implemented through the looping process combined with a threshold setting in order 





 𝑟𝑛 =  𝑟0 + 𝑛𝜇  (𝟏𝟖);𝑤ℎ𝑒𝑟𝑒 𝑟0  𝑖𝑠 𝑡ℎ𝑒 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑, 𝜇 𝑎 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 𝑤ℎ𝑖𝑐ℎ 𝑐𝑎𝑛 𝑏𝑒  
 
𝑑𝑒𝑡𝑒𝑟𝑚𝑖𝑛𝑒𝑑 𝑡ℎ𝑟𝑜𝑢𝑔ℎ 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡 𝑎𝑛𝑑 𝑛 𝑡ℎ𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑙𝑜𝑜𝑝 𝑎𝑝𝑝𝑙𝑖𝑒𝑑.  
 
The table below gives a summary of two main types of systems and example of the threshold 
limits. This includes the model being used to assess a normal system for clustering, 
deterministic classification, probability and predictive classifications, etc. The same model 
with r = r0 = 1 could be employed to assess that a patient’s blood plasma sample is freed from 
early signs of the NPC1 disease, or more advancing secondary signs. 
 
System Type          Normal System           Critical System 
Threshold Limit r0   r ≥ r0 (e.g. r0 = 0.8) r = r0 = 1 
 
Type of Usage 
.Non-Critical                              
.Assessing normal issues 
(Visualisation, Classification,..) 
.Critical                                 .System 
Assessing critical issues                 
.High r0 value for highest criticality  
                                                                                                                      
Table 1 Diverse types of system and the setting of the threshold value based on the type of 
model developed  
 
4. Model flexibility: a certain level of flexibility is set for the model, with the number of loops 
and the threshold value, ro, to be set, depending on the model developed, while 𝜇 will be a 
constant characteristic of the model developed. 
 
5. The notion of alignment level and the level function l are introduced.  
This refers to the correlation between a model’s alignment to the task to be performed. Defining 
the correlation between the model performance and the level of its alignment to the task to be 
performed, this notion establishes that the higher the model performance, the higher its 
alignment level. Thus, a model achieving r = 0.75, for example, will be classified as level 3. 








   Level1     Level 2       Level 3 Level 4 Level 5 
Alignment 
Limits 








50% ≤ align  
≤ 60% 
Aligned 
60% ≤ align  
< 80% 
Strongly aligned 
80% ≤ align  
< 100% 
Perfectly aligned 
Align = 100% 
                                                                                                                                                 
Table 2. Relationship between the alignment level (x) and the model performance rate (a). The 
higher the value of the rate, r = a, the stronger the alignment.                                                                                                                                                            
To further consolidate this notion of alignment, a function has been defined that correlates the 
value of the performance level “a” to the alignment function.  
 
  The Alignment Function Model (AFM) 
𝑇ℎ𝑒 𝑎𝑙𝑖𝑔𝑛𝑚𝑒𝑛𝑡 𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛  𝑙𝑥 𝑖𝑠 𝑑𝑒𝑓𝑖𝑛𝑒𝑑 𝑎𝑠 𝑎 𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑝𝑒𝑟𝑓𝑜𝑟𝑚𝑎𝑛𝑐𝑒 𝑟𝑎𝑡𝑒 "a" 
𝑎𝑠 𝑓𝑜𝑙𝑙𝑜𝑤: 
∀ 𝑎 ∈ [0,1],    ∃ 𝑥 ∈ {1, 2, 3, 4, 5}   𝑓: 𝑎 →  𝑓(𝑎) = 𝑥, 𝑎𝑛𝑑 𝑖𝑠 𝑛𝑜𝑡𝑒𝑑:  𝑙𝑥 = 𝑓(𝑎) = 𝑥   
𝑤ℎ𝑖𝑐ℎ 𝑖𝑠 𝑟𝑒𝑎𝑑 𝑎𝑠 𝑓𝑜𝑙𝑙𝑜𝑤𝑠: 𝐺𝑖𝑣𝑒𝑛 𝑎 𝑝𝑒𝑟𝑓𝑜𝑟𝑚𝑎𝑛𝑐𝑒 𝑟𝑎𝑡𝑒, 𝑤𝑖𝑡ℎ 𝑎 ∈   [0, 1], 𝑡ℎ𝑒𝑟𝑒 𝑖𝑠 𝑎  
𝑛𝑎𝑡𝑢𝑟𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑥 𝑏𝑒𝑙𝑜𝑛𝑔𝑖𝑛𝑔 𝑡𝑜 {1, 2, 3, 4, 5}; 𝑠𝑢𝑐ℎ 𝑡ℎ𝑎𝑡   𝑙𝑥 𝑖𝑠 𝑎 𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑟𝑎𝑡𝑒 
"a" 𝑎𝑛𝑑 𝑖𝑠 𝑒𝑞𝑢𝑎𝑙 𝑡𝑜 𝑥.  𝑇ℎ𝑒𝑟𝑒𝑓𝑜𝑟𝑒, 𝑡ℎ𝑒 𝑓𝑜𝑙𝑙𝑜𝑤𝑖𝑛𝑔 𝑖𝑠 𝑣𝑒𝑟𝑖𝑓𝑖𝑒𝑑:  
 
𝑎 ∈   [0, 0.5[ ,        𝑙1 =  𝑓 (𝑎) = 1 = 𝑙𝑒𝑣𝑒𝑙1 = 𝑃𝑜𝑜𝑟−→ 𝑀𝑜𝑑𝑙𝑒 𝐵𝑎𝑑𝑙𝑦 𝑎𝑙𝑖𝑔𝑛𝑒𝑑;  
𝑎 ∈   [0.5, 0.60[ , . 𝑙2 =  𝑓 (𝑎) = 2 = 𝑙𝑒𝑣𝑒𝑙2 = 𝐹𝑎𝑖𝑟−→ 𝑀𝑜𝑑𝑙𝑒 𝐹𝑎𝑖𝑟𝑙𝑦 𝑎𝑙𝑖𝑔𝑛𝑒𝑑;  
𝑎 ∈   [0.60, 0.80[ ,  𝑙3 =  𝑓 (𝑎) = 3 = 𝑙𝑒𝑣𝑒𝑙3 = 𝐺𝑜𝑜𝑑−→ 𝑀𝑜𝑑𝑙𝑒 𝐴𝑙𝑖𝑔𝑛𝑒𝑑 ;  
𝑎 ∈   [0.80, 1[ ,       𝑙4 =  𝑓 (𝑎) = 4 = 𝑙𝑒𝑣𝑒𝑙4 = 𝑉𝑒𝑟𝑦 𝐺𝑜𝑜𝑑−→ 𝑀𝑜𝑑𝑒𝑙 𝑆𝑡𝑟𝑜𝑛𝑔𝑙𝑦 𝑎𝑙𝑖𝑔𝑛𝑒𝑑 ;  
𝑎 = 1,                        𝑙5 =  𝑓 (𝑎) = 5 = 𝑙𝑒𝑣𝑒𝑙5 = 𝐸𝑥𝑐𝑒𝑙𝑙𝑒𝑛𝑡−→ 𝑀𝑜𝑑𝑒𝑙 𝑃𝑒𝑟𝑓𝑒𝑐𝑡𝑙𝑦 𝑎𝑙𝑖𝑔𝑛𝑒𝑑.  
𝑤ℎ𝑒𝑟𝑒 1, 2, 3, 4, 𝑎𝑛𝑑 5 𝑎𝑟𝑒 𝑣𝑎𝑙𝑢𝑒𝑠 𝑎𝑠𝑠𝑖𝑔𝑛𝑒𝑑 𝑡𝑜 𝑙𝑒𝑣𝑒𝑙1, 𝑙𝑒𝑣𝑒𝑙2, 𝑙𝑒𝑣𝑒𝑙3, 𝑙𝑒𝑣𝑒𝑙4 𝑎𝑛𝑑  
 𝑙𝑒𝑣𝑒𝑙5 𝑟𝑒𝑠𝑝𝑒𝑐𝑡𝑖𝑣𝑒𝑙𝑦, 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑔 𝑎 𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑡ℎ𝑒 𝑙𝑒𝑣𝑒𝑙 𝑜𝑓 𝑎𝑙𝑖𝑔𝑛𝑚𝑒𝑛𝑡 𝑎𝑛𝑑 𝑡ℎ𝑒 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 "𝑎". 
Function 1. Alignment Function Model (AFM) creates a class function for the model 





 The Notion of “intelligent - fit”  
 
The notion of “intelligent - fit” developed allowed the author to define other major criteria for 
judging the model’s fitness for purpose, since it allows the model created to be fit for purpose 
and ‘intelligence’ simultaneously, and hence the reason for the name: “intelligent - fit”.  
Meeting the model development criteria are conditions for it to be fit for purpose. In addition, 
the model should be intelligent, and this can be achieved by reducing the number of steps 
towards the final result, and most importantly improvements in its performance. This definition 
will be set as main criteria for judging the efficacy of the intelligent model developed. 
Therefore the notion of “intelligent fit” noted “IF” could therefore be presented as a function 
of the number of steps to get to the final result in modelling, the speed of the process and the 
alignment level between the technology and the task performed. Thus “IF” can be expressed:  
 
 
"f" = "𝐼𝐹"  , 𝑓 =  𝑓(𝑛, 𝑣, 𝑎);  𝑤ℎ𝑒𝑟𝑒, 𝑛 𝑖𝑠 𝑡ℎ𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑡𝑒𝑝𝑠 𝑡𝑜𝑤𝑎𝑟𝑑𝑠 𝑡ℎ𝑒 𝑓𝑖𝑛𝑎𝑙  
𝑟𝑒𝑠𝑢𝑙𝑡, 𝑣 𝑡ℎ𝑒 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑠𝑝𝑒𝑒𝑑 𝑡ℎ𝑎𝑡 𝑖𝑠 𝑡ℎ𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑛 𝑜𝑓 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑝𝑒𝑟 𝑠𝑒𝑐𝑜𝑛𝑑 𝑡(𝑠), 𝑎𝑛𝑑 𝑎 𝑡ℎ𝑒 
𝑚𝑜𝑑𝑒𝑙 𝑝𝑒𝑟𝑓𝑜𝑟𝑚𝑎𝑛𝑐𝑒 𝑟𝑎𝑡𝑒.  𝑇ℎ𝑒𝑟𝑒𝑓𝑜𝑟𝑒;  𝑔𝑖𝑣𝑒𝑛 𝑎 𝑚𝑜𝑑𝑒𝑙 𝑀𝑖  𝑚𝑒𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑙𝑎𝑠𝑠 𝑜𝑓 𝑀𝑜𝑑𝑒𝑙 𝑀,  
𝑡ℎ𝑒 𝑓𝑖𝑡𝑛𝑒𝑠𝑠 𝑓𝑜𝑟 𝑝𝑢𝑟𝑝𝑜𝑠𝑒 𝑐𝑎𝑛 𝑏𝑒 𝑤𝑟𝑖𝑡𝑡𝑒𝑛/𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑒𝑑:  
∀ 𝑀𝑖  ⊂  𝑀,   𝑀𝑖  𝑖𝑠 "f" = "𝐼𝐹"    /     𝑓 =  𝑓(𝑛, 𝑣, 𝑎) 𝑎𝑛𝑑  𝑀𝑖 = 𝑀𝑚𝑎𝑥 , 𝑤ℎ𝑒𝑟𝑒   




 =  𝑣𝑚𝑎𝑥  ,   𝑖𝑓:  
  1).  𝑛 =  𝑖𝑛𝑐𝑟𝑒𝑎𝑠𝑒𝑠, 𝑎𝑛𝑑 𝑡 → 0, 𝑜𝑟 
                           2).   𝑛 = 𝑖𝑛𝑐𝑟𝑒𝑎𝑠𝑒𝑠, 𝑎𝑛𝑑 𝑡 = 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡𝑒 ≠ 0 𝑜𝑟,  
3).   𝑛 = 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡𝑒, 𝑎𝑛𝑑 𝑡 → 0.     
𝑁𝐵:𝑂𝑛𝑙𝑦 𝑡ℎ𝑒 𝑐𝑎𝑠𝑒 3) 𝑤ℎ𝑒𝑟𝑒 𝑛 = 𝑐𝑡𝑒 =  𝑚𝑖𝑛𝑖𝑚𝑢𝑚, 𝑎𝑛𝑑 𝑡 → 0   
𝑟𝑒𝑠𝑝𝑜𝑛𝑑 𝑡𝑜 𝑡ℎ𝑒 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 𝑐1 𝑑𝑒𝑓𝑖𝑛𝑒𝑑 𝑎𝑏𝑜𝑣𝑒.  
 
Function 2. The IF is defined as a function of the number (n) of steps toward the final result, 
the process speed (v) and the model performance rate (a), where the performance rate is 
equivalent to the level of alignment.  
 
When a model meets IF conditions, the model developed fulfils the IF criteria; therefore, it is 




validation. The number of loops and the value of the threshold to be introduced will depend on 
the project, which will ultimately enable determination of the quality of the IF.  
 
Based on what precedes, a model will be defined as “intelligent-fit” if the number of steps 
taken to gain the best performance is reduced to the minimum, using the optimal algorithm. 
Therefore, the more intelligent the model, the higher the threshold, the faster the task is 
performed, and the better the alignment is. For this purpose, a process flowchart is presented 
below (Figure 2) explaining the different steps involved in using the ITTFM throughout this 
research, given that it can be generalised and applied elsewhere. The process flowchart below 
provides details regarding the overall modelling process, including the steps from the raw data 




n loopings noted L1, L2, L3, L4,…, and Ln show the potential of the modelling process to be 
designed to perfection, with the researcher having to re-start the process which is not meeting 
the validation criteria. Looping can re-start to higher level, i.e. L2 can go back up to S1 instead 
of S4. In addition, thresholds could be set for several steps to be validated. This encompasses 
steps S2, S5, S9, and S14.  
 





Samples Separation Analysis 
Using Criteria mo
Is samples Prepared met Criteria m=mo
Data Conditioning  
Is Data Conditioned meet Criteria V=Vo 
Data Conditioned Analysis 
Using Criteria V
Data Preparation for 
NMR Spectrometry
1D NMR Processor
NMR Spectrometry – Fid Extraction
Data Cleaning and Formatting
Features Selection
SVA Visualisation -                    
OSVM Classification – 
PCR Classification – Visualisation - 
Regression & Ranking 
Results Analysis Using 
Performance r
Results Validation    
Uncompleted
   








































Figure 2.  Process Flowchart and the step by step tasks for completion from the raw data 
collection, the biomarker discovery process and the pathway analysis. Overall, this shows how 
the IMP can be used to make the decision process more rational.  
 
The process flowchart for biomarker discovery and the process sequence analysis presented 
above is said to be intelligent, because the model developed can re-assess itself and hence 
improves the performance value r, with r0 being a threshold value in the development process. 




includes some levels of flexibility, with the possibility of having more than one loop that is as 
much as necessary for the model to achieve maximal perfection. Different values (selected 
constants) have been employed in the sequence flow diagram and for this research, the constant 
mo is the mass of the blood plasma samples; while constant Vo the volume of blood plasma 
utilised for 1H NMR process: i.e. Vo = 5ml.  
 
Assuming that the IMP model performance is set to r = r0 = a = 0.8, i.e.  level 4, and a very 
high alignment of the model with the task to complete, which involves biomarker discovery 
for the NPC1 and the NPC LDD datasets. Therefore, for a given model developed, acceptance 





The validation stage could be combined with the ITTFM and its alignment model. However, 
this validation stage within the intelligent modelling process (IMP) is in line with the validation 
technique further discussed below.  
  
Subsequently, an algorithm that allows the monitoring and validation of the different steps of 
biomarker discovery related to the IMP was developed. The example chosen here is related to 
blood plasma collected from NPC1 disease patients. Therefore, the IAD is used to validate the 
overall process involving data analysis and biomarker discovery. The algorithm even 
introduces the validation process of the biomarker(s) discovered and can be useful, ensuring 
that the entire process follows or is conducted according to standards. This process may give 
rise to improvements in the quality of biomarkers discovered. The different steps are marked i, 
where i is the step or the level. Hence, i = 1 is the starting level or 1st step corresponding to the 
raw sample preparation, i=2 the second step corresponding samples separation analysis,   i = 3 
the third step corresponding to the samples prepared and criteria m = m0, etc. More steps can 
be added or removed from this process, depending on how the whole process is structured, i.e. 








 Intelligent Algorithm Design (IAD) for Biomarker Discovery and Validation  
 
The intelligent algorithm design is related to the steps involved in the independent statistical 
validation of the biomarkers discovered in this work. Researchers have demonstrated that 
predictive biomarkers for the possible response of patients to given treatments can be validated 
using extensive data, while prognostic biomarkers are related to existing diseases or to disease 
progression (Aronson, 2005; Buyse et al., 2010). They have also noted that whenever it is not 
possible to achieve statistical validation in view of requirements constraints, then surrogate 
end-points (i.e. substitute biomarkers) that call for a clinical validation may be applied. 
However, these researchers emphasised that there is no real consensus in the standards and 
processes to follow up regarding the statistical adoption of biomarkers (Buyse et al., 2010;  Fan 
et al., 2013a; Rifai et al., 2006).  
 
The technique proposed in this thesis is based on the process conducted during the experimental 
stages, and the results obtained during the analysis process. It should also be noted that the 
analysis stage 1 has included the scalar visualisation algorithm (SVA) and the support vector 
machine (SVM) techniques which could be performed separately. The same principle applies 
to the principal component regression (PCR) step. However, since the latter determinant 
position in the potential biomarker discovery, the PCR stage has been presented as a separate 
stage after performing visualisation and classification on the datasets. Depending on the 
manner in which researchers conduct their work, including independent statistical validation 
strategies, several options are available, and the algorithm presented below employs one of 
these differing possibilities.  
 
 





































Algorithm 1. Steps involved in the Intelligent Algorithm Development (IAD) for biomarker 
discovery and the independent validation process. The different steps involved can be modified 
depending on the way the research is conducted. In step 24, the researcher might decide to go 
back to step 15 to detect more potential biomarkers or just re-start the miglustat treatment/test 
in step 22. 
 Frame 1 
1. Select NPC1 disease / NPC LDD patients 
2. Collect blood samples / liver extract samples 
3. Store blood / liver samples in vials for conditioning 
4. Perform blood separation (plasma)/liver samples extraction 
5. Measure volume v of plasma/liver extract 
6. Is v = v0? 
7.  {
−𝐼𝑓 𝑌𝑒𝑠 𝑔𝑜 𝑡𝑜 𝑠𝑡𝑒𝑝 8
−𝐼𝑓 𝑁𝑜 𝑔𝑜 𝑡𝑜 𝑠𝑡𝑒𝑝 2
 
8. Apply NMR spectroscopy 
9. Generate Spectra 
10. Is spectra high quality Q = Q0? 
11. {
−𝐼𝑓 𝑌𝑒𝑠 𝑔𝑜 𝑡𝑜 𝑠𝑡𝑒𝑝 12
−𝐼𝑓 𝑁𝑜 𝑔𝑜 𝑡𝑜 𝑠𝑡𝑒𝑝 8
 
 12. Use 1D NMR processor and generate fid 
13. Clean, format, and convert fid files to excel files 
14. Apply features selection   
15. Perform data analysis (1) = {SVA/OSVM}  
16. Assess performance using the ratio r: Is r ≥ r0 = a = 0.80 
17. Validate results: Are potential biomarkers visualised / level of 
classification result (excellent, good,..)? 
18. {
−𝐼𝑓 𝑌𝑒𝑠 𝑔𝑜 𝑡𝑜 𝑠𝑡𝑒𝑝 19
−𝐼𝑓 𝑁𝑜 𝑔𝑜 𝑡𝑜 𝑠𝑡𝑒𝑝 15
 
19. Perform data analysis (2) = {PCR} 
20. Is potential Biomarker discovered? 
21. {
−𝐼𝑓 𝑌𝑒𝑠 𝑔𝑜 𝑡𝑜 𝑠𝑡𝑒𝑝 22
−𝐼𝑓 𝑁𝑜 𝑔𝑜 𝑡𝑜 𝑠𝑡𝑒𝑝 19
 
22. Administer miglustat as established drug for treating NPC1 disease. 
23. Has concentration in biomarker1… biomarker (i) decreased? 
24. {
−𝐼𝑓 𝑌𝑒𝑠 𝑔𝑜 𝑡𝑜 𝑠𝑡𝑒𝑝 25
−𝐼𝑓 𝑁𝑜 𝑔𝑜 𝑡𝑜 𝑠𝑡𝑒𝑝 15/22
 
25. Validate biomarker1… biomarker (i)  




Following this extensive development of the ITTFM, the next step deals with the research 
method used to support the present research project. 
 
3.3. Research Methods  
 
3.3.1. Notion of Research Methods 
Research methods are different steps necessary to conduct the research process, whilst others 
consider them as a set of tools, techniques, or a component of research driven by procedures 
necessary for the collection and analysis of data (Clough and Nutbrown, 2012; Gabriel, 2011; 
McGregor and Murnane, 2010). In this thesis, the notion of research method is related to the 
techniques and procedures used in data collection especially data pre-processing and data 
analysis, which are in turn determined by the methodology applied (McGregor and Murnane, 
2010; Wahyuni, 2012).  
 
Two types of datasets were used during this process, and the data collection methods 
implemented involved in both cases a fieldwork, which was not performed by the author of 
this thesis, and a laboratory-based research work task. Raw data collected in the first fieldwork 
were those arising from blood plasma samples collected from NPC1 disease patients, and in 
the second case liver extract samples obtained from mice; these were in both cases further 
processed prior to data analysis. Therefore, data pre-processing related to 1H NMR 
spectroscopy and 1D NMR processor was conducted. Moreover, noise, etc. was removed from 
such datasets. The features were labelled as NPC1 and WT (wild treated) for NPC1 and NPC 
LDD study.  
 
For these reasons, the research methods that best suits this project is the quantitative research 
method. Several reasons have guided the choice for the research model, and they are been more 
detailed below.  
 




The experimental method was selected according to several rationales that are highlighted as 
follows. Firstly, the research project itself was a succession of empirical works. In reality, two 
parallel experimental processes were conducted throughout this research programme, and in 
terms of the logic and the rationale, they are consistent with the methods chosen. Data sources 
included the collection of data from NPC1 disease patients in the hospital in the National 
Institute of Health Clinical Centre in Bethesda, Maryland (USA). Secondly, datasets employed 
were all quantitative data, which were based on measurements. For example, raw data collected 
from NPC1 disease patients (blood plasma samples) or liver biopsy samples collected from 
experimental animals (mice) analysed via NMR spectroscopy and its associated 1D NMR 
processing software (McGregor and Murnane, 2010). Thirdly, the use of logical and more 
structured steps for data collection, which includes employing the software-based technique to 
generate finalised datasets (Bryan, 2004). In addition, data analysis proceed through structured 
and more controlled processes, and these included sample selection, feature selection, stratified 
cross-validation processes and the use of multiple logistic regression (MLR) as one of the data 
analysis techniques, etc.  
 
Now that the term research method has been linked to the data collection process, an 
explanation on how the data collection steps were implemented is given. Moreover, sampling 
techniques are, of course, very important steps during data collection; these data were acquired 
by a collaborative research team, but for more clarity these steps are succinctly investigated in 
the next section.  
 
3.4. Sampling Techniques  
3.4.1. Introduction 
A sample is a smaller but representative collection of units from an accessible population that 
is used to determine knowledge or truths about the population under study, and it should be 
free from any bias (Field, 2005; Kumar, 2011).  
 
Equally important, are the sample selection techniques that assist the selection of a sufficient 
number of samples representative of the study population. Indeed, they allow the learning 
algorithm to become more accurate, reducing the search space, the time spent in training it, and 




                                 
There are different methods available to perform sample selection. Several options are 
presented below, while emphasising on the sample selection applied in this research project.  
 
3.4.2. Sampling Techniques  
There are two main sampling techniques, including probabilistic and the non-probabilistic 
samplings, whilst a possible third technique exists as a combination of these two approaches. 
Probabilistic sampling includes, amongst others, simple random sampling where each sample 
is given the equal opportunity of being chosen. This technique reduces bias related to sampling, 
ensuring that the sample selected is a true representation of the population of study (Blackstone, 
2012). Another probabilistic sampling technique is the cluster sampling that randomly selects 
n clusters, and the samples within each cluster are randomly selected with equivalent 
probabilities (Blackstone, 2012; Grand Canyon University, 2015; Kumar, 2011; Sandelowski, 
2000).   
 
The non-probabilistic sampling techniques are mostly used for informal non-scientific 
research. They have not been used in this research, and as such will not be further investigated. 
Therefore, only probabilistic sampling techniques were used with the random clustering 
applied to biomedical datasets in order to reduce bias and make statistical inferences (Kumar, 
2011; MEDICI, 2004; Sandelowski, 2000). 
  
The correct implementation of the random sampling methods should allow researchers to make 
a sound prediction, to obtain reliable results that can be generalised with regards to the research 
findings. This, in turn, might pave the way towards successful data analysis, and bring the 
researcher close to the research objectives’ achievement in respect to finding relevant 
biomarkers in the NPC1 disease diagnosis, since good quality data generates an effective data 
analysis  (MEDICI, 2004; van Gulik, 2010). Below are provided more detailed justifications 
of the reasons that commanded the use of some of the techniques while choosing these samples.  
 




Sample selection is extremely important in the data dimensionality reduction, in that it reduces 
the number of samples to be considered. Hence, reducing the processing, training time and the 
learning time for the algorithms utilised, and more importantly the cost of the overall process  
(Li et al., 2015). 
 
Probabilistic sampling techniques, including random sampling and combination cluster random 
sampling were chosen to reduce bias related to sampling since each sample is given equal 
opportunity to be selected, i.e. equal probability of selection: EPS (Kumar, 2011). In addition, 
selecting samples in such a manner that they become truly representative of the population of 
study, positively influence the quality of metabolomics studies, helping in the generalisation of 
the results obtained, but more importantly drawing meaningful inference from the data analysis 
applied (Kumar, 2011; LASER, 2000; van Gulik, 2010; Vuckovic, 2012).   
 
After applying relevant sample selection techniques in order to improve data analysis quality, 
the challenges faced during this research are now noted.  
 
3.5. Research Study Challenges  
 
This literature review shows that different studies were carried out for the purpose of biomarker 
discovery in diseases research in general, and also NPC1 disease and its more severe form 
related to liver dysfunction in particular.  The lack of reliable biomarkers to trace the disease 
during the evolution phases remains a challenge (Fan et al., 2013). Furthermore, it is believed 
that more quality research needs to be conducted to address the lack of relevant biomarkers. In 
this study, challenges faced in research related to NPC1 disease diagnosis are highlighted.    
 
3.5.1. Challenges of the Double Research Study 
Different challenges were to be faced during this thesis. Among others were the following; 
 
1). Typically, biomarkers discovery by the mean of computational intelligent technologies 
(CITs) in this Ph.D. project, is one of the main ways to inter-relate technology and medicine in 




focuses on the pathway follows by biomarkers for an insight into the diseases etiology, 
especially the NPC1 disease and the related liver dysfunction disease. Hence, CITs will be the 
tool helping for instance in measuring the probability of relating a given feature and the NPC1 
disease progression (Fan et al., 2013).  
 
2). Another challenge was to combine three main algorithms on the same objective and purpose 
of detecting biomarkers in disease diagnosis. The complexity being related to the ability of 
making sense of the different algorithms and techniques working together for a common goal.  
 
3). Additionally, finding the same biomarkers or different biomarkers which can work together 
in understand the NPC1 disease etiology was another level of the challenge. Therefore, a lot of 
apprehension in the beginning of this research on how to make all this to work successfully 
was the main worry. 
 
Nevertheless, what was considered at the start of this research as a challenge, quickly became 
one of the main reasons for implementing this current project. The possibility of finding 
biomarkers based on the diseases features to explain their progression and underlying causes 
make it very important to develop on top of the models, the features ranking strategy that was 
not in the agenda, i.e. the starting plan.   
 
Finally, it was a real challenge at the beginning of this project to carry out research on disease 
diagnosis and especially, combining the NPC1 disease diagnosis and measuring the disease 
severity like the effect on the patient’s liver. Although the two levels of research being 
dependent and strongly related to one another (same disease), adding to the fact that the same 
data modelling technique was applied to both datasets and having the biomarkers discovery as 
common objectives, the challenge remains because the research in disease was different from 
my original field of research in technology.  
 
 The data modelling technique used in this research also termed intelligent tri-modelling 
technique (ITMTs) encompasses the use of SVA for data visualisation; SVM for simple 
classification and prediction; and finally, PCR for classification and probabilistic prediction; 





The Diagram below gives a general overview of the current and the future research, with the 
use of the same technological tools in the disease research; while biomarker discovery was 
bridging the gap between technology and medicine. The ITMTs  allowing to detect different 
biomarkers, with biomarkers (1) for NPC1 disease diagnosis and biomarkers (2) for the 
diagnosis of the severe form of the disease related to liver damage. However, the future 
research will attempt to unify these biomarkers into biomarkers (3) = biomarkers (1) + 
biomarkers (2) discovery, that is aiming to find a unique biomarker noted biomarker (3) which 







    INTELLIGENT METHODOLOGY in BIOMARKERS DISCOVERY
Bridging: 











Figure 3. Intelligent methodology for biomarker discovery, bridging the biomedical and 
technological research projects. Research to be performed on the improvement of biomarkers 
discovery and drug-targeting is reserved for future studies. The intelligent methodology will 
help in bridging the gap between the disease diagnosis and the drug development in the NPC1 
disease study.  
 
3.5.2. Challenges in Biomarker Discovery for NPC1 Disease Diagnosis 
Research in disease diagnosis, in general, and particularly the area of biomarker discovery, has 
brought a lot of excitement and enthusiasm within the research community. Many practitioners 





1) The ubiquitous computer and the related computerised systems have made it possible to 
generate a large amount of data as a result of metabolisms, which carry a lot of substantial 
information (Tzoulaki et al., 2014). Metabolomics and Metabolite profiling studies allow us to 
gain access to endogenous information in disease research. However, to date, the detection of 
biomarkers has not provided the “magic solution” for disease diagnosis which the research 
community expected. The reason being that biomarkers discovered could not reveal, uncover 
the “black-box” of occurrences at the molecular and endogenous level. This is valid for disease 
research, especially NPC1 disease. These have been linked to several explanations, including 
the poor level of information obtained from different biomarkers so far discovered (Fan et al., 
2013).  
 
2) Another level of challenge resides in the validation method of the research results, especially 
for biomarkers discovered in the NPC1 disease. For instance, it was noted that sphingolipid 
classes could be used as relevant biomarkers for NPC1 disease ((Fan et al., 2013).  However, 
ensuring that new biomarkers carry more trusted information than the precedents so far 
discovered still represents a challenge. 
  
3) A further challenge is related to the discovery of an adequate treatment to combat the NPC1 
disease, as to date, only an alternative treatment is available. Indeed, miglustat (OGT 918, N-
butyl-deoxynojirimycin) is a substitute treatment for the NPC1 disease and is approved in the 
UK and the USA. Typically, miglustat is directed to the inhibition of the synthesis of the 
glycosphingolipid, and as such can be used as a substitute to treat NPC1 disease patients (Fan 
et al., 2013).   
 
4) The challenge attributable to the high expectation of finding appropriate treatments, is 
clearly related to the finding of appropriate, effective, and reliable new biomarkers for NPC1 
disease treatment. The limited number of study subjects has affected the development of the 
method in the quest of new and appropriate treatments for those suffering from rare diseases, 
especially research based on clinical trials.  
 
5) The reduced number of available patients to follow through the treatment process which can 
be prolonged, combined with the clinical outcomes’ reliability, and its quantification which 




patients, in view of different factors, such as symptoms difficult to identify, or patients unaware 
of their condition, etc., issues that need to be addressed (Fan et al., 2013). This has increased 
the pressure on researchers to come up with new techniques for monitoring NPC1 disease, 
including reliable quantification techniques for clinical trials focused on biomarker discovery.  
 
Therefore, CITs’ support in finding an improved response to NPC1 disease diagnosis is 
required, and this research attempts to provide an answer to this problem. Another level of 
challenge in this study was the possible outcomes of the research.  
 
3.6. Possible Outcomes of the Study 
Two main types of outcomes were possible for this research, this encompasses both expected 
and unexpected outcomes. More detailed explanation in this regard follows below. 
 
3.6.1. Expected Outcomes 
As expected outcomes, different possibilities were available for this research study and 
depending on the way the research was planned and conducted, the objectives were hence 
achieved. The expected outcomes are below listed: 
1) The discovery of new biomarkers related to NPC1 diseases diagnosis; 
2) The discovery of new biomarkers related to NPC liver dysfunction disease (NPC LDD), i.e. 
the severe form of the NPC1 disease; 
Some of the unexpected outcomes of this project are also noted below. 
 
3.6.2. Unexpected Outcomes 
Different unexpected outcomes were produced during this research project. This includes, 
1) The higher number of mathematical models developed to improve the current research 
process. This encompasses the Intelligent technology task fit model (ITTFM), and the 
Intelligent Modelling Processes (IMP) for biomarker discovery and validation. 
2) The consequent high number of algorithms developed to support this research project. This 
includes the Alignment Function Model (AFM) creating a class function for model alignment, 




validation process, and finally, the Intelligent Methodology for Biomarkers Discovery bridging 
the Biomedical and the Technological Research Projects. 
Finally, after this presentation of the possible outcomes expected or unexpected in the present 
chapter, the next section gives a summary of this methodology chapter.  
 
 
3.7. Chapter Summary 
 
In this chapter, the chosen research approach, theory and methods are presented, and they 
supported the intelligent modelling processes (IMP) for biomarker discovery and validation. 
Thus, a quantitative research approach using empirical research method for such several 
reasons; including using quantitative data for research in biomedical, for research repeatability, 
reproducibility, replicability and reliability. Subsequently, the intelligent technology task fit 
model (ITTFM) was developed for matching the intelligent technologies to the tasks to be 
performed, such as improving biomarker discovery success. Moreover, several models and 
algorithms were developed to ease and structure the whole research methodology and research 
process. Furthermore, research challenges were highlighted, such as the challenge to validate 
the research methods and the results obtained. Finally, the outcomes of the study were 




















“What you do makes a difference, and you have to decide what kind of difference you want 
to make.” 
 
 Jane Goodall 
  
4. RESEARCH DESIGN  
 
4.1. Introduction  
 
The previous chapter presented the methodology adopted throughout this research. Hence, the 
use of quantitative techniques as suitable research approaches was justified, followed by a well-
detailed presentation of the intelligent technology task fit model (adopted from the Goodhue 
and Thomson (1995) task-technology fit model). This was completed by an explanation and 
justification of the research model adopted. In this manner, the experimental research method 
was confirmed as a suitable one for the present thesis. Moreover, the sampling techniques 
employed were visited to understand how achieving data dimensionality reduction could be 
decisive in data analysis, especially when a large amount of data becomes available thanks to 
high-throughput technology such as NMR spectroscopy. Furthermore, the different challenges 
faced during this study were highlighted, followed by the possible outcomes.  
 
 Vaus and Vaus (2001) considered research design as the step of structuring a research work in 
general, and particularly a scientific work undertaken by researchers, in order to help them to 
look for answers to research questions.  They argued that research design is about the logical 
structure supporting the research study, helping researchers to plan and answer the research 
questions unambiguously. Therefore, it is necessary to identify the correct and suitable 
evidence that will support and shape the way to answer these questions. Hence, the way in 
which the research is structured and designed will depend on the fieldwork, and the empirical 





Research design is defined as a detailed outline of the way an investigation can be conducted. 
Typically, it includes data collection techniques, the necessary research tools employed, and 
finally the different means available for data analysis (Wyk, 2012).  
 
The research design is the central component of the scientific inquiry, which allows the 
researcher to conduct a study in a way that reduces bias, distortion, random errors, error 
variance due to noise, and deals with the logical rather than the problem logistic (Nwankwo, 
2004;  Yin, 1989). Therefore, planning the set of logical procedures within scientific inquiry, 
are core, and help the researcher to obtain valuable data, or empirical evidence regarding 
isolated variables that are indispensable in conclusive inference about the constructs of the 
research questions. Consequently, certain researchers believe that the best research design is 
the one that best suits a particular problem at a given time (Heppner et al., 2007).  
 
This research design chapter is organised as follows: Section 1) is an introduction to the 
chapter; Section 2) focuses on the mixed experimental research method that combines 
fieldwork and the lab-based research; Section 3) discusses data collection techniques and tools; 
Section 4) attends to data analysis techniques; Section 5) discusses the research validation 
processes; and finally, section 6) summarises of the research design chapter.  
 
The next section to investigate is the mixed experimental research method, which is used to 
collect data required to address the aforementioned issues, including the pertinent research 
questions.    
 
4.2. The “Mixed Experimental” Research Method  
     
4.2.1. Introduction 
The research method employed for this study corresponds to a “mixed experimental” research 
method. Several reasons support the use of this term. For example, a fieldwork was necessary 
to collect biofluid data samples in the United States of America. The blood sample collection 




Maryland, USA. On the other hand, the NPC liver dysfunction disease (NPC LDD) dataset 
collection was performed at the University of Oxford, UK. For more clarification on the 
different steps of the mixed-experimental research method, the present sub-section 
encompasses an introduction and a more detailed analysis of the “mixed experimental” 
research method.  
 
 4.2.2. The “Mixed-Experimental” Research Method  
The research method employed in the current Ph.D. thesis is termed as “mixed experimental” 
research method because it combines a fieldwork and a laboratory-based research method. This 
combined research approach is used to collect the entire data utilised in the current research 
project.  
 
Regarding the biomedical data related to human blood plasma samples, they were collected 
from NPC1 disease patients and healthy control individuals under hospital settings, in the 
National Institute of Health Clinical Centre in Bethesda, Maryland (USA), by an American 
research team. The blood samples were then sent to Oxford University (UK), where it was 
finally turned into Excel files used in this thesis as part of the datasets involved in the current 
multivariate analysis.  
 
The dataset associated to the NPC liver dysfunction disease (NPC LDD) was obtained from 
NPC liver dysfunction associated with this disease in a mouse model. The collection performed 
at Oxford University where mice were bred and housed under standard sterile conditions. A 
mutant mouse model of the NPC on a BALB/C was employed. The cohort encompasses NPC1 
mutants, controls and the NPC1 heterozygous mice that were generated from the heterozygote 
mating. More detailed clarifications on the different stages mentioned above are given in the 
data collection session, while the rationale in using the mixed-experimental research method is 
highlighted below. 
 
 Rational of the “mixed-experimental” research methods 






 Based on fieldworks: 
 With regards to the first series of experimental research conducted, a team of 
researchers from the National Institute of Health Clinical Centre in Bethesda, Maryland, 
USA gathered the relevant data. This includes, the collection of blood samples from 
NPC1 disease patients and healthy control individuals.   
 
 The second series of research-based biomedical study corresponds to the collection of 
set of data related to the NPC liver dysfunction disease (NPC LDD) samples. Mouse 
liver extracts were collected at Oxford University UK, by research group and following 
the protocol approved by the UK Animals Scientific Procedures Act 1986.   
 
 The author of this thesis was not directly involved in these stages of the research related 
to the fieldwork. For this reason, no ethical issues were directly tackled in this thesis, 
especially those related to the blood samples collection from human participants and 
tissue collected from animals. However, these ethical requirements were confirmed by 
the research teams involved in the fieldwork.  
 
 Related to the laboratory-based research  
 The first laboratory-based research is related to the NPC1 disease study. The blood 
samples previously collected in the USA were further processed by team of researchers 
in the University of Oxford. The plasma samples separated from the serum in the blood 
specimen in a laboratory-based research, were used to produce NMR spectra using 1H 
NMR spectroscopy technique, which in turn allowed to finally generate the biomedical 
datasets.  
 
 The second laboratory-based research is related to sample collection from NPC liver 
dysfunction associated with this disease, which was performed on a cohort of NPC1 
mutants, controls and the NPC1 heterozygous mice obtained from the heterozygote 
mating. A portion of the liver sample was weighed with an ice-cold extraction solvent 
that includes 1:1 of H2O:CH3CN with an equivalent of 20µL per mg of tissue. After 
homogenising mixture of solvent - tissue using an electric pestle rotor, and the 
homogenates obtained were centrifuged for 10 minutes at 4 0C at 10,000 x g. Hence, 1 




chloroform (D2O) containing 5.10
-2 sodium 3-trimethylsilyl-(2,2,3,3-2H4)-1-propionate 
(TSP) and 50 µL of a 1 M solution of phosphate buffer (pH=7). Finally, before taken 
to NMR analysis, the samples were centrifuged and rota-mixed for 5 minutes at 5,000 
x g at laboratory temperature, where the supernatants were transferred into NMR vials 
(5 mm) (Ruiz-Rodado et al., 2014). 
 
 Based on the use of metrics - Quantitative data  
 The laboratory-based research involved different processes such as blood plasma 
separation, NMR spectroscopy, in order to generate NMR data, define metrics, 
measurement, tests, etc., performed through stages that are normal steps involved in a 
typical experimental research strategy. Combined with relevant strategies for data 
collection, repeatable measurement steps were included in this research project (Bryan, 
2004; Ross and Morrison, 1996). 
 
 The final dataset used in this research are quantitative data for biomedical research. 
Through high-throughput technology such as NMR spectroscopy, large sets of data 
were generated in the laboratory-based experimental research with a systematic, 
repeatable and scientific approaches that help to build a reliable and more accurate 
model. These steps are in line with the experimental research method (Guo and 
Sheffield, 2006; Ross and Morrison, 1996).  
 
 Converting the final NMR data (spectra) into numerical data was performed using 
software like the NMR spectrometer and the 1D NMR processor. The use of more 
rationale techniques that make the whole process repeatable, replicable and reliable. 
Indeed, employing techniques such as the intelligent binning, zero filing, baseline 
correction, etc…, allow a research team to reproduce this empirical research, adding to 
the fact that it becomes more reliable. These are criteria related to the logical and 
rational processes supporting the use of experimental research methods. 
 





 Experimental research methods steps were employed to answer the research question 
effectively and to meet the research aims and objectives. This includes the discovery of 
biomarkers.  
 
 However, the use of experimental research methods allows the author to discover the 
major biomarkers for NPC1 disease diagnosis while establishing correlations between 
disease features and the disease presence  (Brown, 2010; Liang and Fang, 2006).   
 
 One should note that in the particular case of this research, different combinations were 
possible during the experiments, giving that different models were compared against 
each other. For instance, with regards to SVM and MLR, the dataset standardisation 
application to the model developed was an option available. In addition, to build the 
model, one of these two kernel functions could be used, i.e. the linear or radial basis 
function (RBF) kernel.  Moreover, the feature selections provide the possibility to 
choose between different options to build different models, and their performances 
were compared against each other. This includes the nearest neighbour for feature 
selection and the option of varying the number of features used. Furthermore, the 
possibility of oversampling the original dataset to correct the issues related to an 
imbalanced dataset was performed by using the ADASYN method that facilitates the 
learning process in the case of imbalanced dataset (He et al., 2008). 
The model improved the detection of biomarkers in both studies that was clearly 
identified and presented.  
 
In conclusion, this research which combines two different types of experimental research 
methods, which are the fieldwork and the laboratory-based research is naturally and logically 
more suited to be term as “mixed-experimental” research methods.   
 
4.3. Metabolomics Data Collection Techniques   
4.3.1. Introduction 
During data collection, the techniques employed will help to determine the quality of data that 




problem (Priyan, 2012). Data collection techniques are key steps in the structure of a research 
study because the result of the research depends on its suitability, which could influence the 
validity of the research undertaken (Pratiwi, 2013).  
 
4.3.2. Data Collection Tools 
Different tools, especially intelligent algorithms were utilised during data collection methods. 
However, it should be noted that the tools exposed in this sub-section including the NMR 




 NMR Spectroscopy as Metabolomics Data Collection Tool 
 
The NMR phenomenon was discovered independently, but concurrently by different groups of 
researchers in 1946. It is related to the study and the application of certain properties of atomic 
nuclei; among which the energy variation, especially when the nuclei is placed in a strong 
external magnetic field, and subjected to Radio Frequency (RF) irradiation. Thus, different 
nuclei will absorb RF energy and resonate at different frequencies in the view of the electronic 
environment surrounding them. This resonance frequency difference compared to the standard 
in the magnetic field, known as chemical shift, implies a different level of energy absorption 
and energy emission (De Graaf, 2007).  
 
NMR spectroscopy is a non-invasive, non-destructive and rapid technique used to study a 
plethora of metabolites contained in various metabolomics samples such as biofluid datasets  
(Siddiqui, 2003). NMR spectroscopy is based on the fact that metabolites nuclei exposed to an 
intense external electromagnetic field 𝐵0⃗⃗⃗⃗ , align their magnetic moment against the field 𝐵0⃗⃗⃗⃗  to 
gain a higher energy state or with the field 𝐵0⃗⃗⃗⃗  to attain a lower one that is overall preponderant 
(De Graaf, 2007; Siddiqui, 2003). However, atomic nuclei absorb energy at different resonance 
frequencies due to the energy variation within their vicinity; therefore nuclei in a lower energy 
state may go to a higher energy state, orienting their magnetic moment against the field    𝐵0⃗⃗⃗⃗      





Consequently, the majority of the 1H nuclei from different clusters samples will go to their 
excitation state corresponding to their higher energy state by absorbing RF energy in the region 
of the spectral frequency interval of [0-10] ppm (parts per million) (Siddiqui, 2003). The 
absorption is followed by energy emission (return to a stable state) in the form of photons. The 
energy E absorbed by the 1H nuclei is proportional to the RF, and can be expressed as follows: 
 
𝐸 = ℎ 𝜈   (𝟏𝟖),𝑤𝑖𝑡ℎ ℎ 𝑐𝑜𝑟𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑖𝑛𝑔 𝑡𝑜 𝑡ℎ𝑒 𝑃𝑙𝑎𝑛𝑐𝑘 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 𝑎𝑛𝑑 𝜈 𝑡ℎ𝑒 𝑅𝐹.   
 
 
𝑇ℎ𝑖𝑠 𝑚𝑒𝑎𝑛𝑠 𝑡ℎ𝑎𝑡  𝐸 𝑖𝑠 𝑎 𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦, 𝑡ℎ𝑎𝑡 𝑖𝑠    𝐸 = 𝑓(𝜈).   (𝟏𝟗) 
 
 
The NMR data so generated are presented as a spectrum, which is a signal representing the 
energy amplitude against the frequency; with the 1H spectrum located in lower and higher 
frequency region 0-10 ppm  (De Graaf, 2007; Siddiqui, 2003). A signal is usually referenced 
from an organic solvent such as the tetramethylsilane (TMS) that is used as a chemical shift 
reference (chemical shift of TMS = 0.00 ppm), or a water-soluble derivative TSP, which also   
appears at 0.00 ppm (Siddiqui, 2003).  
 
At resonance, the intensity of the signal obtained is proportional to the product of the number 
of magnetically-equivalent nuclei present in the functional group, together with the 
concentration of the molecules present in the group (Siddiqui, 2003). The NMR spectra 
produced will now be passed on to the 1D NMR processor to be further processed. 
  
 
 The 1D NMR Processor  
 
The 1D NMR processor is a software with different features and functionalities, making it a 
core tool for the current study, especially for laboratory-based research. In fact, the 1D NMR 
processor was used to perform several transformations that improve the overall quality of NMR 
spectra. Amongst these, the Fourier transformation, zero filling, phasing, baseline correction, 
spectrum editor and covariance NMR, peak picking, etc., (Softpedia, 2014). Some of these 
keys features are highlighted here. The baseline correction corresponds to the step where the 




solvent’s high concentration were removed. However, phasing allows minimising the 
discrepancy between resonances and their alignment, especially those from zero-order and 
first-order due to several reasons such as the time-delay between the nuclei excitation and the 
response reception (Ravanbakhsh et al., 2015). Furthermore, the zero filling technique that 
consists on appending zero points to the free induction decay (fid), is performed before a 
Fourier transformation to increase the digital resolution of the spectrum (de Graaf, 2007; 
Keeler, 2004). Through the Fourier transform, the time-dependent free induction decay (fid) is 
converted into a frequency dependent spectrum. Finally, 1D NMR can perform a structural 
elucidation of protons close or adjacent to different functional groups present in the spectral 
data samples.    
 
 
 Consideration  
These techniques are utilised to improve the quality of the spectra produced (see section 2.4 in 
Chapter 2). Indeed, the applied chemistry development (ACD) 1D NMR processing software 
allows further processing of the fid file into excel files ready for analysis.               In addition, 
the ACD 1D NMR has been used to give a clear picture of compounds complexity; this includes 
understanding the bonding between atoms inside the molecules while suggesting possible 
chemical structures.  
 
Spectrum quality is affected by the presence of noise. This, in turn, can affect and be 
detrimental to the metabolomics profiling of small weighted biomolecular concentration (Xi 
and Rocke, 2008). To tackle noise in the spectrum, different means such as the polynomial fit 
and spectrum averaging methods are applied. More detail on these techniques can be found in 
(Halouska and Powers, 2006). Generally, noisy regions in the spectra are removed via 
intelligent bucketing that allows automatic splitting of the spectral regions in the interval, in 
such a way that a spectrum is not divided into adjacent intervals (Halouska and Powers, 2006;  
Worley and Powers, 2015). 
 
 Consideration  
Other tools were involved in this research, especially those related to data analysis, and these 





4.3.3. Data Collection Techniques 
 
 Introduction 
The data collection techniques applied in this research work are typically related to the handling 
of the biomedical data samples throughout the fieldwork, and the laboratory-based research. 
However, because the biomedical data were provided by collaborative research teams, a brief 
reference will be made to this data collection process. Finally, this sub-section includes the 
following: 1) an introduction; 2) biomedical data collection related to NPC1 disease; 3) 
biomedical data collection related to NPC liver dysfunction disease (NPC LDD); and 4) 
molecular assignment of metabolites.  
 
 
 Biomedical Data Collection Related to NPC1 Disease 
This data collection involved gathering data from NPC1 patients and healthy control 
individuals, which were further processed via NMR spectrometry and 1D NMR processor to 
generate metabolomics dataset (see sub-section 4.2.2).  
 
 
 Biomedical Data Collection Related to NPC Liver Dysfunction Disease (NPC 
LDD) 
The data related to the NPC liver dysfunction associated with this disease is obtained from 
mice and performed at the University of Oxford where the mice were bred and housed under 
sterile conditions. However, the 1H NMR spectral acquisition took place at De Montfort 
University, School of Pharmacy. The spectra were generated using a Bruker Advance AM-400 
spectrometer, which operated at 399.94 MHz, 298 K as probe temperature.  The spectral 
acquisition used TOPSPIN version 3.0, Bruker Biospin, with a relaxation time of 3 s, with a 
spectral width of 4,800 Hz. The advanced chemistry development ACD software was 
employed for baseline correction, zero filling, and the binning technique applied. The 
intelligent bucketing was applied to avoid splitting the same signal between two bins or 
buckets. The technique used an algorithm to calculate and determine the maximum size for the 
spectra obtained, which are between 0.02 to 0.06 ppm (Ruiz-Rodado et al., 2014; Sousa et al., 







 Molecular Assignment of Metabolites  
 
For both type of datasets used in this study, the molecular assignment of the 1H NMR spectra 
collected was performed using reference to appropriate materials and publications, and it was 
double checked with the human metabolome database. The spectra identified were generated 
following the process mentioned above.  
 
Now that the NPC1 and the NPC LDD data collection were succinctly mentioned, the different 
stages of the data multivariate analysis are detailed below. The Intelligent Tri-Modelling 
Techniques (ITMTs) were implemented for the data analysis purpose, meet the research 
objectives and answer the research questions. The ITMTs development has for objective the 
improvement and optimisation of both processes related to the discovery of biomarkers in the 
NPC1 and the NPC LDD diagnosis.  
 
4.4. Intelligent Tri-Modelling Techniques for Multivariate Data Analysis 
 
4.4.1. Introduction 
In this thesis, the Intelligent Tri-Modelling Techniques (ITMTs) are developed and applied in 
the multivariate data analysis section. No research study to the author’s knowledge has so far 
used these Intelligent Tri-Modelling Techniques to analyse datasets in biomedical research 
area. Developed around three main algorithms in machine learning and data classification, the 
model detailed below is typically based on data visualisation with SVA, classification with 
SVM, dimensionality reduction and predictive analysis with PCR. In this research, PCR has 
been presented as a combination of PCA and MLR in data analysis. The ITMTs are involved 
in the NPC1 disease diagnosis, conducted in parallel to NPC1 liver dysfunction disease 
diagnosis. Therefore, the ITMTs combine the advantages of the three models taken separately, 
as noted above. Additionally, the intelligent tri-modelling technique takes into account the 
interaction and relationship existing between variables or candidate biomarkers inherent to a 




1) an introduction; 2) the opportunities offered by SVA and the PCA to visualise data and 
determine whether they separate effectively between different classes, before they can be 
further investigated for modelling. In 3), the possibility to perform a deterministic classification 
using SVM with regard to biomedical datasets. Finally, in 4) the potential presented by the 
PCR algorithm using PCA to determine the principal components (PCs) and reduce the data 
dimensionality. This is followed by the MLR for probabilistic prediction in order to establish 
a strong correlation between features, and the risk of developing at an early stage the NPC1 
and its associated liver dysfunction disease (Taooka et al., 2014; Wijburg et al., 2012;  World 
Wide Antimalarial Resistance Network, 2012).  The use of PCA to determine the principal 
components or factors and carry out the analysis based on these uncorrelated principal factors 
can lead to the selection of the potential biomarkers. Indeed, the factor loadings and scores can 
help respectively to determine exactly the correlation of the original features to the principal 
components, and conclude on the contribution of every feature in diseases diagnosis and 
perhaps prognosis (Marcello Manfredi, 2013).  
 
4.4.2. Scalar Visualisation Algorithm (SVA) for Data Analysis 
 
 Theory  
The term visualisation is related to the creation of images that carries information about the 
relationship existing within data in order to gain insight into the underlying data structure 
(Johnsona, 2012). There are different types of visualisation algorithm, including the scalar 
algorithm, the vector algorithm, and the tensor algorithm (Komura, 2016). The scalar 
visualisation algorithm (SVA) that is the focus of this sub-section works by converting scalar 
data type into coloured data. Thus, the 1H NMR resonances produced from the NPC1 and NPC 
LDD metabolomic data is turned into an index that is, in turn, related or assigned to a colour 
selected from a colour lookup table. In this manner, every single signal value (scalar data) is 
mapped to a particular colour in the lookup table, in such a manner that underlying 
transformations at the molecular level can be displayed and visualised. Therefore, the scalar 
visualisation algorithm (SVA) can change the data type, for example, changing scalar data into 
a colour data type (Johnsona, 2012).  The same researcher believes that visualisation is a 




general. For this reason, the technique has been applied in different research domains, including 
computer science, engineering, biology, particle physics, etc., (Johnsona, 2012).   
 
 
 SVA Model Applications 
 
The scalar visualisation algorithm has been applied in different fields of research and some of 
these applications are presented here. In the following study, scalar visualisation algorithm was 
applied in the surgical field where surgeons experienced visualisation of the cerebral vessel 
structure in order to have a clear view of disease diagnosis (Luo, 2013). To overcome the 
problems related to the traditional ray casting of the three dimensional view, which doesn’t 
allow surgeons to establish a clear distinction of the vessels depth, this research proposes a 
distance colour blending and the stereoscopic depth enhancement that allows us to improve the 
depth perception of vessels that have complex structures (Luo, 2013).  
 
Another application of the SVA is related to the adaptive surface visualisation based on the 
contour measurement technique for the assessment of the cardiovascular disease (CVD). The 
approach developed based on different visualisation techniques could improve the vessel 
surface shape and depth visualisation. It is important in the CVD diagnosis process to perform 
a clear visualisation exploration of the blood flow information in the vessel surface area in 
order to understand the blood flow behaviour closely related to the CVD.  Problems such as 
vessel occlusion are common in the case of CVD, and hence blood flow expert visual expertise 
is required. The information required by these experts include quantitative and qualitative 
information that can help to overcome the complexity of the diagnosis, in turn related to the 













Algorithm 2. SVA algorithm for data visualisation for the intelligent tri-modelling technique 
(ITMTs), with possible steps following in colour mapping.  
 
4.4.3. Support Vector Machine (SVM) for Data Analysis 
 Theory 
Frame 2 
1. Select Dataset = {Plasma, Liver} 
2. Select Dataset Normalisation  Option = {ON, OFF} 
3. Select Modelling Type = {SVA, etc.} 
4. Range Scalar Value = Range Colour 
5. Assignment:  
 Assign  Peak minimum value = Blue (Colour) 
 Assign Peak maximum value = Red (Colour) 
6. Colour Look-up Table : Scalar value convert = Index  
 Scalar Minimum = Peak Minimum = Minimum Index = Imin 
 Scalar Maximum = Peak Maximum = Maximum Index = Imax 
 Scalar Value = Peak Value = Index Value = Ii  
 Scalar Value Range = {Imin,……, Ii, …., Imax} 
7. Colour Range ={colour0, colour1, …., colour n-1) 
8. Colour Mapping 
 If  Ii  <  Imin  ,  colour = colourmin  = colour0 = C0 
 If  Ii  <  Imax  ,  colour = colourmax  = colour n-1  = Cn-1 
 Else use colour transfer function ft (Ii) = Ci 
 NB: Combine colour red, green, and blue to generate different colour 
based on peak intensity = index value Ii 
 End If 
 Assign Index to Colour  




The classification tasks involve, amongst others the necessary task of dividing the original 
dataset into training and testing sets.  A kernel function is used to map the training set onto 
higher dimensional space, where a hyperplane can be found to separate the sample into two or 
more distinct classes (McDermott et al., 2013).  
 
In this manner, the model is trained to segregate between two classes C1 (+1) and C2 (-1). For 
example, segregating between diseased and healthy control individuals in the NPC1 disease 
dataset classification. After the training step, the model is ready to classify unknown data 
between the two classes C1 and C2, with each class containing a target value of +1 or -1. The 
SVM has to produce a model that can ultimately predict the target value of every single instance 
(sample) in the testing dataset based on its features (Marcello Manfredi, 2013; Michie et al., 
1994). When such a hyperplane exists that separates the two classes C1 and C2, therefore, a 
vector w and a scalar b verifying the inequalities exist and is expressed by:   
 
𝐺𝑖𝑣𝑒𝑛 𝑡ℎ𝑒 𝑙𝑎𝑏𝑒𝑙𝑒𝑑 𝑡𝑟𝑎𝑖𝑛𝑖𝑛𝑔 𝑠𝑒𝑡 (𝑥𝑖 , 𝑦𝑖), ……… (𝑥𝑙 , 𝑦𝑙),    𝑦𝑖 {−1, 1}   ∶ (𝟐𝟎)  
 
𝑤. 𝑥𝑖 + 𝑏 ≥ 1                       𝑖𝑓 𝑦𝑖 = 1  
 
𝑤. 𝑥𝑖 + 𝑏 ≤ −1                   𝑖𝑓 𝑦𝑖 = −1    ∶ (𝟐𝟏)        (Cortes and Vapnik, 1995). 
 
In the case where the two classes are linearly non-separable, then the problem requires the 
finding of a hyperplane that will carry out the separation with minimum error. However, the 
problem at hand becomes an optimisation problem presented as follows, considering the 
following pairs of instance: 
 
( 𝑥𝑖, 𝑦𝑖), 𝑖 = 1,… . . , 𝑙, 𝑤𝑖𝑡ℎ 𝑥𝑖 ∈ ℛ
𝑛 𝑎𝑛𝑑 𝑦 ∈ {1, −1}𝑙 : (22).    
 
The SVM algorithm has to find a solution to the given optimisation problem  
min
𝑤,𝑏,𝜉
    
1
2
𝑤𝑇𝑤 + 𝐶𝐹 ∑𝜉𝑖
𝑙
𝑖=1
 ∶ (𝟐𝟑);  𝑤ℎ𝑒𝑟𝑒 𝐶 𝑖𝑠 𝑎 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡, 𝐹(𝑢) 𝑤𝑖𝑡ℎ 𝐹(0) = 0 𝑖𝑠 𝑎   
𝑚𝑜𝑛𝑜𝑡𝑜𝑛𝑖𝑐 𝑐𝑜𝑛𝑣𝑒𝑥 𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛, 𝑎𝑛𝑑 𝜉𝑖𝑖𝑠 𝑡ℎ𝑒 𝑠𝑢𝑚 𝑜𝑓 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡𝑟𝑎𝑖𝑛𝑖𝑛𝑔 𝑒𝑟𝑟𝑜𝑟𝑠 
 
 𝐺𝑖𝑣𝑒𝑛 𝑡ℎ𝑎𝑡  𝑦𝑖(𝑤






 SVM Model Applications 
 
The support vector machine is a deterministic classification algorithm using a heuristic method 
for prediction. SVM is based on the principle of detecting a hyperplane that is used as a 
separation n-dimensional plane between two different classes (Verplancke et al., 2008). The 
process of defining a hyperplane can be achieved through a straightforward process or through 
a transformation using a linear kernel function, especially when it is not possible to find such 
hyperplane in a lower dimensional input space, by mapping the dataset into a higher 
dimensional features space. Such a transformation can allow the detection of the separation 
hyperplane  (Grootveld, 2014; Salazar et al., 2012; Zhang et al., 2006). 
 
In the specific case of this binary classification, SVM has been employed in order to 
discriminate between diseased subjects and healthy control ones in relation to two biomedical 
datasets, the NPC1 diseases dataset, and liver dysfunction disease dataset.  
 
 In this project, the SVM uses different setting with the objectives of optimising the 
classifier performances. In this regard, the LibSVM 3.21 folder is added to the search 
path to avoid using the default SVM function provided by Matlab. This choice allows 
the setting that implements the SVM optimisation and it encompasses the following 
options: the dataset standardisation, type of kernel applied, i.e. linear or radial based 
function (rbf), repeated k-fold stratified cross-validation, etc. The main purpose of 
which is to have data of the same scale in order to proceed to an effective comparison 
between them. The result of this optional setting, the auto-scaling will generate a dataset 
with zero mean and a unit variance (Jajuga and Walesiak, 2000; Raschka, 2014).  
 
 The choice was given for the choice of kernel functions used, including the linear or 
the RBF kernel. However, the method used in this research to estimate the classifier 
performances, was conducted through the repeated k-fold stratified cross-validation. 
The k-fold Stratified Cross-Validation provides more reliable estimates than when 
using the single cross-validation technique. Stratification handles the bias and variance 




cross-validation compared to cross-validation allows us to attain a more precise 
estimate of predictive performance (Hastie et al., 2008; Kuhn and Johnson, 2013). 
Hence, estimation of the accuracy without confidence interval has no real value. The 
confidence interval is defined to give more credit to the values of the classifier 
performance (Kohavi, 1995).  Different values of k can be chosen, for example k Є {5, 
10}, with 10-fold stratified cross-validation being more effective in terms of model 
selected for real world datasets (Kohavi, 1995).  
 
 Samples selection applied is based on the ADASYN technique to implement the 
oversampling techniques, in such a manner that synthetic samples in the minority class 
are created to balance the dataset.  
 
 With regard to features selection, a certain number of nearest neighbour parameters are 
used to perform the ReliefF, a features selection method that improves classifier 
performance by removing redundant features (Rosario and Thangadurai, 2015; Zhang 
et al., 2016). Hence, it is a feature elimination technique to remove the less significant 
features in this binary classification process (Guyon et al., 2002), combined with the 
repeated k folds stratified cross-validation technique, where the dataset is divided into 
a total of 5-10 folds. During the modelling process, (k-1) is used for training and 1 (one) 
fold is used for testing the model, and this process is then repeated n times, so that every 
single set is used at least once as training and testing sets. The technique is used to 
validate the whole modelling process (Grootveld, 2014). The algorithm used to develop 















Algorithm 3. SVM model combining grid search technique, cross-validation, and features 




In the present thesis, principal component analysis (PCA) is combined to multiple logistic 
regression (MLR) to generate the principal component regression (PCR) model. These 
algorithms are presented in the very order as previously mentioned, i.e. PCA first and then 
PCR, and they are next to follow in this thesis. 
4.4.4. Principal Components Analysis (PCA)  
Frame 3 
1. Including LibSVM 
2. Select dataset = {Plasma , Liver} 
3. Select data standardisation option ={ON , OFF}  
4. Apply grid search technique for best combination (C , γ) and optimum OSVM 
5. Select k folds = {5 , 10} 
6. Apply k folds cross-validation technique 
7. Select classification function = { Linear, RBF} 
8. Select number of nearest neighbour for ADASYN method = {10 , 15 , 20} 
9. Candidate SV = {closest pair (xi , xi’} from opposite classes} 
10. Select number of nearest neighbour for features selection = {10 , 20} 
11. While there violation points do  
12. Find violator 
13. Repeat = {10 , 20} 
14. Candidate support vector SV = Candidate SV   U   violator 
15. If any αp < 0 due to addition of c (another SV) to S (support vector set) then  
16. N.B. f(x) = ∑ αi. yi. K(xi, x) + b , where f kernel associated with the SV and xi ∈ S 
17. Candidate SV = Candidate SV\p 
18. Repeat until all such points are pruned 
19. End If 






The Principal Component Analysis (PCA) model is a descriptive method that presents the 
original variables in a new reference system characterised by principal components.           PCA 
involves the projection of the original features onto orthogonal planes in order to generate new 
features or factors, reducing the variables space. Therefore, PCA is as well-known data 
dimensionality reduction technique (Marcello Manfredi, 2013). Hence, PCA involves a change 
in variable space, transforming variable space into factor space. In the samples’ space, the 
vectors length correspond to the variability of the variables, while the angle between vectors 
represents the correlation between variables, and is usually expressed as the correlation 
coefficient α for standardised variables (Amath 301, 2016; XLSTAT, 2010). The factors 
(components), also called eigenvectors, are orthogonal and non-correlated, and allow an 
explanation of the variability in the original dataset based on the main PCs (Kumar and Kalra, 
2016; Mahmoodabadi et al., 2008; Nikas and Low, 2011; Rustempasic and Can, 2013).     
 
However, PCA allows visualisation of the correlations between different features. In fact, PCA 
allows the plotting of the data on the principal components (F1, F2, F3 ...) in order to visualise 
whether the different classes C1 and C2 separate well. In this case, further study can determine 
the main features responsible for this total separation given that the principal components are 
linear combinations of the original variables (Marcello Manfredi, 2013; McDermott et al., 
2013). This may provide valuable information regarding the possible presence of biomarker(s), 
which might lead to a possible understanding of the underlying transformation at the molecular 
level with respect to metabolites involved in disease process.  
 
The major reason for the application of PCA is related to the selection of the principal 
components (PCs). More detail explanations are provided below.  
 
 PCA Model Applications 
 
Different cases have been reported in the literature in relation to the application of PCA as a 
visualisation tools to find out whether there is total separation between classes in the PCs’ 
space. With respect to the understanding of the likelihood of a patient developing diseases such 




detection (Marcello Manfredi, 2013). PCA was also employed for the identification of PCs that 
could facilitate the identification of major biomarkers for disease diagnosis and prognosis 
(Cluzeau et al., 2012;  Wang, 2008). 
 
In the present study, PCA is used to define the main factors that are the axes upon which the 
dependent variable Y will be regressed. In this manner, the factors or PCs are expressed as 
linear combinations of original disease features. This has the potential to reduce the disease 
feature space from 55 original features to 10 main ones for plasma datasets, and respectively 
from 143 to 10 for liver dysfunction dataset. This dataset dimensionality reduction has the 
potential to ease and improve model performances. With regard to the selection of the variables 
involved in biomarker discovery, the computational time, and the costs involved can be also 
reduced (Scannell et al., 2012).  In the case of this study, the PCs selected explain more than 
90% of the total variability in the original dataset (Wang and Abbott, 2008; Gauderman et al., 
2007). Finally, the PCs selection was performed using XLSTAT 2016 software, and the 
following pseudo-code highlights the different steps followed. 
 
 













1. Select dataset = {Plasma, Liver} 
2. Select PCA type = Pearson (n) 
3. Option = No Filter & No Rotation 
4. Supplementary data = {No observation} 
5. Supplementary variables = {No supplement variable} 
6. Data option = {No Missing data} 
7. Input = {Descriptive statistic and correlation} 
8. Output = {Eigenvalue, Factor loading, variables/factors correlation} 
9. Factor scores, contributions, squared cosines 
10. Charts = {Observation, Labels and coloured labels} 





Algorithm 4. PCA algorithm implementing principal component selection for the intelligent 
tri-modelling techniques (ITMTs). This allows us to understand the use of PCA as an aid to 
diagnosis. The Pseudo-code exposed is related to the XLSTAT 2016 version software used in 
this research.  
 
 Consideration:  
Based principally on the factor loadings and the factor scores, the principal components (PCs) 
selected undergo principal component regression (PCR) in order to determine the potential 
biomarkers. Further studies may be required to precisely determine the major potential 
biomarkers. Nevertheless, the MLR that is next visited is required to complete this process. 
 
 
4.4.5. Multiple Logistic Regression (MLR) for Data Analysis 
 
 Theory 
Multiple logistic regression (MLR) is a probabilistic classification algorithm using a binary 
nominal dependent variable Y to predict the outcome of an event such as disease likelihood of 
appearance or progression, etc., based on the independent variables Xi, which can be correlated 
or uncorrelated. In this regard, multiple logistic regression (MLR) is a statistics model used in 
data analysis, with one binary nominal variable (dependent variable). For example, the value 
(+1) can be attributed to diseased, male, yes, etc., and the value (0) for healthy, female, no, etc., 
and two or more measurements which are the independent (Schoonjans, 2016). The variation 
in the measurements Xi (which can be correlated) permits prediction of the probability of the 
dependent variable Y. In this manner, MLR determines/defines the best fitting model 
describing the relationship between the dichotomous characteristic of interest (dependent 
nominal variable = outcome variable) and a set of independent or non-independent 
(explanatory) variables. The probability to predict an outcome is provided by the equation (25):  
 
𝑌 = 𝑌0 + α1𝑋1 +  α2𝑋2 + α3𝑋3 …+ α𝑛𝑋𝑛 ∶  (𝟐𝟓).𝐻𝑖𝑔𝑔𝑖𝑛𝑠, (2005)𝑠ℎ𝑜𝑤𝑠 𝑡ℎ𝑎𝑡 𝑡ℎ𝑒 𝑌0   
 
𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 𝑜𝑓 𝑌, 𝑎𝑛𝑑 𝑡ℎ𝑒 𝑣𝑎𝑙𝑢𝑒𝑠 α𝑖  𝑡ℎ𝑒 𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑌′ 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 1 𝑖𝑛𝑐𝑟𝑒𝑚𝑒𝑛𝑡 𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑋𝑖 
 




Moreover, logistic regression generates the coefficient and the standard errors, with a formula 
to predict the logit function that gives the logarithm of the odds p/(1-p) transformation of the 
probability p of the presence of the response or the outcome as outlined below: 
 
𝑙𝑜𝑔𝑖𝑡 (𝑝) =  𝑌 = 𝑌0 + α1𝑋1 +  α2𝑋2 + α3𝑋3 …+ α𝑛𝑋𝑛 ∶  (𝟐𝟔),  
 
𝑤ℎ𝑒𝑟𝑒 𝑝 𝑖𝑠 𝑡ℎ𝑒 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑝𝑟𝑒𝑠𝑒𝑛𝑐𝑒 𝑜𝑓 𝑎 𝑔𝑖𝑣𝑒𝑛 𝑜𝑢𝑡𝑐𝑜𝑚𝑒. 
 






 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑝𝑟𝑒𝑠𝑒𝑛𝑐𝑒 𝑜𝑓 𝑐ℎ𝑎𝑟𝑎𝑐𝑡𝑒𝑟𝑖𝑠𝑡𝑖𝑐
𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑎𝑏𝑠𝑒𝑛𝑐𝑒 𝑜𝑓 𝑐ℎ𝑎𝑟𝑎𝑐𝑡𝑒𝑟𝑖𝑠𝑡𝑖𝑐
 (𝟐𝟕) 
 
𝑙𝑜𝑔𝑖𝑡 (𝑝) = 𝑙𝑛 
𝑝
1−𝑝
 (𝟐𝟖)         (Schoonjans, 2016). 
 
Multiple logistic regression has had different applications in various areas including diseases 
diagnosis and prognosis, etc., some of which are presented below.  
 
 Applications of the MLR Model  
 
The multiple logistic regression (MLR) technique is applied in this research as a probabilistic 
classifier to predict or determine the likelihood of distinguishing between patients with NPC1 
disease and healthy controls or segregate between liver dysfunction disease subjects in 
experimental animals and controls or corresponding heterozygotes (Abbott and Carroll, 1984; 
Schoonjans, 2016; Taooka et al., 2014; Xia et al., 2013).  
 
In this process, detection of the major biomarkers in these cases is important. Bearing in mind 
that in the present case, the original features are not the ones assessed by the MLR model, but 
scores vectors selected by the PCA. However, the resulting biomarkers in terms of original 
features can be detected given that the PCs are linear combinations of these original variables. 







 Pseudo-code: Adapted MLR  
 
 
Algorithm 5. MLR algorithm implementing principal component regression (PCR) for 
potential biomarker discovery for the intelligent tri-modelling techniques (ITMTs), with the 
end of the MLR corresponding also to the end of the PCR.   
It should also be noted that handling high-dimensional features with only a small number of 
observations available is a complex issue in regression analysis. Regressing Y on the principal 
Frame 5 
1. Select Dataset = {Plasma , Liver} 
2. Select dataset Standardisation option = { 
3. ON , OFF} 
4. Select k folds = {5 , 10} 
5. Select Sigmoid Function to represent the model  
6. Split the dataset into training and testing set 
7. Add an incept W0 to the training dataset 
8. Define threshold value 
9. Get the Log likelihood value  
10. Define the weight wi = wi – α df/dwi  [f(x,w)] 
11. Where I is the index of the ith feature 
12. Stop if difference between old and new log likelihood is below threshold f0 
13. Set initial weight woi 
14. df/dw > f0 
15. Where f(x, w) a cost function, and f0 a threshold  
16. While df/dw > f0 is true, find df/dw, such that wi. df/dw < 0 
17. Then update weight using update rule 
18. wi = wi + α∑k [yk – p(yk = 1|xk, w)].xki 
19. If   wi . df/dw > 0, then use updated weight wi 
20. End if     
21. End while 
22. End MLR        




components (PCs) works well, giving acceptable results (Artemiou and Li, 2009; Li, and 
Chiaromonte, 2007). Consequently, PCR as a model is visited next in this thesis. 
4.4.6. Principal Components Regression (PCR) for Data Analysis 
 Theory 
In statistical analysis, principal component regression (PCR) is related to the regression 
analysis technique applied in the principal components analysis (PCA). This combination of 
principal components analysis and regression analysis is useful when there is not a clear 
understanding of the inter-relations between variables. In this case, hypotheses will be 
constructed on a small sample set, that will need to be verified later using a larger dataset 
(Massy, 1965).  
 
Employing PCR in data analysis has been driven by the necessity to address collinearity issues 
in the dataset, especially amongst variables or predictors (Cook, 2007). Indeed, when too many 
predictors exist in a dataset, the task of designating the features responsible for the 
transformation at metabolomics level with regards to disease diagnosis or therapy study 
becomes awkward. Therefore, it is necessary to use principal component (PC) rather than 
scores vectors in order to facilitate our understanding of the system under study.                                                            
 
 PCR Model Applications  
 
Different applications of principal component regression (PCR) have been reported in the 
literature. It has been utilised to understand the traits variance related to underlying genetic 
transformations. Some of the assessments applied were motivated on the necessity to determine 
whether multiple correlations could be found at the genetic level, which may affect and be 
detrimental for the genes as main biomarkers for trait variance  (Schaid et al, 2002; Shen and 
Zhu, 2009). In another case, the assessment was based in developing a new model that was 
compared to existing model, with a view of improving the model’s ability to predict 
progression (Abraham et al., 2016).  
 
In this thesis, however, PCR is employed in two different stages that include the use of  
PCA to determine the main axes or the principal components (PCs) upon which the dependent 




model that applied its probabilistic prediction ability to detect the main biomarkers for NPC1 
disease diagnosis.  
 
Indeed, PCA strategy was employed in order to define the different PCs to be employed during 
the second phase that is MLR. In view of the concern raised about the PCs selection criteria 
not being fully rational, the PCs selected could be unrelated to the outcome (Wang and Abbott, 
2008; Gauderman et al., 2007). Therefore, in the current thesis, the PC selection process was 
made more open, with the PCs chosen explaining up to 90% of the total variability, which 
ensures that only a low level of total variability was left unexplained. However, MLR employed 
different options that allowed the comparison of different combinations of variable selection, 
sample selection that resulted in the model’s improvement in terms of biomarker discovery.  
 
Nevertheless, the different features selected by the PCR technique have to be ranked in such a 
manner that is easy to detect their importance in understanding a disease aetiology. Three main 
ranking techniques were developed in this research and they are outlined below. 
 
 
4.4.7. PCR and Features Ranking Techniques 
 
 Analysis Techniques  
In view of a strong correlation between the different features in the datasets, PCA was 
employed to select the PCs explaining the maximum variability in the original NPC1 disease 
datasets. In addition, the factor loadings and scores are used as new forms of data that will help 
in further analysis. The multiple logistic regression (MLR), the last algorithm of the intelligent 
tri-modelling techniques (ITMTs), was used to regress the PCs on the dichotomous variable Y, 
that takes the values of healthy (0) and diseased (+1). In this manner, the NPC1 disease features 
can be correlated to disease diagnosis. Therefore, a combination of the PCA and the MLR 
allows the implementation of a multivariate logistic regression model of the principal 
component scores vectors also known as principal component regression (PCR). 
The factor scores are used as a new dataset to run the MLR and obtain a classification of the 
PCs with the regression coefficient ri. Moreover, from the factor loadings, the coefficients of 





Two sets of coefficients are used to develop the biomarkers discovery techniques, as proposed 
in this thesis. This encompasses the heuristic method related to the determination of a rapid 
solution, which is appropriate for the time being, although it might not be the best. The sum of 
the product of the coefficients (SPC) refers to the calculation of the sum of the product of the 
coefficients of correlation and regression to deduce the contribution level of each PC. Finally, 
the exponential of the sum of the product of the coefficients refers to the use of the exponential 
value of the sum of the product of the coefficients calculated above.  
 
 Consideration: 
Different assumptions were made in the modelling section. They are all related to the rules 
applied for the selection of the key features. However, no clear-cut rule is set regarding which 
value (r, α, rα, etc.) to use and how to use them on completion of the PCR. After generating the 
PC scores vectors via PCA and the application of the MLR, there is no rational method to apply 
in the case of the multivariate analysis such key feature selections, and hence in defining the 
biomarkers. However, two coefficients are generated, which are the coefficient of regression 
and the correlation coefficient. Based on these coefficients, several combinations and rankings 
can be generated, and hence different features can be considered as being the most important, 
and therefore regarded as major biomarkers in NPC1 disease study.   
 
The technique of rotating the PCs, which consists of selecting one PC as the main one and then 
monitoring the influence on the other features, that is monitoring the effect of this change. This 
technique is not readily applicable to this research since the main aim is to monitor and 
understand the correlation of the different features and their effect on one another. However, 
three alternative methods are presented, including the heuristic method, the sum of the product 
of the coefficients method, and finally the exponential sum of the product of the coefficient 
method. These methods are discussed in detail below. 
 
 Heuristic Method  
The heuristic method used is based on the fact that the algorithm searches for a suitable 
selection of the PCs that is sufficient, although the PCs selected are not necessarily the best 
ones. In this regard, priority is given to the coefficient of regression r, while the largest values 
of the coefficient of correlation α are chosen subsequently to perform the features ranking. For 




r1, r2, and r3 are their coefficients of regression respectively and of value ordered r1 ≥ r2 ≥ r3. 
This feature ranking combined three values that are the coefficient of regression (ri), the 
coefficient of correlation (αi) and the corresponding products riαi. This final value riαi is the 
major value in the heuristic ranking, although ri and αi are carefully checked before validating 
the ranking based on the value of riαi. The final ranking will be x3, x2, and finally x1 if the 
products riαi are ranked as follow: r3α3 ≥ r2α2 ≥ r1α1.   
 
The heuristic approach is based on the researcher’s ability to classify the features according to 
the values r, α and then rα, each in descending order. This approach allows us to make a choice, 
and attain a solution, although some choices (solutions) are not the best. The rationale behind 
this technique is in line with the definition of the heuristic method, which is finding a solution 
that will be primarily effective, although this may not represent / be the best possible solution 
(Martí and Reinelt, 2011). 
 
 Sum of the Product of the Coefficients (SPC) Method  
 
The sum of the product of the double coefficient method is applied in this research, and the 
rationale behind it can be established by the following mathematical reasoning based on 
equations 27 and 28 above: 
 
𝐼𝑛 𝑀𝑢𝑙𝑡𝑖𝑝𝑙𝑒 𝐿𝑜𝑔𝑖𝑠𝑡𝑖𝑐 𝑅𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛, 𝑡ℎ𝑒 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛 𝑏𝑒𝑙𝑜𝑤 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑒𝑠 𝑡ℎ𝑎𝑡 𝑡ℎ𝑒 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑖𝑠 
 
𝑒𝑖𝑡ℎ𝑟 𝑓𝑟𝑜𝑚 𝑡ℎ𝑒 𝑁𝑃𝐶1 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 𝑐𝑙𝑎𝑠𝑠 𝑜𝑟 𝑒𝑖𝑡ℎ𝑒𝑟 𝑓𝑟𝑜𝑚 𝑡ℎ𝑒 𝑐𝑜𝑛𝑡𝑜𝑙 𝑐𝑙𝑎𝑠𝑠. 𝑇ℎ𝑖𝑠 𝑡ℎ𝑒𝑠𝑖𝑠 𝑢𝑠𝑒𝑑 
  
𝑡ℎ𝑒 𝑐𝑜𝑑𝑒 + 1 𝑓𝑜𝑟 𝑏𝑒𝑖𝑛𝑔 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑖𝑐𝑘 𝑐𝑙𝑎𝑠𝑠 𝑎𝑛𝑑 0 𝑓𝑜𝑟 𝑏𝑒𝑖𝑛𝑔 𝑖𝑛 𝑡ℎ𝑒 ℎ𝑒𝑎𝑙𝑡ℎ𝑦 𝑐𝑙𝑎𝑠𝑠. 
  
𝐿𝑒𝑡 𝑌 𝑏𝑒 𝑎 𝑏𝑖𝑛𝑎𝑟𝑦 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒 𝑡ℎ𝑎𝑡 𝑐𝑎𝑛 𝑡𝑎𝑘𝑒 𝑣𝑎𝑙𝑢𝑒𝑠 + 1 𝑎𝑛𝑑 0. 𝑌 𝑖𝑠  𝑑𝑒𝑓𝑖𝑛𝑒𝑑 𝑎𝑠 𝑓𝑜𝑙𝑙𝑜𝑤: 
𝑌 =  {
+1 𝑖𝑓 𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 ℎ𝑎𝑠 𝑔𝑜𝑡 𝑡ℎ𝑒 𝑑𝑖𝑠𝑒𝑎𝑠𝑒
0  𝑖𝑛 𝑐𝑎𝑠𝑒 𝑡ℎ𝑒 𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑖𝑠 ℎ𝑒𝑎𝑙𝑡ℎ𝑦 
  (29)  
(Hosmer and Lemeshow, 2015; Salazar et al., 2012). 
 
𝐼𝑓 𝑤𝑒 𝑐𝑜𝑛𝑠𝑖𝑑𝑒𝑟 𝑝 𝑎𝑠 𝑡ℎ𝑒 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑎 𝑝𝑎𝑡𝑖𝑒𝑛𝑡  ℎ𝑎𝑣𝑖𝑛𝑔 𝑡ℎ𝑒 𝑁𝑃𝐶 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 (+1).  
 





𝑡ℎ𝑒 𝑝𝑟𝑒𝑠𝑒𝑛𝑐𝑒 𝑜𝑣𝑒𝑟 𝑡ℎ𝑒 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑎𝑏𝑠𝑒𝑛𝑐𝑒 𝑏𝑦 𝑡ℎ𝑒 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛:   
 




𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑝𝑟𝑒𝑠𝑒𝑛𝑐𝑒 𝑜𝑓 𝑑𝑖𝑠𝑒𝑎𝑠𝑒
𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑎𝑏𝑠𝑒𝑛𝑐𝑒 𝑜𝑓 𝑑𝑖𝑠𝑒𝑎𝑠𝑒
: (𝟑𝟎) 
 
𝑇ℎ𝑒 𝑙𝑜𝑔𝑖𝑡 𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 𝑖𝑠 𝑑𝑒𝑓𝑖𝑛𝑒𝑑 𝑎𝑠 𝑡ℎ𝑒 𝑙𝑜𝑔𝑔𝑒𝑑 𝑜𝑓 𝑡ℎ𝑒 𝑜𝑑𝑑𝑠 𝑎𝑛𝑑 𝑖𝑠 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑒𝑑 
 
𝑏𝑦 𝑡ℎ𝑒 𝑓𝑜𝑙𝑙𝑜𝑤𝑖𝑛𝑔 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛: log(𝑜𝑑𝑑𝑠) = ln (
𝑝
1−𝑝
) (Schoonjans, 2016): (𝟑𝟏)     
 
𝑇ℎ𝑒 𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛 𝑐𝑎𝑛 𝑏𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑒𝑑 𝑎𝑠 𝑓𝑜𝑙𝑙𝑜𝑤: 𝑌 =  𝑙𝑜𝑔𝑖𝑡 (𝑝) , 𝑤𝑖𝑡ℎ  
 
𝑙𝑜𝑔𝑖𝑡 (𝑝) =  𝑟1 𝐹1 + 𝑟2 𝐹2 + 𝑟3 𝐹3 + ⋯+ 𝑟𝑘 𝐹𝑘 + 𝑌𝑜 ∶ (𝟑𝟐),𝑤ℎ𝑒𝑟𝑒 𝑟1, 𝑟2, … . , 𝑟𝑛 𝑎𝑟𝑒 
 
 𝑡ℎ𝑒 𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡𝑠  (Abbott and Carroll, 1984). Equations (31)𝑎𝑛𝑑 (32) 
 
𝑔𝑖𝑣𝑒 𝑙𝑜𝑔𝑖𝑡 (𝑝) =  ln (
𝑝
1 − 𝑝
) =  𝑟1 𝐹1 + 𝑟2 𝐹2 + 𝑟3 𝐹3 + ⋯+ 𝑟𝑘 𝐹𝑘 + 𝑌𝑜 ∶ (𝟑𝟑),  
 
𝑤ℎ𝑖𝑐ℎ 𝑖𝑠 𝑡ℎ𝑒 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑙𝑜𝑔𝑖𝑡 𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 (Schoonjans, 2016).   
 
𝐵𝑦 𝑎𝑝𝑝𝑙𝑦𝑖𝑛𝑔 𝑡ℎ𝑒 𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛 𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡𝑖𝑎𝑙 𝑡𝑜 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛 33. 𝐿𝑒𝑡 𝑟𝑒𝑐𝑎𝑙𝑙 𝑡ℎ𝑎𝑡:  
 






















= 𝑒(𝑟1 𝐹1+𝑟2 𝐹2+𝑟3 𝐹3+⋯+𝑟𝑘 𝐹𝑘+ 𝑌𝑜)  ∶ (𝟑𝟒), 𝑏𝑦 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑖𝑛𝑔 𝑡ℎ𝑖𝑠 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛 34   
 





  𝑝 =  
𝑒(𝑟1 𝐹1+𝑟2 𝐹2+𝑟3 𝐹3+⋯+𝑟𝑘 𝐹𝑘+ 𝑌𝑜)
1 + 𝑒(𝑟1 𝐹1+𝑟2 𝐹2+𝑟3 𝐹3+⋯+𝑟𝑘 𝐹𝑘+ 𝑌𝑜)
∶ (𝟑𝟓) 
 





) = ln(𝑒(𝑟1 𝐹1+𝑟2 𝐹2+𝑟3 𝐹3+⋯+𝑟𝑘 𝐹𝑘+ 𝑌𝑜)) : (𝟑𝟓′) 
 
𝑅𝑒𝑐𝑎𝑙𝑙: ∀ x ∈ ℝ, ln 𝑒𝑥 = 𝑥 ;  𝐶𝑜𝑚𝑏𝑖𝑛𝑖𝑛𝑔 𝑡ℎ𝑖𝑠 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑙𝑜𝑔𝑖𝑡 𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛, 𝑖𝑡 𝑐𝑜𝑚𝑒𝑠  
 
𝑡ℎ𝑎𝑡: ln(𝑒(𝑟1 𝐹1+𝑟2 𝐹2+𝑟3 𝐹3+⋯+𝑟𝑘 𝐹𝑘+ 𝑌𝑜)) =  𝑟1 𝐹1 + 𝑟2 𝐹2 + 𝑟3 𝐹3 + ⋯+ 𝑟𝑘 𝐹𝑘 + 𝑌𝑜: (35
′′)  
 
𝑓𝑟𝑜𝑚 35′𝑎𝑛𝑑 35′′ : 𝑙𝑜𝑔𝑖𝑡 (𝑝) =  ln (
𝑝
1 − 𝑝
) =  𝑟1 𝐹1 + 𝑟2 𝐹2 + ⋯+ 𝑟𝑘 𝐹𝑘 + 𝑌𝑜 = 𝑌 ∶ (𝟑𝟔); 
 
𝑇ℎ𝑒 𝑓𝑜𝑙𝑙𝑜𝑤𝑖𝑛𝑔 𝑡𝑒𝑟𝑚:  𝑟1 𝐹1 + 𝑟2 𝐹2 + ⋯+ 𝑟𝑘 𝐹𝑘 𝑐𝑎𝑛 𝑏𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑒𝑑 𝑎𝑠 𝑎 𝑠𝑖𝑔𝑚𝑎 = 𝑠𝑢𝑚 




𝑇ℎ𝑒𝑟𝑒𝑓𝑜𝑟𝑒, (36)𝑎𝑛𝑑 (36′)𝑔𝑖𝑣𝑒: 𝑌 =  𝑙𝑜𝑔𝑖𝑡 (𝑝) =  ln (
𝑝
1 − 𝑝
) =  ∑𝑟𝑗 𝐹𝑗
𝑗≤𝑘
𝑗=1
+ 𝑌𝑜 ∶ (𝟑𝟕) 
𝑇ℎ𝑒 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛 𝑜𝑓𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑏𝑎𝑠𝑒𝑑 𝑜𝑛 𝑙𝑜𝑔𝑖𝑡(𝑝) (Hosmer and Lemeshow, 2015;  
 
Salazar et al. , 2012). 𝑇ℎ𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑟𝑗  𝑖𝑠 𝑡ℎ𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑜𝑓 𝑒𝑎𝑐ℎ 𝑃𝐶   
 
𝑡𝑜 𝑡ℎ𝑒 𝑑𝑒𝑡𝑒𝑟𝑚𝑖𝑛𝑎𝑡𝑖𝑜𝑛 𝑜𝑓𝑡ℎ𝑒 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑤ℎ𝑒𝑡ℎ𝑒𝑟 𝑜𝑟 𝑛𝑜𝑡 𝑎𝑛 𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑖𝑠 ℎ𝑒𝑎𝑙𝑡ℎ𝑦   
 
𝑜𝑟 𝑁𝑃𝐶1 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 𝑐𝑎𝑟𝑟𝑖𝑒𝑟. 𝐼𝑛 𝑡ℎ𝑖𝑠 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛, 𝐹𝑗  𝑎𝑟𝑒 𝑡ℎ𝑒 𝑝𝑟𝑖𝑛𝑐𝑖𝑝𝑎𝑙 𝑐𝑜𝑚𝑝𝑜𝑛𝑒𝑛𝑡𝑠 𝑢𝑠𝑒𝑑 
 
 𝑎𝑛𝑑 𝑌𝑜 𝑡ℎ𝑒 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑙𝑖𝑛𝑒.  
 
  𝑂𝑛 𝑡ℎ𝑒 𝑜𝑡ℎ𝑒𝑟 ℎ𝑎𝑛𝑑, 𝑘 𝑖𝑠 𝑡ℎ𝑒 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑟𝑖𝑛𝑐𝑖𝑝𝑎𝑙 𝑐𝑜𝑚𝑝𝑜𝑛𝑒𝑛𝑡𝑠 𝑡ℎ𝑎𝑡 ℎ𝑎𝑣𝑒 𝑏𝑒𝑒𝑛 
 





𝐹𝑟𝑜𝑚 𝑡ℎ𝑒 𝑃𝐶𝐴 𝑓𝑎𝑐𝑡𝑜𝑟 𝑙𝑜𝑎𝑑𝑖𝑛𝑔, 𝑖𝑡 𝑖𝑠 𝑒𝑠𝑡𝑎𝑏𝑙𝑖𝑠ℎ𝑒𝑑 𝑡ℎ𝑎𝑡 𝐹𝑗  𝑖𝑠 𝑎 𝑙𝑖𝑛𝑒𝑎𝑟 𝑐𝑜𝑚𝑏𝑖𝑛𝑎𝑡𝑖𝑜𝑛 
  
 𝑜𝑓 𝑡ℎ𝑒 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒𝑠 𝑋𝑖. 𝑇ℎ𝑢𝑠 𝑖𝑡 𝑐𝑎𝑛 𝑏𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑒𝑑 𝑎𝑠 𝑓𝑜𝑙𝑙𝑜𝑤:      
 
𝐹𝑖 = 𝛼1𝑋1 + 𝛼2𝑋2 + 𝛼3𝑋3 + ⋯+ 𝛼𝑛𝑋𝑛: (𝟑𝟖) −  𝐺𝑖𝑣𝑖𝑛𝑔 𝑡ℎ𝑒 𝑓𝑜𝑙𝑙𝑜𝑤𝑖𝑛𝑔  
 
 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑏𝑒𝑙𝑜𝑤   𝐹𝑖 = ∑ 𝛼𝑖𝑋𝑖
𝑖≤𝑛
𝑖=1 ∶ (𝟑𝟗)     
   
𝑇ℎ𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 𝛼𝑖 𝑖𝑠 𝑏𝑎𝑠𝑒𝑑 𝑜𝑛 𝑡ℎ𝑒 𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛𝑠ℎ𝑖𝑝 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑡ℎ𝑒    
 
𝑓𝑒𝑎𝑡𝑢𝑟𝑒𝑠 𝑎𝑛𝑑 𝑡ℎ𝑒 𝑃𝐶𝑠; 𝑤ℎ𝑒𝑟𝑒 𝑖 ≤ 𝑛 𝑎𝑠 𝑖𝑡 𝑑𝑒𝑝𝑒𝑛𝑑𝑠 𝑜𝑛 𝑡ℎ𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑒𝑎𝑡𝑢𝑟𝑒𝑠 𝑢𝑠𝑒𝑑  
 
𝑡𝑜 𝑑𝑒𝑓𝑖𝑛𝑒 𝑡ℎ𝑒 𝐹𝑖 . 𝐵𝑦 𝑟𝑒𝑝𝑙𝑎𝑐𝑖𝑛𝑔 (34) 𝑏𝑦 𝑖𝑡𝑠 𝑣𝑎𝑙𝑢𝑒 𝑖𝑛 (32), 𝑖𝑡 𝑐𝑜𝑚𝑒𝑠 𝑡ℎ𝑎𝑡:  
 
𝑙𝑜𝑔𝑖𝑡 (𝑝) =  ln (
𝑝
1 − 𝑝






∶ (𝟒𝟎) − 𝑡ℎ𝑎𝑡 𝑖𝑠 
 𝑌 = ∑𝑟𝑗  
𝑗≤𝑛
𝑗=1
 (𝛼𝑗1𝑋1 + 𝛼𝑗2𝑋2 + ⋯+ 𝛼𝑗𝑛𝑋𝑛) + 𝑌𝑜 ∶ (𝟒𝟏) − 𝑡ℎ𝑖𝑠 𝑔𝑖𝑣𝑒𝑠 𝑡ℎ𝑒 𝑓𝑜𝑙𝑙𝑜𝑤𝑖𝑛𝑔 
𝑌 =   𝑟1[((𝛼11𝑋1 + 𝛼12𝑋2 + ⋯+ 𝛼1𝑛𝑋𝑛))] + 𝑟2[((𝛼21𝑋1 + 𝛼22𝑋2 + …+ 𝛼2𝑛𝑋𝑛))] 
 
+⋯+  𝑟𝑚[((𝛼𝑚1𝑋1 + 𝛼𝑚2𝑋2 + ⋯+ 𝛼𝑚𝑛 𝑋𝑛))]  + 𝑌𝑜 ∶ 𝑈𝑠𝑖𝑛𝑔 𝑋𝑖 𝑎𝑠 𝑐𝑜𝑚𝑚𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟  
 
𝑖𝑡 𝑐𝑜𝑚𝑒𝑠: 𝑌 = (𝑟1𝛼11 + 𝑟2𝛼21 + ⋯+ 𝑟𝑚𝛼𝑚1 ) 𝑋1 + (𝑟1𝛼12 + 𝑟2𝛼22 + ⋯+ 𝑟𝑚𝛼𝑚2) 𝑋2  
 










: (𝟒𝟐) 𝑟𝑒𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑠 𝑡ℎ𝑒 𝑐𝑜𝑛𝑡𝑟𝑖𝑏𝑢𝑡𝑖𝑛𝑔  
 





𝑖𝑛𝑓𝑜𝑟𝑚 𝑢𝑠 𝑜𝑓 𝑤ℎ𝑖𝑐ℎ 𝑜𝑛𝑒 𝑜𝑓 𝑡ℎ𝑒𝑠𝑒 𝑓𝑒𝑎𝑡𝑢𝑟𝑒𝑠 𝑐𝑜𝑛𝑡𝑟𝑖𝑏𝑢𝑡𝑒𝑑 𝑚𝑜𝑠𝑡 𝑔𝑟𝑒𝑎𝑡𝑙𝑦 𝑡𝑜 𝑡ℎ𝑒 𝑟𝑒𝑔𝑟𝑒𝑠 
 
-𝑠𝑖𝑜𝑛 𝑙𝑖𝑛𝑒, 𝑖. 𝑒. 𝑤ℎ𝑖𝑐ℎ 𝑜𝑛𝑒 𝑖𝑠 𝑡ℎ𝑒 𝑚𝑜𝑠𝑡 𝑖𝑚𝑝𝑜𝑟𝑡𝑎𝑛𝑡 𝑚𝑎𝑟𝑘𝑒𝑟 𝑖𝑛 𝑡ℎ𝑖𝑠 𝑟𝑒𝑔𝑒𝑠𝑠𝑖𝑜𝑛 𝑎𝑛𝑎𝑙𝑦𝑠𝑖𝑠, 
  
𝑜𝑟 𝑖𝑛 𝑡ℎ𝑖𝑠 𝑚𝑢𝑙𝑡𝑖𝑣𝑎𝑟𝑖𝑎𝑡𝑒 𝑑𝑎𝑡𝑎 𝑎𝑛𝑎𝑙𝑦𝑠𝑖𝑠. 𝐹𝑖𝑛𝑎𝑙𝑙𝑦, 𝑌 𝑐𝑎𝑛 𝑏𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑒𝑑 𝑎𝑠 𝑓𝑜𝑙𝑙𝑜𝑤: 
 
𝑌 =  ln (
𝑝
1 − 𝑝






𝑋𝑖 +  𝑌𝑜   ∶ (𝟒𝟑) − 𝑊ℎ𝑒𝑟𝑒 𝑟𝑗 𝑖𝑠 𝑡ℎ𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓  
 
𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑎𝑛𝑑 𝛼𝑗𝑖  𝑖𝑠 𝑡ℎ𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑓𝑒𝑎𝑡𝑢𝑟𝑒𝑠 𝑎𝑛𝑑 𝑃𝐶𝑠 
 
 𝑚 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑃𝐶𝑠 𝑐𝑜𝑛𝑠𝑖𝑑𝑒𝑟𝑒𝑑 𝑡𝑜 𝑒𝑥𝑝𝑙𝑎𝑖𝑛 𝑡ℎ𝑒 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑣𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑙𝑒𝑣𝑒𝑙,  
 
𝑛 𝑡ℎ𝑒 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑒𝑎𝑡𝑢𝑟𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑑𝑎𝑡𝑎𝑠𝑒𝑡 𝑎𝑛𝑑 𝑌𝑜 𝑡ℎ𝑒 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡. 
 
𝑇ℎ𝑒 𝑣𝑎𝑙𝑢𝑒 𝑝 𝑟𝑒𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑠 𝑡ℎ𝑒 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 ℎ𝑎𝑣𝑖𝑛𝑔 𝑡ℎ𝑒 𝑑𝑖𝑠𝑒𝑎𝑠𝑒.  
 
 𝑇he term 𝐾𝑖𝑗 that is a sum of product corresponds to the  slot of the regression line.  
 
The value of𝐾𝑖𝑗 rerpresents the multiplicative factor by which each feature contributes 
 
to the regression line Y. Therefore, knowing the value of 𝐾𝑖𝑗  𝑤𝑖𝑙𝑙 𝑎𝑠𝑠𝑖𝑠𝑡 𝑖𝑛 𝑓𝑒𝑎𝑡𝑢𝑟𝑒  
 
𝑟𝑎𝑛𝑘𝑖𝑛𝑔𝑠, 𝑎𝑛𝑑 ℎ𝑒𝑛𝑐𝑒 𝑤𝑖𝑙𝑙 ℎ𝑒𝑙𝑝 𝑢𝑠 𝑡𝑜 𝑑𝑒𝑐𝑖𝑑𝑒 𝑤ℎ𝑖𝑐ℎ 𝑓𝑒𝑎𝑡𝑢𝑟𝑒𝑠 𝑎𝑟𝑒 𝑡ℎ𝑒 𝑚𝑜𝑠𝑡  
  
𝑖𝑚𝑝𝑜𝑟𝑡𝑎𝑛𝑡 𝑏𝑖𝑜𝑚𝑎𝑟𝑘𝑒𝑟𝑠 𝑖𝑛 𝑡ℎ𝑖𝑠 𝑟𝑒𝑠𝑒𝑎𝑟𝑐ℎ.  
 
Consideration: 
𝑅𝑒𝑓𝑒𝑟𝑟𝑖𝑛𝑔 𝑎𝑔𝑎𝑖𝑛 𝑡𝑜 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛 (𝟑𝟓), 𝑡ℎ𝑒 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑝 𝑐𝑎𝑛 𝑏𝑒 𝑟𝑒𝑤𝑟𝑖𝑡𝑡𝑒𝑛 𝑎𝑠 𝑓𝑜𝑙𝑙𝑜𝑤  





𝑗=1 𝑋𝑖 +  𝑌𝑜)




𝑗=1 𝑋𝑖 +  𝑌𝑜)










𝑗=1  𝑋𝑖)  exp( 𝑌𝑜)




𝑗=1 𝑋𝑖)  exp( 𝑌𝑜)]
 ∶ (𝟒𝟒); 
 
ℎ𝑒𝑛𝑐𝑒 𝑏𝑦 𝑑𝑖𝑣𝑖𝑑𝑖𝑛𝑔 𝑏𝑦 exp( 𝑌𝑜) 𝑖𝑡 𝑐𝑜𝑚𝑒𝑠 𝑡ℎ𝑎𝑡  𝑝 𝑐𝑎𝑛 𝑏𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑒𝑑 𝑎𝑠 𝑓𝑜𝑙𝑙𝑜𝑤 
 





𝑗=1 𝑋𝑖)  




𝑗=1 𝑋𝑖)  
∶ (𝟒𝟓) 𝑇ℎ𝑒 𝑡𝑒𝑟𝑚 exp(−𝑌𝑜)  𝑖𝑠 𝑎 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡. 
 






𝑿𝒊) ∶ (𝟒𝟔) 𝑖𝑠 𝑡ℎ𝑒 𝑜𝑛𝑙𝑦 𝑡𝑒𝑟𝑚 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑖𝑏𝑙𝑒 𝑓𝑜𝑟  
 
the variation in the contribution to the determination of the probability value p. 
Practically, in the sum of the product of the coefficients (SPC) method, the values αji are 
obtained from the factor loadings, while MLR is run using the factor scores vectors as a new 
dataset to generate the coefficients of regression rj. The coefficients of regression are then used 
in the factor loadings matrix and determined for every row, and the contribution of each 




𝑗=1 .    The results of the 
technique are explained in more detail in the results section below. 
 
 Exponential of the Sum of the Product of the Coefficients (ESPC) Method.  
This alternative method uses the exponential value of the sum of the products of the two 
coefficients. The expression (10) established above justifies the rationale behind the (ESPC) 
method. The scalar generated allows us to classify features based on their exponential values. 
In this manner, negative coefficient will add some positive effect on the overall performance, 
because the function exponential being a positive and ascendant function therefore:  
 
∀ (𝑎, 𝑏) ∈ ℝ2, 𝑖𝑓 𝑎 ≥ 𝑏  𝑡ℎ𝑒𝑛  exp(𝑎) ≥ exp (𝑏).   
 
The values obtained and the techniques implementation, together with the result of the ranking 








To the best of the researcher’s knowledge, no one has established such techniques with regard 
to PCR features ranking related to biomarkers discovery, or any such study based on the use of 
the principal components regression (PCR).  
 
This extensive presentation of the different ranking techniques including the Heuristic, SPC, 
and the ESPC ones completed data multivariate analysis models employed. The results, 
especially the biomarkers discovered can now be interpreted and discussed with the overall 
techniques and models subjected to validation processes that confer more creditability to the 
whole intelligent tri-modelling technique and the findings.  
 
4.5. Research Validation  
 
4.5.1. Definitions  
The term validation is a broad term that can have various interpretations depending on the 
area the research is applied to. Therefore, validity is said to be contextually related (Bapir, 
2010). Validity is related to the extent to which an instrument can correctly perform the 
measurement it is supposed to make. In this respect, external validity is concerned with the 
generalizability of the measurement taken, while the internal validity assesses whether the 
measurement allows researcher to determine what he/she wants to know, what he/she has been 
researching on, etc. (Bapir, 2010). The validity of research results is of paramount importance, 
with researchers having to strive to make sure that their research method, including the 
findings, are valid and in line with appropriate standards (LeCompte and Goets, 1982; 
Research Rundowns, 2009). 
 
The present research work’s validity is tested and measured against standards using two main 
channels, including techniques employed during data analysis results, and the intelligent task 
technology fit models for research method alignment. A standard allows us to establish and 
define a unit of measurement, to give a reference for an instrument, a set of steps or ‘norm’ in 
a process in such a manner, that other instruments can be calibrated, or other process can tested 




is an extension of the task technology fit model (TTFM) developed by Goodhue and Thompson 
in 1975, and is therefore validated against the TTFM used as a standard (Aguinaldo, 2004; 
Goodhue and Thompson, 1995). Based on this, the state of the ITTFM model attained a higher 
level of precision. Thus, a set of activities were defined to allow us to assess research processes 
reaching that of the standard in relation to further the use of CITs in the detection of biomarkers. 
In addition, a threshold was established to measure the standard level achieved by the model. 
For example, the performance rate was set 0.80. This included achieving the standard level in 
visualisation, classification, feature ranking, biomarkers discovery, etc. In this manner, the 




4.5.2. Intelligent Technology Task Fit Model for Validation 
The intelligent technology task fit model (ITTFM) was applied in this research study, but also 
as a research result and model validation technique. The alignment model defined is used to 
determine to what extent the data analysis technique at each stage is aligned with the task to be 
performed. In addition, if the performances are above the acceptance threshold, then 
combinations of criteria allow us to validate the research model developed and the results 
obtained. In contrast to the Goodhue and Thomson (1995) task technology model that was 
developed and based on users’ acceptance of a model, their perception ease to use of a 
technology, and also the advantages and disadvantages of the technology in relation to the task 
to be performed, etc. (D’Ambra et al., 2013) to assess the model performance, the extension 
model applied here uses the CITs performances in terms of modelling to assess it. Therefore, 
the importance of visualisation, classification, ranking and biomarker discovery were used to 
judge the model fit for purpose against an established standard of acceptance. This indicates 
that the model is being assessed and validated against its practical performances, which are 
sketchy at best using valid performance metrics such as ROC AUC, with associated standard 
deviations and the 95% confidence intervals (Hummel et al., 2011; Kounev and Gorton, 2008).  
The Table below assesses the ITTFM model using data analysis results, establishes the 
alignment level, and determines its fitness for this purpose based on the performance 









Alignment Level Intelligent-Fit 
 
 Meeting Standard 
– Conditions 
SVA . Selection and 
ranking performance 
r ≥ 0.8 = r0 
 
Very Good data 
visualisation and 
separation; hence 
alignment level  
a = 0.85 
Good Performance 
Value  
Intelligent Model fit 
for purpose. 
SVA allowing the 
visualisation of 
major potential 
biomarker(s) r ≥ 0.8  
SVM . Iterative training 
and testing to tune 
the model with:  
Av. Gmean ≥ 0.82 
Av. ROC AUC ≥ 
0.83 
Excellent rate of 
classification.  
Alignment level 
 a ≥ 0.85 
Very Good 
Performance  




diseased and wild 
treated individuals. 
Gmean = 0.8 
ROC AUC = 0.8 
PCA . Accurate selection 
of relevant PCs 
rate  ≥ 0.8 
Very Good PCs 
leading to potential 
biomarker 
discovery.  
Alignment level  
a ≥ 0.85 
Good Performance 





Selection rate ≥ 0.8 
PCR . Modelling Quality:  
Av. Gmean ≥ 0.85 
Av. ROC AUC ≥ 
0.87 
. Regression Quality:  
Av. Gmean ≥ 0.85 




Alignment level  
a ≥ 0.85 
Very Good 
modelling rate. 
Alignment level   a 
≥ 0.85  
Very Good 
Performance  
Intelligent Model fit 
for purpose. 
PCR detecting major 
potential biomarkers:  
ROC AUC ≥ 0.8  
 
Table 3. ITTFM assessment based on the relative performance of each model, in relation to 
defined characteristics such as alignment level, performance threshold, and the intelligent 




relation to the performance level established at 80%. The diagram below shows the relationship 
between the algorithms involved in this modelling.  
 
4.5.3. Relationship between the Three Models Apply in the Research 
 
 






Using the intelligent tri-modelling techniques (ITMTs), SVA allows to visualise the internal 
data structure highlighting area of defect in the samples analysed, while OSVM allows to 
establish a segregation between diseased and healthy subjects. Finally, PCR correlates the 
disease features to the disease development. All these will be further developed and detailed 
later in this thesis. 
  
Nevertheless, the results of the analysis performed must be validated in order to provide more 
credit to the techniques and models developed as also presented in Figure 3 above. The next 





4.5.4. Data Analysis Techniques and Validation  
Throughout this thesis, the two dataset analysis techniques results were validated against 
established results measurement standards using different methods and techniques, including: 
1) The nearest neighbour features selection approach allowing the selection of the key features 
that can improve the OSVM overall performances, and they can be also potential biomarkers 
(Lazzarini and Bacardit, 2017; Wang et al., 2005). 
 
2) The oversampling technique based on the ADASYN sampling approach, where synthetic 
data are generated in the minority class, which is harder to learn in order to balance the dataset 
and facilitate the learning stage (He et al., 2008). Indeed, learning algorithms can easily 
accommodate and learn large sets than they do with small sets.  
 
3) The k folds stratified cross-validation approach allowing division of the main dataset into 
training and testing sets and repeat this technique k times across the dataset in order to use the 
whole dataset alternatively as training and testing sets (Scikit Learn, 2016; Schneider, 1997). 
 
4) The intelligent technology task fit model (ITTFM) uses, a set of thresholds to classify the 
data analysis technique, especially the algorithm supporting it into one of the highest classes 
of alignment level, in order to perfectly align and ascertain that the model is fit for purpose. 
Indeed, the intelligent modelling process (IMP) could be used in combination with the ITTFM 
for example in thresholds setting.   
 
5) The results of the analysis were based on validated performance metrics, including the ROC 
AUC and Gmean parameters. In addition, the standard deviation and the 95% confidence 
interval were provided for classification in the OSVM model. The detection of potential 
biomarkers that encompasses well-known biomarkers such as isoleucine, leucine, valine, 
Citrate, N-acetyl-4-O-acetylneuraminate, and glutamine etc., in the SVA model. Finally, 
potential biomarkers were detected using the PCR model, and that includes pyruvate, 
glutamate, taurine, hypotaurine, hippurate, adipate/n-butyrate, etc., for the NPC1 disease 
diagnosis. Other less well-known potential biomarkers were also detected, including adipate, 
hippurate, trigonelline, xanthine, etc. in the NPC1 liver dysfunction disease diagnosis. 
The combination of these different techniques applied throughout this research has ensured that 






4.5.5. Biomarkers Clinical Validation Technique 
While the notion of validation in qualitative research is believed not to be a deterministic 
process, meaning that researchers do not have to demonstrate their methodology, their findings, 
etc., is valid or not, but should be perceived as a continuous process. However, quantitative 
research forces the researcher to go through the process of validation in a deterministic manner, 
i.e. researchers have to prove the validity of their work (Aguinaldo, 2004; Muijs, 2004). In this 
respect, it is understood that more accurate diagnosis and assessment of disease upstream 
should give more insight into disease development, and hence give clinical trials more weight 
in disease research, including useful diagnosis capability and important benefits regarding 
disease treatments. To be approved as a clinically valid test, potential biomarkers detected 
should undergo scrutiny with hundreds of samples being validated, and with a possibility to 
repeat and reproduce these tests, with high specificity, and sensitivity (Zhang et al., 2015).  
 
Biomarkers discovered can be used as a clinical test in order to perform an early test for NPC1 
disease diagnosis, while monitoring its progression. Relevant clinical tests to put in place in 
order to validate biomarkers discovered in this thesis, including adipate, methionine, 
hypotaurine, lysine, ornithine, phenylalanine, nicotinate, and xanthine, may now be based on 
miglustat therapy, the only available and valid treatment to the NPC1 disease approved by the 
American Food and Drugs Administration (Heron et al, 2012). Miglustat has shown to have a 
positive effect, i.e. a stabilising effect on many clinical biomarkers discovered in the study of 
the NPC disease (Patterson et al., 2007). Miglustat is an iminosugar, an inhibitor that plays a 
crucial role in the mice type of NPC disease, by reducing the accumulation of complex lipids 
such as gangliosides in the brain, and in such a manner that it delays the onset of the 
neurological dysfunction, and finally prolongs life expectancies for the diseased rodents. In 
humans, the administration of miglustat to NPC disease patients improves their condition 
considerably, including the amelioration of lipid trafficking, reduction of glycosphingolipid, 
reduction of pathological lipid storage, with an improvement in the endosomal uptake 





In this respect, Patterson et al., (2007) used miglustat to treat NPC disease patients, postulating 
that the administration of the drug would slower the rate of decline of the patients in certain or 
all the biomarkers detected. Two main groups were used for this study, and these included 
those which were miglustat-treated and the care control groups. A group of 20 young NPC 
patients aged 12 years or more received a daily miglustat treatment of 3 x 200 mg, while another 
cohort of 9 children, same age group received a normal care. Both groups were monitored for 
one year. A third group of 12 children, younger than the precedent groups received also 
miglustat treatment, with an appropriate dose related to their body surface. In an extended 
study, the participants were all treated with miglustat for an additional year. The correlation of 
the disease progression and the velocity of the horizontal saccadic eye movement (HSEM) was 
studied. The first series of treatment revealed that the cohort receiving miglustat treatment had 
an improved HSEM compared to the ones who did not receive the miglustat treatment. In 
addition, the overall result showed an improvement in the quality of life of patients under 
miglustat therapy compared to the control group. Areas of improvement included swallowing, 
auditory acuity, and a slow decrease in the ambulatory stability for the patients aged 12 years 
or older treated with miglustat, where the drug tolerability was high (Patterson et al., 2007).  
 
However, based on this study it is difficult to determine which biomarker is responsible for the 
amelioration of their life condition as mentioned above. Indeed, biomarkers GM2 and GM3 
gangliosides concentration increased in diseased neurons, while the accumulation of 
cholesterol and glycosphingolipids is observed in many tissues (Patterson et al., 2007). 
Therefore, the present research can be improved by including the biomarkers as part of the 
variables studied and following the variation of their individual concentrations in both control 
and NPC disease patient groups in order to monitor response to the miglustat therapy on disease 
progression (Giese et al., 2015). Modification in the concentrations of biomarkers will signify 
their active involvement in miglustat therapy processes.  
 
In another study, Probert et al., (2017) used 1H NMR datasets containing information on  
miglustat-treated and untreated, and also heterozygotes and healthy control subjects. 1H NMR 
data generated were analysed using advanced multivariate techniques. The regions of high-
density-lipoprotein (HDL) triacylglycerols of the spectra was found to be effective for 
segregation between NPC1 disease and heterozygotes patients. In the same study conducted, 
the investigation was based this time based on NPC1 disease and healthy controls patients. It 




of lipoprotein triacylglycerol and isoleucine. The 1H NMR profile of NPC1 patients might be 
related to the liver dysfunction associated with the disease. Potential biomarkers were identified 
due to the 1H NMR signal of heterozygotes subjects compared to healthy control ones. 
Additionally, the increase level of amino acids observed might be ascribable to the liver 
parenchyma necrosis related to hepatic fibrosis (Probert et al., 2017). 
 
Heron et al., (2012), used miglustat to treat three main categories of patients. These included 
those with early-infantile neurological onset, patients with late-neurological onset, and patients 
with juvenile neurological onset. The parameters included in their study are clinical parameters 
of neurological disease (NPC functional disability scale, epileptic seizure, cataplexy, video 
recording); whilst laboratory parameters encompasses liver function and haematology. Finally, 
other parameters included psychometric evaluation, hearing, and abdominal ultrasound. 
Descriptive statistics were used as the only way of analysis for the observation of the clinical 
changes. The results obtained showed that for early–infantile neurological disease patients, 
disease progression was slower; however, after 18 months the disability, the score increased as 
a sign of disease progression. Late–infantile neurological disease patients’ disability scale score 
showed an overall stabilisation or improvement of the neurological parameter, with patients 
being freed from seizures after 5 months of miglustat therapy. For juvenile neurological onset 
patients, the disability score scale indicated mix outcomes, i.e. improvement then stabilisation 
for patients, and then use of an alternative therapy to control patient’s cataplectic episodes. 
Overall, miglustat therapy produced more beneficial effect on late-juvenile patients than on 
early-juvenile ones (Heron et al., 2012). The introduction of surface metabolite levels following 
magnetic resonance spectroscopy (MRS), allowed researchers to compare the ratio of three 
main biomarkers, including N-acetyl-aspartate [NAA], creatine [Cr], and choline [Cho]. In 
addition, MRS enabled the identification of some abnormalities in the spectrum, with low NAA 
and/or high Cho producing an increased Cho/NAA ratio. Given that NAA is known to represent 
a biomarker of neuronal viability, its decreases in concentration are consistent with progressive 
neurodegenerative diseases progression, whilst the increase in Cho, which is believed to be a 
biomarker for membrane destruction or related to gliosis, is also consistent with the effect of 
miglustat on NPC disease patients (Heron et al., 2012). This study revealed also that the early 
the miglustat therapy started, the better the effect of the therapy on patients. For those who 
were administered the miglustat treatment late, such as 4.8 years after the disease onset, the 





These last two studies show possible validation routes for the drug miglustat, together with the 
biomarkers included in the research performed here. Therefore, the ratio NAA/Cr, Cho/Cr, and 
Cho/NAA or only the variation in the concentration of each one of these biomarkers, could, at 
least in principle, be used to validate the biomarkers discovered. For example, the study did 
propose the high Cho level producing high Cho/NAA ratios as a marker for this therapeutic 
effect for late-infantile and forms of the disease manifestation, but not for the early-juvenile 
form. Similarly, the increase in concentration of hippurate [Hi] and adipate [Ad] in blood 
plasma samples of NPC1 disease patients when compare to wild type (WT), healthy individuals 
would indicate an active involvement of these biomarkers in miglustat therapy. This process 
can be used as a validation route for the biomarkers (hippurate and adipate) detected in this 
PhD thesis. The lack of available material did not allow the validation to be implemented in 




4.5. Chapter Summary  
 
The research design chapter includes an introductory section that highlights the main sub-
sections of the chapter. Next is discussed the mixed experimental research method, which 
mentions the combination of fieldwork and the laboratory-based research involved in data 
collection. The biomedical data related to the NPC1 disease dataset collection was conducted 
by collaborative research institutes in Maryland, USA and Oxford, UK. The metabolomics data 
collection related to the NPC liver disease is then outlined. Further, data analysis tools were 
visited, giving detailed involvements of each of them in the development of the intelligent tri-







“The only way not to succeed is not to try” 
   
                        Edward Teller 
 
5. DATA ANALYSIS AND RESULTS 
 
5.1. Introduction 
The preceding Chapter (Research Design) explained the “mixed experimental” research 
method, which combined a fieldwork and a laboratory-based research methods.  Computational 
Intelligent Technologies (CITs), including the scalar visualisation algorithm (SVA), the 
optimum support vector machine (OSVM) and principal component regression (PCR) involved 
in the data analysis formed a network of three major algorithms. They are applied in this 
multivariate analysis of metabolomics datasets based on the modelling of the Niemann-Pick 
Class 1 (NPC1) disease and NPC liver dysfunction disease (NPC LDD) datasets. Therefore, 
the modelling and data analysis techniques used are termed intelligent tri-modelling techniques 
(ITMTs). Beyond the modelling based on the numerical values (digits) contained in the 
datasets, the ITMTs enable an understanding of the underlying transformations occurring at 
molecular level in relation to the NPC1 disease and the NPC liver dysfunction disease (NPC 
LDD) diagnosis.  
 
The first model developed, the SVA, provides some insights regarding a preliminary 
understanding of data structures. By creating a ‘pointer’ based on data values, the algorithm 
can assign those values to a set of colours held on a “colour look-up” table. In this manner, data 
dimensionality reduction which is, necessary for the mapping of data from higher to lower 
dimensionalities (2D) representation can be achieved, while coloured maps can highlight the 
internal data structure.  
 
The second modelling phase is related to the use of the OSVM as a powerful algorithm for a 
deterministic classification that discriminates between diseased individuals and healthy 




the exact feature (s) responsible for the underlying transformations at the molecular level, 
principal components regression (PCR) is applied as a model, allowing a probabilistic 
determination of potential biomarkers discovered in the different datasets explored.  
 
5.2. Intelligent Tri-Modelling Techniques and the NPC1 Disease Dataset 
Multivariate Analysis  
 
5.2.1. Introduction 
The detection of biomarkers can be a possible solution to detect NPC1 disease’s first 
symptomatic appearance, and perhaps also its progression. These tri-modelling techniques can 
be used to scrutinise the NPC1 disease dataset and determine biomarkers involved. Thus, the 
tri-modelling techniques applied includes a Matlab model for the NPC1 disease dataset 
visualisation, the optimum support vector machine (OSVM) for the dataset classification, and 
principal component regression (PCR) for potential biomarker detection.  
 
Principal components regression (PCR) is implemented as a combination of the principal 
component analysis (PCA) and the multiple logistic regression (MLR) of the principal 
component scores vectors previously generated through PCA. For the OSVM and PCR, use of 
classification metrics such as the geometric means (Gmean), the receiver operating 
characteristic area under the curve (ROC AUC), confidence intervals (CIs), and the standard 
deviation(Std) will be used to assess the models’ performance in order to validate the 
biomarkers discovered. The dataset involved this modelling process is below described.  
 
5.2.2. Description of the NPC1 Disease Dataset   
 Description 
The NPC1 disease dataset encompasses 130 observations and 55 features (chemical shifts). 
They were obtained using NMR spectroscopy on blood samples collected from human subjects 
in hospital setting. The NMR spectrometry generates spectra amplitudes against radio 
frequency converted into chemical buckets expressed in ppm (part per million). Initially 133 




the rows with 0 values (1 observation) and rows with duplicated values (2 observations). The 
remaining 130 were carried forward for analysis. Amongst these, 71 were blood samples 
collected from healthy control subjects and the remaining 59 were NPC1 disease patients. The 
statistics obtained using XLSTAT are briefly shown below, the full set of this summary 




Different statistics were generated from the XLSTAT software and are included in the 
following Table 4. 
 
 
Table 4. Part of the summary statistics obtained from XLSTAT running PCA of the NPC1 
disease dataset of human-model. The variables are chemical buckets with the means and 
standard deviation shown on the right hand-side. The very low standard deviation show that 
the data point are not widely spread out (for this partial summary statistics). 
 
 
This visualisation of the internal data structure of the NPC1 disease (human-model) and the 
series of developmental processes involved in the data analysis are outlined below.  
 
5.2.3. NPC1 Disease Data Visualisation  
 Scalar Visualisation Algorithm and the NPC1 Disease (Human-model) Dataset 
Summary statistics:
Variable ObservationsOb . with missing dataObs. wi hout missing dataMinimum Maximum Mean Std. deviation
[0.68 .. 0.71] 130 0 130 0.000 0.003 0.001 0.000
[0.71 .. 0.73] 130 0 130 0.000 0.002 0.001 0.000
[0.73 .. 0.75] 130 0 130 0.000 0.002 0.001 0.000
[0.75 .. 0.77] 130 0 130 0.000 0.003 0.001 0.000
[0.77 .. 0.79] 130 0 130 0.000 0.004 0.002 0.001
[0.81-0.89] 130 0 130 0.095 0.187 0.132 0.018
[0.89 .. 0.95] 130 0 130 0.016 0.051 0.028 0.005
[0.95-1.06] 130 0 130 0.019 0.038 0.028 0.004
[1.13 .. 1.15] 130 0 130 0.000 0.006 0.002 0.001




Matlab as a matrix-based computational language allows us to develop mathematical models 
for the analysis of datasets in general, and that of the current NPC1 dataset, in order to gain 
insights from the disease data (MathWorks, 2016). Two main options exist for Matlab to 
generate graphs. This includes the option of creating graphs through the Matlab toolbox, or 
entering in the command window the Matlab graphics command. The first option was chosen 
for its flexibility and allows Matlab to work as an unsupervised ‘learner’ that uses data 
presented to it, and model it in such a manner that the hidden underlying information related to 
the data features are made apparent. Therefore, Matlab, using the scalar visualisation 
algorithms (SVA), generates such plots. They allow the visualisation and targeting of important 
features involved in NPC1 disease (Human-model) diagnosis.  
 
The colour mapping algorithm (CMA) maps scalar in the dataset to a specific colour in the 
colour look-up table, and hence defines a colour as a function of a scalar in the dataset (Komura, 
2016; MathWorks, 2016a).  Assorted colours are used to represent distinct regions in the 
dataset in such a manner that differences in the underlying data structure can be perceived and 
highlighted. However, the contouring or isosurfaces algorithm allows the construction of 
delimitation zones between different parts of the dataset. In this manner, the structural 
difference in the dataset can be identified. The application of these two algorithms generates 
the following graphs, in which the main features have been detected. 
 
 
Figure 5. Plasma full boxplot showing features in order of importance according to the intensity 
level in the boxplot 13, 14, 6, 7, 8, 32, 25, 24, 33, 37, 28, 27, and 34 corresponding respectively 
to the following chemical shifts 1.21-1.31, 1.31-1.37, 0.81-0.89, 0.89-0.95, 0.95-1.03, 2.52-
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most important biomarkers in the NPC1 disease (human-model) diagnosis. These correspond 




Figure 6. Plasma contour plot showing brighter colour for the main features 13, 14, 6, 7, 8, 32 
and 25, 26. The values on the x axis correspond to the 55 features present in the plasma dataset. 
The corresponding biomolecules have 1H NMR of chemical shift buckets 1.21-1.31, 1.31-1.37, 
0.81-0.89, 0.89-0.95, 0.95-1.06, 2.52-2.58, 2.03-2.09, 2.09-2.12 ppm corresponding 
respectively to (R)-3-hydroxybutyrate, L-fucose, lactate; 3-hydroxyisovalerate, 
hexacosanoate, L-isoleucine, leucine, valine, Citrate, N-acetyl-4-O-acetylneuraminate, and 
glutamine respectively that are considered as potential biomarkers in NPC1 disease diagnosis. 
 
 
Figure 7. Plasma filled contour plot showing brighter colour for the features 13, 14, 6, 7, 8, 32, 
25; since the values on the x axis correspond to the 55 features present in the plasma dataset. 
Plasma Contour Plot - Main Features Highlight
 
 















Plasma Filled Contour Plot - Main Features Highlight
 
 



















The corresponding biomolecules have 1H NMR of chemical shift buckets 1.21-1.31, 1.31-1.37, 
0.81-0.89, 2.52-2.58, 2.03-2.09 ppm corresponding respectively to (R)-3-hydroxybutyrate, L-
fucose, lactate; 3-hydroxyisovalerate, L-isoleucine, leucine, valine, Citrate, and N-acetyl-4-O-
acetylneuraminic acid respectively that are considered as potential biomarkers in NPC1 disease 
(human model) diagnosis.  
 Consideration 
The SVA using the technique of look-up table transforms the peak amplitude values into 
colours from bleu (low) to orange (high). 
 
 Results and the Data Analysis 
Results of the scalar visualisation process have been grouped in the following table in order to 















Boxplot 13, 14, 6, 32, 
25, 24, 33, 37, 
28, 27, 34 
[1.21…1.31] [1.31...1.37] 
[0.81…0.89]  [2.52…2.58]  
[2.03…2.09] [1.98…2.03] 
[2.68…2.74] [5.26…5.37] 






CH3; 2-hydroxyglutarate; Citrate; 
α-Glucose; Allantoate; Pyruvate; 
Glutamate; Methionine; Glutamine; 
Trimethylamine 
Plot 13, 14, 6, 32, 
25, 24, 33, 37  
[1.21…31] [1.31…1.37] 
[0.81…0.89]  [2.52…2.58]  
[2.03…2.09]  [1.98…2.03] 












13, 14, 6, 32, 
25, 24, 33, 37, 
28, 27, 34 
[1.21…1.31] [1.31…1.37] 
[0.81…0.89]  [2.52…2.58]  
[2.03…2.09] [1.98…2.03] 
[2.68…2.74] [5.26…5.37] 






CH3; 2-hydroxyglutarate; Citrate; 
α-Glucose; Allantoate; Pyruvate; 




13, 14, 6, 32, 
25, 24, 28, 27, 
34 
[1.21…1.31] [1.31…1.37] 








CH3; 2-hydroxyglutarate; Pyruvate; 
Glutamate; Methionine; Glutamine; 
Trimethylamine 
Contour Plot 13, 14, 6, 7, 
32, 25, 33 
[1.21…1.31]  [1.31…1.37]  
[0.81…0.89] [0.89…0.95]  
[2.52…2.58]  [2.03…2.09]  
3-Hydroxybutyrate; L-Fucose;      
3-Hydroxyisovalerate; Lactate; 
Hexacosanoate; isoleucine;              




Table 5. Patterns of features detected in the NPC1 disease dataset, independently of the data 
visualisation plotting technique – Chemical shifts and potential biomarkers names. 
 
 Considerations  
Two important plotting techniques were applied in the NPC1 disease dataset. The colour map 
algorithm (CMA) is based on the definition of a function between the scalars values in the data 
matrix and used as index to locate the colours stored in the colour look-up table. This technique 
allowed the mapping and plotting of the 76 features resonances for 159 samples collected 
during the fieldwork and the laboratory-based research. The plots generated include plot, 




14, and 6 corresponding to the following biomolecules 3-hydroxybutyrate; L-fucose; 3-
hydroxyisovalerate; lactate; hexacosanoate as the most important ones for NPC1 disease 
(human-model) diagnosis. Other features were found to be important during the data 
visualisation process, including features 32, 25, 24, 33, 37, 28, 27, and 34 corresponding to the 
biomolecules listed below N-acetylaspartate; N-acetylneuraminate; N-acetyl-X-CH3; 2-
hydroxyglutarate; Citrate; α-Glucose; allantoate; pyruvate; glutamate; methionine; glutamine. 
The colour coded technique applied is from blue (low) to red (high) peak intensities.  
 
However, the contouring algorithm creates boundaries between different regions of the data 
characterised by constant amplitude or intensity values. The plots generated through this 
technique selected features 13, 14, and 6 as the most important ones for NPC1 disease. Other 
features, including 32, 25, 24, 33, 37, 28, 27, 34 corresponding to the biomolecules listed below 
N-acetylaspartate; N-acetylneuraminate; N-acetyl-X-CH3; 2-hydroxyglutarate; Citrate; α-
Glucose; allantoate; pyruvate; glutamate; methionine; glutamine were considered important, 
but to a lesser degree.     
 
Furthermore, feature 7 detected by the contour plot as an important feature was classified by 
the boxplot as a zero none deterministic feature in the dataset. These results related to the 
importance of the features mentioned above has to be verified using alternative data analysis 
techniques such OSVM and PCR. Thus, OSVM will be employed in section 5.2.3. 
 
   5.2.4. Optimum Support Vector Machine (OSVM) and the NPC1 Disease Dataset 
Classification  
The optimum support vector machine is the second model developed in this intelligent tri-
modelling technique applied. Used as a deterministic binary classifier, it employs a hyperplane 
to segregate between two classes of individuals, typically NPC1 patients and the wild treated 
individuals (Fu et al., 2016). Below, the technique employed is dissected in order to reveal the 








 Data analysis techniques 
 
In the present research work, the OSVM is used for a binary or dichotomous classification of 
the NPC1 disease dataset based on the disease’s potential biomarker. In order to detect major 
discriminants in the NPC1 disease dataset that might inform us of the disease’s early 
development and progression, a setting is put in place to enable the OSVM classifier to 
segregate between the two classes of individuals diseased and healthy. The setting of this 
OSVM classifier involves making an optimal choice in terms of feature selection. The 
combination of choice should render the OSVM classifier to be effective and efficient with 
respect to selection of the major biomarkers. 
 
The first choice made includes the selection of the best kernel function to be used in the data 
analysis stage, i.e. choosing between linear are RBF kernel. Although the RBF kernel has been 
presented in several studies as out-performing the linear kernel and many other  classification 
algorithms (Maji et al., 2013;  Sharma et al., 2011); in this current study linear and RBF kernel 
functions are used in order to compare their performances from several runs on the actual NPC1 
disease dataset. However, combinations and optimisations of the penalty cost for 
misclassification noted in this study costC, the kernel function parameter gamma   (𝛾)   through 
the grid search algorithm was found to profoundly influence the model’s generalisability 
(Akay, 2009). Similar techniques employed in previous research have subsequently allowed 
reduction of the computational cost by using a heuristic search technique (Boardman and 
Trappenberg, 2006;  Fu et al., 2016; Maji et al., 2013; Mountrakis et al., 2011). 
 
The second choice is related to the ‘tuning’ of the OSVM classifier through costC and gamma 
selection. Gamma is considered as the inverse of the influence of sample(s) selected by the 
model as a support vector, which can be far from or close to the decision boundary respectively 
for low or high values of gamma. Therefore, it determines the generalisation and the 
complexity of the SVM built, while allowing the monitoring and the fitting of a separation plan 
between the different classes explored (Boser et al., 1992;  David et al., 2016;   Pedregosa et 
al., 2011; Verplancke et al., 2008).  
 
Notwithstanding, costC is known as a ‘penalty’ cost for misclassifying samples, i.e. it is a trade-
off between the optimisation of the margin width and minimising sample misclassification rates 




values of costC indicating a smoother decision surface, while higher values suggest more 
constraint on the classification algorithm (see 4.4.3 in CH4). This includes, for example, 
attempts to perfectly classify all the training samples, giving rise to small levels of bias (Cortes 
and Vapnik, 1995;   Pedregosa et al., 2011; David et al., 2016). 
 
For the models’ implementation, values of costC and gamma were determined through a grid 
search technique based on a heuristic one. The heuristic allows us to gain a solution for a given 
problem although it is not always the best solution, or it can simply approximate the exact 
solution to the problem (Boardman and Trappenberg, 2006; Martí and Reinelt, 2011). This 
process handled by the grid search algorithm reduces the searching space in the purpose of 
finding local minima (Woodford and Phillips, 2011). Hence, based on the precedent 
information, the algorithm approximates the result and decides on the next step that leads to 
the identification of the local maximum or the optimal solution.   
 
The third choice involves the selection of the best classifier performance metrics. The choice 
is made between the area under the curve of the receiver operating characteristics (AUC ROC), 
and the geometric mean (Gmean).    
 
The fourth choice is related to the determination of validating instance. The performance 
metrics are compared against each other, together with the standard deviation and confidence 
intervals related to those values. Therefore, the standard deviation will inform on how far from 
the mean the data values are spread. Confidence intervals for each choice, which will inform 
us regarding whether or not the values obtained fall within the 95% confidence intervals.                     
 
The fifth set of choice, which is related to the type of features and sample selection techniques 
implemented, are defined and are related respectively to the repeated k folds stratified cross-
validation (RSCV) techniques and the nearest neighbour features selection (NNFS). The RSCV 
is a cross validation technique which allows the introduction, in every single sub-set of the 
current dataset, a fair representation of each class involved in the OSVM classification. It 
generates a more reliable estimate than running a single cross-validation technique (Kim, 
2009). However, the ADASYN oversampling technique is implemented to balance the NPC1 
dataset. By generating synthetic data samples in the minority class, it aims to obtain 
approximately the same number of diseased patients and wild treated cohorts. This allows the 




majority class (Blagus and Lusa, 2012; He et al., 2008). Overall, the ‘tuning’ of these different 
parameters is a very important part of the optimisation strategy adopted in order to improve the 
overall OSVM classifier performances when compared to similar SVMs using different 
settings (Kim, 2009).  
 
 Results and analysis 
 
Different combinations of the OSVM classifier setting were used in generating the following 
results. This includes, using the nearest neighbour samples for oversampling (NNO), with the 
ADASYN algorithm. The repeated stratified K folds cross-validation simply labelled K- folds 
used (KFU) and the number of repeated stratified cross-validation (RSCV).  The proportion of 
features used (POFU) for the reliefF based features selection technique is stronger in feature 
interactions and does not really function on the basis of heuristics (Nguyen and de la Torre, 
2010). Finally, standardisation of the dataset could be set “ON” (SON) or set “OFF” (SOFF).  
The results of these combinations related to our 1H NMR plasma dataset are reported below. 
 
 OSVM Results Employing the Kernel RBF and Gmean Performance Metrics 
The general condition applicable is as follows: NNO = 10; KFU = 10; RSCV = 10; NNFS = 
10; POFU = 1; SOFF   --- RBF and Gmean --- The values in the 1st column (blue) relate to 
that general condition. Changes are included in the changed variables section.  
 
Changed Variable(s)  NNO=10 NNO=15 NNFS=15 POFU=0.5 POFU=0.75 KFU=5 
Gamma 11.65952 4.088607 3.267071 15.67023 15.50455 2.81658 
CostC 8655.016 5410.832 8837.593 547.7823 1515.231 4064.99 
Average Gmean 0.884739 0.885154 0.886074 0.886129 0.884972 0.88474 
Standard Deviation 0.012223 0.013046 0.01093 0.012036 0.013471 0.01408 
95% Confidence 
Interval 
±0.02396 ±0.02557 ±0.02142 ±0.023591 ±0.026404 ±0.0276 
 
Table 6. Modification of variables and the corresponding increases in OSVM classifier 
performances with the percentage of folds used (POFU = 0.5) giving the best average value 





 Results:  
The OSVM classifier performances using RBF kernel and the Gmean as performance metrics 
shows that an increase in oversampling, the number of nearest neighbour features selected, the 
proportion of features used, the number of K folds used and the number of repeated stratified 
cross-validations improves OSVM classifier performance. 
                                                      
These results suggest that increasing selected parameters, including NNO, KFU, RSCV, 
NNFS, and POFU increases the overall classifier power in discriminating between the NPC1 
disease patients and the wild treated individuals, with higher accuracies indicated by standard 
deviation and 95% confidence interval reductions.  
 
 
 Results and Analysis of OSVM Performances for Linear Kernel and Gmean 
Performance Metrics 
The general conditions applicable are: NNO = 10; KFU = 10; RSCV = 10; NNFS = 10; 
POFU = 1; SOFF   --- Linear and Gmean --- The values in the 1st column (blue) relate to the 
general condition. Modifications are included in the modified variables section.  
 
Modified Variable (s) NNO=10 NNO=20 NNFS=15 POFU=0.75 KFU=5 
Average Gamma        0 0 0        0       0 
Average CostC 16411.91 18577.03 15715.29 16666.77 16411.91 
Average Gmean 0.875935 0.87298 0.877246 0.864075 0.86569 
Standard Deviation 0.014592 0.013232 0.014508 0.012844 0.01609 
95% Confidence Interval ±0.028601 ±0.025934 0.028435 ±0.025174 ±0.031536 
 
 Table 7. Modifications of variables and corresponding increases in OSVM classifier 
performances and the average Gmean = 0.8711852, with the increase in the NNFS giving            
the best performance value average Gmean = 0.877246.  
 




The OSVM Classifier Performances obtained using Linear kernel and the Gmean as 
performance metrics showed that increasing the number of nearest neighbour features selected, 
the proportion of features used, the number of K folds used and the number of times the 
stratified cross-validation is repeated, ultimately improves OSVM classifier performances. 
This result suggests that increasing the different parameters including NNO, KFU, RSCV, 
NNFS, and also the POFU, increases the overall classifier power in discriminating between the 
NPC1 disease carriers and the wild treated individuals, with higher accuracies given that the 
standard deviation and the confidence intervals decrease.  
 
For this model, the increase oversampling does not show increases in OSVM classifier 
performances. This may be ascribable to several factors, such as over-fitting that renders the 
classifier to model noise instead of actual data  (Kotsiantis et al., 2006;  Lin and Chen, 2013; 
Tang et al., 2009). 
 
 Results and Analysis of the OSVM Performance Based on Linear Kernel and the 
AUC ROC Performance Metrics  
The general conditions applicable (values in the 1st column Table 7 below – in blue) are: 
NNO = 10; KFU = 10; RSCV = 10; NNFS = 10; POFU = 1; SOFF. Modified variables are 
included in the modified variables section.  
 
Modified Variable (s) NNO=10 NNO=15 NNFS=15 POFU=0.5 KFU=5 
Average Gamma 0 0      0 0 0 
Average CostC 21673.04 22804.12 23142.06 5873.269 22541.95 
Average AUC ROC 0.939407 0.93997 0.939514 0.933813 0.932763 
Standard Deviation 0.005404 0.005456 0.006524 0.005194 0.008348 
95% Confidence Interval ±0.010592 ±0.010693 ±0.012787 ±0.010181 ±0.016362 
 
Table 8. Modifications of variables and corresponding increases of the OSVM classifier 
performances, with the average value of the AUC ROC value being 0.9371 with the increase 






 Results  
OSVM Classifier Performances using the linear kernel and the AUC ROC as performance 
metrics. This shows that increasing the oversampling, the number of nearest neighbour features 
selected, the proportion of features used, and the number of k folds used in the cross-validation 
strategy employed improves OSVM performance. This result suggest that increasing the 
differing parameters, including NNO, KFU, RSCV, NNFS, and POFU increases the classifier 
power in segregating between the NPC1 disease carriers and the wild treated individuals 
(human model), with higher accuracies deriving from the corresponding standard deviation and 
the confidence interval decreases.   
 
 Results and Analysis of the OSVM Performance Based on the RBF Kernel and the 
AUC ROC Performance Metrics 
The general conditions applicable (values in the 1st column Table 8 below – in blue) are: 
NNO = 10; KFU = 10; RSCV = 10; NNFS = 10; POFU = 1; SOFF   --- RBF and AUC ROC -
--. Modified variables are included in the changed variables section.  
 
Changed Variable (s) NNO=10 NNO=15 NNFS=15 POFU=0.75 KFU=5 
Average Gamma 21.90145 14.68029 22.83431 2.026036 5.563069 
Average CostC 5598.358 578.5882 521.4192 11631.33 4963.132 
Average AUC ROC 0.944326 0.944657 0.94784 0.940831 0.94188 
Standard Deviation 0.005268 0.005126 0.006619 0.008974 0.007157 
95% Confidence Interval ±0.010326 ±0.010048 ±0.012973 ±0.017588 ±0.014028 
 
Table 9. Modifications of variables and corresponding increases in the OSVM classifier 
performances. The average value of the AUC ROC was 0.9439, where NNFS produces the best 
average Gmean = 0.94784.  
 
Results:  
The OSVM Classifier Performances obtained using the RBF kernel and the AUC ROC 
strategies as performance metrics shows that increasing the oversampling, the number of 




employed, and the number of times the stratified cross-validation was repeated, improved 
OSVM performances.  
 
The results acquired suggested that increasing the different parameters including NNO, KFU, 
RSCV, NNFS, and POFU, increased, the classifier power in segregating between the NPC1 
disease carriers and the wild treated individuals, with higher accuracies, as noted from 
decreases in the standard deviation and confidence intervals in this human model study.  
 
 Results and analysis of the OSVM performance: Comparison of the functions 
applied and performance metrics 
The general condition applicable is as follow:  NNO = 10; KFU = 10; RSCV = 10; NNFS = 
10; POFU = 1; SOFF   with --- Linear and Gmean; Linear and AUC ROC; RBF and Gmean; 
RBF and AUC ROC --- Changes are included in the modified variables section.  
 








Average Gamma 0 0 11.65952 21.90145 
Average CostC 16411.91 21673.04 8655.016 5598.358 
Average Gmean /AUC ROC 0.875935 0.939974 0.884739 0.944326 
Standard Deviation 0.014592 0.005097 0.012223 0.005268 
95% Confidence Interval ±0.028601 ±0.00999 ±0.023957 ±0.010326 
 
Table 10. Modifications of variables and corresponding increases of the OSVM classifier 
performance - The AUC ROC outperformed with respect to Gmean values while RBF 
application gave an improved performance over that of the linear kernel technique. 
 
 Results  
The OSVM classifier performances by arising via modifications of linear to RBF kernels, and 
the Gmean to AUC ROC performance metrics obtained showed an increase in the OSVM 
classifier performance. These results suggest that combination the RBF kernel with AUC ROC 




and the wild treated individuals, with higher accuracy, and a notable decrease in standard 
deviation and associated 95% confidence interval (human-model).  
 
It should to be noted that the increase in the discriminating power is improved using RBF and 
AUC ROC respectively as a kernel function than using the linear function and Gmean 
approach, which is in line with previous research conducted (Martí and Reinelt, 2011; Tang et 
al., 2009).  
 
 Consideration:  
With regards to the tuning of the different parameters involved in the optimum support vector 
machine (OSVM) classification, all the parameters (NNO, NNFS, POFU, RSCV, and KFU) 
increase the classifier’s performances. Therefore, the OSVM becomes more powerful in 
discriminating between the NPC1 diseased patients and wild treated individuals. In addition, it 
was established that the RBF kernel over-performed the linear kernel, while the AUC-ROC 
provides an improved result over that of the Gmean. This final result will be used in the 
remaining data classification, and also for reasons of conciseness. Thus, the only function used 
will be the RBF kernel, while the performance metric used will be the AUC-ROC one. Given 
that the results achieved by the OSVM classifier that featuring, principal component regression 
is next to follow.  
 
5.2.5. Principal Component Regression for Biomarkers Discovery in NPC1 
Disease Diagnosis 
Principal component regression is being implemented in two stages, and these include principal 
component analysis in order to select PC scores vectors and regressing the response variable 
(Y) axis on these PCs. Thus, due to a very strong correlation between the features involved in 
the NPC1 disease analysis, it appeared necessary to used uncorrelated features that will clearly 
attribute features level of involvement on the aforementioned disease diagnosis.     
  
 Principal component analysis (PCA) for the selection of the principal components 
(PCs) for NPC1 disease diagnosis 
 




PCA is used here as a data analysis tool since it allows a dimensionality reduction from higher 
to much lower ones, where only a few of those PCs will be sufficient to explain the variability 
observed in the dataset. Therefore, by applying PCA to the original NPC1 disease dataset, this 
research aims at defining new features, i.e. principal components (PCs) that are uncorrelated 
in order to determine their importance in NPC1 disease diagnosis. Once the PCs   defined, 
defined, it is easier to return to the original dataset and determine the original features’ roles in 
the NPC1 disease aetiology and diagnosis. The analysis undertaken was based on certain 
numbers of considerations, the main one based on the importance of the eigenvectors and their 
implications. The assumption made is that given that none of the factors are simply 
predominant explaining the variability in the original dataset. Therefore, many of the PCs were 
considered to explain the maximum variability in the NPC1 disease (human-model) dataset. In 
addition, different levels of variability were considered in this analysis. Therefore, 90% 
variability was first considered, i.e. F1, F2, F3,…, F13, and F14 were necessary to explain this 
level of variability in the NPC1 dataset. 
 
 
Thereafter, the 80% of variability was considered which necessitated, in turn, the involvement 
of the principal components F1, F2, F3,…, F8 and F9. Next was the case of the explanation of 
70% of the variability in the NPC1 disease dataset, which necessitated the PCs F1, F2, F3, F4, 
and F5. Finally, 60% variability was considered, and which only necessitated the PCs F1, F2, 





 PCA results related to the NPC1 disease diagnosis 
The results generated are presented below, and include factor scores vectors, eigenvalues, and finally factor loadings that provides the influence 
and or contribution of each feature in corresponding PCs. These values will be employed subsequently in the selection of the main markers required 
for NPC1 disease diagnosis.  
 








Principal Components  F1 F2 F3 F4 F5 F6 F7 F8 F9 F10  F11 F12 F13 F14 
Eigenvalue 16.431 10.680 4.832 4.168 2.782 1.680 1.608 1.277 1.170 1.075 0.985 0.890 0.831 0.652 
Variability (%) 29.875 19.419 8.785 7.578 5.059 3.055 2.923 2.321 2.127 1.955 1.792 1.618 1.511 1.186 
Cumulative % 29.875 49.293 58.079 65.656 70.715 73.770 76.693 79.014 81.141 83.096 84.887 86.505 88.017 89.203 
  
           Table 11. Eigenvalues from principal components 1 (F1) to principal components 14 (F14), where F1<=>F14 explains more than 89%     
variability, meaning that these 14 PCs are enough to explain maximum variability in the dataset.   




 Factor Loadings 
 
 
Table 12. Partial visualisation of contributions of the NPC1 disease features to each one of the factors (PCs), where positive values are showing 
important contribution to the corresponding factor.  The chemical buckets correspond to the features and are the biomolecules resonance frequency 
interval expressed in part per million (ppm).   
 
Chemical Buckets F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 
[0.68 .. 0.71] -0.105 0.805 0.272 -0.343 0.174 0.105 -0.081 0.051 -0.073 0.007 0.022 -0.103 -0.086 0.139 
[0.71 .. 0.73] 0.052 0.909 0.163 -0.244 0.147 0.064 -0.063 0.008 -0.078 0.034 0.061 -0.057 -0.013 0.094 
[0.73 .. 0.75] 0.141 0.925 0.259 -0.152 0.059 0.027 -0.043 0.025 -0.043 0.017 0.025 -0.050 0.004 0.056 
[0.75 .. 0.77] 0.159 0.922 0.277 -0.138 0.036 0.007 -0.025 0.016 -0.050 0.021 -0.003 -0.055 0.000 0.069 
[0.77 .. 0.79] 0.114 0.941 0.154 -0.169 0.111 -0.026 -0.053 0.002 -0.044 0.023 -0.010 -0.046 -0.008 0.052 
[0.81 .. 0.89] 0.037 0.161 0.581 0.601 -0.172 -0.257 0.000 0.114 -0.124 -0.042 -0.195 -0.042 0.057 -0.042 
[0.89 .. 0.95] -0.087 -0.056 -0.610 0.078 0.629 -0.174 0.000 -0.074 0.046 0.160 0.148 -0.006 -0.013 -0.047 
[0.95 .. 1.06] 0.555 0.243 -0.312 0.260 0.030 0.085 -0.047 -0.375 0.048 0.306 0.150 -0.104 -0.089 -0.205 
[1.13 .. 1.15] 0.138 0.563 0.300 -0.302 0.334 0.159 0.162 0.086 -0.104 0.022 0.272 -0.137 -0.021 0.069 







 Factor scores 
 
Observations F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 
Obs1 -0.566 -2.816 -0.299 -2.194 1.548 1.377 0.373 0.482 0.969 3.066 0.130 2.107 -0.179 0.194 
Obs2 1.792 -1.611 -4.272 -1.779 1.358 -1.701 0.793 -0.774 -1.115 0.139 -0.635 0.064 0.300 -0.019 
Obs3 0.066 -2.933 0.119 -1.895 -0.294 0.511 0.338 -1.603 -0.846 -0.240 0.061 0.274 0.433 0.309 
Obs4 1.057 -2.154 0.179 0.445 0.672 -0.716 0.410 -0.769 -0.021 0.429 0.247 -0.703 -0.343 -0.725 
Obs5 -1.680 -2.818 1.183 -1.070 -0.157 1.470 1.023 -0.868 -0.127 -0.245 -0.102 -0.072 0.813 0.671 
Obs6 -4.669 -0.289 0.149 -1.912 -0.869 -0.352 0.539 -2.523 -0.295 0.011 0.112 -0.032 0.819 0.894 
Obs7 -3.849 2.158 -1.911 -1.626 -0.568 1.353 0.572 -0.095 0.330 -0.868 -0.539 -0.412 0.799 -0.254 
Obs8 -0.968 -0.608 1.132 -0.445 0.566 -0.966 -0.216 -0.077 0.457 -0.596 -0.870 -0.598 -0.001 0.232 
Obs9 -0.051 -3.845 -2.928 2.824 2.408 1.418 -0.980 0.624 1.849 1.208 -0.274 -0.010 1.374 0.211 
Obs10 3.259 -0.402 0.441 -2.988 -1.142 0.190 -1.006 -2.655 1.320 0.317 0.306 0.879 1.473 1.574 
 
Table 13. Partial visualisation of the factor scores related to the scores of the contribution of each observation to the factors/principal components 
of the NPC1 disease (human-model) features. The high positive values expressing important contribution to the corresponding factor. For instance, 







     
 
 Figure 8.  Biplots showing two separate classes in the NPC1 disease dataset, with red representing the NPC1 disease patients and the blue 
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[1.80 .. 1.86]
[ .90 .. . 2]
[1.92 .. 1 94]
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 Consideration  
 
Using PCA, 55 PCs were determined and only the first 14 of them were used to explain 89% of variability of the present NPC1 disease dataset 
based on these new features, the PCs. Knowing that this requirement was achieved in terms of selecting the necessary PCs, the multivariate logistic 
regression was applied to complete the principal components regression (PCR) analysis. 
 
 PCR results related to the NPC1 disease diagnosis – Human model 
 
 PCR results based on the tri-ranking techniques (TRTs) defined for potential Biomarker discovery in the NPC1 disease dataset 
 






NPC1 Disease Diagnosis for the 90% Variability    
Model Statistics Coefficient SE t-statistics P Value 
Deviance of the Fit: 67.9777 Null Null Null 
Degrees of Freedom: 114 Null Null Null 
Estimated dispersion parameter: 0.832 Null Null Null 
Feature Number     
0 0.299   >0.05 
1 -1.392 0.4191 -3.3218 0.0009 
2 -1.2947 0.3795 -3.4117 0.0006 
3 -0.3291   >0.05 
4 -2.7617 0.5821 -4.7445 0 
5 0.0309   >0.05 
6 0.3156   >0.05 
7 0.6039 0.3059 1.9746 0.0483 
8 0.1099   >0.05 
9 0.8591 0.3379 2.5425 0.011 
10 -0.6418   >0.05 
11 0.7331   >0.05 
12 -0.8776   >0.05 
13 1.0659 0.3842 2.7747 0.0055 
14 0.8635 0.4336 1.9913 0.0464 
15 -0.8216   >0.05 
* Feature number 0 is the intercept. Null Null Null Null 
Null Null Null Null Null 
  
Table 14. 90% variability model and the different statistics, giving PCs coefficient of regression 
estimate dispersion and deviance of the fit. The lower the coefficients of deviance of the fit and 
estimate dispersion parameter, the better the model could explain the level of variability in the 
dataset. Therefore, low value of coefficients of deviance of the fit = 67.9777 and low value of 
Estimated dispersion parameter = 0.832 correspond to high variability 90% variability with 
higher overall ranking performance. The features coefficients allow performance of the ranking 




are in this order of importance 13, 14, 9, and 7; based on their coefficient of regression, and a 
small p value < 0.05. The features with p value > 0,05 are statistically insignificant.  
 
The PCR model uses the equation 42 below (established in CH4) to calculate the contribution 
of each feature to the relevant principal component, while equation 43 corresponds to the 
regression line’s one:  
𝐾𝑖𝑗 = ∑ ∑𝑟𝑗
𝑖≤𝑛
𝑖=1




𝑌 =  ln (
𝑝
1 − 𝑝






𝑋𝑖 +  𝑌𝑜       ∶ (𝟒𝟑) 
𝑟𝑗  𝑖𝑠 𝑡ℎ𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑎𝑛𝑑 𝛼𝑗𝑖  𝑖𝑠 𝑡ℎ𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑎𝑛𝑑  
 
 𝑃𝐶𝑠, 𝑤𝑖𝑡ℎ 𝑚 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑃𝐶𝑠 𝑐𝑜𝑛𝑠𝑖𝑑𝑒𝑟𝑒𝑑 𝑡𝑜 𝑒𝑥𝑝𝑙𝑎𝑖𝑛 𝑡ℎ𝑒 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑣𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑙𝑒𝑣𝑒𝑙, 𝑛 
 
 𝑡ℎ𝑒 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑒𝑎𝑡𝑢𝑟𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑑𝑎𝑡𝑎𝑠𝑒𝑡. 𝑇ℎ𝑒 𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑖𝑠 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑒𝑑 𝑎𝑠 𝑎 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦,  
 
 𝑇ℎ𝑒 𝑣𝑎𝑙𝑢𝑒 𝑝 𝑟𝑒𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑖𝑛𝑔 𝑡ℎ𝑒 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 ℎ𝑎𝑣𝑖𝑛𝑔 𝑡ℎ𝑒 𝑑𝑖𝑠𝑒𝑎𝑠𝑒. 𝑇ℎ𝑒 𝑡𝑒𝑟𝑚 𝐾𝑖𝑗   
   
 𝑖𝑠 𝑡ℎ𝑒 𝑠𝑢𝑚 𝑜𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑐𝑜𝑟𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑠 𝑡𝑜 𝑡ℎ𝑒  𝑠𝑙𝑜𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑙𝑖𝑛𝑒.  𝐼𝑡𝑠 𝑣𝑎𝑙𝑢𝑒 𝑟𝑒𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑠  
 
 𝑡ℎ𝑒 𝑚𝑢𝑙𝑡𝑖𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑣𝑒 𝑓𝑎𝑐𝑡𝑜𝑟 𝑏𝑦 𝑤ℎ𝑖𝑐ℎ 𝑒𝑎𝑐ℎ 𝑓𝑒𝑎𝑡𝑢𝑟𝑒 𝑐𝑜𝑛𝑡𝑟𝑖𝑏𝑢𝑡𝑒 𝑡𝑜 𝑡ℎ𝑒 𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑙𝑖𝑛𝑒 𝑌.  
 
An example of the calculation of the contribution factor    𝐾𝑖𝑗     is given for the 60% to make 
it easier for the reader in term of the calculation length (see Table 22 below). Thus, the PCs 
coefficients of regression in Table 12 and Table 21 are used to perform the ranking obtained 
by the PCR and other ranking techniques separately.   
 
 













































Table 15. Shows the partial chemical shifts buckets related to the NPC1 disease dataset (human 
model), used in the identification of the different buckets involved in the ranking established 





           Probable Biomarkers 
1 [1.55…1.61] Isocaproate-CH2 
2 [1.53…1.55]  Adipate/n-butyrate 
3 [2.34...2.39] Pyruvate-CH3; Glutamate-C3-CH2 
4 [1.31…1.37] Lactate-CH3; 2-Hydroxyisobutyrate-CH3's 
5 [1.21…1.31] 3-D-Hydroxybutyrate-CH3; L-Fucose-CH3; and 3-
Hydroxyisovalerate-CH3 
6 [7.85...7.91] 1-Methylhistidine-C4-CH 
7 [7.91…7.97] Quinolinate-C5-CH 
8 [7.45…7.51]  Indoxyl sulphate-C6-CH and Benzoate-C3/C5-CH 
9 [1.98…2.03] 2-Hydroxyglutarate-C3-CHB 
10 [1.13…1.15] 2,3-Butanediol 
11 [5.26...5.37] α-Glucose 
12 [8.28...8.31] Hypoxanthine-C2/C7-CH 
13 [0.89…0.95] Isoleucine-CH3 
14 [1.92…1.94] Acetate-CH3 
15 [8.17…8.23] Trigonelline-C5-CH 
16 [0.68…0.71] Cholesterol-C18-CH3 
17 [7.14...7.16] Hydroxyphenyl-acetate aromatic ring protons 
18 [6.87…6.89] 3-(3-hydroxyphenyl)-3-hydroxypropanoate-C1/C6-CH 
19 [7.08…7.14] Histidine  
20 [2.48…2.50] Glutamine-C4-CH2 
21 [2.50...2.52] Methylamine  
22 [2.03…2.09] N-acetylaspartate-CH3; Nacetylneuraminate-CH3; and N-
acetyl-X-CH3 
23 [7.40…7.45] Indoxyl-sulphate-C6/C9-CH 





 PCR results based on the tri-ranking techniques (TRTs) defined for the potential 
biomarkers discovery in the NPC1 disease diagnosis (90% variability) 
 
The percentage of selections are noted correct ranking = CR and incorrect ranking = IR in 
comments column. 
 
Ranking Method Potential Biomarkers (90% Var.) Comments 
 
Heuristic Method  
[1.55...1.61] [1.31…1.37] [2.34...2.39]  
[1.21...1.31] [1.53…1.55] [7.79...7.85] 
[7.85...7.91]  [5.26...5.37] [8.28...8.31] 
[7.91..7.97] [7.51…7.56] [1.98...2.03] 
[7.45 .. 7.51] [1.13...1.15] [1.92...1.94] 
[0.68...0.71] [7.14…7.16] [6.87…6.89] 
[8.17...8.23] [2.03...2.09] [7.08…7.14] 
[2.48...2.50] [7.40…7.45] [0.71…0.73] 
Compared to SPC 
 CR = 22/24 = 91.67% 
IR = 2/24 = 08.33% 
In blue the 10 most effective 
biomarkers detected by the 
heuristic ranking technique – 
In red the ones incorrectly 
ranked 
 
The Sum of the 
Product of the 
Coefficients (SPC) 
Method  
[1.55...1.61] [1.53…1.55] [2.34…2.39] 
[1.31…1.37] [1.21…1.31] [7.85…7.91] 
[7.91…7.97] [7.79...7.85] [1.98...2.03] 
[7.51...7.56] [7.45…7.51] [1.13…1.15] 
[5.26...5.37] [8.28...8.31] [0.89…0.95] 
[1.92…1.94] [8.17…8.23] [0.68...0.71] 
[7.14...7.16] [6.87…6.89] [7.08…7.14] 
[2.48…2.50] [2.50...2.52] [2.03…2.09]  
Reference Patterns  
In blue the 10 most effective 
biomarkers detected by the 
SPC ranking techniques  
 
The Exponential of 
the Sum of the 
Product of the 
Coefficients 
(ESPC) Method  
[1.55…1.61] [1.53…1.55] [2.34…2.39] 
[1.31…1.37] [1.21…1.31] [7.85…7.91] 
[7.91…7.97] [7.79…85] [1.98…2.03] 
[7.51...7.56] [7.45…7.51] [1.13…1.15] 
[5.26…5.37] [8.28...8.31] [0.89...0.95] 
[1.92…1.94] [8.17...8.23] [0.68...0.71] 
[7.14…7.16] [6.87... 6.89] [7.08...7.14] 
[2.48…2.50] [2.50...2.52] [2.03...2.09] 
Correct Classification 
Compared to SPC  
CR = 24/24 = 100% 
IR = 0/24 = 0% 
In blue the 10 most 
effective biomarkers 






Table 16.  24 most important buckets corresponding to the 24 best markers detected by the tri-
ranking techniques and potential biomarkers for the 90% total variability dataset. The blue 
colour shows the 8 best buckets and the red shows some differences in the feature ranking 
between the different techniques with regard to the 10 best buckets.     
                                                                                                                                           
The different PCs and their corresponding r values are obtained by repeating the MLR 
operation several times. Table 16 above gives the main PCs involved in the 90%, variability 
that are being analysed. The deviance of the model is 67.98 and the estimated dispersion is < 
1. The statistics show that this model successfully fit the dataset under scrutiny, although some 
argue that the deviance is not a measure of fit in binary regression (Ronneberg, 2015). 
Nonetheless, it should be noted that the linear combination of the values of r and α permits a 
final classification of the features with regard to their importance in biomarker discovery 
regarding the NPC1 disease diagnosis (human model). The result of the NPC1 disease dataset 
analysis (Table 15) shows that the heuristic and the SPC strategies give almost the same 
ranking, while potential biomarkers selected by the SVA are also detected by all tri-ranking 
techniques. However, heuristic is the only one ranking technique which performed differently 
from the other two models with a value of correct ranking of 91.67%.  
 
 PCR results based on the tri-ranking techniques (TRTs) employed for potential 
biomarker discoveries in the NPC1 disease dataset 
 
 PCR modelling results – 80% variability 
NPC1 Disease Diagnosis for the 80% Variability   
Model Statistics Coefficient SE t-statistics p value 
Deviance of the Fit: 93.9176 Null Null Null 
Degrees of Freedom: 120 Null Null Null 
Estimated dispersion parameter: 1.273 Null Null Null 
Feature Number     
0 0.3181   >0.05 
1 -0.9565 0.2982 -3.2077 0.0013 
2 -0.921 0.2892 -3.1842 0.0015 
3 -0.2677   >0.05 




5 0.0892 -         - >0.05 
6 0.28 -        - >0.05 
7 0.4893 -         - >0.05 
8 0.3419 -         - >0.05 
9 0.6164 0.2776 2.2201 0.0264 
** Feature number 0 is the intercept. Null Null Null Null 
Null Null Null Null Null 
 
Table 17. 80% variability model and the different statistics, giving PCs coefficient of regression 
estimate dispersion and deviance of the fit. The relatively low coefficient of deviance and high 
coefficient of dispersion explained 80% of the total variation and a higher overall ability in 
ranking performance was achieved. Features 1, 2, 4, and 9 are statistically very important in 
this feature ranking process, with p value < 0.05. This Table provides different PCs feature 
coefficients of regression, which are used to perform the following ranking based on the PCR 
model, and the rankings arising from use of the different techniques.  Features with p value > 
0.05 are not statistically significant, therefore their standard error (SE) and t-statistic values are 
not provided. The feature 0 is the intercept, and the ranking results are obtained via the 
approach outlined below. Statistical significant features with p value < 0.05 are in bold.  
 
 PCR Results Based on the tri-ranking techniques (TRTs) defined for Potential 
Biomarker Discoveries in the NPC1 Disease Diagnosis (80% Variability) 
Ranking Method  Potential Biomarkers (80% Var.) Comment 
Heuristic Method  [2.34…2.39] [1.31…1.37] [1.55…1.61] 
[7.91…7.97] [7.85…7.91] [1.21…1.31] 
[7.51…7.56] [1.53…1.55] [5.26…5.37] 
[7.79…7.85] [1.92…1.94] [8.17…8.23] 
[8.28…8.31] [7.45…7.51] [2.03…2.09] 
[1.98…2.03] [0.68…0.71] [1.13…1.15] 
[6.87…6.89] [7.08…7.14] [7.14…7.16] 
[2.50…2.52] [2.48…2.50] [7.40…7.45] 
Compared to SPC 
 CR = 23/24 = 95.83 % 
IR = 1/24 = 4.17% 
In blue the 10 most 
effective biomarkers 
detected by the heuristic 
ranking technique 
The Sum of the 
Product of the 
Coefficients (SPC) 
Method  
[1.55…1.61] [2.34…2.39] [1.31…1.37] 
[1.53…1.55] [8.17…8.23] [1.21...1.31] 
[7.85…7.91] [7.91…7.97] [1.98…2.03] 
[7.51…7.56] [7.45…7.51] [1.92…1.94] 
The Pattern detected by 





[7.79…7.85] [0.89…0.95] [8.28…8.31] 
[5.26…5.37] [2.03…2.09] [1.13…1.15] 
[0.68…0.71] [2.50…2.52] [6.87…6.89] 
[7.08…7.14] [7.14…7.16] [2.48…2.50] 
In blue the 10 most 
effective biomarkers 
detected by the SPC 
ranking techniques 
The Exponential of 
the Sum of the 
Product of the 
Coefficients (ESPC) 
Method  
[1.55…1.61] [2.34…2.39] [1.31…1.37] 
[1.53…1.55] [8.17…8.23] [1.21…1.31] 
[7.85…7.91] [7.91…7.97] [1.98…2.03] 
[7.51…7.56] [7.45…7.51] [1.92…1.94] 
[7.79…7.85] [0.89…0.95] [8.28…8.31] 
[5.26…5.37] [2.03…2.09] [1.13…1.15] 
[0.68…0.71] [2.50…2.52] [6.87…6.89] 
[7.08…7.14] [7.14…7.16] [2.48…2.50] 
Correct Classification 
Compared to SPC  
CR = 24/24 =100 % 
IR = 0/24 = 0% 
In blue the 10 most 
effective biomarkers 
detected by the ESPC 
ranking techniques 
 
Table 18. 24 chemical most important shifts corresponding to the 24 best markers detected by 
the tri-ranking techniques and the potential biomarkers for the model with a total 80% 
variability. The blue colour shows the 10 most important chemical shifts/“biomarkers” and the 
red one shows some differences in the features ranking between the different techniques.    
 
Table 18 above gives the main PCs involved in the of 80% maximum variability model that is 
analysed in this section. The deviance of the model is = 93.918, and the estimated dispersion 
is = 1.273. The statistics show that the current model still effectively fits the data under scrutiny, 
but to a lesser degree than the previous with case 90% variability. The three ranking models 
have detected and ranked amongst the 10 most effective features, 8 most effective biomarkers. 
In addition, 23 out of 24 main biomarkers are detected by the three different ranking techniques. 
The heuristic model is the only one performing differently, a value of    CR = 95.83% being 
obtained in this respect is important. Therefore, the difference observed is probably related to 
the fact that the heuristic technique does involve a rapid, although not a perfect solution.  
 
 PCR results based on the tri-ranking techniques (TRTs) selected for potential 
biomarkers discovery in the NPC1 disease dataset  
 





NPC1 Disease Diagnosis for the 70% Variability   
Model Statistics Coefficient SE t-statistics P Value 
Deviance of the Fit: 104.71 Null Null Null 
Degrees of Freedom: 124 Null Null Null 
Estimated dispersion parameter: 1.397 Null Null Null 
Feature Number     
0 0.2509   >0.05 
1 -0.9945 0.2893 -3.4376 0.0006 
2 -0.9352 0.275 -3.4006 0.0007 
3 -0.246   >0.05 
4 -2.0131 0.3615 -5.5685 0 
5 0.0537   >0.05 
* Feature number 0 is the 
intercept. 
Null Null Null Null 
Null Null Null Null Null 
 
Table 19. 70% variability model and the different statistics, giving PCs coefficient of regression 
estimate dispersion and deviance of the fit. The high coefficient of deviance of the fit = 104.7 
and the estimate dispersion parameter = 1.397 (> 1) could explain the lower overall ranking 
performance achieved. The features with p values > 0.05 are not statistically significant, and 
hence the standard error (SE) and the t-statistic values are not provided for these. The feature 
“o” is the intercept and the ranking results obtained are provided below based on PCR model 
and the differing features coefficients of regression given in Table 19. 
 
 PCR results based on the tri-ranking techniques (TRTs) selected for potential 
biomarkers discovery in the NPC1 disease diagnosis dataset (70% Variability) 
 
Ranking Method Potential Biomarkers (70% Var.) Comment 
 
Heuristic Method  
[1.31…1.37] [2.34…2.39] [7.91…7.97] 
[1.55…1.61] [1.21…1.31] [7.51…7.56] 
[5.26…5.37] [7.85…7.91] [7.79…7.85] 
[1.53…1.55] [7.45…7.51] [8.28…8.31] 
Compared to SPC 
CR =21/24 = 87.5% 




[0.68…0.71] [1.92…1.94] [8.17…8.23] 
[1.98…2.03] [7.08…7.14] [7.14…7.16] 
[6.87…6.89] [1.13…1.15]  [2.03…2.09] 
[0.71…0.73] [7.16…7.18] [2.48…2.50] 
. In blue the same        10 
most effective 
biomarkers detected by 
the heuristic ranking 
technique like the ones 
detected by SPC. 
 
The Sum of the 
Product of the 
Coefficients (SPC) 
Method  
[1.55…1.61] [1.31…1.37] [2.34…2.39] 
[1.53…1.55] [1.21…1.31] [7.91…7.97] 
[8.17…8.23] [7.51…7.56] [8.28…8.31] 
[7.85…7.91] [1.98…2.03] [7.79…7.85] 
[7.45…7.51] [5.26…5.37] [0.89…0.95] 
[1.92…1.94] [0.68…0.71] [7.14…7.16] 
[6.87…6.89] [2.03…2.09] [1.13…1.15] 
[7.08…7.14] [7.40…7.45] [2.50…2.5]
  
. The Pattern detected 
by SPC are used as 
Reference Patterns. 
.In blue the 10 most 
effective biomarkers 
detected by the SPC 
ranking techniques. 
 
The Exponential of 
the Sum of the 
Product of the 
Coefficients (ESPC) 
Method 
[1.55…1.61] [1.31…1.37] [2.34…2.39] 
[1.53…1.55] [1.21…1.31] [7.91…7.97] 
[8.17…8.23] [7.51…7.56] [8.28…8.31] 
[7.85…7.91] [1.98…2.03] [7.79…7.85] 
[7.45…7.51] [5.26…5.37] [0.89…0.95] 
[1.92…1.94] [0.68…0.71] [7.14…7.16] 
[6.87…6.89] [2.03…2.09] [1.13…1.15] 
[7.08…7.14] [7.40…7.45] [2.50…2.52] 
Correct Classification 
Compared to SPC  
CR = 24/24 = 100% 
IR =0/24 = 0% 
. In blue the same        10 
most effective 
biomarkers detected by 
the ESPC ranking 
technique like the ones 
detected by SPC. 
 
 Table 20. 24 most important chemical shifts corresponding to the 24 most prominent 
biomarkers detected by the tri-ranking techniques and the potential biomarkers for the 70% 
variability. The blue colour showing the same 10 best chemical shift biomarker buckets 
detected by all the tri-ranking techniques, including heuristic, SPC, and ESPC. Based on the 
reference patterns these correspond to the following molecules presented below: isocaproate-
CH2; actate-CH3 2-hydroxyisobutyrate-CH3; pyruvate-CH3, glutamate-C3-CH2; adipate/n-




CH; hippurate-C3/C5-CH; hypoxanthine-C2/C7-CH; and 1-methylhistidine-C4-CH. The red 
shows some difference in features rankings between the heuristics ranking technique, the SPC, 
and the ESPC.  
 
Table 20 above gives the main PCs involved in the 70%, variability being analysed in this 
section. The deviance of the model is = 104.71, and the estimated dispersion is = 1.397. The 
statistics show that the current model still fit the data being analysed, but to a lesser degree than 
the model involving 90% and 80% total variability. The three ranking models commonly 
detected the same 10 main biomarker buckets. In addition, 21 out of 24 main buckets are 
detected by the three different ranking techniques. The heuristic model was the only one 
performing differently, with a CR value of 87.5%. Additionally, this ranking technique gives 
preference to speed at the expenses of both precision and accuracy, consequently does not 
detect isoleucine (0.89-0.95 ppm) amongst the 24 main biomarkers. 
 
 PCR results based on the tri-ranking techniques (TRTs) selected for potential 
biomarkers discovery in the NPC1 Disease Dataset 
 PCR Modelling Results – 60% Variability 
NPC1 Disease Diagnosis for the 60% Variability    
Model Statistics Coefficient SE t-statistics p value 
Deviance of the Fit: 104.7645 Null Null Null 
Degrees of Freedom: 125 Null Null Null 
Estimated dispersion parameter: 1.39 Null Null Null 
Feature Number     
0 0.248 -             - >0.05 
1 -0.9952 0.289 -3.4442 0.0006 
2 -0.9388 0.2753 -3.4107 0.0006 
3 -0.2453 -             - >0.05 
4 -2.0141 0.3611 -5.5775 0 
** Feature number 0 is the intercept. Null Null Null Null 
Null Null Null Null Null 
 
Table 21. Ranking of PCs based on the regression coefficient and a percentage of total 




dispersion parameter = 1.39 i.e. (> 1) could explain the lower overall ranking performance 
achieved in this model. For the features that are not statistically significant (p value > 0.05), 
the standard error (SE) and the t-statistic values are not provided and the ranking results 
obtained are as follow. An example of the calculation for 60% variability for the sum product 
of the coefficients is:     Kij = ∑rα = α1 r1 + α2 r2 + α3 r3 + α4 r4    : (42) 
 
 
Table 42. Example of calculation related to the SPC ranking for the 60% maximum variability 
model for the NPC1 disease diagnosis dataset. The example is showing how the following 
biomarkers were ranked using the values of Kij = ∑rα, including isocoprate-CH2, and 
isoleucine-CH3. The calculation is applied to the feature ranking in relation to the different 
variability, and the results obtained for the 60% maximum variance model is provided below. 
The same calculation technique is applied to the ESPC but using the exponential values of the 
products.  
 
Ranking Method Potential Biomarkers (60% Var.) Comment 
Heuristic Method  [1.31…1.37] [2.34…2.39] [7.91...7.97] 
[1.55…1.61] [1.21…1.31] [7.51...7.56] 
[5.26…5.37] [7.85…7.91] [7.79…7.85] 
[1.53…1.55] [7.45…7.51] [8.28…8.31] 
[0.68…0.71] [8.17…8.23] [1.98…2.03] 
[7.08…7.14] [7.14…7.16] [1.92…1.94] 
[6.87…6.89] [1.13…1.15] [2.03…2.09] 
[0.71…0.73] [7.16…7.18] [2.48…2.50] 
Compared to SPC 
 CR = 21/24 = 87.5% 
IR = 3/24 = 12.5% 
In blue the same 10 most 
effective biomarkers 
detected by the heuristic 
ranking technique like the 
ones detected by SPC. 
The Sum of the 
Product of the 
[1.55…1.61] [1.31…1.37] [2.34...2.39] 
[1.53...1.55] [1.21…1.31] [7.91...7.97] 
The Pattern detected by SPC 
are used as Reference 































[8.17...8.23] [7.51…7.56] [8.28...8.31] 
[7.85…7.91] [1.98…2.03] [7.79…7.85] 
[7.45…7.51] [5.26…5.37] [0.89...0.95] 
[1.92…1.94] [0.68…0.71] [7.14…7.16] 
[6.87…6.89] [2.03…2.09] [7.08…7.14] 
[1.13…1.15] [7.40…7.45] [2.50…2.52]
  
Patterns. In blue the 10 most 
effective biomarkers 
detected by the SPC ranking 
techniques. 
The Exponential of 
the Sum of the 
Product of the 
Coefficients (ESPC) 
Method 
[1.55…1.61] [1.31…1.37] [2.34…2.39] 
[1.53...1.55] [1.21…1.31] [7.91…7.97] 
[8.17…8.23] [7.51...7.56] [8.28...8.31] 
[7.85...7.91] [1.98…2.03] [7.79…7.85] 
[7.45…7.51] [5.26…5.37] [0.89...0.95] 
[1.92...1.94] [0.68…0.71] [7.14…7.16] 
[6.87…6.89] [2.03...2.09] [7.08…7.14] 
[1.13…1.15] [7.40…7.45] [2.50...2.52] 
Correct Classification 
Compared to SPC  
CR = 24/24 = 100% 
IR = 0/24 = 0% 
In blue the same 10 most 
effective biomarkers 
detected by the ESPC 
ranking technique like the 
ones detected by SPC. 
 
Table 23. Display of potential biomarkers based on the three main techniques developed for 
the 60% total variance model. The blue colour shows the 10 main chemical shift buckets and 
the red ones the main differences in feature ranking obtained between the heuristic and the 
ESPC techniques.  
The deviance of the model is 104.7645, and the estimated dispersion is 1.39 (Table 21). The 
statistics show that the current model still fits the data being analysed effectively, but to a lesser 
degree than those observed with 90 and 80% variability. The three models commonly detected 
the same 10 main biomarkers. In addition, 21 out of 24 major biomarkers are detected by the 
three different ranking techniques (Table 23). The heuristic model was the only one which 
performed differently, and its correct ranking value of 87.5% enables an acceptable comparison 
between the techniques. However, this technique did not detect isoleucine (0.89-0.95 ppm) in 
view of its propensity to favour speed at the expense of precision and accuracy. 
 
A comparison between the four variability levels is next presented, with special regard to the 





 Comparing the Four Types of Variability  
 
90% Variability 80% Variability 
[1.55...1.61]  [1.53…1.55]   [2.34…2.39] 
[1.31…1.37]  [1.21…1.31]   [7.85…7.91] 
[7.91…7.97]  [7.79...7.85]  [1.98...2.03] 
[7.51...7.56]  [7.45…7.51]  [1.13…1.15] 
[5.26...5.37] [8.28...8.31] [0.89…0.95] 
[1.92…1.94]  [8.17…8.23]  [0.68…0.71] 
[7.14...7.16] [6.87…6.89] [7.08…7.14] 
[2.48…2.50]   [2.50...2.52]   [2.03…2.09] 
[1.55…1.61]  [2.34…2.39]   [1.31... .37] 
[1.53…1.55]  [8.17...8.23]  [1.21..1.31] 
[7.85…7.91]  [7.91...7.97]   [1.98…2.03] 
[7.51…7.56] [7.45…7.51]  [1.92…1.94] 
[7.79…7.85]  [0.89...0.95]  [8.28…8.31] 
[5.26…5.37]  [2.03…2.09]   [1.13...1.15] 
[0.68…0.71]  [2.50...2.52]  [6.87…6.89] 
[7.08...7.14]   [7.14…7.16]   [2.48...2.50] 
70% Variability 60% Variability 
[1.55…1.61] [1.31...1.37] [2.34…2.39] 
[1.53…1.55] [1.21…1.31]  [7.91...7.97] 
[8.17...8.23] [7.51…7.56] [8.28…8.31] 
[7.85…7.91] [1.98…2.03] [7.79…7.85] 
[7.45…7.51] [5.26…5.37] [0.89…0.95] 
[1.92…1.94] [0.68…0.71]  [7.14…7.16] 
[6.87…6.89] [2.03…2.09]  [1.13…1.15] 
[7.08…7.14] [7.40…7.45]  [2.50…2.52] 
[1.55 .. 1.61]  [1.31 .. 1.37]  [2.34…2.39] 
[1.53…1.55]  [1.21…1.31]  [7.91…7.97] 
[8.17…8.23]  [7.51…7.56]  [8.28...8.31] 
[7.85…7.91]  [1.98…2.03]  [7.79…7.85] 
[7.45…7.51]  [5.26…5.37 ]  [0.89...0.95] 
[1.92…1.94]   [0.68…0.71]   [7.14…7.16] 
[6.87…6.89]  [2.03…2.09]  [7.08...7.14] 
[1.13…1.15]   [7.40…7.45]  [2.50…2.52] 
                                                                                          
Table 24. Sequence of the ranking of potential biomarkers (as 1H NMR chemical shift buckets) 
detected. The consistency and the consecutiveness of the different biomarkers discovered are 
shown in green, while the ones in blue does not follow this sequence of the 10 best ranked 
biomolecules. Isocaproate, adipate/n-butyrate, pyruvate, glutamate, and lactate represent some 
of the major biomarkers highly ranked by all four variability levels. Thus, those depicted in 
green are correctly ranked in the top 10 biomarkers amongst the 24, while those in blue are 
incorrectly ranked amongst these top 10. The ones in black have been detected by the four 
variabilities levels amongst the 24, while those in red have not been detected by more than 2 
levels of variability. These are differing common markers amongst the 24 best potential 
biomarkers. Additionally, the ranking of the top 10 best potential biomarkers show some 
consistency for 90% (2 biomarkers are misclassified) and the rest 80, 70 and 60% with 3 






The consistency, consecutiveness and importance of the biomarkers discovered revealed that 
80% and 90% total variability are models to be considered as the best and second best available 
for NPC1 disease diagnosis in blood plasma samples. However, more statistics can be gathered 
to ascertain this classification model. Comparison of these models based on the percentage of 
variability (below) assists in this respect.  
 










the CR (%) 
Model 
Deviance  




Degrees of  
Freedom 
(DoF)  
90  100 91.67 67.9777 0.832 114 
80 100 95.83 93.9176 1.273 120 
70  100 87.50 104.71 1.397 124 
60 100 87.50 104.7645 1.39 125 
 
Table 25. Percentage (%) of the correct ranking (CR) perform by the Heuristic and SPC 
(identical to ESPC) strategies. Also shown are performance statistics related to each level of 
variability. The smaller the model deviance of the fit, and the parameters estimated, the more 
reliable are the variability model performances. 80% and 90% appear to be the best model in 
terms of their correct ranking ability. 
 
 Considerations 
1. Heuristic model provides the only ranking technique with different performances, and 
therefore its level of correct ranking (CR) will be determinant for comparisons between the 
different models, or those between different levels of variability. 
 
2. SPC and ESPC ranking methods achieve the same high level of correct rankings or selection, 
and are therefore the best ranking techniques based on these criteria.                                                  
 
3. Ranking abilities confirmed that 80% and then 90% respectively were the best and second-





It should be noted that 80% variability, although having a high level of deviance of the fit 
(93.9176 > 67.9777), and also a high level of parameters estimated, i.e. dispersion (1.273 > 
0.832) than 90% variability, performed better in terms of correct ranking than the second model 
mentioned.  Indeed, it is expected that the smaller the deviance of the model fit and parameter 
of estimate dispersion, the more improved the level of variability and the model. Finally, the 
models’ ability for correctly ranking the features, i.e. 95.83% CR for 80% model against 
91.67% CR for 90% model, allows us to choose 80% model to be considered as the best level 
of variability followed by 90% as second best for this dataset.  
 
The Table below gives the full range of 24 major potential biomarkers, together with those 
discovered by the PCR model applied in this study. Comparisons are made with already 
established biomarkers from literature (Ruiz-Rodado et al., 2014; Ruiz-Rodado, 2016). 
 
 
 Molecular assignment of the 24 main biomarkers in the NPC1 disease 

















           Probable Biomarkers Comment on the 
Biomarkers Discovered 
1 [1.55 .. 1.61] Isocaproate-CH2 Potential Biomarker 
2 [1.53 .. 1.55]  Adipate/n-butyrate New Biomarkers 
3 [2.34 .. 2.39] Pyruvate-CH3; Glutamate-C3-
CH2 
Existing Biomarkers  
4 [1.31 .. 1.37] Lactate-CH3; 2-
Hydroxyisobutyrate-CH3's 
Potential Biomarkers 




6 [7.85 .. 7.91] 1-Methylhistidine-C4-CH Potential Biomarker 
7 [7.91 .. 7.97] Quinolinate-C5-CH Potential Biomarker 
















                           
 
     
 
Table 26. Existing, potential, and probable new biomarkers discovered by the PCR model for 
NPC1 disease diagnosis (human model). Pyruvate (3rd), glutamate (3rd), and isoleucine (13th) 
were detected amongst the 24 best biomarkers; while adipate/n-butyrate (2nd), and hippurate 
(24th) appeared as probable new biomarker in the NPC1 disease diagnosis.  
 
Results arising from this analysis using the PCR techniques, i.e. the combination of PCA and 
MLR, permitted the detection of probable biomarkers for NPC1 disease diagnosis, including 
adipate/n-butyrate, hydroxyphenyl-acetate, and hippurate.  
 
In this respect, the TRTs have all detected the same main biomarkers overall, However, the top 
10 differ with changes in variability. This is principally ascribable to the knowledge that the 
more rapidly, and heuristic technique displays different results, and is based on finding an 
9 [1.98…2.03] 2-Hydroxyglutarate-C3-CHB Potential Biomarker 
10 [1.13…1.15] 2,3-Butanediol  
11 [5.26...5.37] α-Glucose Existing Biomarker 
12 [8.28...8.31] Hypoxanthine-C2/C7-CH Potential Biomarker 
13 [0.89…0.95] Isoleucine-CH3 Existing Biomarker 
14 [1.92…1.94] Acetate-CH3    Existing Biomarker 
15 [8.17…8.23] Trigonelline-C5-CH Potential Biomarker 
16 [0.68 .. 0.71] Cholesterol-C18-CH3’s Existing Biomarker 
17 [7.14...7.16] Hydroxyphenyl-acetate 





19 [7.08…7.14] Histidine  Existing Biomarker 
20 [2.48…2.50] Glutamine-C4-CH2 Existing Biomarker 
21 [2.50...2.52] Methylamine Existing Biomarker 




23 [7.40…7.45] Indoxyl-sulphate-C6/C9-CH Potential Biomarker 




approximate solution, hence favour the speed at the expenses of precision and accuracy. 
Additionally, the SPC and the ESPC approaches give the same ranking results. Moreover, the 
80% variability model was found to be the best level of variability to be incorporated amongst 
the four explored.  
 
However, the main biomarkers discovered by the tri-ranking techniques are predominantly the 
same, and include nearly all the biomarkers discovered, by application of the SVA model. 
Finally, the list of the 7 best biomarkers formally detected by all four variability levels in 
relation to the PCR model selection is adipate/n-butyrate, isocaproate-CH2, pyruvate-CH3, 
glutamate-C3-CH2, lactate-CH3, 2-hydroxyisobutyrate-CH3, 3-hydroxybutyrate-CH3, L-
fucose-CH3, 3-hydroxyisovalerate-CH3, 1-methylhistidine-C4-CH, and quinolinate-C5-CH. 
Amongst these, the main biomarkers suggested by the SVA model are highlighted in bold. 
These markers detected by the SVA approach are important markers for NPC1 disease 
diagnosis. Other important biomolecules in the NPC1 disease diagnosis were detected, 
including glutamate, histidine, etc., and will be discussed further in the next sub-section.   
 
 
5.3. Biomarker Pathway Analysis in the NPC1 Disease Research 
5.3.1. Data Normalisation Results  
 
The pathway analysis was performed using MetaboAnalyst 3.0 version (comprehensive tools 
for metabolomics data analysis). In order to carry out this pathway analysis, data was firstly 
pre-processed to ensure that data correspond to the software criteria. No missing value 
estimates, were performed. All features with more than 50% missing values were removed, 
whilst the remaining missing values were replaced with the column features mean values.    In 
addition, data filtration was performed in order to improve the analysis results by removing the 
proportion of tests that are truly null, leaving only those that are differentially expressed. 
Filtering is used to reduce the number of tests, but it increases the power of detection of true 
differences (Hackstadt and Hess, 2009). Furthermore, the following transformations were 
performed, and these included, sample normalisation by the sum, data transformation by cube 




centring and division by the square root of the standard deviation of each variable.  The 







Figure 9.  Results of the sample normalisation by the sum, cube-root data transformation and 
the Pareto data scaling applied on the NPC1 disease dataset. The features density distribution 
squeeze to the right is after normalisation represented by a normal bell-shaped curve meaning 
a normal distribution of these features density. 
One-way analysis of variance (ANOVA) was performed to found out whether there are 
statistical difference between the mean values of NPC1 disease features or group of features. 
A correlation diagram based on Pearson r value with dendrograms applied to the columns and 
rows highlights results of the relationships between the different metabolites present in the 
NPC1 disease dataset. 
 
 
Figure 10. Correlation diagram based on the Pearson’s r value with dendrograms applied to 
the columns and rows, showing relationships between the different potential biomarkers 





The correlation diagram revealed a strong correlation zone on the y-axis at 4-hydroxybenzoic 
acid up to the methylglutarate to the same metabolites on the x-axis. This agglomerate 
hierarchy clustering technique used the importance of biomolecules in the disease development 
to group them together in clusters. Hence, some very strong correlation zones appear such as 
the ones between alanine and the leucine, valine, lysine, methionine, Citrate, 3-hydrophnyl, 
phenol, L-histidine, indoxyl sulfate, glutamine, methyl -phenylacetate, glutamine-1, and the 
dimethylglycine as shown on the correlation diagram (Figure 10). Indeed, alanine biosynthesis 
is shown in the pathway analysis presented below.  
 
 
Figure 11. Heatmap using the Euclidean distance presents metabolites using the clustering ward 
with t-test, with the samples not reorganised which allows to obtain two separate classes as 
label with NPC in red and WT in blue. The data source was normalised and the autoscaled 




group (NPC) and the wild treated (WT) or healthy control group in the plasma dataset. 
Dendrograms generated using the hierarchal clustering algorithm have been applied in order to 
aggregate the rows and columns of the heatmap, with the left appearing cooler that is lower 
presence of NPC1 disease patients or higher presence of healthy control individuals, and the 
right hotter with a higher presence of NPC1 disease patients in this blood plasma dataset 
(human-model).  
Heatmap shows a high to very high concentration of the 3 top biomarkers including 3-
hydroxybutyrate, isocaproate-CH2, and adipate in the NPC1 disease class when compared to 
the control group. This is further supported by the light-brown colour and dark-brown colour 
on the top right corner of the heatmap (Figure 11). However, trimethylamine, dimethylglycine 
and the methylglutarate are high in the control group. The pathways followed by different 




Pathway Name Match 
Status 





2.4815E-5 2.4815E-5 0.05634 KEGG  
Phenylalanine metabolism 6/45 9.6042E-5 9.250
7 
0.0075874 0.0038417 0.15056 KEGG SMP 
Glycolysis or 
Gluconeogenesis 
5/31 1.5408E-4 8.778 0.012018 0.0041089 0.1067 KEGG SMP SMP 




0.08095 0.021026 0.06148 KEGG SMP 
Nitrogen metabolism 4/39 0.0042331 5.464
8 
0.32172 0.061099 0.0 KEGG SMP 




0.34368 0.061099 0.05395 KEGG SMP 
Alanine, aspartate and 
glutamate metabolism 






1.0 0.14799 0.35294 KEGG SMP 
Pyruvate metabolism 3/32 0.017244 4.060
3 
1.0 0.15328 0.41957 KEGG SMP 




1.0 0.2269 0.02232 KEGG SMP 
Butanoate metabolism 3/40 0.031199 3.467
4 








1.0 0.25529 0.02448 KEGG SMP 
Tyrosine metabolism 4/76 0.041485 3.182
4 
1.0 0.25529 0.04724 KEGG SMP SMP 
Citrate cycle (TCA cycle) 2/20 0.046311 3.072
4 





1.0 0.29381 0.00321 KEGG SMP 




1.0 0.35235 0.05455 KEGG SMP SMP 




1.0 0.35235 0.0 KEGG SMP 




1.0 0.35235 0.008 KEGG SMP 
Pyrimidine metabolism 3/60 0.085146 2.463
4 
1.0 0.35851 0.04303 KEGG SMP 
Synthesis and degradation 
of ketone bodies 
1/6 0.10033 2.299
3 
1.0 0.40133 0.0 KEGG SMP 
 
 
Table 27. NPC1 Disease Metabolomic Pathway Analysis, showing 3 main pathways to be 
significantly important in the disease process. The low Holm adjusted p value and a small value 
of FDR (< 0.05) in bold show that these pathways are strongly expressed regarding the NPC1 
disease aetiology based on a human model.   
The information inferred from the Table 27 is used below to analyse the most significant 
pathways detected in the NCP1 disease dataset.  Based on the value of the Holm adjusted       p 
value and the false detection rate FDR the 3 first pathways are shown to be significantly 
involved in the current NPC1 disease process underlying transformations at the molecular 
level. The pathway analysis highlights the involvement of the different biomolecules in the 
disease development, including the transformation of one biomolecule to the next.  
 
 
5.3.2. Pathway Analysis Results  
 
Metabolomic pathway analysis conducted showed that several transformations appeared 
significantly involved in NPC1 disease progression. The changes observed included 
aminoacyl-tRNA biosynthesis, phenylalanine metabolism, and glycolysis or gluconeogenesis. 




the present disease aetiology. These pathways exhibit a Holm adjusted p value < 0.05 with 
respectively 2.4815E-5, 0.0075874, and 0.012018. These Holm adjusted p values lower than 
0.05 indicate a higher level of statistical significance of the different pathways in the current 
analysis. The information obtained from Table 27 is further corroborated by the most 





 Overview of Pathway Analysis  
 
 
Figure 12. Pathway overview showing from top to bottom the first three main pathways, with 
their -log(p) value, including aminoacyl-tRNA biosynthesis (14.986), then phenylalanine 
metabolism (9.2507) and finally (glycolysis or gluconeogenesis (8.778), as the most significant 
pathways in this NPC1 disease dataset. The metabolite pathway decreases from red to yellow 












 Figure 13. Aminoacyl-tRNA biosynthesis involving in red and from left to right the followed 
metabolites L-histidine, L- phenylalanine, L- glutamine, L- methionine, L- valine, L- alanine, 
L- lysine, L- isoleucine, leucine and L-tyrosine present in the current blood plasma dataset. 
The low Holm adjusted p value 2.4815E-5, and the small value of FDR 2.4815E-5 show that 
the current pathway is strongly expressed in the NPC1 disease aetiology.  The ones in bold are 
the ones shown in red on this Figure and are present in the current dataset. 
Several metabolites were observed in the present 1H NMR spectra acquired, and are followed 
with respect to aminoacyl-tRNA biosynthesis. The L-glutamine can generate ornithine, which 
in turn produces the pyruvate, with all the three biomolecules present in this pathway. Ornithine 
can be transformed into the gamma-aminobutyric acid, which is present in the current pathway. 
This transformation is performed through different intermediate such as the 4-
acetamidobutanoate. However, L-aspartic acid can generate creatine. In this pathway analysis, 
pyruvate, glutamine and glutamate exert the greatest pathway impact, followed by alanine and 




phenylalanine metabolism which is next investigated. The information obtained from Table 27 
are further corroborated by the most significant pathways detected and their analysis that follow 
below (Ruiz-Rodado et al., 2014). 
 
 Phenylalanine Pathway Analysis 
  
 
Figure 24. Phenylalanine metabolite pathway analysis with a Holm adjusted p value of 
0.0075874 a pathway impact of 0.15 and an FDR of 0.0038. Therefore, the current pathway is 
strongly differentially expressed in the NPC1 disease dataset, with the presence of the following 
metabolites, including p-hydroxyphenylacetate, hippurate, pyruvate, fumarate and the 
succinate. 
Phenylalanine metabolism pathway starts with phenylalanine (C00079) itself, and tyrosine 
(C00082) can be directly generated by oxidation, other metabolites not present in the present 
dataset allow the generation of 3-hydroxyphenylacetate (C05593), and then the end product on 
this sub-pathway, which is the benzoyl-CoA. However, phenylalanine can generate trans-
cinnamate (C00423), which, in turn can produce hippurate (C01586) through several 




(C00180), which generates the hippurate with one of the highest importance rates 0.0315 for 
this pathway. Finally, the hippurate can produce the benzoyl-CoA, the terminal product of this 
pathway analysis.  
 
 Pathway Analysis of the Glycolysis or Gluconeogenesis 
 
 
Figure 35. Glycolysis or gluconeogenesis showing in red from the top right corner the 
sequences of transformation from glucose (C00031), to lactate (C00186), then pyruvate 
(C00022), followed by ethanol (C00469), and finally on the top bottom left corner to acetate 
(C00033). Intermediates including alpha-glucose, acetyl-CoA (C00024), acetaldehyde 
(C00084), (C00074), (C00084), (00068), etc.  
However, the matched pathway impact shows that pyruvate, glutamine, and glutamate 
metabolism exhibit the highest impact on the present glycolysis pathway while the aminoacyl-
tRNA biosynthesis shows the highest -log(p) with the smallest Holm adjusted p value and the 
smallest false detection rate (FDR) in the NPC1 disease dataset.  
The glycolysis pathway produces several intermediate metabolites, most of which are not 
present in this dataset. For example, the intermediate acetyl-CoA (C00024) can generate 
acetate following several routes as shown above on the Figure 15. The end product of glycolysis 




pyruvate (importance = 0.0953) production. Pyruvate serves as an important intermediate in 
the metabolism of proteins and fats (Pubchem, 2017). It has been detected by the intelligent 
tri-modelling techniques as one of the main biomarkers in the disease diagnosis and 
development, i.e ranked 3rd main biomarker (see Table 25). Further transformation can occur 
with ethanol oxidisation into acetaldehyde before further oxidation to acetate.  
 
5.4. Intelligent Tri-Modelling Techniques and the NPC Liver Dysfunction 
Disease (NPC LDD) Dataset Analysis – Mouse Model-Based   
 
 5.4.1. Introduction 
Niemann-Pick type C1 disease is related to the defect of lipid storage at the lysosomal level 
that end up with fat storage and obesity. More damage can be observed in term of patient’s 
health condition, with cell and tissue death such as liver-related diseases (liver damage). 
Although such damage may be modulated, the disease can be fatal to some patients (Sayre et 
al., 2010). Vital and more effective treatments can be administered if NPC disease is discovered 
early, and hence is potentially circumventable. The use of techniques such as the intelligent tri-
modelling techniques (ITMTs) applied in this research can provide answers regarding the 
discovery of potential biomarkers in the NPC-associated liver dysfunction, more severe form 
of the NPC1 disease (first study conducted in this thesis). The current intelligent tri-modelling 
techniques will alternatively involve the scalar visualisation algorithm (SVA), the optimum 
support vector machine (OSVM) and the principal components regression (PCR) for the 
scrutiny of this NPC liver dysfunction disease (NPC LDD) dataset, based on mouse model.   
 
5.4.2. Description of the Liver Dysfunction Disease Dataset   
 Description 
The liver dysfunction disease dataset encompasses 65 observations and 143 chemical shifts. 
They were obtained using NMR spectroscopy on liver extracts collected from mutant mice. 
The NMR spectrometry generates spectra amplitudes against radio frequency converted into 
chemical buckets expressed in ppm (part per million). Initially 71 observations were obtained 




observations) and rows with duplicated values (4 observations). The remaining 65 were carried 
forward for analysis. The statistics obtained and briefly shown below.   
 
Amongst these, 38 were liver extracts samples collected from healthy control mice and the 
remaining 27 were NPC disease mutant mice. The statistics obtained using XLSTAT are briefly 




Different statistics were generated form the XLSTAT software and are below presented. 
 
 
Table 28. Partial summary statistics obtained from XLSTAT running PCA on the liver 
dysfunction disease dataset (mice-model). The variables are chemical buckets with the means 
and standard deviation shown on the right hand-side of the table. The small values of the 
standard deviation show that the data point are not widely spread out (for this partial summary 
statistics). 
 
This visualisation of the internal data structure of NPC liver dysfunction disease (mice-model) 




Variable ObservationsOb . with missing dataObs. without missing dataMinimum Maximum Mean Std. deviation
[0.77 .. 0.80] 65 0 65 0.000 0.027 0.004 0.004
[0.80 .. 0.82] 65 0 65 0.000 0.035 0.005 0.006
[0.82 .. 0.84] 65 0 65 0.001 0.040 0.007 0.007
[0.84 .. 0.86] 65 0 65 0.002 0.043 0.009 0.008
[0.86 .. 0.92] 65 0 65 0.013 0.097 0.038 0.016
[0.92 .. 0.94] 65 0 65 0.006 0.034 0.015 0.005
[0.94 .. 0.99] 65 0 65 0.025 0.178 0.073 0.031
[0.99 .. 1.05] 65 0 65 0.010 0.096 0.035 0.019
[1.05 .. 1.08] 65 0 65 0.003 0.038 0.013 0.006




5.4.3. NPC Liver Dysfunction Disease (NPC LDD) Dataset Analysis using 
Scalar Visualisation Algorithm (SVA)  
 
 Liver dysfunction disease dataset analysis by the SVA 
The scalar visualisation algorithm (SVA) as part of the ITMTs will be used for the primary 
assessment of the NPC liver disease dataset. In order to identify the underlying data structure 
and detect possible biomarkers that could provide an effective response to the liver failure that 
occurs in the worst-case scenario.  SVA creates a function between the scalar dataset and the 
selected colours, in such a manner that the current dataset can be visualised while highlighting 
some more important features (Komura, 2016). The result of this scalar data visualisation 




Figure 46. Zooming in the NPC liver disease (mice model) boxplot features showing that the 
features 69, 67, 59, 70, 68, 60, 55, 54, 63, 62, 64, 66, 72, 65, 90, 91 as potential biomarkers 
including glutamate, glutamine, taurine, lactate, glycerophosphocholine, myo-Inositol, gamma-
phosphorylcholine, leucine, isoleucine, alanine, etc., in the NPC liver dysfunction disease 
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Figure 57.  The Scale Data Plot showing significant changes of intensity for the main features 
69, 68, 70, 67, 58, 59, 60, 55, 54, 17, 18 – corresponding to the following biomolecules 
glutamate, glutamine, taurine, lactate, glycerophosphocholine, myo-Inositol, alanine, leucine, 
and isoleucine considered as potential biomarkers in the liver dysfunction and associated 





Figure 68. Contour plot showing significant changes of intensity for the most relevant features 
69, 68, 70, 67, 55, 54, 17, 18 corresponding respectively to the following biomolecules; 
glutamate, glutamine, taurine, lactate, glycerophosphocholine, myo-Inositol, alanine, leucine, 
and isoleucine considered as potential biomarkers in the liver dysfunction disease (mouse 
model-based) diagnosis according to the contour plot. 
Liver Scale Data Plot - Main Features Highlight
 
 
















Liver Contour Plot - Main Featurers Highlight
 
 




















The results of the scalar visualisation process have been grouped in the following Table 29 in 










Names of Molecules 
Detected 
Boxplot 69, 67, 59, 70, 68, 
60, 55, 17, 54, 7, 
63, 62, 64, 66, 72, 
18 
[3.81…3.87] [3.71…3.77] 
















 Plot 69, 68, 70, 67, 58, 
59, 60, 55, 54, 17 
[3.81…3.87] [3.71…3.77] 







e, Myo-Inositol, … 
Data Scale 
Plot 
69, 68, 70, 67, 58, 
59, 60, 55, 54, 17, 
18, 7    
 [3.81….3.87][3.71…3.77] 













69, 68, 70, 67, 58, 
59, 60, 55, 54, 17, 
18, 7 
[3.81…3.87] [3.71…3.77] 
















Table 29. SVA Identification patterns of potential biomarkers obtained from several plotting 
techniques. In green SVA selection of key biomarkers, and in blue fairly important ones. The 
one in red have not been identified (see Table 52 appendix) although they are important 
biomarkers in certain plotting techniques such the plot and data scale plot in this mouse-model 
study. 
Features selected from the boxplot representation are those with the amplitude ≥ 0.05. Thus, 
the different results obtained by the SVA show a great level of consistency with respect to the 
important features discovered in the different plots.  
With regard to the colour mapping algorithm (CMA), the three main plots generated are the 
plot, the boxplot and the scale data plot, and these show that the chemical shift buckets 
[3.71…3.77], [3.39…3.44], [3.87…3.93], and [3.77…3.81] ppm corresponding to the to the 
following features glutamine, glutamate, taurine, and glycerophosphocholine,  are very 
important regarding NPC LDD diagnosis mouse model-based, while those at [3.26…3.31], 
[3.21..3.26], [3.57…3.62], [3.62…3.66] and [3.69…3.71] ppm corresponding to the 
biomolecules taurine, myo-inositol, phosphocholine, and gamma-phosphorylcholine are 
important to a lesser degree.   
 
Although it is difficult to make a clear-cut distinction between the features based on the scale 
data and contour plots, the liver disease boxplot allows us to do so; a clear distinction is made 
between the features and their supposed role in understanding the NPC liver disease (mice 
model) aetiology.  
 
Regarding the contour plot, the result acquired found the same important features, providing a 
clear understanding of the NPC liver disease development, and also the ones that play a less 
important role. However, the feature (3.37-3.39) ppm has been detected via the boxplot as a less 
important feature, whilst in all the other plots it presents as a major feature and it has not been 
identified (see Table 49). Moreover, a clear determination of the value of certain features can 
be difficult; however, overall the plotting techniques have suggested potential biomarkers 





5.4.4. Optimum Support Vector Machine and the NPC Liver Dysfunction 
Disease (NPC LDD) Data Classification  
 Data analysis techniques 
 
The analysis of the NPC LDD dataset is quite similar to the one used in the NPC1 disease 
dataset analysis (paragraph 5.2.3) as they relate to the same disease. In addition, based on the 
results obtained from the NPC1 patients’ blood plasma analysis, the RBF kernel was 
outperforming the linear kernel and the same results were obtained in similar studies performed 
elsewhere (Martí and Reinelt, 2011; Tang et al., 2009). And the results of the comparison 
between the AUC ROC and the Gmean, which show that the former is more appropriate to this 
research than the latter. Consequently, the application of the OSVM in this second part of this 
research will be shorten with less tuning process needed, less step in future selection, etc.   
 
Therefore, the result of the present analysis will be focus only on the best OSVM built from 
precedent data analysis techniques. After confirming through the NPC1 disease dataset, that 
the optimum SVM (OSVM) model build in the present research is in line with most of the 
findings related to the OSVM. This includes the RBF kernel outperforming the linear kernel, 
while the AUC ROC value, when used as performance metrics generates more improved results 
with the OSVM classifier than the Gmean one (Martí and Reinelt, 2011; Tang et al., 2009).  
 
The optimum support vector machine (OSVM) model built will be used only optimal. 
Therefore, the analysis in the remainder of this thesis will be using different combinations 
enabling the normal SVM classifier to be transformed into the OSVM, with their performances 
being compared against each other. For example, the current dataset was not standardised nor 
normalised prior used in this model. This was however, included as option in the modelling 
stage. Therefore, it important and relevant to include the option of standardisation “ON’’ 
(SON) and standardisation “OFF” (SOFF) in the tuning of the OSVM. Overall, the following 
variables setting were used, including the nearest neighbour for oversampling (NNO), the k 
folds Used (KFU), the number of repeated stratified cross-validation (RSCV), and the 
proportion of features used (POFU) for the reliefF algorithm. Furthermore, the nearest 





 Consideration   
  
The combination selected for the OSVM model included the choice of the parameter values 
that optimised the classifier. Consequently, the following parameters setting was adopted. The 
RBF kernel function was chosen over the linear kernel, whilst, the AUC ROC was selected 
over the Gmean as a performance metric for improved performance. However, the proportion 
of features used (POFU) was 1. Therefore, no nearest neighbour features selection (NNFS) was 
applied. The k folds used was KFU ≥ 10, whilst the repeated stratified cross-validation values 
were set to RSCV ≥ 10. The RSCV allows to have a fair representation of each class in each 
subset of the NPC liver dysfunction dataset used during the cross-validation process (Kim, 
2009).     
 
Furthermore, the selection of the parameters C and gamma for tuning the OSVM classifier is 
performed through the grid search algorithm, which reduces the search space in order to seek 
local maxima. The different values selected by the algorithm for each local maximum are used 
for the OSVM dichotomous classification that aims to discriminate between the diseased 
subjects and the wild treated ones. As a consequence, a set of OSVM classifier performance 
measures is generated from which an average value is calculated. It should also be noted that 
the LIBSVM as a stochastic classifier will generate different performance values for different 
runs of the classifier, and hence the need to determine an average value (McCullagh and Yang, 
2006). The OSVM offers potential to discriminate between the NPC liver disease animals and 
the healthy control ones. Therefore, a real opportunity to predict the NPC liver dysfunction 
(mouse model-based) and associated disease aetiology at an early stage with higher accuracy, 
and using the segregation method noted above.   
 
 
 OSVM classification results  
In Table 30 the general condition applied involves NNO = 10; KFU = 10; RSCV = 10; POFU 
= 1; --- RBF and AUC ROC --- (the values in the 1st column relate to that general condition - 















Gamma 0.239578 0.001159 0.001281 0.001437 0.001059 
CostC 12570.77 12.38028 69.37684 12.68029 31.828 
AUC ROC 0.950102 0.978896 0.978913 0.979904 0.978455 
Standard Deviation 0.009304 0.003783 0.004056 0.003168 0.003793 
95% Confidence Interval ±0.018235 ±0.007416 ±0.00795 ±0.00621 ±0.007434 
 
Table 30. Modifications of variables and the corresponding increases in the OSVM classifier 
performances, with RSCV = 15 producing the best AUC ROC value of 0.9799 with minimum 
standard deviation and confidence interval.  
 
 Consideration 
The OSVM classifier performances using the standardisation on (SON), the RBF kernel, and 
the AUC ROC as performance metrics show that increasing the oversampling, the number of 
repeated stratified cross-validation, the proportion of features used, and the number of K folds 
employed in the cross-validation process improves the OSVM performance. This result 
suggests that increasing the different parameters, including NNO, KFU, RSCV, and 
standardising the dataset increases the classifier power in segregating between the NPC liver 
disease animals and the wild treated (WT) ones, with higher accuracy gives that the average 
AUC ROC value is ≥ 0.979, and the average standard deviation is 0.0037 and the confidence 
intervals fluctuating, although the variation being very small values with an average of ± 
0.0073.   
 
A similar result has already been established in previous studies (Martí and Reinelt, 2011; Tang 
et al., 2009).  However, the classification result achieved by the OSVM is far higher than the 
research results noted above.   
 
5.4.5.  Principal Components Regression for the NPC Liver Dysfunction 




This principal components regression strategy was implemented in two stages, which included principal components analysis (PCA) to define the 
principal components (PCs) which are axes orthogonal to each other, and the actual responses/dependents variables Y, which is regressed on these 
PCs. Each PC is a linear combination of the original variables/features, with each PCi explaining as much of the remaining variability as possible 
in the dataset, i.e. they are independent of each other (Anton, 1987;  Manfredi, 2013).  
 
 PCA and the NPC liver dysfunction disease (NPC LDD) dataset 
 
 PCA analysis techniques 
In this analysis, none of the principal components/factors were predominant for an explanation of variability. Therefore, a certain number of the 
PCs is detected to give a sound variability explanation in the NPC LDD. Finally, different levels of variability were considered, including the 90, 
80, 70, and the 60% levels in the NPC LDD mouse model dataset. This corresponds to a certain number of PCs necessary to cover the necessary 
level of variability in the aforementioned dataset. The application of PCA follows the same principle used in section 5.2.4., visited above.  
 
 Results of the PCA 
The results presented are those really important regarding the remainder of the data analysis, especially for the MLR study that will follow after 
this section. Based on this reality, the following are presented; this includes the eigenvalues to inform on the level of variability to be considered, 
and the related number of PCs involved. The factor loadings and the distribution of the features based on the PCs are explored as well. Partial 
values of PCs, factors loadings, and factor score vectors were presented to allow deeper understanding and the involvement of some of these 
values, such as the coefficients of correlation and regression, in the selection of the main biomarkers.  
 




 Partial table of eigenvalues 
PCs  F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 
Eigenvalue 52.567 19.267 15.312 10.811 7.598 6.660 5.187 3.518 2.853 2.402 2.370 
2.024 1.741 1.333 
Variability (%) 36.760 13.473 10.708 7.560 5.313 4.658 3.627 2.460 1.995 1.680 1.657 1.415 1.217 0.932 
Cumulative % 36.760 50.234 60.942 68.501 73.814 78.472 82.099 84.559 86.555 88.234 89.891 91.307 92.524 93.456 
 
Table 31. Eigenvalues providing variability and the cumulative variability levels. Whereas, only three PCs are needed to explain 60% of the 
variability, ten are required to explain 90% of the variability. They are used to create biplots in Figure 19 below.  
 
 Partial Table of factor loadings 
Features  F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 
[0.77 .. 0.80] 0.747 0.025 -0.112 -0.425 -0.108 0.305 -0.267 0.102 -0.075 0.009 
0.038 -0.165 -0.009 0.038 
[0.80 .. 0.82] 0.598  0.020 -0.102 -0.378 -0.102 0.420 -0.405 0.155 -0.153 0.065 0.064 -0.195 -0.100 0.064 
[0.82 .. 0.84] 0.637 0.020 -0.096 -0.374 -0.098 0.409 -0.396 0.133 -0.134 0.060 0.050 -0.189 -0.097 0.050 
[0.84 .. 0.86] 0.624 -0.007 -0.097 -0.331 -0.093 0.450 -0.405 0.120 -0.141 0.077 0.048 -0.191 -0.114 0.048 
[0.86 .. 0.92] 0.897 -0.111 0.008 -0.171 -0.038 0.132 -0.209 -0.170 0.058 -0.016 -0.075 -0.036 -0.071 -0.075 
[0.92 .. 0.94] 0.932 -0.171 0.022 0.008 0.016 -0.053 -0.118 -0.140 0.049 -0.058 -0.124 0.066 0.050 -0.124 
[0.94 .. 0.99] 0.790 -0.278 -0.049 0.331 0.136 -0.059 -0.188 -0.064 0.005 -0.054 -0.185 0.173 0.007 -0.185 
[0.99 .. 1.05] 0.782 -0.203 -0.152 0.065 0.054 0.243 -0.412 0.117 -0.084 0.029 -0.099 -0.019 -0.052 -0.099 
 





 Partial Tables of factor scores 
 
Observation F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 
Obs1 -9.269 -1.709 -3.233 -2.041 -0.554 0.531 1.303 -1.146 -0.823 -0.892 0.141 1.108 -1.075 0.240 
Obs2  -3.341 -0.062 7.808 -0.468 -0.791 2.415 2.574 -1.194 0.440 0.004 -0.021 0.693 0.181 -0.876 
Obs3 0.327 -0.522 3.431 2.549 0.628 -1.107 0.239 0.260 0.404 0.643 -2.451 2.020 0.065 0.994 
Obs4 -9.507 -1.488 1.032 -0.974 -0.932 2.938 1.247 -2.017 0.038 -0.466 0.008 0.020 -0.096 -0.437 
Obs5 -8.809 3.733 -7.050 -3.268 -0.676 -1.359 2.622 6.268 6.045 0.433 -2.374 -0.735 -0.404 -3.871 
Obs6 -4.401 0.482 0.425 -1.205 -0.204 -2.172 0.527 2.402 -0.268 0.409 -0.439 0.032 -1.085 0.013 
Obs7 5.530 -3.627 -7.301 2.109 0.814 -0.764 2.108 -0.345 -0.759 1.196 0.650 0.840 -1.638 0.504 
Obs8 9.877 -4.174 -6.913 K0.033 -0.824 0.791 6.813 -0.402 -2.211 -1.590 -0.321 1.065 -0.276 0.136 
Obs9 -6.193 -0.446 -1.267 -1.463 -0.488 -1.094 -0.676 -0.379 -0.287 -0.762 -0.029 -0.061 0.067 0.823 
Obs10 -8.254 2.074 -3.429 -3.396 -0.239 -0.524 -0.304 -2.012 0.177 -0.723 -0.890 0.008 0.259 -0.049 
 













Figure 79. The biplots for factors (F1, F2) and (F2, F3), showing a distinct segregation between the NPC liver disease features, with the red colour 
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 Principal components regression and the NPC liver dysfunction disease (NPC LDD) dataset 
 
 Analysis techniques  
As in section 5.2.4., a correlation exist between the different features in the NPC liver dysfunction disease (NPC LDD) datasets; 
consequently the PCA and MLR were employed in the following data analysis. 
 
The PCA was used to select the PCs explaining the maximum variability in the original NPC LDD datasets. However, MLR was employed to 
regress the dependent variable Y on the PCs. Hence, correlating the NPC LDD features to the disease diagnosis and progression. Therefore, a 
combination of these two techniques allows the implementation of principal components regression (PCR). 
 
Two sets of coefficients including the coefficient of regression (r) and the coefficient of correlation (α) were generated following the 
implementation of the PCR. They are used to rank the key features and detect biomarkers using the TRTs, similar to section 5.2.4. This includes, 
the heuristic model, the sum product of the coefficients, and the exponential of the sum of the product of the coefficients’ techniques, which 
subsequently are employed in the biomarkers discovery for the NPC liver dysfunction disease diagnosis. 





 PCR results for the NPC liver dysfunction disease (NPC LDD) dataset  
Based on the percentage of variability, different PCs regression value are obtained. The sum of the product of the regression values (r) by the 
correlation coefficient values (α) allows to get a final classification for the original features with regards to their importance related to the detection 
of the potential biomarkers in the NPC LDD using a mouse model. The different statistics related to the model and the features are provided as 
well.  
 
 Biomarker discovery in NPC liver dysfunction disease (NPC LDD) with 90% variability  
The results of the ranking obtained, the determination of the potential biomarkers in the NPC1 disease diagnosis for a maximum 90% variability 
based on the sum of the product of the coefficients, the heuristic parameter, and the exponential sum of the product of the coefficient methods are 
given in the following Tables, with some statistics related to the method and the PC. 
 
Liver Dysfunction Disease 90% Variability    
Model Statistics Coefficient SE t-statistics p-value 
Deviance of the Fit: 7.5737 null Null Null 
Degrees of Freedom: 52 null Null Null 
Estimated dispersion parameter: 0.423 null Null Null 
Feature Number     
0 -5.6936  Statistically insignificant >0.05 
1 -2.0553                     "                                               >0.05
2 1.5886                     "                                               >0.05




4 11.1199                     "                                               >0.05
5 11.9522                     "                                               >0.05
6 16.3454                     "                                               >0.05
7 3.392                     "                                               >0.05
8 4.4974                     "                                               >0.05
9 -9.2118                     "                                               >0.05
10 -3.8479                     "                                               >0.05
11 -14.3557                     "                                               >0.05
12 -5.2846                     "                                               >0.05
*Feature number 0 is the intercept. Null null Null Null 
Null Null null Null Null 
 
Table 34. Principal components and the related coefficients of regression and associated statistics such as the standard error, and the p values for 
the 90% variability. The ranking obtained based on the different statistics provided above and the tri-ranking techniques (TRTs) follows below.  
The percentage of selections are noted correct ranking = CR and incorrect ranking = IR in comments column. 
 
Ranking Method Potential Biomarkers (90% Var.) Comment 
Heuristic Method  [7.47…7.52] [8.12….8.15] [7.65…7.70] 
[7.72…7.78] [7.62…7.65] [8.08…8.12] 
[8.69…8.74] [4.47…4.53] [2.59…2.62] 
[7.07…7.12] [2.62...2.67] [3.93…3.95] 
[3.95...3.99] [7.30...7.35] [7.70...7.72] 
Compared to SPC 
CR =18/24 = 75% 
IR =6/24 =25% 
In red are the biomarkers not  




[4.16…4.21] [1.13…1.15] [1.15…1.17] 
[7.41…7.47] [0.99…1.05] [4.30…4.35] 
[4.24…4.27] [4.61…4.63] [7.17…7.23] 
Sum of the 
Product of the 
Coefficients 
(SPC) Method 
[7.47…7.52] [8.12…8.15] [7.65…7.70] 
[7.72…7.78] [8.08…8.12] [7.62…7.65] 
[8.69…8.74] [7.07…7.12] [2.62…2.67] 
[7.70…7.72] [4.24…4.27] [0.99…1.00] 
[2.99…3.05] [2.67…2.72] [3.05…3.11] 
[4.16…4.21] [7.30…7.35] [7.17…7.23] 
[0.94…0.99] [4.30…4.35] [1.70…1.74] 
[4.47…4.53] [8.15…8.17] [2.79…2.81] 
Reference Patterns 
In green the 24 most effective  
biomarkers detected by the  
SPC ranking techniques 
Exponential 
Of the Sum of the 




[7.47…7.52] [8.12…8.15] [7.65…7.70] 
[7.72…7.78] [8.08…8.12] [7.62…7.65] 
[8.69…8.74] [7.07…7.12] [2.62…2.67] 
[7.70…7.72] [4.24…4.27] [0.99…1.05] 
[2.99…3.05] [2.67…2.72] [3.05…3.11] 
[4.16…4.21] [7.30…7.35] [7.17…7.23] 
[0.94…0.99] [4.30…4.35] [1.70…1.74] 
[4.47…4.53] [8.15…8.17] [2.79…2.81] 
Correct Classification 
Compared to SPC  
CR = 24/24 = 100% 
IR = 0/24 = 0% 
Same ranking ability as the  





Table 35. Potential biomarkers based on the three different techniques involved above. The tri-ranking techniques (TRTs) generally gives rise to 
the same selection for the main biomarkers in the NPC liver disease dataset. The 10 most important biomarkers out of 24 are identical (in blue) 
for the tri-ranking techniques, with different performance especially for heuristic model. 
 
Based on the percentages of variability accounted for, the different PC regression value are obtained. The sum of the product of the regression 
values (r) via the correlation coefficient values (α) allows us to attain a final classification for the original features with regard to their importance 
in detection of the potential biomarkers. Nonetheless, the results of the ranking obtained shows that determinations of potential biomarkers in the 
NPC LDD diagnosis for up to 90% variability, based on the heuristic model, the sum of the product of the coefficients (SPC), and the exponential 
methods are consistent. However, identical major biomarkers are featured. The heuristic and the SPC provide the same rankings. Potential 









 Biomarker discovery in NPC liver dysfunction condition with 80% variability  
The results of the ranking obtained and determination of the potential biomarkers for the 80% 
variability model, based on the double coefficients, the heuristic, and the exponential methods 
are provided in the following tables, together with statistics related to the model and its features.  
 
Liver Dysfunction Disease 80% Variability    
Model Statistics Coefficient SE t-statistics p-value 
Deviance of the Fit: 27.5949 Null Null null 
Degrees of Freedom: 57 Null Null null 
Estimated dispersion parameter: 0.758 Null Null null 
Feature Number     
0 -1.0643   >0.05 
1 -1.0626   >0.05 
2 2.8073   >0.05 
3 -2.0675 0.9604 -2.1527 0.0313 
4 7.6167 2.7247 2.7955 0.0052 
5 -3.3453   >0.05 
6 2.6602 1.0261 2.5925 0.0095 
7 -0.4302   >0.05 
* Feature number 0 is the intercept. null Null null null 
Null Null Null null null 
 
Table 36. Different PCs and related coefficients regression, and correlation and associated 
statistics in the model 80% variability. The small deviance of the fit and estimated dispersion 
parameter informs of the probable importance of this 80% variability level. The ranking 
obtained is based on the statistic values provided above and the TRT. 
 
Ranking Method  Potential Biomarkers (80% Var.) Comment 
Heuristic Method  [6.88…6.93] [7.35…7.41] [7.52…7.58] 
[7.91…7.94] [7.23…7.28] [8.39…8.44] 
[7.85…7.91] [8.47…8.53] [7.30…7.35] 
[2.59…2.62] [7.41…7.47] [7.28…7.30] 
Compared to SPC 
 CR =20/24 = 83.33% 




[6.86…6.88] [7.58…7.62] [8.36…8.39] 
[7.70…7.72] [3.93…3.95] [3.77…3.81] 
[2.62…2.67] [7.72…7.78] [7.62…7.65] 
[2.67…2.72] [2.79…2.81] [3.95…3.99] 
In red are the biomarkers  
not detected by the  
model 
Sum of the 
Product of the 
Coefficients (SPC) 
Method 
[6.88…6.93] [7.35…7.41] [7.52…7.58] 
[7.91…7.94] [7.23…7.28] [8.39…8.44] 
[8.47…8.53] [7.85…7.91] [7.30…7.35] 
[2.59…2.62] [7.41…7.47] [7.58…7.62] 
[7.28…7.30] [8.36…8.39] [6.86…6.88] 
[8.44…8.47] [7.70…7.72] [7.47…7.52] 
[3.77…3.81] [3.93…3.95] [2.99…3.05] 
[2.62…2.67] [7.72…7.78] [7.94…7.99] 
Reference Patterns 
In green are the 10 most  
effective biomarkers  
detected based on the  
ranking technique 
Exponential 
Of the Sum of the 
Product of the 
Coefficients (ESPC) 
Method 
[6.88…6.93] [7.35…7.41] [7.52…7.58] 
[7.91…7.94] [7.23…7.28] [8.39…8.44] 
[8.47…8.53] [7.85…7.91] [7.30….7.35] 
[2.59…2.62] [7.41…7.47] [7.58…7.62] 
[7.28…7.30] [8.36…8.39] [6.86…6.88] 
[8.44…8.47] [7.70…7.72] [7.47…7.52] 
[3.77…3.81] [3.93…3.95] [2.99…3.05] 
[2.62…2.67] [7.72…7.78] [7.94…7.99] 
Correct Classification 
Compared to SPC  
CR = 24/24 = 100% 
IR = 0/24 = 0% 
In green are the 10 most  
effective biomarkers  
detected based on the  
ranking technique 
 
Table 37. 24 most important buckets corresponding to the 24 best markers (in green) detected 
by the tri-ranking techniques and potential biomarkers for the 80% total variability dataset. 
Potential biomarkers based on three techniques applied. In general, the tri-ranking techniques 
selected the same features as major biomarkers in the NPC liver disease dataset. The 10 most 
important biomarkers out of 24 are identical for the tri-ranking techniques, with different 
performance especially for heuristic model (in blue in SPC and ESPC sections). 
NB: In orange biomolecules non-identified. 
 
 Results for a maximal 80% variability are very similar to those obtained for 90% variability. 
Indeed, most of the potential biomarkers discovered in both cases are the same, although there 






 Biomarker discovery in NPC liver disease with a maximum70% variability 
The results of the rankings obtained, and the identification of potential biomarkers in the NPC1 
disease diagnosis for a total 70% variability, which is based on the coefficients of regression 
and the coefficient of correlation, the heuristic, the SPC and the ESPC methods, are given in 
the following Tables 38, and 39 together with statistics related to the model and the features.  
 
NPC Liver Dysfunction Disease - 70% Variability    
Model Statistics Coefficient SE t-statistics p-value 
Deviance of the Fit: 39.1255 Null null Null 
Degrees of Freedom: 59 Null null Null 
Estimated dispersion parameter: 1.205 Null null Null 
Feature Number     
0 -1.4455 0.5227 -2.7657 0.0057 
1 -0.7047   >0.05 
2 -1.5026   >0.05 
3 -0.8017   >0.05 
4 3.8655 1.0493 3.684 0.0002 
5 0.403   >0.05 
* Feature number 0 is the 
intercept. 
null Null null Null 
Null null Null null Null 
 
Table 38. PCs and their related coefficients of regression and associated statistics for the 70% 
variability model. The fairly higher deviance of the fit and estimated dispersion parameters 
express the probable low importance of the 70% level of ranking acquired. Feature number 4 
in green is the only one to be statistically significant with a p value of value 0.0002 < 0.05. 
 
Ranking Method  Potential Biomarkers (70% Var.) Comment 
Heuristic Method  
 
[7.30…7.35] [2.62…2.67] [2.79…2.81] 
[2.67…2.72] [6.88…6.93] [7.85…7.91] 
 [2.32…2.37] [7.35…7.41] [7.52…7.58] 
[2.81…2.87] [7.91…7.94] [8.47….53]  
[2.59…2.62] [3.05…3.11] [7.23…7.28] 
[8.39…8.44] [0.94…0.99] [2.99…3.05] 
Compared to SPC 
CR = 18/24 = 75% 
IR = 6/24 = 25 % 
In red are the biomarkers  




[3.95…3.99] [3.93…3.95] [2.37…2.42] 
[1.70…1.74] [3.31…3.35] [7.17…7.23] 
Sum of the 
Product of the 
Coefficients 
(SPC) Method 
[2.62…2.67] [2.79…2.81] [2.67…2.72] 
[7.30…7.35] [2.81…2.87] [2.32…2.37] 
[2.59…2.62] [3.05…3.11] [0.94…0.99] 
[2.99…3.05] [3.31…3.35] [1.70…1.74] 
[2.37…2.42] [3.11…3.15] [3.15…3.17] 
[7.17…7.23] [6.88…6.93] [2.26…2.32] 
[3.95…3.99] [7.85…7.91] [7.41…7.47] 
[2.72…2.77] [7.35…7.41] [4.16…4.21]  
Reference Patterns 
In green are the 24 best  
biomarkers detected based on 
ranking criteria 
Exponential 
Of the Sum of the 
Product of the 
Coefficients (ESPC) 
Method 
[2.62…2.67] [2.79…2.81] [2.67…2.72] 
[7.30…7.35] [2.81…2.87] [2.32…2.37] 
[2.59…2.62] [3.05…3.11] [0.94...0.99] 
[2.99…3.05] [3.31…3.35] [1.70…1.74] 
[2.37…2.42] [3.11…3.15] [3.15…3.17] 
[7.17…7.23] [6.88…6.93] [2.26…2.32] 
[3.95…3.99] [7.85…7.91] [7.41…7.47] 
[2.72…2.77] [7.35…7.41] [4.16…4.21] 
Correct 
Classification 
Compared to SPC  
CR = 24/24 = 100% 
IR = 0/24 = 0% 
 
Table 59. Potential biomarkers based on the three main features ranking techniques formally 
identified. The ranking techniques select the same features as major biomarkers in the NPC 
liver disease diagnosis. 
Results for 70% maximum variability model are very similar to the one obtained with 90% 
variability. Indeed, most of the potential biomarkers discovered in both cases are the same, 
differences observed relating only to rankings. In addition, 70% could not detect all the 
biomarkers selected by the reference ranking technique, and includes variation in ranking with 
regard to common biomarkers detected, including the 10 most important biomarkers out the 24 
main ones (in blue).  
 
 Biomarker discovery in NPC liver disease with 60% variability 
The results of the ranking obtained, determination of the potential biomarkers in the NPC liver 
disease dataset for a model with a maximum 60% variability is shown in Table 40 below. This 
is based on the coefficients of correlation and regression, the heuristic, the SPC and the ESPC 





NPC Liver Dysfunction Disease - 60% Variability    
Model Statistics Coefficient SE t-statistics p-value 
Deviance of the Fit: 83.2905 Null Null Null 
Degrees of Freedom: 61 Null Null Null 
Estimated dispersion parameter: 1.105 Null Null Null 
Feature Number     
0 -0.5652 0.2653 -2.1305 0.0331 
1 0.0952   >0.05 
2 -0.4132   >0.05 
3 -0.1481   >0.05 
*Feature number 0 is the intercept. Null Null Null Null 
Null Null Null Null Null 
 
Table 40. PCs and related coefficients of regression, in addition to different statistics for the 
60% variability model. The higher deviance of the fit and estimated dispersion parameters 
express the probable low importance of the 60% level of ranking acquired. Feature 1, 2, 3 in 
are less statistically significant with a p value > 0.05.  
 
 
The ranking obtained from application of the TRT are in Table 41 below. 
 
Ranking Method  Potential Biomarkers (60% Var.) Comment 
Heuristic Method  [2.67…2.72] [2.79…2.81] [2.72…2.77] 
[2.81…2.87] [3.05…3.11] [2.26…2.32] 
[3.15…3.17] [3.11…3.15] [2.51…2.53] 
[2.87…2.90] [3.31…3.35] [2.62…2.67] 
[2.37…2.42] [1.05…1.08] [3.17…3.19] 
[1.70…1.74] [1.74…1.79] [1.95…1.97] 
[0.94…0.99] [1.89…1.95] [1.97…1.99] 
[2.32…2.37] [2.01…2.04] [0.99…1.05] 
Ranking Performance 
compared to that of the   
SPC  
CR = 24/24 = 100% 
IR = 0/24 =0 % 
 
 
Sum of the 
Product of the 
Coefficients (SPC) 
[2.67…2.72] [2.79…2.81] [2.72…2.77] 
[2.81…2.87] [3.05…3.11] [2.26…2.32] 
[3.15…3.17] [3.11…3.15] [2.51…2.53] 
Reference Patterns  





Method [2.87…2.90] [3.31…3.35] [2.62…2.67] 
[2.37…2.42] [1.05…1.08] [3.17…3.19] 
[1.70…1.74] [1.74…1.79] [0.94…0.99] 
[1.95…1.97] [2.32…2.37] [1.89…1.95] 
[1.97…1.99] [2.01…2.04] [0.99…1.05] 
detected based on the  
ranking criteria 
Exponential 
Of the Sum of the 
Product of the 
Coefficients (ESPC) 
Method  
[2.67…2.72] [2.79…2.81] [2.72…2.77] 
[2.81…2.87] [3.05…3.11] [2.26…2.32] 
[3.15…3.17] [3.11…3.15] [2.51…2.53] 
[2.87…2.90] [3.31…3.35] [2.62…2.67] 
[2.37…2.42] [1.05…1.08] [3.17…3.19] 
[1.70…1.74] [1.74…1.79] [0.94…0.99] 
[1.95…1.97] [2.32…2.37] [1.89…1.95] 
[1.97…1.99] [2.01…2.04] [0.99…1.05] 
Ranking Performance 
compared to that of the   
SPC  
CR = 24/24 = 100% 
IR = 0/24 = 0% 
 
 
Table 41. Potential biomarkers based on the three main features ranking techniques formally 
identified for a maximum 60% variability level. These ranking techniques selected the same 
24 main potential biomarkers. The ranking performance for heuristic and ESPC methods have 
been compared to that of the SPC used as ranking reference model. The 10 most important 
biomarkers of 24 are identical for the three techniques. 
Results for this 60% variability model are that TRTs performed an extreme high level of 
ranking, with the same selection of 24 most effective biomarkers. This can be explained by the 
low level of variability, i.e. 60% variability only explained. These features ranked are related 




 Comparing the four levels of variability  
 
Table below is obtained from the precedent features ranking, and using the SPC method as reference 








[7.47…7.52]  [8.12…8.15]  [7.65…7.70] 
[7.72…7.78]  [8.08…8.12]  [7.62…7.65] 
[8.69…8.74]  [7.07…7.12]  [2.62…2.67] 
[7.70…7.72]   [4.24…4.27]  [0.99…1.0] 
[2.99…3.05]  [2.67…2.72]  [3.05…3.11] 
[4.16…4.21]   [7.30…7.35]  [7.17…7.23] 
[0.94…0.99]  [4.30…4.35]  [1.70…1.74] 
[4.47…4.53]  [8.15…8.17]  [2.79…2.81] 
[6.88…6.93]  [7.35…7.41]  [7.52…7.58] 
[7.91…7.94]  [7.23…7.28]  [8.39…8.44] 
[8.47…8.53]  [7.85…7.91]  [7.30…7.35] 
[2.59…2.62]  [7.41…7.47]  [7.58…7.62] 
[7.28…7.30]  [8.36…8.39]  [6.86…6.88] 
[8.44…8.47]  [7.70…7.72]  [7.47…7.52] 
[3.77…3.81]  [3.93…3.95]  [2.99…3.05] 
[2.62…2.67]  [7.72…7.78]  [7.94…7.99] 
70% 60% 
[2.62…2.67]  [2.79…2.81]  [2.67…2.72] 
[7.30…7.35]  [2.81…2.87]  [2.32…2.37] 
[2.59…2.62]  [3.05…3.11]  [0.94…0.99] 
[2.99…3.05]  [3.31…3.35]  [1.70…1.74] 
[2.37…2.42]  [3.11…3.15] [3.15…3.17] 
[7.17…7.23]  [6.88…6.93]  [2.26…2.32] 
[3.95…3.99]  [7.85…7.91]  [7.41…7.47] 
[2.72…2.77]  [7.35…7.41]  [4.16…4.21] 
[2.67…2.72]  [2.79…2.81]  [2.72…2.77] 
[2.81…2.87]  [3.05…3.11]   [2.26…2.32] 
[3.15…3.17]  [3.11…3.15]   [2.51…2.53] 
[2.87…2.90] [3.31…3.35]    [2.62…2.67] 
[2.37…2.42]  [1.05…1.08]   [3.17…3.19] 
[1.70…1.74]   [1.74…1.79]   [0.94…0.99] 
[1.95…1.97]   [2.32…2.37]   [1.89…1.95] 
[1.97…1.99]    [2.01…2.04]  [0.99…1.05] 
                                                                                          
Table 42. Major potential biomarkers detected at different levels of variability with the 
selection 90% used as variability reference. In green are the features detected by all the four 
levels of variability, in blue are the ones detected by three levels of variability, and in red are 
those detected by two levels of variability and in black those detected by only one level of 
variability.  It should be noted that only (2.62-2.67) ppm corresponding to methionine and 
hypotaurine was detected by the 4 levels of variability amongst the 24 best biomarkers. 90% 
variability could detect most of the biomarkers detected by the other three levels of variability. 
This includes nicotinate, xanthine, lysine, ornithine, Citrate, phenylalanine, leucine/isoleucine, 
and aspartate which have been classified as very important biomarkers in the NPC1 disease 
diagnosis (see Tables 42). The two sets of findings are in line with the fact that methionine and 
hypotaurine are the most important biomarkers detected by the intelligent tri-modelling 
techniques developed (ITMTs) are they are ranked No1 in terms of potential biomarkers 
detected in the NPC liver dysfunction dataset (identified as probable new biomarkers).  The 
other potential biomarkers detected including nicotinate, xanthine, lysine, ornithine, Citrate, 
phenylalanine, leucine/isoleucine, and aspartate are ranked amongst the 15 most effective 


























90  100 75 7.5737 0.423 52 
80 100 83.33 27.5949 0.758 57 
70  100 75 39.1255 1.205 59 
60 100 100 83.2905 1.105 61 
 
Table 63. Percentage of the correct ranking (CR) performed by the Heuristic method and 




1. The Heuristic ranking performance involving the level of correct (CR) is used to compare 
models as well as the level of variability. 
2. The SPC and ESPC ranking methods achieved the same level of rankings were considered 
as the best ranking techniques based on these criteria.                                                  
3. The model deviance and the parameters’ estimated dispersion established that 90% and then 
80% respectively serve as the best and second-best variability percentages in the NPC LDD 
diagnosis dataset. This is ascribable to the minimum level of deviance (7.57 < 27.59) and the 
estimated dispersion (0.423 < 0.758) for 90% and 80 % variabilities respectively. However, 
based on the heuristic method which is the ranking technique with the lowest ranking ability, 
the level of correct ranking performance (CR) for the 80% variability model appears to offer 
improvements over the 90% level one. In addition, ranking being the main objective in this 
section, therefore, 80% is considered to be the best level of variability followed by 90% 
variability although the latter has better statistical parameters.  This result is consistent with the 





The Table below gives the full range of the 20 main potential biomarkers discovered by the 
PCR model developed in this study; they are compared to existing biomarkers.  
 
 Related molecular assignment - 20 most effective biomarkers: 
 
Ranking  Chemical 
Shift 
Probable Biomarkers in NPC Liver 
Dysfunction Disease Mouse-Model 
Comments on 
Biomarkers Discovered 
1 [2.62…2.67] Methionine / Hypotaurine Probable Biomarkers 
2 [2.99…3.05] Lysine / Ornithine Existing Biomarkers 
3 [7.30…7.35]   Phenylalanine Existing Biomarker  
4 [7.47…7.52]   Phenylalanine Existing Biomarker 
5 [7.72…7.78]   Hippurate-C4-CH Probable New Biomarker  
6 [7.70…7.72] Nicotinate / Xanthine  Probable New Biomarkers  
7 [2.67…2.72] Citrate-CH2A / CH2B Probable Biomarker 
8 [4.16…4.21]    Phosphorocholine Probable Biomarker 
9 [7.17…7.23] Tyrosine   Existing Biomarker 
10 [0.94…0.99]   Leucine-CH3 / Isoleucine Existing Biomarker 
11 [1.70…1.74] Lysine-C5-CH2 Existing Biomarker 
12 [2.79…2.81]   Aspartate Probable Biomarker 
13 [2.81…2.87]   Aspartate Probable Biomarker 
14 [2.32…2.37]  Pyruvate-CH3; Glutamate-C3-CH2 Existing Biomarkers 
15 [3.05…3.11]   Ornithine-CS  Probable Biomarker 
16 [3.31…3.35]   Cystine-C3/C6-CH2 Probable Biomarker 
17 [1.70…1.74] Lysine-C5-CH2 Probable Biomarker 
18 [2.37…2.42] Glutamate-C3-CH2; Succinate-CH2's Existing/Probable  Biomarkers 
19 [3.11…3.15]   Glucuronate- C2-CH Probable Biomarker  
20 [3.15…3.17] 9-Methyluric acid   Probable Biomarker  
 
Table 44. Full list of 20 potential biomarkers with probable new biomarkers discovered by the 
PCR model in the NPC liver dysfunction disease dataset mouse model. Hippurate (5th) and the 







 Consideration  
 
For the NPC liver dysfunction dataset mouse-model, the tri-ranking techniques employed have 
discovered the same main biomarkers overall, However, the top 10 differ from one level of 
variability to the next. However, for the four different variabilities, the rankings obtained are 
the same for SPC and the ESPC. The list of the 7 main biomarkers formally detected by all 
four levels of variability is methionine, hypotaurine, lysine, ornithine, phenylalanine, 
hippurate, nicotinate, xanthine, and Citrate.  
 
Following the detection of the 7 main biomarkers, their relation to our understanding of NPC1 
liver disease allows to carry out a pathway analysis that is next to come. 
 
5.4.6. Biomarkers Pathway Analysis of the NPC Liver Dysfunction Disease  
 Result of pathway analysis 
 
 Table of major metabolomics pathway in the NPC LDD 
 
 








9/24 5.4248E-9 19.032 4.4484E-7 4.4484E-7 0.7194 KEGG  
Aminoacyl-tRNA 
biosynthesis 
11/69 1.6168E-6 13.335 1.3096E-4 6.6287E-5 0.0 KEGG  
Arginine and 
proline metabolism 






3/5 2.1629E-4 8.4389 0.017087 0.004434 1.0 KEGG  
Nitrogen 
metabolism 
3/9 0.0016751 6.3919 0.13066 0.027472 0.0 KEGG  
Citrate cycle (TCA 
cycle) 











Valine, leucine and 
isoleucine 
biosynthesis 







2/4 0.0047257 5.3547 0.3497 0.043057 1.0 KEGG  
Glycine, serine and 
threonine 
metabolism 






2/9 0.025861 3.655 1.0 0.19278 0.4 KEGG  
Glutathione 
metabolism 


























1/3 0.084374 2.4725 1.0 0.40698 0.0 KEGG  
Lysine biosynthesis 1/4 0.11092 2.1989 1.0 0.50532 0.0 KEGG  










Table 45. Metabolomics pathway analysis results derived from the identification of biomarker 
metabolites in NPC mouse model liver dysfunction process datasets facilitate our 
understanding of disease aetiology. Based on the Holm adjusted p values (p value < 0.05) and 
the false detection rate (FDR< 0.05), it is clear that the first metabolomics pathways with the 




first lines corresponding to major pathways appear to be significantly important in this process 
are further discussed below.       
                                                                                                                                                        
 Pathway Overview 
 
 
Figure 20. Pathway overview showing from top to bottom on the graph in descend order of 
importance the different pathway involved in this NPC mouse model liver dysfunction disease 
study. Thus, the significance of the pathway decreases going from red to yellow. Therefore, 
alanine, aspartate, and glutamate metabolism (–log(p) of 19.032), followed by aminoacyl-
tRNA biosynthesis (–log(p) of 13.335), then arginine and proline metabolism (–log(p) of 
10.82) and finally glutamine and glutamate metabolism (–log(p) of 8.4389), appeared as the 










Figure 21. Pathway analysis alanine, aspartate and glutamate metabolism, where the 
following statistics are presented; Holm adjusted p values of 4.4484E-7, a FDR of 4.4484E-7 
and a high pathway impact of 0.7194. Hence, this pathway is highly differentially expressed in 
the NPC (mice model) liver disease.  
The current pathway is highly differentially expressed, and involves, the N-acetyl-L-aspartate 
(C01042), which can generate L-aspartate (C00049), which in turn can be transformed to 
fumarate through different intermediates metabolites not present in this dataset. However, L-
alanine (C00041) can produce pyruvate (C00022), and also, L-glutamate (C00025) can 
generate L-glutamine (C00064) directly, or gamma-aminobutyrate (C00334), which in turn, 
produces succinate (C00042).  These metabolites featured highly on this pathway except 







 Pathway Analysis of Aminoacyl-tRNA biosynthesis 
 
 
 Figure 22. Aminoacyl-tRNA metabolomics pathway analysis with a Holm adjusted p value of 
1.3096E-4, a FDR of 6.6287E-5, and a pathway impact of 0.0, and the second highest        -
log(p) of 13.335). Therefore, this pathway is differentially-expressed, with major contribution 
of L-glutamate (C00025), L-tyrosine (C00082), L-leucine (C000123), L-isoleucine (C00407), 
L-lysine (C0047), L-alanine (C00079), L-methionine (C00073), L-aspartate (C00049), glycine 
(C00037), glutamine (C00064), and L-phenylalanine (C00079).    
Several metabolites were observed in the present 1H NMR spectra and are monitored with 
regard to aminoacyl-tRNA biosynthesis. The current pathway analysis could start from the L-
glutamate, then to L-tyrosine through intermediaries which can also generate L-leucine through 
intermediaries. The latter can produce L-isoleucine, leading to L-lysine, then L-alanine, leading 
to L-methionine, then L-aspartate, producing glycine, then glutamine and finally, L-
phenyalanine are all highly featured on this pathway. However, this series of reactions are 
performed using intermediaries most of which are not present in this dataset and are excluded 
from the enrichment analysis. It is important to mention that glutamate an anion of glutamic 





 Pathway Analysis for arginine and proline metabolism 
 
 
Figure 23. Arginine and proline metabolomics pathway analysis with a Holm adjusted p value 
of 0.0015996, a FDR of 5.4652E-5, and a pathway impact of 0.24479. Therefore, this pathway 
is strongly differentially-expressed, and features modified concentration of                                          
p-hydroxyphenylacetate, hippurate, pyruvate, fumarate and succinate. 
L-glutamine (C0064) generates the ammonia (C0014), which in turn can go through 
intermediaries to produce L-arginine. Indeed, the L-arginine (C0062) can be generated going 
through two intermediaries, which in turn will produce creatine (C00300). On the other hand, 
arginine (C0062) can produce ornithine (C00077) which can generate glutamate (C0025). 
However, glutamate can generate also ammonia. Nevertheless, peptide (C0012) can produce 
proline (C00148), which in turn can be converted to pyrroline-5-carboxylate (C03912) which 
produces L-glutamate. All the biomolecule highlighted in bold are highly present on this 
pathway. Nevertheless, in the liver, especially in the cells surrounding its central membrane, 
ornithine is used for the synthesis of glutamate and glutamine, and can also be used in 




Dynamic network of cholesterol trafficking plays the important role of maintaining the 
cholesterol content of subcellular membranes.  For instance late endosomal transmembrane 
NPC proteins in the lysosome lumen interact for the transportation of the cholesterol from the 
endosome to the plasma membrane and the endoplasmic reticulum. The unesterified 
cholesterol will be accumulated at endosomal level as a consequence of a dysfunction 
(Kennedy et al., 2016). 
 




Figure 24. Pathway analysis of glutamine and glutamate metabolism, with the following 
statistics; Holm adjusted p values of 0.017087, a FDR of 0.004434 and a high pathway impact 
of 1.0. Hence, this pathway is highly differentially expressed in the NPC (mice model) liver 
disease.  
The current pathway is highly differentially expressed, and involves, L-glutamine (C00064), 
which can generate L-glutamate (C00025), and the latter can be converted to oxoglutarate 
(C00026) absent in this dataset. Glutamine can directly produce glutamate, and the metabolism 
of the latter involves several reversible or irreversible reactions. Thus, the transformation of 
the L-glutamate to N-acetyl-L-glutamate takes place in the presence of N-acetylglutamate 
synthase (NAGS) with the help of L-arginine as activator, and several inhibitors, including 
succinate, coenzyme A, N-acetyl-L-aspartate and N-acetyl-L-glutamate (SHIGESADA and 
TATIBANA, 1978; Yelamanchi et al., 2016). In the same manner, the conversion of glutamine 




glutamine-fructose-6-phosphate transaminase (GFPT1 and GFPT2) and finally phosphoribosyl 
pyrophosphate amidotransferase (PPAT) (Hu et al., 2010; Yelamanchi et al., 2016). It should 
be noted that glutamate is the highest concentration of molecule in the brain cells and is the 
canal used by the nerve cells to send signal to other cells. 
 
 General Consideration:  
 
1H NMR spectra generated from aqueous extracts of mice liver samples with a group of the 
NPC liver dysfunction disease (NPC LDD) carriers and a control group representing the 
healthy mice were very informative. Amongst important biomarkers features amino acid such 
as alanine, leucine, isoleucine, valine etc.; organic acid anion such as glutamate, formate, 
fumarate, lactate, and pyruvate. Other resonance features in these spectra were assignable to 
methylalanine, dimethylamine, etc. Moreover, bile acids which are usually associated with 
taurine or glycine in the liver were also identified by the different modelling techniques 
employed, including SPC, ESPC and Heuristic. The scalar visualisation technique could detect 
these major biomarkers from the raw data analysed without any strong data pre-processing 
technique applied to it. Moreover, the OSVM could unambiguously segregate between the two 
classes of liver extract samples with a high-performance value from the AUC ROC that was 
selected as better performance metric than the Gmean. Finally, using the PCR model, allowed 
the selection of major biomarkers, together with their pathway analysis that connected a 
different group of metabolites and the underlying development of the NPC (mice-model) liver 
dysfunction disease aetiology.  
 
Following the detection of these biomarkers and the analysis of the main pathways related to 
them, the next step is dealing with the modelling techniques validation. This should give more 
credit to the TRT model developed together with the findings.  
 
5.5. Research Model Validation  
 




The intelligent tri-modelling techniques implemented in this thesis use three different 
algorithms for modelling the different datasets involved in this research. This encompasses the 
use of three modelling techniques. The first algorithm used is the scalar visualisation algorithm 
(SVA). This is a valid technique acquired from the Matlab toolbox and creates a ‘look-up’ table 
of colours that are matched with indexes based on the resonance of the 1H NMR spectra of the 
different metabolites found in the datasets. The algorithm is valid and has been already used in 
different research studies to gain insight into data structure and the relationship between 
features ( Johnson, 2015; Johnsona, 2012; Komura, 2016; Peng, 2011). 
  
The second model used is the optimum support vector machine (OSVM). This model is a 
support vector machine tuned to its optimum performance using the maximum ‘tuning’ 
capability of the different parameters used in the SVM. Similar SVM has already been 
developed, and this includes those focused in improving classification on imbalanced datasets, 
or developing efficient models (Köknar-Tezel and Latecki, 2011; Maji et al., 2013). 
 
The third algorithm used in this research is the principal component regression (PCR). 
Although the current PCR involved the PCA algorithm for the detection and selection of 
principal components PCs, and the multiple logistic regression (MLR) strategy allowing to 
regress the dependent variable Y on the PCs.  The same technique has been additionally used 
in several research studies, and has been well validated (Boston University School of Public 
Health, 2013; Kumar and Madhu, 2012).  
 
Another level of validation was implemented based on the research results obtained. 
 
5.5.2. Research Result Validation   
Different techniques were implemented in order to validate the results obtained. This includes 
the stratified k folds cross-validation technique enabling to generate k subsets of the dataset 
with k-1 subsets used for training and 1 subset for testing. This helps us to assess how the 
system learns from training processes. However, the stratification technique allows to have in 
each subset a fair representation of the minority group. In addition, the ADASYN technique 
that creates synthetic samples in the minority class in order to balance the dataset and alleviate 




to the support vector machine were ‘tuned’ based on the training and testing sets in order to 
permit the classifier to perform at its maximum performance level, and hence the label of 
optimum support vector machine (OSVM) for the SVM employed in this thesis.  
 
It should also be noted that the results of this research are validated against the appropriate 
standard, based on the knowledge that the different techniques used are all standard and valid 
techniques in data classification. This includes k-fold cross-validation techniques, grid search 
methods, the ADASYN technique, the variable selection techniques, etc. In addition, the 
different classification performance rates based on the AUC ROC and Gmean values that are 
means of the different models were run several times to generate conclusive results, i.e. AUC 
ROC = 0.944 and Gmean = 0.885 as mean values for NPC1 disease dataset. Furthermore, SVA 
could detect several major biomarkers identified by all three algorithms involved in the present 
intelligent tri-modelling techniques. For example, SVA could highlight pyruvate, glutamate, 
lactate, 2-hydroxyisobutyrate, 3-hydroxybutyrate, L-fucose, 3-hydroxyisovalerate, 2-
hydroxyglutarate, etc., as major biomarkers for NPC1 disease diagnosis, and valine and leucine 
in the NPC LDD dataset. Finally, the result produced in relation to the validation of the 
biomarkers discovered is discussed below.  
 
5.5.3. Independent statistical validation  
Effective validation of the biomarkers discovered should involve a combination of a clinical 
and statistical processes. The clinical validation will not be discussed in this research because 
it is beyond the scope of it. However, the independent statistical validation process that intends 
to establish a correlation between miglustat treatment and these biomarkers is succinctly 
highlighted in this sub-section.  
 
Biomarkers discovered required candidate biomarkers to undergo two stages in the validation 
process, including clinical and statistical validations. The statistical validation, which has been 
covered in this thesis, included an initial stage where a correlation will be established between 
the biomarker(s) discovered and NPC1 disease diagnosis. This stage has been completed with 
the discovery of the potential biomarkers using NPC1 disease patients’ blood plasma and liver 
extracts of mouse model datasets. Secondly, independent statistical testings will help us to 




NPC1 disease patients’ conditions (Buyse et al., 2010). The intelligent algorithm development 
(IAD) presented above (see 3.2.2) highlights stages of an independent validation process for 
such biomarkers. Indeed, if miglustat treatment reduces the concentration of the biomarkers 
discovered, which include hippurate and adipate in blood plasma, then these biomarkers may 
indeed be considered as valid for this NPC1 disease study.  
 
Finally, the processes implemented during this research were validated against the theoretical 
framework developed (ITTFM) noted below. 
 
5.5.4. Research theory validation  
 
The theory of intelligent technology task fit model (ITTFM) has to be validated against 
standard. The diverse set of operations taking place during experimental manipulations, 
including the disease samples selection, the NMR process and spectra quality, the SVA 
processing time, the SVA major biomarkers detection processes, and accuracy, the OSVM 
classification performance rates, the PCR biomarker detection process, etc., could be 
considered as ideal characteristics of the measurement of the performances and the validation 
of the ITTFM (Albro et al., 2010; Bird et al., 2014;  Chau et al., 2008;  Murphy and Kerr, 2004; 
Venkatraman, 1988). 
 
Therefore, the possibility of using the different activities taking place, in order to ensure that 
they have been verified, as a mean of validating the model’s suitability, could be undertaken 
too. This technique could be regarded as a validation step of the ITMTs. Similar studies have 
been conducted to validate the theory developed (Albro et al., 2010; Venkatraman, 1988). 
In the present thesis, the theory of the ITTFM related to the human involvement in the process 
of detection, discovery of biomarkers in disease diagnosis. Therefore, the concept of ‘fit-as-
match’ attempts to detect the level of matching between the process and the high standards 
required in biomarker discovery. However, the concept of ‘fit-as-deviation’ investigates the 
level of deviation between the process and the algorithm employed for biomarker discovery; 
while the ‘fit-as-profile’ concept determines the level of convergence between the process and 





 Consideration  
 
The model profile is related to the different variables necessary in the current biomarker 
discovery process. They include the two main steps that are data collection and data analysis. 
Setting process scheduler allows us to ensure for example that different batch of the blood 
samples going through NMR spectroscopy are run identically for consistence, repeatability, 
reproducible, and verifiable. This was implemented during data collection, data analysis, and 
is now used as technique and standard in the validation of the intelligent technology task fit 
model.  
 
  ITTFM model validation  
 
Processes Fit-as-profile Fit-as-match Fit-as-deviation Comments  
Data collection Define a metric 






Standard was met for 
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Standard was met 
with regards to 
parameters selection 
and tuning 
SVA for Data 
Visualisation  









Standard was met for 
all the datasets. 
SVM for Data  
Classification 
and Prediction 









Standard was met for 















Detection of known 
and probable new 
biomarkers. 
 
Table 46. Matching with standards in data collection, data processing and analysis research 
model validation using the ITTFM theory. The different characteristics defined in alignment 
levels models (Table 3) allow us to validate the ITTFM model. 
 
The intelligent technology task fit model was validated against standard, especially against the 
theory of the task technology fit model developed by Goodhue and Thompson by applying 
rigorous scientific processes that are genuine, sequential, replicable, and reproducible. In 
addition, the different steps involved can be assessed throughout the development process 
(Albro et al., 2010; Bird et al., 2014; European Commission, 2010; Goodhue and Thompson, 
1995).   
  
 
5.6. Chapter Summary  
 
The data analysis and results chapter include an introductory section that highlighted the main 




the NPC1 disease (human model-based) data multivariate analysis, using the scalar 
visualisation algorithm for data visualisation, the optimum support vector machine for data 
classification and the principal components regression for data classification, regression and 
biomarkers discovery was explored. The ITMTs were then explored for the liver dysfunction 
disease dataset (mouse model-based) multivariate analysis. Hence, these represent the three 
main algorithms used for the scrutiny of the analysis of the dataset to seek important 
biomarkers. Pathway analysis of these biomarkers was then carried out, allowing us to have 
more insight into their relation and involvement in the NPC1 disease diagnosis in general. 
Following this approach, the research model was validated, including validation of the ITMTs, 
and the results of the research performed within it. Finally, the data analysis and results chapter 























“Logic will get you from A to B. Imagination will take you everywhere” 
 






In the precedent chapter, data analysis and the results chapter explored different processes such 
as operating different algorithms and analysing the results obtained. In this respect, different 
biomarkers were detected amongst those already established such as glutamate, pyruvate, 
taurine, hypotaurine, etc. in the NPC1 disease diagnosis set, and the phenylalanine, glutamine, 
trigonelline, pyruvate, fumarate, etc., in NPC1 liver dysfunction. Others are less well-known 
as potential biomarkers in the NPC1 liver dysfunction disease diagnosis (mouse model-based), 
and these include adipate, xanthine, hippurate, etc.  
 
In this chapter, the focus is placed on discussing results produced and the different implications 
with regard to our understanding of the underlying transformations at the molecular level, 
especially the related pathways analysis involved. In this manner, two main discussions will 
take place in this chapter.  In the first section, the discussion will involve the NPC1 disease 
diagnosis, with related biomarkers discovered and the relevant pathway analysis. In the second 
section, the discussion is related to the NPC1 liver dysfunction, and the relevant pathway 
analysis to consider. In the final section a summary of the discussion section will be presented.  
 





 6.2.1. Discussion Based on the NPC1 Disease Statistical Analysis   
The statistical analysis performed was built on the following logic, which includes starting by 
segregating between the diseased group and the wild treated/healthy control one. The optimum 
support vector machine (OSVM) is used as a deterministic classifier to establish separation. 
Henceforth, a visualisation algorithm is used to understand the underlying relationships 
between the disease features responsible for this clear separation. Finally, the principal 
component regression (PCR) is employed as a probabilistic classifier to predict the influence 
of disease features. However, because the current PCR employed the principal components 
analysis (PCA) and then multiple logistic regression (MLR) analysis of PC scores vectors, it 
allowed the dimensionality reduction, the visualisation and ascertainment of the two classes, 
the former defined by the PCs, and finally ranking the features in terms of their ability to predict 
their effects on disease progression.   
 
The optimum support vector machine was able to correctly distinguish between the class of 
NPC1 disease patients and the wild-type (WT) healthy individuals with a higher level of 
performance.  
In this regard, it uses two main functions and two main performance metrics that are for the 
functions the radial based function (RBF) and the linear function in the data classification 
fields, and includes the geometric mean (Gmean), and the area under the curve receiver 
operating characteristics (AUC ROC) for the performance metrics. A combination of the RBF 
and AUC ROC approaches was found to yield improved performances compared to the others. 
For example, the Gmean average performance based on the RBF function was 0.88530 (Table 
5), while the Gmean average performance based on the linear function was 0.871 (Table 6). 
The AUC ROC average performance based on the linear AUC ROC function was 0.937 (Table 
7), while the AUC ROC average performance based on the RBF function 0.944 (Table 8). 
These were expected results in line with different research carried out using the same function 
and performance metrics (Martí and Reinelt, 2011; Tang et al., 2009). Indeed, linear function 
was observed to be less reliable than the RBF function, furthermore, the Gmean approach was 
less effective than the AUC ROC one.  
 
Consequently, most of the results discussed are based on the RBF - AUC ROC combination 
applied. Hence, the OSVM participants’ discriminative power successfully differentiates 




carried out, and different parameters were used to assess their influence on classifier 
performances. The current research has also shown that increasing the number of k folds in the 
cross-validation, the number of times that the stratified cross-validation is repeated, the number 
of nearest neighbours in the features selection, the proportions of features used, and finally 
increases in oversampling improve the OSVM model’s overall performances. 
 
This can be explained by the fact that increasing the number of k folds increases the number 
and size of the training set whilst reducing the corresponding number and size of testing set. 
Hence, the OSVM is trained on a bigger range of data and testing on a smaller set. Furthermore, 
the computational time of the classifier increases. Likewise, increasing the number of times the 
stratified cross-validation training is repeated allows the classifier to ‘learn’ more from the 
dataset. However, there is a risk in this case of ‘overfitting’ the ‘learner’ that might indeed learn 
the dataset too well to be able to perform on unknown dataset (Buduma, 2015). Nevertheless, 
the stratified cross-validation technique is able to tackle and avoid this potential risk of 
overfitting. Increases in the number of k folds and the number of repetitions has a limit over 
which the classifier performance is affected by constant decreases. For example, the number 
of k folds varied from 5 - 15. However, the number of repeats were kept under a more 
reasonable proportion in the range of 10 - 20, especially since increases in the processing time, 
and the high level of processing effort required.  
 
Results achieved by the OSVM in terms of feature classification in two major classes is further 
support by the fact that a clear visualisation difference could be made between these using 
biplots in the principal components analysis PCA (Figure 8).  
Nonetheless, the focus in this discussion section is on the scalar visualisation algorithm. The 
statistical results obtained from the NPC1 disease dataset presents significant changes on the 
1H NMR profile of the NPC1 disease patients’ class compared to that of wild treated class 
(Figure 6).  
 
Henceforth, the scalar visualisation algorithm (SVA) displayed a significant change in the 
following areas. The first area covering the chemical shift regions 0.81-0.89 ppm 
corresponding to the metabolites hexacosanoate, the area covering the chemical shift 0.89-
0.95 ppm corresponding to the biomolecule L-isoleucine, and the area 0.95-1.06 ppm 
corresponding to both L-Leucine and L-Valine. These three branch chain amino acids 




aminoacyl-tRNA biosynthesis pathway, because they can initiate the formation of aminoacyl-
tRNA derivatives, which can generate in turn proteins production. However, excessive 
accumulation of protein can lead to chronic liver disease such as liver fibrosis and liver failure 
(Bataller and Brenner, 2005; Monirujjaman and Ferdouse, 2014). Indeed, this selection is 
confirmed by the pathway statistics including the very low values of the Holm adjusted p values 
and the FDR value < 0.05. Additionally, the presence of the valine, leucine, isoleucine and 
pyruvate have been detected by the PCR, which ranked them at a higher level, and this will be 
further discussed below.   
 
The second group of biomarkers detected by the SVA are related to the chemical shift region 
1.21-1.31 ppm corresponding to the (R)-3-hydroxybutyric acid, and L-fucose; the chemical 
shift range 1.31-1.37 ppm corresponds to the lactate, 3-hydroxyisovaleric acid and the 
chemical shift 1.45-1.50 ppm (less pronounced) corresponds to L-alanine, which has been 
shown to be important in acute liver failure (Thodou et al., 2017). On the other hand, pyruvate 
is very important in aminoacyl-tRNA biosynthesis performed in liver, where it is transformed 
into glucose using the adenosine triphosphate ATP, a very high energy metabolite. Moreover, 
lactate, succinate, etc., can be transformed into glucose. This reaction is reversible, with 
glucose being transformed during glycolysis into pyruvate using ATP, and then to lactate 
(Silva, 2002). However, glucose can be transformed into fatty acids and stored at the lysosomal 
and endosomal levels, with the risk of aggravation of NPC1 disease.  
 
Furthermore, plasma filled contour plot could detect important change of structure in the 0.81-
0.89 ppm chemical shift region corresponding to hexacosanoate or cerotate. These molecules 
are long-chain saturated fatty acids, important for the build-up of fat in the human body. These 
three sets of biomolecules are the most important biomarkers for the NPC1 disease diagnosis 
by the SVA technique.   
 
The third group of biomarkers detected by the SVA strategy, although to a lesser degree, 
include the chemical shift 1.96-1.98 ppm, corresponding to the biomolecule methylglutarate 
and that covered by the bucket 1.98-2.03 ppm chemical shift range, corresponding to             2-
hydroxyglutarate. Other chemical shift buckets detected are 2.12-2.17 ppm corresponding to 
L-methionine, and L-glutamine, and the 2.34-2.39 ppm one for pyruvate and glutamate. 
Moreover, the chemical shift region 2.68-2.74 ppm corresponds to the Citrate, which is a 




2.88 ppm zone corresponding to trimethylamine; these compounds were detected in the plasma 
filled contour plot and the full boxplot with a medium peak amplitude. The SVA modelling 
technique suggested only a medium contribution in the explanation of the NPC1 disease 
difference observed.  
 
The visualisation algorithm (SVA) using the principal of look-up table correlates the                    
1H NMR bucket values as an index to a unique colour located in the Table. Therefore, the 
difference in colour ranging from blue (0) to red (0.35) shows the extent of the transformation 
occurring at molecular level. Indeed, the level of transformation is shown on the features maps 
with the variation in colour (Figures 6 & 7) and the boxplot with amplitude of the boxes (Figure 
5). This shows that the features number 13 and 14 correspond respectively to the chemical 
shifts buckets 1.21-1.31 and 1.31-1.37 ppm corresponding to lactate and 3-hydroxyisovalerate, 
and therefore they can be considered as major biomarkers in the current disease aetiology with 
respect to SVA modelling approaches.  
 
The SVA uses a scalar algorithm to map the underlying changes at the molecular level, and 
displays them on the colour map representing different biomolecules, together with the 
relationships existing between the diseases’ metabolome. As a consequence, molecules and 
their particular characteristics can be visualised, in such a manner that allows major biomarkers 
to stand out from the tens of different biomarkers detected in the multivariate analysis (Figure 
6 & 7).  For example, the plasma contour plot (Figure 6) highlights the pattern differences and 
changes in the feature map, with change in colour and brightness showing a difference between 
features in columns 6, 13, 14, 25, 26, and 27. These columns correspond, respectively to the 
chemical shifts buckets 0.81-0.89, 1.21-1.31, 1.31-1.37, 2.03-2.09, 2.09-2.12, and 2.12-2.17, 
which in turn are the hexacosanoate, the (R)-3-hydroxybutyrate and L-fucose; the lactate; the 
3-hydroxyisovalerate; the Citrate; the N-acetyl-4-O-acetylneuraminate; methionine and 
glutamine. For example, the glutamine’s importance has been highlighted in the aminoacyl-
tRNA biosynthesis pathway (see 5.3.5). However, methionine is used for methyl group transfer 
in most biosynthetic reactions, especially in amino acid catabolism. The methyl group transfer 
is preferably accomplished by the S-Adenosylmethionine (adoMet) used as cofactor. The 
adoMet is produced by the action of the methionine and ATP, catalysed by methionine 
adenosyl transferase. This reaction, in which the sulphur atom is involved in a nucleophilic 
substitution by attacking the methyl group of the ribose moiety rather than the carbon on the 




methyl group of the ribose, which is partially positive charged. This in turn confirms the 
importance of methionine in the NPC1 disease  (Cox and Nelson, 2013; Iyer and Hengge, 
2008). 
  
It should also be noted that most of these biomarkers were also detected by other modelling 
techniques employed in this research, especially that involving principal component regression 
PCR. This data analysis technique was employed for a probabilistic classification that 
ultimately could determine and detect major biomarkers using the intelligent tri-modelling 
techniques (ITMTs) (Schöfl et al., 2016). The PCR strategy firstly employed principal 
component analysis scores vectors and then multiple logistics regression (MLR). Their 
respective statistics are highlighted with their importance in the features ranking (see 5.4.4).  
 
Different PCs and their corresponding r values obtained by running MLR several times, were 
used in combination with the correlation factor between the original features and the PCs. Table 
11 above gives the main PCs involved in the 90%, variability together with the deviance of the 
fit (67.98) and the estimated dispersion parameter (0.832 < 1). Based on these different 
statistics and the level of the ranking achieved, 80% and 90% variability were considered the 
most reliable. Other statistics have to be considered; for example, although 80% variability 
model has larger deviance of fit (93.92 > 67.98) and estimated dispersion parameter, gave rise 
to an improved level of ranking, and appeared to be more reliable compared to 90%. In 
addition, 80% variability shows more consistency in the ranking of the 10 main biomarkers out 
of the 24 ranked using all the four levels of variability, i.e. 90, 80, 70 and 60% variabilities; 
with the correct ranking (CR) following values 95.83% for 80% variability, against 91.67% for 
90% variability models (see 5.4.4). In this manner, the 80% model was finally chosen and 
confirmed as providing the most effective level of variability.   
 
This selection/ranking of the level of variability is based on a certain level of logic.  Indeed, 
ranking the biomarkers is one of the main objectives of biomarker discovery. Knowing which 
ones carry the maximum weight for disease diagnosis purposes is of much greater importance. 
For example, the biomarkers importance can be related to the impact value of the pathways 
implicated for NPC1 disease. However, the 4 levels of variability were assessed based on this 
same NPC1 disease dataset. Therefore, the disease factor is a constant related to all the 4 levels 
of variability, and use of the consistencies in rankings, and the level of correct ranking (CR) is 





Another key point is that the 80% and 90% levels of variability could detect with differing 
levels of importance, three key biomarkers amongst the 24 top ones selected. These include 
pyruvate, and glutamate, isoleucine, and also glutamine. However, the 70% and 60% levels of 
variability could detect only the first three biomarkers, including pyruvate, glutamate, and the 
isoleucine. The importance of glutamine and isoleucine in the aminoacyl-tRNA biosynthesis 
pathway has been highlighted, and will be further discussed within the next sub-section (6.2.2) 
related to pathway analysis. Pyruvate is also important in phenylalanine metabolism and in 
glycolysis. Through glycolysis,  glucose is transformed into pyruvate, and therefore pyruvate 
plays a key role and also maintain blood glucose levels via  gluconeogenesis (Godoy et al., 
2010; Silva, 2002). Notably, pyruvate was detected as one of the main biomarkers amongst the 
7 main ones selected by this probabilistic modelling technique.  
 
Other very important techniques used to support the different level of variability in ranking the 
different features were the tri-raking techniques (TRT). Indeed, TRT played a main role in 
feature rankings, and their performance level is therefore dissected and discussed. This includes 
the sum of the products of the coefficients (SPC), the exponential sum of the product of the 
coefficients (ESPC), and finally the heuristic model. Two of these have had the same level of 
performance throughout and include the SPC and the ESPC approaches. The heuristic model 
being the only one performing differently; hence, it is used to assess the differences between 
the performances.  
 
The SPC model was used as a reference, since the development of the other two feature ranking 
techniques were based on the mathematical fundamental relating the coefficient of regression 
r and the coefficient of correlation α to the contribution of each feature to the regression line. 
Thus, these ranking techniques were introduced based on the SPC technique. It is therefore, a 
question of logic that SPC be used as a reference technique for the assessment of the other two 
models.  
 
The TRT model developed achieved ranking scores of 100% for ESPC at all four levels of 
variability, while heuristics achieved the following; (for 90% variability) CR values of 91.67%, 
(for 80% variability) 95.83%, and (for 70% and 60% CR variability) 87.50%.  These results 
place SPC and the ESPC as the most effective ranking methods, and with the heuristic 




consistent with the logic associated with their development. In the light of this ranking, 
biomolecules primarily detected by these techniques are provided below. In a selection of the 
10 best out of a selection of 24, the tri-ranking techniques identified adipate, pyruvate, 
glutamate, lactate, 2-hydroxyisobutyrate, 3-D-hydrodybutyrate, L-fucose, 3-
hydroxyisovalerate, 1-methylhistidine, quinolinate, methylxanthine, and 4-hydroxybenzoate. 
From this first selection of the 10 best markers in the NPC1 disease development were detected; 
including the pyruvate, the glutamate, and the lactate.  
 
Isoleucine and pyruvate were ranked respectively 13th and 3rd best biomarkers respectively in 
understanding this disease’s underlying biochemical effects, and hence the importance of 
isoleucine in aminoacyl-tRNA biosynthesis, and that of pyruvate in the alanine, aspartate, and 
glutamate metabolism. Moreover, all the ranking techniques performed similarly with different 
ranking abilities, and expressing different levels of importance based on the technique. Hence, 
the sum product of the coefficients (SPC) and the exponential of the sum product of the 
coefficients (ESPC) have ranked the isoleucine in the 17th position, and valine and leucine at 
the 40th place.  
 
However, the heuristic approach ranked them the 26th and 42nd best biomarkers for NPC1 
disease diagnosis. Additionally, this heuristic technique failed to rank the isoleucine amongst 
the 24 best features, unlike the other two techniques applied. This can be explained by the fact 
that the heuristic search technique, by definition, is one which allows to find a more rapid 
solution which may not be the best; hence, a ‘trade-off’ has to be made between accuracy and 
the speed of the analysis (Masulli et al., 2013; Shi and Ólafsson, 2008). 
  
Nonetheless, when extended to the 24 best markers, more of these were captured in this 
ranking/selection process. For example, glucose, glutamine, methionine, etc., were included in 
the selection, which are also important in the different pathways detected. During the 
glycolysis, the glucose is broken down in the cytosol, while pyruvate the product of glycolysis 
is transformed to Acetyl CoA. On the other hand, through gluconeogenesis the glucose is 
transformed to pyruvic or fat, with the former being also an important intermediate in fat 
production (Cox and Nelson, 2013). Whereas, glutamine, methionine and histidine are shown 
to be important in aminoacyl-tRNA biosynthesis, glutamine can generate ornithine which, in 
turn, can be transformed to pyruvate. The latter importance has been already established 





6.2.2. Pathway Analysis and NPC1 Disease Diagnosis 
With regard to the NPC1 disease diagnosis, the main pathways and related biomarkers involved 
will be scrutinised through an extensive discussion in order to permit a thorough understanding 
of disease diagnosis and prognosis. The NPC1 disease dataset pathway analysis and ranking in 
accordance to their importance in the disease aetiology, are based on the Holm adjusted p value 
to select the following pathways as the main ones involved in the disease diagnosis and 
progression. Three main pathways detected are outlined below. 
 
 
 Aminoacyl-tRNA Biosynthesis 
Aminoacyl-tRNA is composed of an amino acid part and a transfer ribosome nucleotide 
adenosine (tRNA). The aminoacylation adds an aminoacyl group to the compound, is as well 
related to the transport or transfer of an amino acid group to the fabric of proteins that is in fact 
the ribosome. In this manner, tRNA serves as a transportation means by adding the aminoacyl 
group to the tRNA molecule used in the biosynthesis of new protein (Cox and Nelson, 2013). 
 
The current pathway involves different intermediates including glutamine, methionine, valine, 
alanine, lysine and the isoleucine. Increases in concentration of glutamine, methionine, valine, 
alanine, lysine, as detected by the heatmap from the list of the 26 top biomarkers, shows the 
importance of the aminoacyl-tRNA route and the subsequent production of proteins. 
Furthermore, the PCR technique could detect glutamine and isoleucine as major biomarkers in 
the NPC1 disease group compared to the wild treated cohorts. The aminoacyl-tRNA 
biosynthesis is linked to the protein production, with new protein biosynthesis taking place as 
a consequence of the tRNA adding an amino acid group to the new protein being constructed. 
The 1H NMR metabolic profile of the NPC1 disease patients’ blood plasma exhibited an 
increase of the 1-methylhistidine as confirmed by the PCR main biomarkers selection. This 
amino acid generation is usually linked to protein degradation, and as a consequence muscle 
mass loss, which is a sign of the NPC1 disease progression (Garver et al., 2007; Ruiz-Rodado 
et al., 2014). Therefore, the increase of glutamine levels for NPC1 disease subjects is consistent 
with protein degradation which, in turn, reduces the concentration of alanine in blood plasma. 




parenchyma necrosis, which is connected to the hepatic fibrosis (Cox and Nelson, 2013; 
Garber, 1978; Probert et al., 2017). 
Furthermore, BCAAs are important in terms of the regulation of the glucose levels in the 
bloodstream. After meals, the level of insulin and glucagon varies in the opposite direction, 
maintaining the sugar level balanced in blood. Hence, the elevated levels of BCAAs are in line 
with the muscle protein deterioration level (Garver et al., 2007; Ruiz-Rodado et al., 2014). 
Nevertheless, other pathways can assist in clarifying metabolic NPC1 disease changes. 
 
 Phenylalanine Metabolism 
Phenylalanine metabolism pathway is related to a phenylketonuria (PKU), an inborn error of 
metabolism, which is responsible for some form of neural development deficiency or mental 
retardation. In reality, phenylalanine can be converted to tyrosine by hydroxylation with the 
enzyme phenylalanine hydroxylase. The deficit of this intermediate can cause an excess of the 
phenylalanine. However, another pathway can be used for phenylalanine metabolism, and this 
involves reaction of phenylalanine with pyruvate to form the phenylpyruvate, which then 
accumulates  in patients’ blood (Bioinformatics, 2017). Under those circumstances, increases 
in phenylalanine and phenylpyruvate levels can exert grave consequences such as an advanced 
mental retardation due to slow brain development, which might be observed in some NPC1 
patients developing the disease at an early age. Excess levels of amino acids, including 
phenylalanine can cause a deficiency in some metabolic routes. Consequently,  phenylalanine 
and other amino acids being in excess in the patients’ blood while competing to be shifted in 
the blood (Bioinformatics, 2017). In this respect, it has to be remembered  that a study has 
shown that the level of phenylalanine in the blood is important as it is an indication of the 
abnormal development of the brain at younger age resulting in serious mental health problems 
for the NPC1 disease patients (Bioinformatics, 2017).  
 
PCR has detected pyruvate as one of the main biomarkers while phenylalanine was seen to be 
important but to a lesser degree. This might be related to the fact that different model uses 
different algorithm that might better recognise a biomarker than another model (Les et al., 
2016; McIntosh et al., 2016).  
 
The next pathway which is very important in the understanding of the NPC1 disease aetiology 






 Glycolysis and Gluconeogenesis  
Glycolysis as a metabolic pathway takes place in the cytosol of the molecular cells and does 
occur under aerobic or anaerobic (absence of oxygen) condition. This process of breaking down 
the glucose at different stages and the production of different intermediates such as the glucose-
6-phosphate leads to the production of the pyruvate as end-product of the glycolysis. Lactate 
was detected by SVA and PCR models in higher concentration in the NPC1 disease patients’ 
blood plasma over those of healthy controls individuals. The different ranking techniques 
featured it amongst the 3 major biomarkers detected. This attests to the importance of the 
glycolysis pathway in NPC1 disease aetiology.  Indeed, the pyruvate can be converted back to 
glucose via the gluconeogenesis pathway, or using the acetyl-CoA route enabling the 
production of fatty acids. Therefore, it is understood that fat build-up at lysosomes and late 
endosome is related to the mutation of NPC1 genes, the potential lack of regulation of the 
trafficking of cholesterol, lipids such as sphingolipids due to defective NPC1 genes, 
ineffectiveness and inoperability can cause the aggravation of the NPC1 disease leading to cell 
death (Blom, 2003; Garver et al., 2007; Xu et al., 2010).  
  
6.3. Discussion Based on NPC Liver Dysfunction Disease (NPC LDD) 
Dataset  
 
6.3.1. Statistical Analysis and the NPC Disease Dataset 
The severity of NPC1 disease could reach the extent where the patient’s liver can be seriously 
affected. The following discussion is related to this next stage. The use of ITMTs to enhance 
our understanding of this disease development has been performed here through all the three 
models taken separately.    
 
The OSVM technique could distinguish between the main classes of mice, i.e. those with the 
NPC-associated liver dysfunction disease (NPC LDD) and healthy control mice. The 
classification performances vary from one set of implementations to the next, in view of one 
model applying a specific algorithm, and hence achieving a particular performance. The setting 




measurement indicator was employed since the combination RBF-AUC ROC was found to 
perform more effectively than all other combinations, involving linear function and the Gmean 
performance metrics. Under those conditions, the average values obtained were AUC ROC = 
0.973, std. deviation = 0.0048 and 95% confidence interval  ±0.009449 (Table 30) are all 
consistent or improved on similar research performed (Martí and Reinelt, 2011; Tang et al., 
2009). In a similar manner, the results also show that increasing the variable such as the number 
of time the stratified cross validation is repeated, the number of k folds used, and finally the 
application of standardisation, increases OSVM performance. The rationale behind this has 
been explained in subsection 6.2.1. These values attest the highest level achieved by the OSVM 
using a combination of the RBF-AUC ROC approach in discriminating between the two 
classes. The results are further corroborated by the scalar visualisation algorithm that is 
outlined below.  
 
The SVA creates a relationship between scalar values or an index corresponding to the peak 
amplitude and the colour in the colour look-up table, and hence allows the matching between 
a scalar value and a colour in the look-up table. This, in turn, enables a visualisation of the 
changes in the concentration of the main metabolites involved in the NPC LDD. The change 
of colour, pattern, etc., can reveal a significance difference between a given metabolite and the 
rest of the metabolome involved in the study. In this manner, major or potential biomarkers 
can stand out from the different metabolites present in this dataset, and therefore aids our 
understanding of disease aetiology. In the NPC liver scale data plot (Figure 17) changes in 
intensity, colour and structure signify a major difference between the current feature and the 
remaining metabolites in the dataset. In the same manner, the contour plot (Figure 18) shows 
significant change in intensity and structure that might explain the NPC disease’s main causes 
of progression. Thus, the column numbers 69, 68, 70, 67, 58, 59, 60, 55, 54, 17, 18, 7 (in 
decreasing order of importance) may indeed represent potential biomarkers for NPC liver 
dysfunction disease (NPC LDD) diagnosis. The corresponding chemical shifts are [3.81…3.87] 
[3.71…3.77] [3.39...3.44] [3.87…3.93] [3.77…3.81] [3.44…3.50] [3.37…3.39] [3.26…3.31] 
[3.21...3.26] [1.30…1.36] [1.45...1.51] [0.94...0.99] ppm. The change of colour is related to the 
importance in the disease aetiology, with green very important, light green fairly important and 
bleu less important. The respective metabolites detected are glycogen, the glutamate, 
glutamine, taurine, glycerophosphocholine, cysteine, myo-inositol, gamma-





The markers discovered by the SVA strategy are therefore either very important biomarkers or 
potential ones for NPC LDD. For example, the glycogen that is the main form of storage of 
glucose in the liver of the human and animal cells (HMDB, 2017). In the isoleucine, valine and 
leucine biosynthesis, the three amino acids known as the branch-chain amino acids BCAAs. 
Their degradation involves the pyruvate that is in turn important in maintaining the glucose 
level in the blood. Additionally, the pyruvate is the anion and conjugate form of the pyruvic 
acid, with the latter producing through gluconeogenesis the fats. The fat storage for lack of 
gene providing the necessary transportation for degradation is one of the major source of the 
NPC LDD.  
 
However, the PCR technique could detect the main biomarkers using the tri-ranking techniques 
developed. In the NPC LDD dataset, the following biomarkers were detected and ranked as 
very important in terms of the system studied. The 13 best biomarkers were methionine, 
hypotaurine, lysine, ornithine, phenylalanine, hippurate, nicotinate, xanthine, citrate, 
phosphorocholine, tyrosine, leucine, and isoleucine. It has to be remembered that pyruvate is 
present amongst the highly ranked (24 top) biomarkers detected by the PCR.  
 
The model ranked methionine and hypotaurine as the best potential biomarkers in the NPC 
LDD dataset. Their actual relation to disease prognosis and diagnosis is therefore of paramount 
importance. Methionine metabolism has been shown to be related to two pathways, including 
the methionine cycle and the methionine trans-sulfuration. Different intermediates are 
necessary to produce homocysteine and adenosine. However, Trans sulfuration of 
homocysteine generates the cysteine that is converted into propionyl-CoA that is, in turn, 
transformed into succinyl-CoA (Cox and Nelson, 2013; SMPDB, 2015b). It should be noted 
that the cystine obtained from the oxidation of two molecules of cysteine is a more stable form 
of the latter. Current pathway controls are related to the availability of both methionine and 
cysteine, which in turn will favour production of cysteine and α-ketobutyrate, these being more 
glucogenic (Cox and Nelson, 2013; SMPDB, 2015b). In addition, the hypotaurine has also been 
shown to be a very important marker in the NPC-associated liver dysfunction (Hansen and 
Horslen, 2008; Mato et al., 2008; Ruiz Rodado et al., 2016). 
 
Furthermore, 1H NMR-detectable metabolites of mice liver dysfunction samples lysine and 
ornithine were classified 2nd best biomarkers. Lysine catabolism is achieved through a series 




pathway produce ketones, especially under fasting conditions (Cox and Nelson, 2013; SMPDB, 
2015c). Ornithine (classified amongst the 13 most significant biomarkers in the NPC LDD) 
can generate pyruvate or be transformed to gamma aminobutyrate. Pyruvate importance in the 
NPC1 disease dataset has been already established in this study (see 5.3.5). In a similar manner, 
its importance in the NPC-associated liver dysfunction has been noted both here and 
previously. For instance, the upregulated concentrations of lysine/ornithine in the NPC liver 
disease samples relative to those of wild treated (WT)  was highlighted (Ruiz-Rodado et al., 
2016).  
 
Nevertheless, further statistics included in the present study, including a pathway’s impact on 
an understanding of disease aetiology, the false detection rate (FDR), and the Holm adjusted p 
values provided further valuable information.   
 
6.3.2. Pathway Analysis and NPC Liver Dysfunction  
The pathway analysis for a given metabolite or group of metabolites is related to the biological 
pathway used to produce the molecules involved. Several molecular pathways analysis will be 
discussed, together with their involvement in the NPC liver dysfunction disease’s diagnosis. 
Amongst these are alanine, aspartate and glutamate metabolism, phenylalanine metabolism, 
and arginine and proline metabolism, etc.    
 
 
 Alanine, Aspartate and Glutamate Metabolism 
The current pathway is highly differentially expressed, with elevated levels of the following 
metabolites, including N-acetyl-L-aspartate, aspartate that can be transformed to the fumarate 
through different intermediates. From alanine and aspartate, glutamate can be produced in 
combination with 2-oxoglutarate through the enzyme transaminase. The result of this reaction 
is the production of pyruvate and oxaloacetate, which are very important in glucose formation 
or degradation, i.e. gluconeogenesis or glycolysis (Cox and Nelson, 2013; SMPDB, 2015d). 
The importance of glucose in this pathway has been demonstrated, with the potential 
production of pyruvate and the reverse reaction producing glucose. The amination of pyruvate 




means of generating alanine (Cox and Nelson, 2013; SMPDB, 2015e). However, aspartate 
synthesis in the human body is achieved by transamination of oxaloacetate using aspartate 
aminotransferase. The aspartate synthetised is used in protein production (Cox and Nelson, 
2013; SMPDB, 2015f). Glutamine can be hydrolysed and transformed to glutamate (Glu) an 
alpha amino acid that can be synthetised by the human body. The latter can then be converted 
to gamma-aminobutyrate which, in turn, will produce the succinate. It should also be noted that 
glutamate plays a crucial role in the neural activation system in humans. This may explain 
certain conditions related to the NPC disease in general, and the stiffness of the NPC1 disease 
carrier.  
 
 Arginine and Proline Metabolism 
Arginine and proline metabolism give rise to production of arginine, ornithine, proline, 
citrulline and glutamate. In fact, the production of glutamate and proline from ornithine is an 
option available on the current pathway.  For example, proline can be biosynthesised from 
glutamate and 1-pyrroline-5-carboxylate. Since the production of arginine, glutamine and 
proline can be bidirectional, depending on the cell type, the development processes, their 
stages, and concentrations vary significantly at the small intestinal level. Indeed, here, 
glutamine and glutamate produce citrulline that is extracted at the kidney level, i.e. removed 
from the circulation and transformed to arginine and then re-introduced to the circulation. 
Therefore, problem at kidney level will affect the arginine production, which in turn needs to 
be re-introduced in the in the circulation process. Arginine serves as precursor in the synthesis 
of various agents such as nitric oxide, creatine, polyamines, agmatine, and urea. Nitric oxide is 
believed to relax blood vessels  (Frolkis et al., 2010; Jewison et al., 2014; Morris, 2007;  
SMPDB, 2010).  
 
 It should therefore be noted that proline and arginine are amino acids that are involved in 
protein synthesis using prolyl-tRNA and the arginyl-tRNA, themselves produced by their 
corresponding tRNA synthetases. However, at the liver level, ornithine is used in the cells as 
both an intermediate in the urea cycle, or for the synthesise of glutamate and glutamine, or 
glutamate and proline (Jewison et al., 2014; SMPDB, 2010). Indeed, ornithine is a major 
component involved in the current pathway, and is used in the liver, for the synthesis of 
glutamate and glutamine; however, in peripheral tissues it is involved in the synthesis of the 






 Glutamine and Glutamate Metabolism 
 
The two main metabolites present in this pathway will be followed to understand the process 
of conversion of glutamine to glutamate. Glutamate is considered as a non-essential amino acid 
which can be produced by the human body. As a precursor molecule, it is involved in the 
production of different metabolites such as N-acetyl-L-glutamate, L-γ-glutamyl—L-cysteine, 
etc. It is also employed in the biosynthesis of certain amino acids, which include L-proline and 
L-arginine  (Collard et al., 2010; Murphy et al., 1996; Yelamanchi et al., 2016).  
 
Glutamate is produced from glutamine, alpha-ketoglutarate and 5-oxoproline. The synthesis of 
glutamate involves several reversible and irreversible reactions, which are catalysed by 
enzymes and the help of activators and inhibitors. For example, L-glutamine is transformed to 
N-acetyl-L-glutamate in the presence of N-acetylglutamate synthase, where L-arginine plays 
the role of activator and the inhibitors are succinate, coenzyme A, N-acetyl-L-aspartate and N-
acetyl-L-glutamate (Shigesada and Tatibana, 1978; Yelamanchi et al., 2016). 
 
However, the conversion of glutamine to glutamate requires enzymes such as glutaminase 
(GLS/GLS2), glutamine-fructose-6-phosphate transaminase (GFPT1 and GFPT2) and 
phosphoribosyl pyrophosphate amidotransferase (PPAT) (Hu et al., 2010; Yelamanchi et al., 
2016). Glutamine is the precursor in reactions generating various metabolites such as N-acetyl-
L-glutamate, L-γ-glutamyl-L-cysteine, δ-1-pyrroline-5-carboxylate,  β-citrylglutamate 
(Battaglioli et al., 2003; Yelamanchi et al., 2016). Also, as a precursor of glutamate, glutamine 
plays a protective role in the human body essentially against nutrient depletion and certain 
tumour stresses. In a similar manner, enzymes related to glutamate metabolism or the alteration 
in glutamate metabolism are closely related to different other forms of neurodegenerative 
diseases (Burbaeva et al., 2005; Qi et al., 2013). The reversible transformation between 
glutamate and glutamine is presented through this research study as ones of the most significant 
pathways in NPC1 disease diagnosis.  Therefore, alteration of glutamate metabolism will have 
significant effect on the NPC1 disease development.  
 
This latter stage of the Discussion shows how the different pathways detected, and especially 




highlight the importance of biomarkers discovered for NPC1 disease, and the more severe 
forms of the disease involving liver dysfunction.   
 
 
6.4. Chapter Summary 
 
Throughout the current discussion, the following results were attained and were related to the 
diagnosis of NPC1 disease, together with the more severe form of the disease affecting patients’ 
liver (NPC LDD). This includes the points noted below;   
1). Results from the optimum support vector machine (OSVM) classifier confirms that a 
combination of the RBF kernel and the AUC ROC approaches performed more effectively than 
the combinations involving the linear kernel and the Gmean techniques.  
 
2). The OSVM model using a combination of RBF-AUC ROC could segregate the two classes 
of individuals in both the NPC1 disease and the NPC LDD datasets, achieving a very high level 
of performance, i.e. 0.944 and 0.973 respectively.  
 
3). The scalar visualisation algorithm (SVA) could detect several biomarkers has been shown 
to be important in the NPC1 and the NPC LDD aetiologies. This included, hexacosanoate, (R)-
3-hydroxybutyrate, L-fucose, the lactate, 3-hydroxyisovalerate, citrate, N-acetyl-4-O-
acetylneuraminate, methionine, and glutamine for the NPC1 disease, and Glycogen, glutamate 
and glutamine, taurine, glycerophosphocholine, acetoacetate, taurine, myo-inositol, lactate, 
leucine, isoleucine, and alanine for NPC-associated liver dysfunction disease.   
 
4). The PCR as last ITMTs  model developed, and could as well detect several biomarkers that 
have been shown to be important in the NPC1 and the NPC LDD aetiologies. Other biomarkers 
also have been discovered the importance of which has not been emphasised in any previous 
research performed in relation to these conditions. This includes, the adipate and hippurate for 
NPC1 disease diagnosis, given that adipate/n-butyrate is a mixture of both molecules. 
Consequently, this biomarker can also be considered as important biomarkers in perhaps 
disease progression. In this NPC LDD study, most of the main biomarkers detected have 
already been discovered as important biomarkers in the NPC1/NPC LDD (both diseases being 




phenylalanine, nicotinate, xanthine, etc. Nevertheless, hippurate has not been formally 
categorised as probable main biomarker in the NPC liver associated with this disease. Finally, 
adipate and hippurate have been included as possible major biomarker for NPC1 disease 
diagnosis by the Computational Intelligence Techniques (CITs) based on the intelligent tri-
modelling techniques (ITMTs) applied in this PhD thesis. 
 
5). The intelligent tri-modelling techniques (ITMTs) combined with the tri-ranking techniques 
(TRTs) are valid strategy developed that have shown their importance, effectiveness and 
accuracies in the detection and ranking of biomarkers in the quest for a clear understanding of 






























“The only thing you absolutely need to know, is the location of the library” 
 
Albert Einstein   
 
 
7. CONCLUSIONS - CONTRIBUTION TO KNOWLEDGE & 




This chapter acts as a closing section to this PhD thesis, where a final summary of the research 
work’s achievements are provided. Indeed, it highlights the contribution to knowledge; and 
also notes limitations of the research. This chapter also presents the further research planned in 
relation to the NPC1 disease research in general. Finally, an overall conclusion to the whole 
research investigations conducted is made.  
 
7.2. Summary of Research 
 
This research commenced by mining in a theoretical field of study to find a suitable one in 
order to give appropriate support to the present research. This allow to widen the researcher’s 
own understanding of the research area. The notion of metabolomics was defined, together 
with related terms such as metabolites and the metabolomes. In addition, Computational 
Intelligence Techniques (CITs) based on the intelligent tri-modelling techniques (ITMTs) to 
be developed in this study were introduced, presenting some of the algorithms necessary to 
support this empirical research. The next chapter commenced by simply mentioning the notion 
of research methodology, while describing the terms ‘approach’ and ‘theory’. Thus, the 
intelligent technology task fit model (ITTFM) was developed and supported the development 




fieldwork and laboratory-based research being more adapted to this research. Although both 
datasets were supplied by collaborating Universities such as Oxford University (UK), etc., the 
method used was briefly presented. Furthermore, samples and feature selections were 
investigated given that some of the techniques were applied in the design process. The different 
challenges were identified, with methods employ to overcome the ones highlighted.  
 
The next chapter related to the research design focussed on the mixed-experimental design, 
with data collection techniques and data analysis tools presented. To complete the design 
chapter, the technique to be applied in the validation stage was analysed, with notes on the dual 
validation processes addressed. This included a validation process related to the performance 
measurement based on the standard, a second validation procedure based on the theoretical 
framework developed in this thesis, a third validation is related to the data analysis technique 
utilised, and a final validation involving biomarkers discovered statistical validation. The result 
chapter and the related analysis encompasses two main sections, i.e. the results of the NPC1 
disease and NPC liver dysfunction disease (NPC LDD) diagnosis, together with the different 
biomarkers and related pathways analysis. Furthermore, the classification algorithm OSVM 
could perfectly discriminate with higher performance using the RBF kernel the different groups 
that are NPC1 patients and wild treated/healthy control group with an AUC ROC value of 
94.4%. However, the NPC liver dysfunction dataset was discriminated with an AUC ROC 
value of 97.3%. Chapter 6 involved a discussion section focussed on the metabolic featured 
pathways detected, and the main biomarkers placed on these pathways. How they are connected 
to one another in our understanding of the NPC1 disease’s aetiology. In the final chapter which 
is related to the conclusion, the contribution to knowledge and further research, findings are 
dissected together with their importance in terms of NPC1 disease diagnosis. In this last 
chapter, recommendations are made regarding the possibility of carrying this research work 
further in the near future.  
 
 
7.3. Contribution to Knowledge 
 
Different contributions were made in different area of the PhD thesis. Indeed, contributions 
were made with relation to the research methodology applied including the research method 




development of the tri-ranking techniques (TRTs). More importantly is the discovery of the 
biomarkers in the NPC1 and related diseases diagnosis, which could ultimately improve the 
research based on the NPC1 disease diagnosis in general. Henceforth, 
 
 The development of the ITTFM allows us to streamline the different stages of the 
development process where different software and algorithms are involved. The 
sequences of research and selection of the Computational Intelligence Techniques 
(CITs) developed in this research supported by different algorithms such as the 
intelligence algorithm development for process validation purposes.  
 
 The computational intelligence techniques (CITs) used in this research were based on 
the intelligent tri-modelling techniques (ITMTs) that are three different algorithms. 
Among the model included in the ITMTs are the optimum support vector machine 
(OSVM) for classification purpose and prediction, which is an optimal model of a 
conventional support vector machine. The scalar visualisation algorithm that, in turn, 
allows us to visualise the underlying transformation occurring at the molecular level, 
and which can explain the metabolic transformations. Finally, principal component 
regression (PCR) was presented as a combination of the principal component analysis 
(PCA) and multiple logistic regression (MLR). The objectives in using PCR in this 
research was to devise a strategy of detecting principal components in diseases analysis 
in view of strong correlations between the disease features in such a manner that the 
features can be correlated to the disease detection. Additionally, it allowed a ranking of 
disease features based on their importance in explaining the disease chemopathology.  
 
 
 The tri-ranking techniques (TRTs) were developed to enable and improve the ranking 
of the diseases features based on their importance in its aetiology. In this manner, the 
top ranked features are considered to be the main biomarkers.  The feature ranking 
techniques developed include the sum product of the coefficients (SPC), the 
exponential sum product of the coefficients (ESPC), and finally, the heuristic approach 





 The PCR model using the tri-ranking techniques have detected and ranked the 
following biomarkers as main biomarkers for NPC1 disease and the main complex form 
of the disease that is the NPC liver dysfunction associated with this disease. These are 
respectively the adipate and the hippurate. Furthermore, the intelligent tri-modelling 
techniques and the tri-ranking techniques have allowed to confirm previous biomarkers 
detected in other studies. This includes, pyruvate, glutamate, isoleucine,…etc., for 
NPC1 disease. Additionally, lactate, leucine, isoleucine, alanine, methionine, 
hypotaurine, lysine, ornithine, phenylalanine, nicotinate, and xanthine were confirmed 
as main biomarkers in NPC liver dysfunction disease (NPC LDD).   
 
 Indeed, biomarkers such as methionine, hypotaurine, lysine, and phenylalanine have 
been detected as main biomarker in study conducted elsewhere (Mato et al., 2008; Ruiz-
Rodado, 2016). In addition, validation procedures have been applied and explained in 
chapter 5, with regards to previous study conducted  (Heron et al, 2013), which shows 
the validity of the techniques developed, and the research methodology applied.                             
 
 
7.4. Research Limitations 
 
NPC1 disease lies amongst the restricted circle of rare diseases termed as ‘orphan’ diseases, 
where the investment for research is quite limited. This is ascribable to the fact that the number 
of known people with the condition is limited. Moreover, patients are still struggling in terms 
of being aware of their own conditions, making it difficult to know the exact number of patients 
and carry out upstream treatment in order to minimise the effect of the disease on them. The 
present study carries some limitations in view of several factors. Among these are: 
 Possible biomarkers needing further investigation to confirm their status. 
 Exponential sum product of the coefficients (ESPC) ranking technique can be further 
developed in terms of its mathematical formula.   
 Involvement of negative coefficients, including the negative coefficients of regression 
and correlation may be important in features ranking. The present techniques did not 
emphasise on this aspect thoroughly. Indeed, it can be demonstrated that the greater the 




effect on the ranking result. This can be performed by introducing the technique known 
as the Absolute Value of the Sum Product of the Coefficients (AVoSPC), which was 
not applied in this research (included in further research).  
 The biomarkers detected by the scalar visualisation does not in all the cases correspond 
to an exact number, hence the biomarker detected might not be precise.   
 
 
7.5. Further Research Proposed 
    
In the light of the present study, the possibility of taking it forward for future research is 
available. Some of these possibilities are outlined below with their main and planned direction 
to follow highlighted.  
   
 Further mathematical development of the exponential sum product of the coefficients 
(ESPC), in which the terms related to feature contributions as exponential terms can be 
further developed.  
 The development of the Absolute Value of the Sum Product of the coefficient 
(AVoSPC) techniques. This further development may favour more the negative terms, 
and hence should be regulated with appropriate coefficient or weightings ascribed to 
feature contributions.  
 Application of these techniques and models developed in the drug development field, 
especially those designed for NPC1 disease treatment and secondary conditions.  
 The development of sound biomarkers validation technique for the ones discovered, 
including pyruvate and adipate.  
 
             
7.6. Conclusion 
 
This research was focused on the detection of biomarkers in order to improve our 




applying different intelligent modelling techniques supported by Computational Intelligence 
Techniques (CITs). Biomarkers discovered included well-known ones and the others not 
strongly connected to present disease development. In addition, ranking techniques were 
developed. Amongst the biomarkers discovered some well-known ones, and also new ones 
were detected, including adipate and hippurate. Biomarkers detection techniques developed 
were validated by standard performance analysis methods such as combining kernel RBF 
function and ROC-AUC as performance measure. However, different techniques generated 
different ranking for biomolecules detected. In this regard, biomarker discovery through 
sphingolipids profiling has provided evidence that the pathogenesis of the NPC1 disease is very 
complex and therefore the use of a given biomarker or class of biomarkers is most unlikely to 
provide a clear solution. Therefore, tackling this disease using different approaches i.e., 
targeting different aspects of the pathology, might be more productive in terms of effectiveness 
in its diagnosis (Fan et al., 2013a). Such biomarkers discovery may play a key role again in the 
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1. DATA ANALYSIS 
 
1.1. Factor Loadings 
Chemical Shifts  F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 12 F13 
[0.68 .. 0.71] -0.105 0.805 0.272 -0.343 0.174 0.105 -0.081 0.051 -0.073 0.007 0.022 -0.103 -0.086 
[0.71 .. 0.73] 0.052 0.909 0.163 -0.244 0.147 0.064 -0.063 0.008 -0.078 0.034 0.061 -0.057 -0.013 
[0.73 .. 0.75] 0.141 0.925 0.259 -0.152 0.059 0.027 -0.043 0.025 -0.043 0.017 0.025 -0.05 0.004 
[0.75 .. 0.77] 0.159 0.922 0.277 -0.138 0.036 0.007 -0.025 0.016 -0.05 0.021 -0.003 -0.055 0 
[0.77 .. 0.79] 0.114 0.941 0.154 -0.169 0.111 -0.026 -0.053 0.002 -0.044 0.023 -0.01 -0.046 -0.008 
[0.81-0.89] 0.037 0.161 0.581 0.601 -0.172 -0.257 0 0.114 -0.124 -0.042 -0.195 -0.042 0.057 
[0.89 .. 0.95] -0.087 -0.056 -0.61 0.078 0.629 -0.174 0 -0.074 0.046 0.16 0.148 -0.006 -0.013 
[0.95-1.06] 0.555 0.243 -0.312 0.26 0.03 0.085 -0.047 -0.375 0.048 0.306 0.15 -0.104 -0.089 
[1.13 .. 1.15] 0.138 0.563 0.3 -0.302 0.334 0.159 0.162 0.086 -0.104 0.022 0.272 -0.137 -0.021 
[1.15 .. 1.17] 0.137 0.865 0.186 -0.162 0.246 0.061 0.016 -0.02 0.092 0.024 0.07 0.005 -0.006 
[1.17 .. 1.19] 0.075 0.555 0.074 0.052 0.113 0.136 -0.082 -0.001 -0.013 -0.327 0.131 0.451 -0.126 
[1.19 .. 1.21] 0.3 0.59 0.261 0.237 0.006 -0.012 -0.039 0.011 0.157 -0.251 0.269 0.324 -0.032 
[1.21 - 1.31] -0.76 -0.39 0.309 0.126 0.279 -0.007 -0.018 -0.02 0.092 -0.031 0.128 -0.076 -0.062 
[1.31 .. 1.37] 0.142 0.167 -0.548 -0.657 -0.178 0.016 0.143 -0.151 -0.118 0.015 -0.13 0.098 0.106 
[1.45 .. 1.50] 0.692 -0.152 -0.15 0.055 -0.198 0.142 0.26 -0.093 0.012 0.334 0.083 0.08 0.168 
[1.53 .. 1.55] -0.207 -0.741 0.041 0.004 0.377 0.175 0.031 -0.031 0.107 0.047 0.221 0.084 -0.086 
[1.55 .. 1.61] -0.575 -0.604 -0.088 -0.095 0.363 0.132 -0.102 -0.032 0.133 -0.038 0.163 -0.065 -0.163 




[1.80 .. 1.86] 0.335 -0.101 -0.199 0.186 -0.588 0.291 -0.339 0.058 0.03 -0.018 0.11 -0.161 -0.212 
[1.90 .. 1.92] 0.411 0.427 -0.49 0.028 0.291 -0.107 -0.189 -0.009 -0.203 0.066 -0.124 -0.054 -0.04 
[1.92 .. 1.94] 0.673 -0.092 0.269 -0.337 0.108 0.312 0 -0.232 0.187 0.135 -0.075 -0.005 -0.076 
[1.94 .. 1.96] 0.595 0.069 0.504 0.214 0.232 0.066 -0.007 -0.183 0.243 0.043 -0.086 0.037 0.247 
[1.96 .. 1.98] 0.365 0.062 0.688 0.364 0.071 -0.04 0.239 0.024 0.138 0.093 -0.052 0.025 0.215 
[1.98 .. 2.03] -0.412 -0.345 0.641 0.098 0.103 -0.09 0.03 0.16 0.166 0.091 -0.232 -0.123 -0.112 
[2.03 .. 2.09] 0.504 0.162 -0.242 -0.24 0.159 -0.321 -0.282 0.276 0.412 0.076 -0.147 0 -0.195 
[2.09 .. 2.12] 0.574 0.161 -0.442 0.095 0.381 -0.039 -0.232 0.221 0.22 -0.029 -0.089 -0.005 0.142 
[2.12 .. 2.17] 0.744 0.12 0.124 0.084 -0.275 0.332 -0.207 -0.068 0.289 0.011 -0.002 -0.099 -0.12 
[2.34 .. 2.39] 0.386 -0.3 -0.07 -0.506 -0.411 0.238 0.16 0.121 0.139 0.063 0.088 0.08 -0.016 
[2.43 .. 2.48] 0.791 -0.055 -0.057 0.232 -0.142 0.247 -0.109 0.055 0.124 -0.104 -0.024 -0.019 0.206 
[2.48 .. 2.50] 0.618 -0.345 -0.239 0.112 0.304 0.355 -0.011 0.21 0.019 -0.149 -0.173 -0.061 0.21 
[2.50 .. 2.52] 0.645 -0.33 -0.088 0.036 0.243 0.457 0.108 0.228 -0.054 -0.14 -0.165 -0.068 -0.055 
[2.52 .. 2.58] 0.73 0.497 -0.239 0.125 -0.153 -0.024 -0.006 0.158 -0.094 -0.081 0.037 0.041 0.027 
[2.68 .. 2.74] 0.737 0.313 -0.113 0.066 -0.295 -0.034 -0.012 0.321 -0.066 -0.05 0.001 0.132 -0.085 
[2.85 .. 2.88] 0.26 0.108 0.254 0.601 0.217 0.13 -0.079 -0.194 -0.265 0.18 -0.255 0.124 -0.24 
[2.90 .. 2.94] 0.706 0.174 0.069 0.423 0.135 0.271 -0.059 -0.113 -0.228 0.05 -0.157 0.075 -0.183 
[5.22 .. 5.24] 0.098 0.133 0.039 0.786 0.014 -0.013 -0.201 0.115 0.066 0.108 0.336 -0.01 0.113 
[5.26 .. 5.37] -0.638 -0.375 0.196 0.372 -0.177 0.062 -0.153 0.175 -0.005 0.099 0.124 0.045 -0.085 
[6.87 .. 6.89] 0.429 -0.654 -0.244 0.159 0.123 0.008 0.013 0.052 -0.258 -0.082 0.097 0.15 -0.113 
[6.89 .. 6.92] 0.747 -0.017 -0.195 0.231 -0.113 -0.212 0.158 0.041 -0.156 0.17 0.296 -0.096 0.102 
[7.02 .. 7.08] 0.852 -0.115 -0.081 0.123 0.019 -0.013 0.282 -0.046 -0.05 -0.103 0.078 0.043 -0.003 
[7.08 .. 7.14] 0.791 -0.358 0.22 -0.192 -0.118 -0.187 -0.11 -0.106 0.037 -0.067 -0.047 0.041 -0.088 
[7.14 .. 7.16] 0.696 -0.451 0.094 -0.127 0.127 -0.168 -0.239 -0.136 -0.055 -0.122 0.017 0.098 0.143 
[7.16 .. 7.18] 0.738 -0.44 -0.05 0.06 0.28 -0.069 -0.1 0.055 -0.083 -0.116 -0.038 -0.046 0.094 




[7.29 .. 7.35] 0.886 0.04 0.048 -0.094 -0.083 -0.337 -0.001 0.057 0.124 -0.039 -0.006 -0.024 -0.142 
[7.35 .. 7.40] 0.869 -0.108 0.114 -0.058 0.048 -0.265 0.068 -0.088 -0.014 -0.136 0.06 -0.056 -0.184 
[7.40 .. 7.45] 0.704 -0.313 0.367 -0.096 -0.089 -0.032 0.133 -0.233 0.027 -0.049 0.083 -0.088 -0.215 
[7.45 .. 7.51] 0.513 -0.645 0.257 -0.132 0.188 -0.229 0.102 -0.016 -0.057 -0.112 0.039 -0.017 -0.042 
[7.51 .. 7.56] 0.479 -0.629 0.232 -0.219 0.143 -0.011 -0.081 -0.02 -0.252 -0.008 0.026 0.026 0.001 
[7.74 .. 7.79] 0.579 0.156 -0.144 0.108 0.318 0.031 0.576 0.141 -0.02 -0.099 -0.016 -0.168 -0.15 
[7.79 .. 7.85] 0.559 -0.205 0.311 -0.375 0.032 -0.074 -0.22 -0.322 0.053 -0.043 0.009 0.184 0.181 
[7.85 .. 7.91] 0.467 -0.416 0.391 -0.291 0.064 0.097 0.072 0.257 0.039 -0.041 0.205 -0.128 0.018 
[7.91 .. 7.97] 0.323 -0.475 0.406 -0.357 -0.133 -0.039 -0.323 0.094 -0.195 0.068 -0.043 -0.026 -0.063 
[8.17 .. 8.23] 0.08 -0.204 0.188 -0.273 0.148 0.012 0.131 0.375 0.008 0.545 -0.05 0.461 -0.084 
[8.28 .. 8.31] 0.304 -0.167 0.395 -0.332 0.049 0.123 -0.411 0.18 -0.359 0.143 0.144 -0.134 0.182 
 
 
Table 47. Full visualisation of contributions of the NPC1 disease features to each one of the factors where positive values are showing important 
contribution to the corresponding factor. 
 
1.2. Factor Scores  
 
Observation F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 
Obs1 -0.566 -2.816 -0.299 -2.194 1.548 1.377 0.373 0.482 0.969 3.066 0.130 2.107 -0.179 
Obs2 1.792 -1.611 -4.272 -1.779 1.358 -1.701 0.793 -0.774 -1.115 0.139 -0.635 0.064 0.300 
Obs3 0.066 -2.933 0.119 -1.895 -0.294 0.511 0.338 -1.603 -0.846 -0.240 0.061 0.274 0.433 
Obs4 1.057 -2.154 0.179 0.445 0.672 -0.716 0.410 -0.769 -0.021 0.429 0.247 -0.703 -0.343 
Obs5 -1.680 -2.818 1.183 -1.070 -0.157 1.470 1.023 -0.868 -0.127 -0.245 -0.102 -0.072 0.813 




Obs7 -3.849 2.158 -1.911 -1.626 -0.568 1.353 0.572 -0.095 0.330 -0.868 -0.539 -0.412 0.799 
Obs8 -0.968 -0.608 1.132 -0.445 0.566 -0.966 -0.216 -0.077 0.457 -0.596 -0.870 -0.598 -0.001 
Obs9 -0.051 -3.845 -2.928 2.824 2.408 1.418 -0.980 0.624 1.849 1.208 -0.274 -0.010 1.374 
Obs10 3.259 -0.402 0.441 -2.988 -1.142 0.190 -1.006 -2.655 1.320 0.317 0.306 0.879 1.473 
Obs11 3.219 -2.337 -0.646 -0.499 0.566 0.520 1.008 0.632 1.080 -0.727 0.854 -0.579 -0.084 
Obs12 0.672 2.872 -0.215 -0.977 -0.114 -0.083 1.000 0.384 1.333 -1.127 -0.306 0.123 1.435 
Obs13 3.608 -0.014 0.425 -1.608 -1.329 2.132 0.432 -1.138 0.893 -0.517 -2.035 0.709 1.766 
Obs14 -11.125 -1.433 1.803 0.457 1.213 -1.408 0.264 0.683 -0.291 -0.501 0.713 -0.502 0.228 
Obs15 -12.453 -4.388 -0.176 -0.416 0.680 -1.281 0.172 0.036 -0.928 -0.792 0.064 -1.616 -0.463 
Obs16 -3.794 -3.083 0.957 -0.562 -0.883 0.231 1.478 0.532 -0.588 0.059 -0.986 -0.737 0.373 
Obs17 -3.565 -0.499 -0.522 0.411 2.074 2.355 0.017 -0.354 1.098 0.115 1.071 -0.188 0.569 
Obs18 -3.927 -2.328 0.587 -1.094 0.335 0.393 -1.224 -2.325 0.579 0.307 0.511 0.613 1.715 
Obs19 -3.446 -0.922 1.579 -0.749 2.146 1.834 0.002 -0.791 1.331 -0.188 1.719 0.761 -0.164 
Obs20 7.482 -2.717 1.297 -3.045 0.713 -2.429 -1.659 -1.023 0.701 -1.117 0.200 1.124 -0.799 
Obs21 6.387 -2.061 1.874 -3.236 -0.649 3.710 -4.748 -0.409 -0.980 1.168 0.185 -0.655 1.437 
Obs22 -2.624 -2.858 -1.138 0.293 0.800 -0.290 -0.388 -0.660 0.580 -0.671 0.205 -0.494 -0.521 
Obs23 -6.253 -2.913 -2.265 -1.005 -1.662 1.662 -0.610 -0.231 -0.785 -0.765 -0.174 -1.100 -1.433 
Obs24 -5.780 -3.902 -1.921 -0.922 1.128 0.811 -0.198 -0.711 -0.620 -0.640 0.501 -0.782 -0.392 
Obs25 -2.798 1.793 -2.981 -0.970 2.850 1.325 -0.883 -0.959 0.361 0.398 0.808 -0.506 0.010 
Obs26 -5.864 -2.661 -0.206 -2.156 1.177 1.182 -1.393 -1.644 0.144 -0.333 1.036 0.368 -0.148 
Obs27 1.220 0.297 -3.029 -1.198 -2.199 1.848 -1.885 0.299 2.121 -0.898 -0.213 -1.271 -3.064 
Obs28 -2.918 -0.826 -0.908 -1.817 1.063 2.158 0.265 -0.127 0.384 -0.302 0.276 -0.252 0.113 
Obs29 -4.674 2.509 1.461 1.291 -1.480 -0.630 0.351 0.893 1.142 -0.216 -0.504 -1.112 0.413 
Obs30 -0.454 -5.158 3.103 -1.853 -2.331 0.063 -3.943 0.923 -0.706 0.221 -0.246 -1.211 0.163 
Obs31 -3.829 6.068 3.455 -1.960 -2.544 -1.254 -1.120 -1.446 -0.014 -1.455 0.133 1.776 0.165 
Obs32 -1.291 -2.322 -0.855 -0.136 -0.900 -1.299 0.172 -0.346 -0.057 -0.164 -0.778 -0.678 -0.799 
Obs33 -5.996 4.405 1.550 -2.557 -1.203 -0.400 1.472 2.802 -0.707 0.902 -0.950 1.015 -0.839 
Obs34 -5.038 -5.770 0.250 -1.147 -0.320 -2.449 -0.107 1.344 -1.214 0.202 -0.845 -1.257 -0.917 




Obs36 -2.500 -2.587 -0.289 -2.779 -0.332 0.010 -0.164 2.014 -0.117 -0.938 -0.787 0.418 -1.231 
Obs37 3.295 -3.092 0.571 -0.163 -0.840 -1.170 0.599 -0.260 -1.026 -0.771 -0.239 -0.293 -1.060 
Obs38 -1.568 -2.820 1.719 -0.301 0.688 0.877 -0.049 1.184 0.908 -1.473 -1.277 -0.676 0.512 
Obs39 -1.503 1.212 -5.691 -0.845 4.120 1.138 -1.845 2.744 -0.218 -2.241 -2.320 0.252 0.986 
Obs40 -7.016 4.413 2.261 -2.468 -1.045 0.153 -0.088 -0.303 -0.280 -0.753 -1.037 -0.255 -0.001 
Obs41 3.452 -0.754 -2.237 0.292 2.527 -1.104 -0.159 0.317 -0.565 -1.185 0.306 1.315 1.455 
Obs42 2.710 -2.338 -0.987 -1.582 -1.152 0.146 1.624 -0.552 0.673 -0.658 -1.059 0.207 0.709 
Obs43 -4.235 0.644 -3.092 0.402 1.940 0.939 -0.197 0.269 0.074 -1.598 2.186 1.520 -0.188 
Obs44 -4.853 -0.112 0.411 1.439 0.361 0.293 -0.058 0.427 0.533 -0.724 0.409 -0.963 0.765 
Obs45 1.580 -2.786 0.188 -3.098 1.534 -0.130 2.076 0.844 -0.796 1.010 1.230 -2.046 -2.162 
Obs46 3.523 6.420 -3.585 -0.158 -1.403 -2.785 0.179 -0.658 0.091 0.800 1.166 -0.832 1.113 
Obs47 2.320 -2.766 2.549 -1.914 0.406 -2.344 -2.402 1.217 1.295 0.043 -0.270 2.792 -0.313 
Obs48 -0.506 4.837 -3.749 -0.347 -0.421 -0.712 -1.047 0.600 -0.445 0.241 -1.330 -1.015 0.137 
Obs49 -1.552 -2.354 3.774 -0.757 -0.826 -0.336 -0.942 -0.739 1.779 -0.356 -1.141 0.941 1.900 
Obs50 -2.111 -1.789 -1.546 -1.397 1.027 1.138 1.783 -1.203 -0.841 0.079 0.675 -0.594 0.083 
Obs51 7.090 5.593 6.890 -5.407 2.581 2.031 1.378 2.128 -3.908 -0.647 4.000 -1.422 1.062 
Obs52 -2.843 7.181 0.922 -1.600 -2.393 -0.578 0.807 -0.629 -0.009 -0.483 -0.505 -0.064 0.047 
Obs53 1.387 -0.993 -1.950 1.498 1.199 -2.000 1.198 -1.372 1.322 1.390 0.664 -1.253 0.355 
Obs54 -8.427 2.780 1.239 -1.125 0.920 0.527 0.033 -1.320 0.975 -0.374 2.028 -0.081 -0.641 
Obs55 -0.123 3.855 -0.163 -0.818 -1.993 1.995 1.049 -0.261 0.348 -0.595 0.436 -1.272 0.170 
Obs56 -1.797 -2.181 -1.705 0.433 -0.359 1.520 -0.263 0.139 0.840 -0.219 -0.853 -0.510 -0.420 
Obs57 -4.273 3.501 1.407 -1.563 -2.204 1.225 1.738 -0.460 -0.824 -1.215 -0.191 -0.707 2.083 
Obs58 0.471 -0.928 -0.463 -0.198 -1.323 2.194 1.037 0.750 0.521 0.923 -2.174 -0.267 1.016 
Obs59 5.250 -6.314 -0.981 -0.321 -1.847 -0.106 1.888 1.135 0.034 -0.829 0.187 -0.121 -0.250 
Obs60 2.848 -2.122 -0.330 -2.794 1.158 0.587 1.277 1.411 -1.584 0.892 -0.019 1.167 0.696 
Obs61 -3.222 -0.195 0.434 -0.323 0.901 -1.062 0.576 0.400 0.752 -1.114 0.618 -0.500 0.037 
Obs62 4.989 5.829 2.300 1.801 -0.399 -0.386 0.854 1.381 1.849 -1.643 2.560 -0.382 -0.686 
Obs63 2.120 -2.416 -2.135 -2.463 -0.389 -0.306 2.064 -0.117 -0.217 -0.684 0.393 -0.448 -0.043 




Obs65 6.535 -1.822 -1.167 -2.522 -1.894 0.088 2.947 2.107 1.589 1.443 -0.460 1.979 -0.062 
Obs66 -2.482 2.063 -0.245 -2.645 0.268 0.099 2.556 0.890 0.680 3.003 0.854 2.313 -0.161 
Obs67 7.898 0.269 0.645 -2.576 1.364 -1.362 1.323 0.060 -0.401 -1.434 0.596 0.562 -0.053 
Obs68 6.920 -5.245 -4.012 3.993 -0.943 1.058 0.313 0.937 1.530 -0.992 0.815 -0.990 1.137 
Obs69 -3.540 -6.066 5.364 -1.762 -1.017 -1.172 -4.575 1.929 -1.773 1.094 -0.599 -0.946 1.000 
Obs70 -1.691 -0.166 1.727 -1.733 -3.043 -2.147 -2.054 -0.398 0.851 0.566 0.808 -0.557 0.193 
Obs71 -6.633 -1.525 1.476 -2.269 0.200 -0.014 2.413 1.637 0.479 3.647 0.360 1.558 -0.940 
Obs72 -2.945 1.102 -1.970 0.862 2.216 -1.170 0.387 -1.858 -0.349 1.127 0.777 -0.500 0.605 
Obs73 -3.837 1.798 -1.104 1.760 1.621 -1.386 -0.549 -0.885 0.413 0.112 0.912 0.801 1.290 
Obs74 -3.026 -1.489 -6.520 0.092 3.549 -2.293 -1.497 -0.537 -2.029 1.444 0.830 0.396 -0.858 
Obs75 0.798 -1.643 1.779 1.701 0.517 -2.515 -0.167 -1.397 -0.259 0.129 -0.383 0.503 -0.777 
Obs76 0.686 3.716 -2.443 0.715 -0.458 -0.635 0.164 -0.683 -0.517 0.575 -1.388 -0.480 1.083 
Obs77 1.637 -2.326 1.072 1.667 0.604 0.831 0.380 -1.637 -0.580 1.092 -0.413 -0.330 0.372 
Obs78 0.385 0.049 1.544 2.141 -0.622 -1.706 1.244 0.529 0.452 -0.618 -0.512 -0.388 0.122 
Obs79 -0.573 4.622 2.259 2.979 0.292 0.210 1.138 0.168 0.438 0.474 0.507 -0.280 1.282 
Obs80 1.987 0.449 0.800 2.590 1.039 -0.290 0.358 0.787 0.624 -0.472 -0.447 0.350 1.613 
Obs81 0.971 -2.024 1.928 6.059 1.740 -0.171 -0.638 0.913 0.949 0.042 1.619 -0.264 0.542 
Obs82 -2.188 -1.838 1.927 2.058 0.617 -0.284 1.387 0.467 -0.283 -0.767 -0.487 -0.665 2.023 
Obs83 1.206 -4.109 0.485 1.662 0.390 -1.290 0.955 1.382 0.693 -0.687 -0.545 -0.099 -0.224 
Obs84 1.019 3.197 2.539 6.107 -1.843 1.241 -1.723 0.277 0.388 0.492 1.248 -0.228 -1.768 
Obs85 2.604 9.907 -1.134 -0.683 3.906 -0.383 -1.927 -0.458 -1.440 0.668 -2.442 0.641 -1.548 
Obs86 -2.852 6.547 1.545 0.808 0.411 1.055 -0.877 0.619 0.190 0.979 -0.414 0.598 -1.765 
Obs87 -4.506 -0.481 2.586 1.344 1.364 -1.468 -0.257 0.278 0.263 0.524 0.086 0.308 -0.385 
Obs88 0.833 -1.998 3.665 2.022 0.728 -0.863 0.536 1.290 -1.505 0.689 -0.703 1.329 0.586 
Obs89 0.000 -1.714 1.724 2.418 -0.372 -1.126 1.281 -0.349 -0.599 -0.522 -1.538 0.202 0.223 
Obs90 1.111 -0.887 0.852 2.615 0.874 -0.175 -0.026 -0.207 -0.481 1.334 0.026 -0.273 -0.815 
Obs91 0.967 3.228 1.712 1.378 0.844 0.196 0.195 0.715 0.560 0.176 -1.238 -0.111 -0.208 
Obs92 -1.245 1.799 3.001 1.620 -0.561 -0.438 0.011 -0.754 -0.407 -1.255 -1.580 0.999 -0.832 




Obs94 -4.881 2.931 0.939 3.758 0.084 2.619 -1.123 0.112 0.647 1.509 -0.560 0.282 0.352 
Obs95 1.352 2.297 1.941 3.253 -0.611 0.461 1.063 -0.427 -0.930 0.192 -1.394 -0.031 0.187 
Obs96 2.218 -0.332 0.201 1.289 1.728 1.383 -0.549 0.443 0.245 -0.252 -0.774 0.387 -0.452 
Obs97 0.362 -1.267 1.787 2.174 -0.783 -0.131 1.519 -1.079 -1.455 -0.002 -0.449 -0.490 -0.345 
Obs98 -0.369 -2.617 -0.708 1.578 -0.892 1.360 0.868 -1.927 -0.354 0.697 -0.607 -0.511 -0.366 
Obs99 -2.501 -1.226 -1.239 0.912 1.053 0.988 -0.112 -1.099 -0.246 0.284 0.416 0.003 -0.603 
Obs100 1.326 -2.880 0.324 1.256 -0.315 0.689 0.348 -0.976 -2.661 -0.129 -0.567 0.095 -1.077 
Obs101 -5.267 -1.428 0.640 2.061 1.291 1.437 -0.435 -0.096 -0.903 -4.150 0.668 4.651 -1.345 
Obs102 2.186 -4.083 1.695 3.307 0.842 -1.233 1.050 0.528 -0.109 0.004 -0.505 0.683 0.331 
Obs103 2.929 4.662 4.706 5.893 1.701 -0.271 -0.709 1.006 0.773 0.348 1.182 -0.702 -0.668 
Obs104 -2.179 6.332 0.368 -1.409 -2.194 0.525 0.820 -0.096 0.032 -0.280 0.146 -0.247 -0.403 
Obs105 7.353 -0.934 -0.333 0.655 -0.684 0.883 1.497 0.789 -0.129 -1.073 0.659 0.221 -0.156 
Obs106 5.818 -1.027 -0.331 -0.961 -2.532 -0.004 1.179 -0.284 -1.120 -0.754 0.399 -1.044 -0.458 
Obs107 6.577 1.983 -4.193 0.172 0.702 -0.112 -1.102 0.118 -1.158 -1.751 0.087 1.251 -0.179 
Obs108 6.110 4.344 -1.406 -1.326 2.646 -0.834 -0.916 1.082 -1.647 -0.047 -0.459 -0.906 0.703 
Obs109 -4.175 7.650 -4.149 1.062 -2.013 -0.786 -1.817 2.628 -1.197 1.888 0.299 0.071 1.929 
Obs110 -3.976 -4.837 -6.059 4.460 -9.104 0.271 -0.984 2.157 -2.318 0.665 3.339 2.038 0.554 
Obs111 5.530 -1.352 -1.793 0.838 -2.999 3.078 -0.517 -0.052 -0.386 0.366 0.092 0.261 -1.198 
Obs112 2.315 5.792 -1.446 -0.555 0.515 0.462 -0.742 0.187 -0.883 -0.753 0.520 -0.559 -0.802 
Obs113 -1.522 4.792 -4.636 0.514 -1.106 -3.058 -0.975 1.184 -0.638 -0.558 0.925 0.479 1.393 
Obs114 6.920 2.357 -2.088 0.017 0.133 0.513 -0.241 -0.239 -0.886 -0.636 -0.194 -0.778 -0.924 
Obs115 1.706 3.282 -0.041 -1.439 -0.629 -0.322 -0.070 0.173 1.597 -0.470 0.133 -0.250 -0.746 
Obs116 10.793 -2.694 1.714 -1.902 -1.262 -1.285 -2.934 -1.827 -0.078 0.190 1.522 0.619 0.735 
Obs117 1.171 3.624 -2.596 -0.696 0.855 -1.504 -1.261 -0.032 1.596 0.701 -0.100 -1.372 -0.496 
Obs118 -2.695 6.371 1.121 -1.429 -2.528 -0.592 0.446 -1.474 -0.505 0.042 -0.363 1.011 -1.372 
Obs119 7.662 0.358 2.796 0.733 0.810 0.208 0.075 0.208 -1.937 1.205 0.023 -0.521 0.150 
Obs120 4.117 -1.302 1.446 3.311 1.003 2.718 -1.073 -0.163 -1.452 0.536 -1.154 0.497 -1.152 
Obs121 2.309 -0.672 -0.446 1.040 -0.424 -1.504 1.061 -1.944 -1.107 -0.098 -1.191 0.195 -0.409 




Obs123 3.473 3.743 -0.425 1.951 -0.697 0.989 0.218 -0.670 -0.309 -0.543 -1.226 0.732 -0.753 
Obs124 0.087 3.681 -2.042 1.482 -2.360 1.342 0.268 -1.290 -0.307 1.664 -0.659 0.375 -0.069 
Obs125 2.582 -1.002 -1.201 0.855 1.370 0.536 0.611 -1.898 -0.013 1.918 0.244 0.294 -0.593 
Obs126 -1.493 -3.012 0.354 1.617 -1.431 -1.146 -0.327 0.308 0.185 -0.112 0.024 -0.947 -0.645 
Obs127 5.368 2.035 2.407 0.496 -0.041 -0.459 -0.679 -1.581 2.095 0.595 1.101 -0.399 -0.044 
Obs128 1.579 0.963 0.781 -3.004 1.309 0.649 -0.579 2.070 1.524 1.905 -0.496 -0.631 -0.343 
Obs129 4.565 -3.745 -0.306 -3.249 -1.640 -1.176 -1.346 0.305 1.483 0.685 -0.520 0.389 -0.767 
Obs130 3.435 2.104 -1.284 -1.520 -1.831 -1.210 -0.356 0.875 3.417 -0.597 -0.428 -0.886 -0.783 
 
Table 48. Full visualisation of the factor scores related to the scores of the contribution of each observation to the factors or principal 
components of the NPC1 disease features. The high positive values expressing important contribution to the corresponding factor. For instance, 
observation 10 is making a big contribution to the factor F1.  
 
1.3. Chemical shifts/buckets of biomolecules related to NPC1 disease dataset   
   
Features Number Chemical Shift Molecules Names 
1 [0.68 .. 0.71] L-Lactate 
2 [0.71 .. 0.73] Noisy – Noisy 
3 [0.73 .. 0.75] 16b-Hydroxyestradiol 
4 [0.75 .. 0.77] Noisy – Noisy 
5 [0.77 .. 0.79] Masoprocol 
6 [0.81-0.89] Hexacosanoate 




8 [0.95-1.06] Leucine; Valine 
9 [1.13 .. 1.15] Propionylglycine 
10 [1.15 .. 1.17] Ethanol 
11 [1.17 .. 1.19] Isopropyl hexadecanoate 
12 [1.19 .. 1.21] 3-Aminoisobutyrate 
13 [1.21 - 1.31] (R)-3-Hydroxybutyrate; L-Fucose;  
14 [1.31 .. 1.37] Lactate; 3-Hydroxyisovalerate 
15 [1.45 .. 1.50] Alanine 
16 [1.53 .. 1.55] Adipate 
17 [1.55 .. 1.61] Adipate 
18 [1.69 .. 1.75] Lysine 
19 [1.80 .. 1.86] Thymine; 2-Hydroxyglutarate 
20 [1.90 .. 1.92] Lysine 
21 [1.92 .. 1.94] Acetic acid 
22 [1.94 .. 1.96] Ornithine 
23 [1.96 .. 1.98] Methylglutaric acid 
24 [1.98 .. 2.03] 2-Hydroxyglutarate 
25 [2.03 .. 2.09] N-Acetyl-4-O-acetylneuraminic acid 
26 [2.09 .. 2.12] Glutamine 
27 [2.12 .. 2.17] Methionine; Glutamine 
28 [2.34 .. 2.39] Pyruvate; D-Glutamate 
29 [2.43 .. 2.48] Glutamine 




31 [2.50 .. 2.52] Methylamine 
32 [2.52 .. 2.58] Citrate 
33 [2.68 .. 2.74] Citrate 
34 [2.85 .. 2.88] Trimethylamine 
35 [2.90 .. 2.94] Dimethylglycine 
36 [5.22 .. 5.24] α-Glucose 
37 [5.26 .. 5.37] α-Glucose; Allantoate 
38 [6.87 .. 6.89] 3-(3-Hydroxyphenyl)-3-hydroxypropanoate 
39 [6.89 .. 6.92] 3-hydrophenyl 
40 [7.02 .. 7.08] Phenol 
41 [7.08 .. 7.14] L-Histidine 
42 [7.14 .. 7.16] Syringic acid 
43 [7.16 .. 7.18] Tyrosine 
44 [7.18 .. 7.24] Indoxyl sulfate 
45 [7.29 .. 7.35] Methyl phenylacetate 
46 [7.35 .. 7.40] Indoxyl sulfate; Phenylalanine 
47 [7.40 .. 7.45] Indoxyl sulfate 
48 [7.45 .. 7.51] Indoxyl sulfate; Benzoate 
49 [7.51 .. 7.56] Hippurate 
50 [7.74 .. 7.79] 4-Hydroxybenzoate 
51 [7.79 .. 7.85]  7-Methylxanthine; 4-Hydroxybenzoate 
52 [7.85 .. 7.91] 1-Methylhistidine 
53 [7.91 .. 7.97] Quinolinate 
54 [8.17 .. 8.23] Trigonelline 
55 [8.28 .. 8.31] Hypoxanthine 
 
Table 49. Complete chemical shifts/buckets related to the NPC1 disease dataset, used to identify the different molecules involved in the ranking 








Table 50. Statistics Related to the NPC LDD, with the values of the means and standard 
deviation of the features provided.  
 
  
XLSTAT 2016.07.39157  - Principal Component Analysis (PCA) - Start time: 26/12/2016 at 20:38:01 / End time: 26/12/2016 at 20:40:25 / Microsoft Excel 16.07571
Observations/variables table: Workbook = PLASMA.1.03.xlsm / Sheet = Sheet2 / Range = Sheet2!$A$1:$BC$131 / 130 rows and 55 columns
PCA type: Pearson (n)
Type of biplot: Correlation biplot / Coefficient = Automatic
Run again:
Summary statistics:
Variable ObservationsObs. with missing dataOb . without missing dataMinimum Maximum Mean Std. deviation
[0.68 .. 0.71] 130 0 130 0.000 0.003 0.001 0.000
[0.71 .. 0.73] 130 0 130 0.000 0.002 0.001 0.000
[0.73 .. 0.75] 130 0 130 0.000 0.002 0.001 0.000
[0.75 .. 0.77] 130 0 130 0.000 0.003 0.001 0.000
[0.77 .. 0.79] 130 0 130 0.000 0.004 0.002 0.001
[0.81-0.89] 130 0 130 0.095 0.187 0.132 0.018
[0.89 .. 0.95] 130 0 130 0.016 0.051 0.028 0.005
[0.95-1.06] 130 0 130 0.019 0.038 0.028 0.004
[1.13 .. 1.15] 130 0 130 0.000 0.006 0.002 0.001
[1.15 .. 1.17] 130 0 130 0.001 0.005 0.003 0.001
[1.17 .. 1.19] 130 0 130 0.004 0.018 0.006 0.001
[1.19 .. 1.21] 130 0 130 0.007 0.024 0.014 0.002
[1.21 - 1.31] 130 0 130 0.158 0.391 0.241 0.042
[1.31 .. 1.37] 130 0 130 0.062 0.284 0.203 0.036
[1.45 .. 1.50] 130 0 130 0.009 0.022 0.016 0.002
[1.53 .. 1.55] 130 0 130 0.001 0.006 0.003 0.001
[1.55 .. 1.61] 130 0 130 0.005 0.030 0.014 0.005
[1.69 .. 1.75] 130 0 130 0.006 0.015 0.011 0.002
[1.80 .. 1.86] 130 0 130 0.003 0.034 0.011 0.005
[1.90 .. 1.92] 130 0 130 0.002 0.014 0.004 0.002
[1.92 .. 1.94] 130 0 130 0.001 0.005 0.003 0.001
[1.94 .. 1.96] 130 0 130 0.003 0.006 0.005 0.001
[1.96 .. 1.98] 130 0 130 0.006 0.012 0.009 0.001
[1.98 .. 2.03] 130 0 130 0.024 0.046 0.035 0.004
[2.03 .. 2.09] 130 0 130 0.034 0.057 0.044 0.005
[2.09 .. 2.12] 130 0 130 0.003 0.009 0.005 0.001
[2.12 .. 2.17] 130 0 130 0.006 0.020 0.013 0.002
[2.34 .. 2.39] 130 0 130 0.003 0.025 0.011 0.004
[2.43 .. 2.48] 130 0 130 0.003 0.015 0.008 0.002
[2.48 .. 2.50] 130 0 130 0.000 0.003 0.001 0.001
[2.50 .. 2.52] 130 0 130 0.000 0.002 0.001 0.000
[2.52 .. 2.58] 130 0 130 0.023 0.080 0.055 0.012
[2.68 .. 2.74] 130 0 130 0.014 0.044 0.031 0.006
[2.85 .. 2.88] 130 0 130 0.000 0.014 0.003 0.003
[2.90 .. 2.94] 130 0 130 0.002 0.011 0.006 0.002
[5.22 .. 5.24] 130 0 130 0.000 0.009 0.002 0.002
[5.26 .. 5.37] 130 0 130 0.019 0.058 0.031 0.006
[6.87 .. 6.89] 130 0 130 0.000 0.000 0.000 0.000
[6.89 .. 6.92] 130 0 130 0.000 0.002 0.001 0.000
[7.02 .. 7.08] 130 0 130 0.000 0.002 0.001 0.000
[7.08 .. 7.14] 130 0 130 0.000 0.002 0.001 0.000
[7.14 .. 7.16] 130 0 130 0.000 0.001 0.000 0.000
[7.16 .. 7.18] 130 0 130 0.000 0.000 0.000 0.000
[7.18 .. 7.24] 130 0 130 0.001 0.003 0.002 0.000
[7.29 .. 7.35] 130 0 130 0.001 0.003 0.002 0.000
[7.35 .. 7.40] 130 0 130 0.000 0.001 0.001 0.000
[7.40 .. 7.45] 130 0 130 0.000 0.001 0.001 0.000
[7.45 .. 7.51] 130 0 130 0.000 0.000 0.000 0.000
[7.51 .. 7.56] 130 0 130 0.000 0.000 0.000 0.000
[7.74 .. 7.79] 130 0 130 0.000 0.002 0.001 0.000
[7.79 .. 7.85] 130 0 130 0.000 0.002 0.000 0.000
[7.85 .. 7.91] 130 0 130 0.000 0.001 0.000 0.000
[7.91 .. 7.97] 130 0 130 0.000 0.001 0.000 0.000
[8.17 .. 8.23] 130 0 130 0.000 0.001 0.000 0.000










L-Lactic acid16b-HydroxyestradiolMa oprocolHexacosanoic acidL-IsoleucineLeucine PropionylglycineEthanol Isopropyl hexadecanoate3-Aminois butyrate(R)-3-Hydroxybutyric acid  3-Hydroxyisovaleric acidAlanine A ipic acid Adipate Lysine Thymine Lysine Acetic acidOrnithine Methylglutaric acid2-HydroxyglutarateN-Ace yl-4-O-acetylneuraminic acidGlutamine Methionine Pyruvic acid 
S1 0.00111 0.000664 0.00144 0.113 0.0322 0.0277 0.00204 0.00338 0.00609 0.0112 0.26 0.211 0.021 0.00494 0.0181 0.0111 0.00806 0.00375 0.00356 0.00455 0.00842 0.0349 0.0474 0.00553 0.0132 0.0149
S2 0.000953 0.000634 0.00148 0.106 0.0352 0.0304 0.00179 0.00299 0.00621 0.00961 0.197 0.284 0.0174 0.00351 0.0141 0.0127 0.00767 0.0072 0.00272 0.00415 0.00759 0.0311 0.0478 0.00582 0.0105 0.0111
S3 0.000934 0.000608 0.00128 0.119 0.0266 0.0262 0.00204 0.00321 0.00564 0.0113 0.246 0.239 0.0169 0.00378 0.0161 0.0103 0.0112 0.00389 0.00348 0.00471 0.00846 0.0337 0.0399 0.00454 0.0121 0.0149
S4 0.00104 0.000704 0.00135 0.135 0.0285 0.0332 0.00194 0.00316 0.00549 0.0129 0.257 0.191 0.0155 0.00354 0.0153 0.0123 0.0104 0.00412 0.00333 0.00498 0.00911 0.036 0.0448 0.00521 0.0127 0.00883
S5 0.00117 0.0007 0.00146 0.132 0.0262 0.0246 0.00198 0.00322 0.00561 0.0114 0.276 0.202 0.0182 0.00443 0.0166 0.00916 0.00949 0.00346 0.0034 0.00456 0.0092 0.0367 0.0357 0.00435 0.0131 0.0158
S6 0.00128 0.000835 0.00162 0.121 0.0257 0.0262 0.00233 0.00333 0.00558 0.0113 0.27 0.244 0.0149 0.00351 0.0164 0.00875 0.00862 0.00331 0.00296 0.00418 0.00813 0.0359 0.0377 0.00382 0.0108 0.0109
S7 0.00145 0.00102 0.00189 0.109 0.0259 0.0257 0.00249 0.00386 0.00649 0.0131 0.248 0.261 0.0131 0.00282 0.0155 0.00979 0.0109 0.00328 0.00249 0.00395 0.00761 0.0335 0.0405 0.00505 0.0129 0.0123
S8 0.00135 0.000886 0.00171 0.145 0.028 0.0262 0.00216 0.0035 0.00598 0.0128 0.258 0.193 0.0139 0.00304 0.0157 0.0102 0.00877 0.00367 0.00317 0.00484 0.00845 0.0389 0.0453 0.00498 0.0125 0.00886
S9 0.000434 0.000283 0.000846 0.115 0.0342 0.033 0.00173 0.00279 0.00471 0.0113 0.287 0.159 0.0158 0.00402 0.0237 0.0131 0.00952 0.00419 0.00285 0.00463 0.00819 0.0371 0.044 0.00705 0.0142 0.00775
S10 0.00136 0.00099 0.00187 0.114 0.0264 0.0314 0.00233 0.00379 0.00663 0.0131 0.217 0.238 0.0201 0.00301 0.0135 0.0124 0.00965 0.00371 0.00373 0.00502 0.00839 0.0329 0.0464 0.00485 0.0157 0.0185
S11 0.00084 0.0006 0.00126 0.116 0.0268 0.0307 0.0032 0.00346 0.00605 0.0141 0.232 0.21 0.0162 0.00354 0.0164 0.0124 0.0136 0.00379 0.00306 0.00492 0.00905 0.0351 0.0478 0.0059 0.015 0.0157
S12 0.00141 0.00118 0.00227 0.13 0.0248 0.0272 0.00281 0.00424 0.00721 0.0156 0.224 0.22 0.0171 0.00259 0.0119 0.0114 0.00681 0.00376 0.00269 0.00472 0.00917 0.0348 0.0467 0.00594 0.0132 0.0146
S13 0.00113 0.00104 0.00193 0.132 0.0233 0.0275 0.00205 0.0033 0.00568 0.0134 0.196 0.242 0.0188 0.00277 0.00849 0.0114 0.0135 0.00407 0.00427 0.00548 0.0097 0.0313 0.0411 0.00573 0.0157 0.0162
S14 0.00117 0.000682 0.00132 0.134 0.0282 0.019 0.00208 0.00367 0.00558 0.0109 0.376 0.154 0.009 0.00352 0.0265 0.00552 0.00321 0.00169 0.0017 0.00394 0.00815 0.0424 0.0355 0.00312 0.00639 0.00345
S15 0.00104 0.000289 0.000769 0.123 0.0285 0.0187 0.0015 0.00245 0.00393 0.00807 0.391 0.171 0.00915 0.00402 0.0301 0.00565 0.00419 0.00172 0.00156 0.00285 0.00678 0.0419 0.0358 0.00322 0.00624 0.00478
S16 0.0011 0.000612 0.00132 0.145 0.0246 0.0236 0.00173 0.00275 0.00462 0.00974 0.278 0.192 0.0162 0.00385 0.0166 0.00912 0.00744 0.0031 0.00279 0.00407 0.0089 0.0414 0.0381 0.00399 0.0103 0.0162
S17 0.00125 0.000785 0.00167 0.112 0.0305 0.0291 0.00264 0.00364 0.00621 0.0137 0.279 0.199 0.0142 0.00475 0.0205 0.00935 0.00843 0.00383 0.00346 0.00502 0.00893 0.0354 0.0414 0.00556 0.013 0.00966
S18 0.00108 0.000667 0.00143 0.12 0.0302 0.0256 0.00194 0.00282 0.00517 0.012 0.294 0.203 0.0152 0.00427 0.0195 0.00876 0.00876 0.00316 0.0035 0.00483 0.00846 0.035 0.0385 0.00444 0.0117 0.0105
S19 0.00123 0.000883 0.00178 0.115 0.0268 0.0266 0.00311 0.00425 0.00674 0.0151 0.282 0.194 0.015 0.00575 0.0216 0.00883 0.00542 0.00344 0.00357 0.00484 0.0089 0.0385 0.0418 0.00498 0.0133 0.01
S20 0.00116 0.000906 0.00172 0.112 0.0269 0.0267 0.00214 0.00352 0.00634 0.0143 0.21 0.221 0.0168 0.0039 0.0133 0.0139 0.00911 0.00404 0.00379 0.00505 0.00906 0.0336 0.0545 0.00634 0.0159 0.0151
S21 0.00135 0.001 0.00165 0.116 0.0254 0.0319 0.00229 0.00343 0.00586 0.0118 0.198 0.222 0.0172 0.00366 0.0128 0.0141 0.0194 0.00477 0.00452 0.00521 0.00836 0.0323 0.0445 0.00593 0.019 0.0177
S22 0.00084 0.000489 0.00125 0.119 0.0318 0.0281 0.00167 0.00279 0.00507 0.0129 0.278 0.195 0.0129 0.00387 0.0209 0.0105 0.00904 0.00355 0.00303 0.00449 0.00781 0.0361 0.0442 0.00502 0.0118 0.00895
S23 0.0011 0.000458 0.00117 0.117 0.0275 0.0246 0.00161 0.00258 0.00489 0.00977 0.295 0.207 0.0131 0.00349 0.0239 0.0084 0.0201 0.00294 0.00245 0.00331 0.00583 0.0348 0.0391 0.00401 0.0111 0.0142
S24 0.000971 0.000402 0.00109 0.109 0.0326 0.0257 0.00161 0.0027 0.00486 0.0104 0.309 0.209 0.0132 0.00407 0.0257 0.00864 0.0103 0.00303 0.00254 0.00384 0.00654 0.0336 0.039 0.00465 0.0101 0.00996
S25 0.00149 0.0011 0.00196 0.0949 0.041 0.0301 0.00265 0.00398 0.00647 0.0127 0.243 0.253 0.0137 0.00382 0.0176 0.0101 0.00991 0.00628 0.00328 0.0046 0.008 0.0304 0.0441 0.00581 0.0127 0.00712
S26 0.00115 0.000631 0.00144 0.105 0.0316 0.0249 0.00218 0.00344 0.00605 0.0118 0.309 0.207 0.0134 0.00438 0.0253 0.0082 0.0116 0.00302 0.003 0.00427 0.00712 0.0344 0.0399 0.00455 0.011 0.0124
S27 0.0012 0.000803 0.0016 0.0992 0.0263 0.0303 0.00212 0.00331 0.00646 0.0135 0.219 0.227 0.0132 0.00298 0.0169 0.0132 0.032 0.00412 0.00324 0.0042 0.00686 0.0312 0.0535 0.00607 0.0179 0.0155
S28 0.00128 0.000822 0.00177 0.107 0.0301 0.0259 0.0023 0.00355 0.00607 0.0125 0.264 0.229 0.0156 0.00403 0.0196 0.00995 0.0106 0.00364 0.00321 0.00447 0.00781 0.0342 0.0414 0.00516 0.0119 0.0145
S29 0.00152 0.0011 0.00208 0.152 0.0224 0.0274 0.00213 0.00351 0.00573 0.0137 0.269 0.169 0.0135 0.00288 0.0139 0.00924 0.00903 0.0029 0.00224 0.00443 0.00968 0.0417 0.0428 0.00478 0.0125 0.00714
S30 0.00103 0.000557 0.00109 0.141 0.0227 0.0253 0.00162 0.00276 0.0048 0.0105 0.256 0.19 0.0149 0.00364 0.0171 0.00962 0.0212 0.00289 0.00286 0.00455 0.00866 0.041 0.0432 0.00465 0.0148 0.0123
S31 0.00186 0.0016 0.00284 0.157 0.0197 0.0269 0.00271 0.00476 0.00804 0.0204 0.23 0.217 0.0114 0.00217 0.00668 0.00886 0.00772 0.00248 0.00278 0.00442 0.00897 0.0352 0.0422 0.00349 0.0111 0.0101
S32 0.000826 0.000547 0.00137 0.145 0.0293 0.0274 0.00161 0.0027 0.00479 0.0117 0.24 0.205 0.0154 0.00361 0.0151 0.0107 0.0106 0.00485 0.00325 0.00419 0.00776 0.0358 0.0447 0.00483 0.012 0.0106
S33 0.00224 0.00144 0.00266 0.144 0.0216 0.0204 0.00252 0.00391 0.00634 0.0142 0.25 0.223 0.0146 0.00231 0.012 0.00787 0.00468 0.00285 0.00255 0.00344 0.00736 0.0406 0.0449 0.00349 0.0094 0.00875
S34 0.000791 0.000265 0.000869 0.146 0.0283 0.0209 0.00128 0.0022 0.00372 0.00741 0.293 0.192 0.0128 0.00426 0.0196 0.00851 0.00777 0.00245 0.00249 0.00326 0.00723 0.0429 0.0447 0.00468 0.00922 0.00965
S35 0.00116 0.000655 0.00135 0.135 0.0274 0.025 0.00182 0.0032 0.0055 0.0125 0.296 0.164 0.0119 0.00403 0.0223 0.00903 0.0084 0.00282 0.00271 0.00437 0.00853 0.0408 0.0475 0.00483 0.0115 0.00807
S36 0.0013 0.000725 0.00142 0.106 0.0234 0.0191 0.00195 0.00303 0.00513 0.0123 0.255 0.229 0.0149 0.00397 0.0212 0.00924 0.0046 0.00304 0.00278 0.00351 0.00705 0.0391 0.05 0.00477 0.0119 0.0147
S37 0.000788 0.000661 0.0014 0.147 0.0251 0.0304 0.00168 0.00312 0.00545 0.0121 0.225 0.195 0.0158 0.00358 0.0116 0.012 0.0125 0.00496 0.0033 0.00446 0.00868 0.0357 0.0427 0.00496 0.0137 0.0125
S38 0.00101 0.000651 0.00125 0.124 0.024 0.021 0.00191 0.00313 0.00543 0.0125 0.278 0.195 0.0124 0.00389 0.0188 0.0094 0.0112 0.00302 0.00306 0.0053 0.01 0.0419 0.0435 0.00526 0.0134 0.0115
S39 0.00138 0.000879 0.00206 0.113 0.0405 0.0231 0.0021 0.00351 0.00834 0.0112 0.223 0.241 0.0125 0.00309 0.0159 0.01 0.00785 0.00709 0.0029 0.00386 0.00659 0.0309 0.0511 0.00897 0.00901 0.00717
S40 0.00215 0.00149 0.00261 0.141 0.0212 0.0209 0.00282 0.00413 0.00665 0.0125 0.27 0.22 0.0109 0.00283 0.0123 0.00749 0.00838 0.00294 0.003 0.00408 0.00838 0.0397 0.0408 0.00364 0.0104 0.0101
S41 0.000995 0.000778 0.00167 0.119 0.0344 0.0253 0.00229 0.00361 0.00742 0.0143 0.217 0.22 0.018 0.00375 0.0142 0.0119 0.00712 0.00697 0.00295 0.00505 0.00899 0.0313 0.0464 0.00677 0.0119 0.00919
S42 0.0008 0.0006 0.00122 0.11 0.0225 0.0233 0.00173 0.00327 0.00562 0.0114 0.209 0.267 0.02 0.00365 0.0122 0.012 0.01 0.0037 0.00369 0.00481 0.00952 0.0331 0.0463 0.00562 0.0142 0.0136
S43 0.00126 0.000771 0.00159 0.109 0.0337 0.0284 0.00255 0.00379 0.00665 0.0188 0.266 0.214 0.0142 0.00521 0.0212 0.00883 0.00432 0.00356 0.00201 0.00353 0.00691 0.0276 0.0414 0.00622 0.0114 0.00755
S44 0.00134 0.000833 0.00158 0.143 0.0264 0.0255 0.00214 0.00355 0.00573 0.0123 0.309 0.157 0.0137 0.00351 0.0196 0.00895 0.00728 0.00289 0.00236 0.00423 0.00824 0.0383 0.0408 0.00452 0.0123 0.00703
S45 0.000996 0.000593 0.00123 0.1 0.0275 0.0248 0.00542 0.00337 0.00474 0.007 0.26 0.205 0.0175 0.00486 0.0194 0.0114 0.00909 0.00545 0.00399 0.00367 0.00972 0.0393 0.0466 0.00474 0.0122 0.0153
S46 0.00147 0.00139 0.00261 0.122 0.0274 0.0332 0.00255 0.00452 0.00696 0.0143 0.171 0.261 0.0184 0.00189 0.00548 0.0143 0.0149 0.00892 0.00241 0.00439 0.00851 0.0262 0.0472 0.00682 0.0143 0.00953
S47 0.000925 0.000719 0.00142 0.129 0.0256 0.0239 0.00176 0.00332 0.00603 0.0171 0.25 0.191 0.0121 0.00363 0.0151 0.0123 0.0101 0.00307 0.00325 0.00493 0.0094 0.0376 0.0523 0.00573 0.0142 0.00889
S48 0.00145 0.00123 0.00243 0.128 0.0308 0.0305 0.00212 0.00408 0.00656 0.0116 0.189 0.244 0.0143 0.00239 0.00912 0.012 0.0106 0.0103 0.00256 0.00369 0.00723 0.0328 0.0495 0.00536 0.0145 0.00736
S49 0.00115 0.000741 0.00149 0.148 0.0231 0.0209 0.00197 0.00332 0.00573 0.0129 0.275 0.171 0.0164 0.00359 0.0157 0.00957 0.00784 0.00278 0.00352 0.0056 0.0105 0.0431 0.044 0.00444 0.0139 0.0146
S50 0.00116 0.000746 0.00163 0.114 0.0321 0.029 0.00207 0.00332 0.00582 0.0106 0.267 0.226 0.0187 0.00422 0.018 0.0103 0.00769 0.00373 0.00309 0.00392 0.00776 0.0337 0.0372 0.00478 0.0107 0.014
S51 0.00266 0.00209 0.00346 0.129 0.0211 0.0258 0.00645 0.00531 0.00909 0.0184 0.211 0.214 0.0162 0.00258 0.00812 0.0105 0.00806 0.00451 0.00413 0.00554 0.0108 0.0331 0.0381 0.00462 0.0134 0.0154
S52 0.00189 0.00166 0.00304 0.142 0.0222 0.0278 0.00271 0.00435 0.00778 0.0153 0.218 0.242 0.0135 0.00162 0.00603 0.00962 0.00886 0.00299 0.00289 0.00427 0.00886 0.0344 0.0426 0.00453 0.0138 0.0093
S53 0.000749 0.000664 0.00164 0.138 0.0375 0.0366 0.0017 0.003 0.00555 0.0129 0.239 0.191 0.0199 0.00349 0.0139 0.0139 0.00644 0.00579 0.00306 0.0049 0.00911 0.0351 0.0474 0.00559 0.0129 0.00729
S54 0.00161 0.00116 0.00214 0.115 0.0301 0.0251 0.00312 0.00441 0.00748 0.0158 0.328 0.192 0.0122 0.00398 0.0208 0.00631 0.00977 0.00242 0.00256 0.0045 0.0086 0.0354 0.0381 0.00459 0.011 0.0068
S55 0.00168 0.00134 0.00241 0.131 0.0217 0.0331 0.00229 0.00452 0.00741 0.0131 0.217 0.228 0.0156 0.00243 0.00986 0.0113 0.0152 0.00401 0.00292 0.00411 0.00839 0.0338 0.039 0.00461 0.016 0.0138
S56 0.00094 0.000549 0.00119 0.125 0.0285 0.0277 0.00168 0.00279 0.00553 0.0117 0.259 0.197 0.016 0.00377 0.0185 0.0114 0.0134 0.00399 0.00319 0.00419 0.00784 0.0366 0.0443 0.00535 0.0136 0.0119
S57 0.00152 0.00127 0.00208 0.12 0.016 0.0236 0.0034 0.00352 0.00619 0.0137 0.201 0.188 0.0139 0.00187 0.00658 0.00778 0.00778 0.00319 0.0025 0.00475 0.00899 0.0303 0.0344 0.00389 0.0125 0.0101
S58 0.000973 0.000796 0.00137 0.135 0.0219 0.0269 0.00191 0.00301 0.0054 0.0109 0.223 0.229 0.0176 0.00337 0.0114 0.0121 0.0135 0.0042 0.00342 0.00486 0.00946 0.0359 0.0428 0.00534 0.0146 0.0135
S59 0.00034 0.000267 0.000804 0.125 0.0246 0.0287 0.00135 0.00261 0.00501 0.0114 0.211 0.215 0.0188 0.0036 0.0142 0.0123 0.017 0.00368 0.00304 0.00471 0.00923 0.0361 0.0443 0.00533 0.0139 0.0245
S60 0.000973 0.000732 0.0014 0.115 0.0285 0.0247 0.00338 0.00317 0.00536 0.0123 0.21 0.261 0.0178 0.00356 0.013 0.0114 0.00886 0.00415 0.00338 0.00486 0.00882 0.031 0.0436 0.00545 0.0129 0.0126
S61 0.00123 0.000859 0.00165 0.131 0.0295 0.0235 0.00256 0.00341 0.00594 0.0137 0.293 0.179 0.0139 0.00361 0.0183 0.0091 0.00705 0.00311 0.00266 0.00449 0.0088 0.036 0.0444 0.00491 0.0108 0.00949
S62 0.00175 0.00157 0.00279 0.155 0.024 0.0297 0.00304 0.00438 0.0078 0.0238 0.218 0.153 0.0148 0.00266 0.00668 0.0129 0.0111 0.00493 0.00325 0.00509 0.0105 0.0316 0.048 0.00587 0.0169 0.0118
S63 0.000978 0.000674 0.00138 0.11 0.0277 0.0261 0.00187 0.00316 0.00541 0.0114 0.223 0.258 0.0179 0.00349 0.015 0.0119 0.00833 0.00378 0.00326 0.00407 0.00733 0.0303 0.0444 0.00526 0.0124 0.0183
S64 0.000912 0.000665 0.00142 0.109 0.0334 0.0265 0.00213 0.00364 0.00608 0.0125 0.262 0.186 0.0174 0.00454 0.0188 0.0118 0.00969 0.00463 0.0033 0.0048 0.00925 0.0362 0.0507 0.00617 0.013 0.0165
S65 0.000706 0.000671 0.00135 0.111 0.0241 0.0275 0.00171 0.00334 0.00606 0.0142 0.17 0.258 0.0211 0.00329 0.00918 0.0135 0.0106 0.00375 0.00372 0.00505 0.00976 0.0309 0.051 0.00606 0.0146 0.0254
S66 0.00135 0.00102 0.00192 0.119 0.0287 0.0283 0.00296 0.00436 0.00699 0.014 0.253 0.231 0.0168 0.00327 0.0128 0.0106 0.00792 0.00344 0.00327 0.00432 0.00877 0.032 0.0423 0.00458 0.0106 0.0147
S67 0.00149 0.00119 0.0021 0.121 0.0267 0.0289 0.00329 0.00413 0.0071 0.0151 0.195 0.238 0.0184 0.00284 0.00955 0.0128 0.00683 0.00364 0.00365 0.00536 0.00915 0.0297 0.0496 0.00585 0.0143 0.015
S68 0 7.09E-05 0.000445 0.122 0.0302 0.0333 0.00153 0.00258 0.0048 0.012 0.222 0.172 0.0195 0.00372 0.0154 0.0143 0.0225 0.00396 0.00291 0.00472 0.00887 0.0316 0.0462 0.00634 0.0165 0.0163
S69 0.000868 0.000501 0.00113 0.161 0.0232 0.0199 0.00166 0.00258 0.00464 0.011 0.324 0.142 0.0132 0.00416 0.0172 0.00893 0.0143 0.00268 0.00263 0.0047 0.01 0.0434 0.0415 0.00462 0.0117 0.0132
S70 0.00115 0.000921 0.00185 0.142 0.0254 0.0284 0.00194 0.00325 0.00616 0.0139 0.255 0.206 0.0153 0.00276 0.013 0.00966 0.012 0.00254 0.00295 0.00463 0.00814 0.0358 0.0441 0.00463 0.0139 0.012
S71 0.00139 0.000806 0.00167 0.12 0.0257 0.0265 0.00227 0.00335 0.0053 0.0108 0.299 0.196 0.0156 0.00455 0.0205 0.00806 0.00423 0.00282 0.00268 0.00367 0.00922 0.0455 0.0395 0.00386 0.00862 0.018
S72 0.00127 0.00091 0.00187 0.122 0.0366 0.036 0.00227 0.00354 0.00588 0.0138 0.268 0.209 0.0144 0.00372 0.0166 0.0121 0.00622 0.00539 0.00242 0.00472 0.00884 0.0336 0.0404 0.00539 0.00891 0.00697
S73 0.00111 0.000876 0.00186 0.126 0.0361 0.0275 0.00222 0.00371 0.0066 0.0161 0.264 0.208 0.0136 0.00342 0.016 0.00967 0.00618 0.00306 0.00242 0.00494 0.00905 0.0327 0.0427 0.00581 0.00913 0.00564
S74 0.00104 0.000585 0.00148 0.104 0.0512 0.0324 0.00176 0.00296 0.00496 0.0102 0.254 0.225 0.0137 0.00365 0.0209 0.0109 0.00825 0.00744 0.00204 0.00363 0.00606 0.0292 0.0472 0.00654 0.00785 0.00756
S75 0.000842 0.000716 0.00153 0.159 0.0293 0.0308 0.00205 0.00307 0.00563 0.0143 0.249 0.173 0.0144 0.00355 0.0123 0.0114 0.00842 0.00404 0.00286 0.00491 0.00982 0.0372 0.0447 0.00491 0.0121 0.00707
S76 0.00123 0.00112 0.00229 0.14 0.029 0.0332 0.0024 0.00374 0.00606 0.0126 0.191 0.243 0.0153 0.00223 0.00768 0.013 0.0117 0.00586 0.00246 0.00479 0.00915 0.0298 0.045 0.00622 0.0124 0.011
S77 0.000766 0.000603 0.00127 0.142 0.0271 0.0332 0.00203 0.00312 0.0057 0.0129 0.251 0.189 0.0171 0.00359 0.0134 0.0125 0.0118 0.005 0.00358 0.00542 0.0101 0.035 0.0386 0.00505 0.0148 0.00799
S78 0.000821 0.000846 0.00152 0.162 0.0252 0.0262 0.00231 0.00328 0.00577 0.015 0.249 0.177 0.0156 0.00328 0.00905 0.0107 0.0103 0.00321 0.00261 0.00517 0.0106 0.0355 0.0442 0.00552 0.0128 0.00766
S79 0.00161 0.00142 0.00251 0.165 0.0276 0.0281 0.00262 0.00411 0.00718 0.018 0.246 0.165 0.0178 0.00258 0.00876 0.0104 0.00928 0.00435 0.00292 0.00565 0.0109 0.0352 0.0417 0.00502 0.013 0.00713
S80 0.00105 0.001 0.0017 0.156 0.0283 0.0279 0.00236 0.00353 0.00701 0.0149 0.226 0.179 0.0171 0.00319 0.00925 0.0116 0.0101 0.00369 0.00283 0.00557 0.0107 0.0367 0.0462 0.00682 0.0128 0.009
S81 0.000572 0.000674 0.00119 0.163 0.0318 0.0284 0.0022 0.00347 0.00594 0.0158 0.297 0.0834 0.0166 0.00419 0.0149 0.011 0.0125 0.00438 0.00257 0.00545 0.0111 0.0378 0.0441 0.00578 0.0136 0.00818
S82 0.000922 0.000706 0.0013 0.164 0.0257 0.025 0.0021 0.00308 0.00502 0.0133 0.279 0.174 0.0152 0.0039 0.0119 0.00953 0.00835 0.003 0.00255 0.00537 0.011 0.0378 0.0383 0.00482 0.011 0.00678
S83 0.000513 0.0004 0.00099 0.155 0.027 0.0272 0.00171 0.00288 0.00528 0.0131 0.251 0.169 0.0148 0.00394 0.0143 0.0121 0.0111 0.0035 0.00274 0.00488 0.00965 0.0391 0.0466 0.00553 0.0126 0.0105
S84 0.00139 0.00127 0.00219 0.177 0.0238 0.0301 0.00251 0.00398 0.00724 0.0159 0.265 0.0733 0.0177 0.00353 0.0111 0.011 0.0218 0.00456 0.00296 0.00477 0.00976 0.0371 0.0395 0.00523 0.0196 0.00687
S85 0.00245 0.00198 0.00378 0.129 0.035 0.0302 0.00356 0.00544 0.00929 0.0156 0.185 0.213 0.0146 0.00186 0.00722 0.013 0.00882 0.0135 0.00308 0.00512 0.0084 0.0305 0.0547 0.00627 0.0118 0.00787
S86 0.00209 0.00162 0.0028 0.135 0.0263 0.0293 0.00299 0.0046 0.00762 0.0174 0.249 0.185 0.0108 0.00235 0.0132 0.0097 0.0129 0.00442 0.00281 0.00459 0.00887 0.0368 0.0432 0.00513 0.0152 0.00631
S87 0.00125 0.000873 0.00167 0.149 0.0284 0.023 0.00227 0.00349 0.00596 0.014 0.311 0.157 0.0125 0.00338 0.0183 0.00851 0.0064 0.00288 0.00272 0.00495 0.00927 0.0396 0.0433 0.00451 0.0104 0.00535
S88 0.00091 0.000863 0.00156 0.171 0.0243 0.024 0.00216 0.00332 0.00581 0.0146 0.27 0.146 0.0171 0.00349 0.0118 0.0101 0.00641 0.00333 0.00288 0.00526 0.0108 0.0385 0.0406 0.00496 0.0125 0.00645
S89 0.000639 0.000665 0.00123 0.157 0.0237 0.0258 0.00185 0.00306 0.00555 0.0139 0.244 0.192 0.0156 0.00328 0.0103 0.0104 0.00877 0.00324 0.00274 0.00502 0.0107 0.0382 0.0419 0.00502 0.0122 0.00811
S90 0.00123 0.000841 0.00165 0.149 0.0283 0.033 0.00218 0.00327 0.00591 0.0133 0.25 0.159 0.0163 0.00344 0.0148 0.0123 0.0101 0.0043 0.00322 0.00468 0.00904 0.0389 0.0423 0.00538 0.0133 0.00736
S91 0.00162 0.00132 0.00235 0.15 0.0253 0.0272 0.00259 0.00424 0.00697 0.0151 0.228 0.183 0.0156 0.00274 0.0111 0.0117 0.0114 0.00407 0.00296 0.00509 0.00974 0.0378 0.0457 0.00579 0.0142 0.00744
S92 0.00133 0.00112 0.00202 0.156 0.0217 0.0254 0.00217 0.00368 0.00679 0.0174 0.248 0.183 0.0126 0.00296 0.0105 0.0104 0.0125 0.00306 0.00276 0.00532 0.0106 0.0381 0.0421 0.00432 0.0122 0.00805
S93 0.000765 0.0007 0.00149 0.132 0.0259 0.0349 0.00208 0.00337 0.0061 0.0139 0.237 0.214 0.0172 0.0032 0.0134 0.0126 0.0103 0.00365 0.00316 0.005 0.0095 0.0345 0.043 0.00448 0.0118 0.00855
S94 0.00125 0.00103 0.00201 0.14 0.0272 0.0283 0.00247 0.00391 0.00684 0.0149 0.258 0.177 0.0147 0.00313 0.0142 0.00948 0.0131 0.00335 0.00301 0.00494 0.00983 0.038 0.0405 0.00544 0.0133 0.00715
S95 0.00122 0.00112 0.00216 0.167 0.0244 0.0286 0.00228 0.00359 0.00646 0.0142 0.22 0.178 0.0168 0.00273 0.00756 0.0113 0.00871 0.00376 0.00299 0.00502 0.0106 0.0368 0.039 0.00507 0.014 0.0099
S96 0.00114 0.000839 0.00159 0.131 0.0286 0.0299 0.00248 0.00402 0.00682 0.0147 0.245 0.176 0.0158 0.00334 0.0161 0.012 0.0128 0.00402 0.00308 0.00498 0.00911 0.0348 0.0477 0.00589 0.0145 0.0109
S97 0.000931 0.000798 0.00148 0.157 0.0246 0.0282 0.00216 0.00306 0.00543 0.0137 0.252 0.179 0.0166 0.00322 0.0119 0.0104 0.0137 0.00353 0.00281 0.00497 0.00973 0.0361 0.0351 0.00449 0.0122 0.0102
S98 0.000697 0.000503 0.00106 0.133 0.0266 0.035 0.00189 0.00274 0.00501 0.0125 0.259 0.187 0.0182 0.00342 0.0156 0.0114 0.0141 0.00355 0.00295 0.00459 0.00857 0.0352 0.0381 0.00481 0.0127 0.0147
S99 0.000922 0.000671 0.0014 0.118 0.0299 0.0317 0.00219 0.00345 0.00606 0.0135 0.273 0.203 0.015 0.00379 0.02 0.0104 0.00948 0.00329 0.00279 0.00419 0.00792 0.033 0.0424 0.00511 0.0125 0.00788
S100 0.00101 0.000685 0.00126 0.136 0.0244 0.0277 0.00184 0.00293 0.00522 0.0118 0.245 0.198 0.0181 0.00341 0.0144 0.0109 0.0137 0.00352 0.00301 0.00421 0.00815 0.0342 0.0392 0.00458 0.0128 0.00955
S101 0.000764 0.000417 0.00103 0.139 0.0275 0.0227 0.00164 0.00241 0.0181 0.0156 0.302 0.166 0.0122 0.00382 0.0205 0.00815 0.00745 0.00475 0.0025 0.00409 0.00822 0.039 0.0364 0.00425 0.0105 0.0066
S102 0.000425 0.0004 0.000958 0.16 0.0271 0.0253 0.00169 0.00273 0.00507 0.0147 0.256 0.16 0.0154 0.00398 0.013 0.0115 0.00874 0.00422 0.00318 0.0054 0.0104 0.0373 0.0407 0.00535 0.0132 0.00744
S103 0.00187 0.00168 0.00271 0.187 0.0279 0.0309 0.00291 0.00446 0.00884 0.017 0.266 0.0618 0.0169 0.00303 0.00896 0.0117 0.0139 0.0036 0.00282 0.00578 0.0116 0.0396 0.0466 0.00595 0.0154 0.00682
S104 0.00194 0.00155 0.00279 0.134 0.0218 0.0293 0.00291 0.00438 0.00756 0.0168 0.216 0.234 0.0144 0.00217 0.00848 0.01 0.0137 0.00355 0.00291 0.00441 0.00872 0.0333 0.0422 0.00466 0.0141 0.0118
S105 0.000907 0.000833 0.0017 0.14 0.0248 0.0332 0.00196 0.00337 0.0063 0.0176 0.177 0.207 0.0188 0.00319 0.00895 0.0142 0.0124 0.00467 0.0036 0.0049 0.0092 0.0322 0.044 0.00601 0.0163 0.0166
S106 0.000993 0.000913 0.00164 0.135 0.023 0.0303 0.00191 0.00333 0.00588 0.0135 0.18 0.239 0.0183 0.00271 0.00812 0.0124 0.0204 0.00409 0.00343 0.00457 0.00877 0.0314 0.042 0.00538 0.0159 0.0169
S107 0.00104 0.000988 0.00187 0.127 0.0307 0.0377 0.00224 0.0038 0.00716 0.0209 0.158 0.237 0.017 0.00294 0.00881 0.0138 0.0142 0.00986 0.00289 0.00447 0.0074 0.0241 0.0473 0.0073 0.0142 0.0118
S108 0.0021 0.00163 0.00293 0.129 0.0312 0.032 0.00294 0.00441 0.00672 0.0137 0.177 0.227 0.0159 0.00253 0.0087 0.0138 0.0102 0.00904 0.0031 0.005 0.00876 0.0317 0.0511 0.00729 0.0132 0.00927
S109 0.00142 0.00144 0.00278 0.139 0.0298 0.0304 0.00267 0.00441 0.00711 0.0135 0.18 0.243 0.0149 0.00144 0.00479 0.0109 0.0101 0.00745 0.00186 0.00356 0.0071 0.0282 0.049 0.00669 0.0111 0.00751
S110 0 0 0 0.123 0.0243 0.0251 0.000106 0.00094 0.00573 0.0123 0.202 0.224 0.0199 0.00324 0.0118 0.00983 0.0344 0.00259 0.00125 0.00268 0.00697 0.0266 0.0369 0.00293 0.0109 0.0196
S111 0.000907 0.000749 0.00138 0.13 0.024 0.0343 0.00192 0.003 0.00557 0.0144 0.176 0.221 0.0187 0.00355 0.01 0.013 0.0313 0.0044 0.00369 0.00523 0.00882 0.0258 0.0411 0.00599 0.0191 0.017
S112 0.00189 0.00156 0.00295 0.135 0.0315 0.0302 0.0028 0.00439 0.0075 0.0159 0.194 0.222 0.0161 0.00259 0.00878 0.0105 0.0133 0.00804 0.00324 0.00438 0.0075 0.0263 0.046 0.00552 0.0152 0.00818
S113 0.0011 0.00108 0.00248 0.136 0.0332 0.0287 0.00215 0.00382 0.00677 0.0151 0.196 0.241 0.0153 0.00218 0.00829 0.0101 0.0116 0.00661 0.0017 0.00364 0.00705 0.0259 0.0466 0.00753 0.00986 0.00829
S114 0.00135 0.0012 0.00235 0.128 0.0289 0.0327 0.00239 0.00374 0.00732 0.0146 0.168 0.229 0.0179 0.00293 0.00862 0.0135 0.0157 0.00964 0.0039 0.0048 0.00833 0.0286 0.0468 0.00612 0.0173 0.00986
S115 0.00174 0.0013 0.00242 0.126 0.027 0.029 0.00254 0.004 0.00718 0.0161 0.224 0.201 0.0168 0.00264 0.0123 0.0115 0.0115 0.00359 0.00343 0.00481 0.00846 0.0332 0.0518 0.0058 0.0149 0.0145
S116 0.000971 0.000869 0.00169 0.128 0.0258 0.034 0.00199 0.0033 0.00642 0.015 0.177 0.207 0.0196 0.00301 0.0102 0.0147 0.0174 0.00488 0.00436 0.00546 0.00898 0.0314 0.0509 0.00595 0.0187 0.0158
S117 0.00144 0.00118 0.00227 0.121 0.0362 0.031 0.00233 0.00377 0.00659 0.0136 0.209 0.224 0.0155 0.00284 0.0113 0.0124 0.0143 0.00963 0.00319 0.00473 0.00848 0.0315 0.0557 0.00603 0.0145 0.00799
S118 0.00181 0.00155 0.00279 0.143 0.0229 0.0311 0.00272 0.00451 0.00921 0.015 0.21 0.239 0.0139 0.00203 0.00546 0.00983 0.0101 0.00349 0.00256 0.00416 0.00876 0.0338 0.044 0.00401 0.0127 0.0166
S119 0.00137 0.0012 0.00218 0.14 0.0242 0.0329 0.00235 0.00372 0.0062 0.0146 0.185 0.209 0.0196 0.00293 0.00795 0.0134 0.00785 0.00412 0.00377 0.0055 0.0106 0.0354 0.0472 0.0056 0.0154 0.0093
S120 0.00118 0.00085 0.00161 0.144 0.0254 0.0333 0.00225 0.00327 0.00644 0.0144 0.224 0.163 0.0167 0.00349 0.0134 0.0125 0.0158 0.00447 0.00354 0.00514 0.00963 0.0364 0.0414 0.00569 0.0168 0.00994
S121 0.000805 0.000671 0.00156 0.144 0.0268 0.027 0.00185 0.00333 0.00595 0.0122 0.221 0.22 0.0168 0.00329 0.0112 0.012 0.00757 0.00552 0.00352 0.00466 0.00867 0.0345 0.0416 0.00476 0.0128 0.00886
S122 0.000978 0.00078 0.00178 0.149 0.0266 0.0303 0.00199 0.00351 0.00629 0.0131 0.21 0.184 0.0182 0.00349 0.0101 0.0129 0.0111 0.00667 0.00311 0.00486 0.00978 0.0368 0.043 0.00608 0.0139 0.00871
S123 0.00106 0.00103 0.00211 0.141 0.0237 0.0307 0.00239 0.00474 0.00816 0.0158 0.193 0.21 0.0156 0.00265 0.00785 0.0131 0.0104 0.00626 0.00363 0.00489 0.00926 0.0323 0.0443 0.00536 0.0161 0.0081
S124 0.00113 0.00101 0.00205 0.121 0.0264 0.0329 0.00221 0.00396 0.0071 0.0135 0.184 0.248 0.022 0.00216 0.00783 0.0113 0.0118 0.00523 0.00312 0.00438 0.00824 0.0323 0.0432 0.00484 0.0159 0.00809
S125 0.000974 0.000708 0.00158 0.112 0.0313 0.0376 0.00201 0.00327 0.00601 0.0139 0.23 0.218 0.0185 0.0035 0.016 0.0126 0.00644 0.00524 0.00368 0.00506 0.00867 0.0335 0.0451 0.00541 0.0145 0.00811
S126 0.00083 0.000512 0.00129 0.152 0.0262 0.0269 0.0016 0.00255 0.0051 0.0121 0.265 0.168 0.0161 0.00312 0.0177 0.0101 0.0152 0.00335 0.00294 0.00421 0.00808 0.0404 0.0435 0.00454 0.0127 0.00857
S127 0.00151 0.00133 0.00224 0.141 0.0262 0.0363 0.00257 0.00402 0.0075 0.017 0.212 0.178 0.0182 0.00292 0.0108 0.0138 0.0144 0.00476 0.0043 0.00582 0.0106 0.0369 0.0485 0.00582 0.0168 0.0107
S128 0.00176 0.00117 0.00209 0.123 0.0299 0.0297 0.00275 0.00391 0.0067 0.0125 0.222 0.209 0.0175 0.00315 0.0141 0.0128 0.00703 0.00431 0.00382 0.00494 0.00865 0.0394 0.0568 0.006 0.0137 0.0176
S129 0.000779 0.0006 0.00127 0.119 0.0278 0.0275 0.00193 0.00288 0.00558 0.0116 0.188 0.242 0.0174 0.00318 0.0119 0.0131 0.0167 0.00383 0.00383 0.00478 0.008 0.0361 0.0568 0.00605 0.0161 0.0222






Table 51. NPC1 Dataset encompassing the 130 rows and 55 features peaks values. 
  
Glutamine L-GlutamineMethylamineCitrate Citrate TrimethylamineD methylglycineAlpha-D-Glucose Antoate 3-(3-Hydroxyphenyl)-3-hydroxypropanoic acid3-hydrophenylP enol L-Histidine Syringic acidTyrosine Indoxyl sulfateM thyl phenylacetateI doxyl sulfate Indoxyl sulfate  B nzoate Hippurate 4-Hydroxybenzoic acid 7-Methylxanthine 1-MethylhistidineQuinolinic acidTr gonellineHypoxanthine
0.00751 0.0014 0.00117 0.0415 0.0276 0.00243 0.00545 0.00136 0.0317 0.000153 0.000723 0.00126 0.00109 0.000236 0.000198 0.00157 0.00143 0.000625 0.000593 0.000192 0.00016 0.000988 0.000613 0.000265 0.000223 0.000862 1.52E-05
0.0075 0.00185 0.00116 0.0547 0.0312 0.00181 0.00522 0.000901 0.0246 0.000197 0.00116 0.00148 0.00114 0.000284 0.0003 0.002 0.00192 0.000858 0.000612 0.000294 0.000171 0.00129 0.000599 0.000114 6.85E-05 0.000125 2.43E-06
0.00749 0.00119 0.00115 0.0476 0.0262 0.00223 0.00551 0.00139 0.0297 0.000193 0.000793 0.0015 0.00133 0.000296 0.000245 0.00168 0.00167 0.000736 0.000714 0.000211 0.000204 0.000938 0.000753 0.000209 0.000181 9.65E-05 2.41E-05
0.00812 0.00128 0.00128 0.0493 0.0286 0.00197 0.00545 0.00227 0.0321 0.000203 0.00114 0.00141 0.00123 0.000226 0.000247 0.00201 0.00165 0.000784 0.000695 0.000269 0.000238 0.00124 0.000498 0.000186 0.000254 0.000121 3.07E-06
0.00928 0.00145 0.00109 0.0426 0.025 0.00179 0.00489 0.00108 0.0321 0.000146 0.000722 0.00124 0.0011 0.00023 0.000214 0.00154 0.00143 0.000641 0.000565 0.000277 0.00017 0.000924 0.000519 0.000239 0.000262 8.48E-05 0
0.00616 0.000558 0.000518 0.0404 0.0223 0.000996 0.00385 0.00104 0.0316 0.000044 0.000813 0.00108 0.00102 0.000222 0.000115 0.00146 0.00125 0.00058 0.0005 0.00019 6.83E-05 0.000594 0.000746 3.97E-05 0 0 0
0.00894 0.00138 0.000867 0.0474 0.0248 0.00075 0.00434 0.001 0.0272 2.28E-05 0.000713 0.00113 0.000686 0.000131 0.000169 0.00154 0.00139 0.000516 0.000343 2.32E-05 0 0.00102 0.000255 3.09E-05 0 5.59E-05 0
0.0084 0.00138 0.00105 0.0489 0.0263 0.00193 0.00493 0.00192 0.0321 0.000101 0.000813 0.00123 0.00131 0.000215 0.000206 0.00196 0.00174 0.000699 0.000516 0.000276 0.000165 0.00102 0.000534 0.000157 0.00019 9.13E-05 0
0.0125 0.00246 0.0015 0.0537 0.0264 0.00278 0.00674 0.00493 0.0303 0.000148 0.00096 0.00137 0.000912 0.000302 0.000311 0.00172 0.00137 0.000639 0.000425 0.000115 0.000104 0.000978 0.00041 0.000106 1.05E-05 0.000458 0
0.0112 0.00145 0.000859 0.0523 0.031 0.00197 0.00548 0.0011 0.0253 8.79E-05 0.00102 0.00141 0.00142 0.000397 0.000277 0.00209 0.00191 0.000814 0.000693 0.000229 0.00017 0.000388 0.00132 0.000252 0.000205 6.58E-05 0
0.0105 0.00197 0.00147 0.054 0.031 0.00173 0.00605 0.00128 0.0308 0.000186 0.00112 0.00163 0.00125 0.000282 0.000306 0.00229 0.00195 0.00084 0.00062 0.000291 0.000241 0.00129 0.0005 0.000359 8.25E-05 0.000112 0
0.011 0.00152 0.000865 0.0611 0.0311 0.00059 0.00528 0.00102 0.0273 6.38E-05 0.000852 0.00137 0.000965 0.000186 0.000237 0.00197 0.00183 0.000747 0.000459 0.000142 0.000027 0.00122 0.000633 0.000136 0 0 0
0.0105 0.00231 0.00194 0.0614 0.0346 0.00154 0.00602 0.000855 0.0264 0.000109 0.000777 0.00146 0.00148 0.000243 0.000217 0.00183 0.00178 0.000813 0.000711 0.000205 0.000145 0.000849 0.00102 9.88E-05 0.000148 0.000176 0
0.00385 0.000655 0.000388 0.0309 0.0175 0.000321 0.00218 0.00327 0.0418 3.36E-05 0.000594 0.000576 0.000591 8.15E-05 8.94E-05 0.00122 0.00112 0.00043 0.000321 0.000111 2.86E-05 0.000527 0.000158 0.000122 0 0.000214 0
0.00322 0.000586 0.000478 0.0225 0.0143 0.000753 0.00185 0.0011 0.0412 5.15E-05 0.000579 0.000536 0.000513 8.99E-05 0.000101 0.00107 0.000929 0.0004 0.000339 0.000119 6.89E-05 0.000501 0.000178 0.000149 1.26E-05 0 0
0.00696 0.00137 0.00112 0.0414 0.0266 0.00125 0.00429 0.000927 0.0374 0.000138 0.000744 0.00115 0.000952 0.000167 0.000171 0.00152 0.00139 0.000612 0.000509 0.000215 0.000116 0.000952 0.000381 0.000209 0.000202 9.01E-05 3.61E-06
0.00774 0.00131 0.00117 0.0456 0.024 0.00201 0.00479 0.00331 0.0362 0.00018 0.000766 0.00111 0.000724 0.000139 0.000165 0.00133 0.00114 0.000414 0.000357 0.00009 0.000087 0.00104 0.000273 0.000179 7.36E-05 0 0
0.00709 0.000923 0.00065 0.0425 0.0222 0.00189 0.00397 0.00241 0.0332 0.000094 0.000774 0.00103 0.000953 0.000334 0.000198 0.00136 0.00116 0.000526 0.000444 0.000136 6.45E-05 0.000392 0.001 0.000174 0.000209 7.99E-05 0
0.00799 0.00108 0.000842 0.0421 0.0255 0.00184 0.00451 0.00249 0.0396 0.000165 0.000722 0.00104 0.000923 0.000199 0.000163 0.00116 0.00116 0.000612 0.000546 0.000188 0.000106 0.000832 0.000491 0.000196 0.000144 9.63E-05 0
0.0101 0.00135 0.00129 0.0634 0.0349 0.00278 0.00743 0.00135 0.026 0.000235 0.00106 0.00178 0.00201 0.000592 0.000307 0.00244 0.0028 0.00126 0.000853 0.000448 0.000324 0.000958 0.00124 0.000272 0.000383 0.000166 2.41E-05
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2. SVA FEATURES PLOTS FOR THE NPC1 DISEASE 
DIAGNOSIS  
 
2.1. Plot of NPC1 Disease Dataset 
 
Figure 25.  Plot showing the 1H NMR resonance intensities for the most important features 
found in human plasma i.e. (column number) 13, 14, 6, 32, 25, 24, 33, 37, 28, 27, 34 
corresponding to the chemical shift [1.21…1.31], [1.31…1.37], [0.81…0.89], [2.52…2.58], 
[2.03…2.09], [1.98…2.03], [2.68…2.74], [5.26…5.37], [2.34…2.39], [2.12…2.17], and 
[2.85…2.88] for NPC1 disease diagnosis. They correspond to the following potential 
biomarkers (R)-3-hydroxybutyrate; L-fucose; lactate; 3-hydroxyisovalerate, hexacosanoate, L-
isoleucine, 2-hydroxyglutarate, Citrate, α-glucose, allantoate, pyruvate, methionine, glutamine, 
glutamate, and trimethylamine. 
 
Full Boxplot of NPC1 Disease Dataset 
 
Figure 26. Full Boxplot showing the most important features found in human blood plasma 
(column number) 13, 14, 6, 32, 25, 24, 33, 37, 28, 27, and 34 corresponding to the chemical 
shift [1.21…1.31], [1.31…1.37], [0.81…0.89], [2.52…2.58], [2.03…2.09], [1.98…2.03], 




































Plasma Full Boxplot & Main Features











[2.68…2.74], [5.26…5.37], [2.34…2.39], [2.12…2.17], and [2.85…2.88] for NPC1 disease 
diagnosis. They correspond to the following potential biomarkers (R)-3-hydroxybutyrate; L-
fucose; lactate; 3-hydroxyisovalerate, hexacosanoate, L-isoleucine, 2-hydroxyglutarate, 
Citrate, α-glucose, allantoate, pyruvate, methionine, glutamine, glutamate, and trimethylamine. 
 
2.2. Zoomed Plasma Boxplot of NPC1 Disease Dataset 
 
 
Figure 27. Blood plasma boxplot for important features in the intervals 1-25, showing the 
significance of features 13, 14 and 6 corresponding to chemical buckets [1.21…1.31], 
[1.31…1.37], and [0.81…0.89] for NPC1 disease diagnosis. They correspond to the following 
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Figure 28. Plasma Filled Contour Plot showing brighter colours for the features 13, 14, 6, 32, 
25, 24, 33, 37, 28, 27, 34, corresponding to chemical shift [1.21…1.31], [1.31…1.37], 
[0.81…0.89], [2.52…2.58], [2.03…2.09], [1.98…2.03], [2.68…2.74], [5.26…5.37], 
[2.34…2.39], [2.12…2.17], and [2.85…2.88] which are considered as potential biomarkers for 
NPC1 disease diagnosis. They correspond to the following potential biomarkers (R)-3-
hydroxybutyrate; L-fucose; lactate; 3-hydroxyisovalerate, hexacosanoate, L-isoleucine, 2-
hydroxyglutarate, Citrate, α-glucose, allantoate, pyruvate, methionine, glutamine, glutamate, 
and trimethylamine. 
 
2.4. Contour Plot of NPC1 Disease Dataset 
 
Figure 29. Contour Plot showing brighter colours for the main features (13, 14, 6, 7, 32, 33, 
25), corresponding to the chemical shifts [1.21…1.31], [1.31…1.37], [0.81…0.89], 
[0.89…0.95], [2.52…2.58], [2.68…2.74], and [2.03…2.09], which are potential biomarkers 
for NPC1 disease diagnosis. They correspond to (R)-3-hydroxybutyrate; L-fucose; lactate; 3-
hydroxyisovalerate, hexacosanoate, L-isoleucine, Citrate, etc., considered as main biomarkers, 
according to the present technique.  
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3. SVA FEATURES PLOTS FOR THE NPC LIVER 
DYSFUNCTION DISEASE (NPC LDD) DIAGNOSIS  
 
3.1. Chemical shifts/buckets of biomolecules related to NPC LDD dataset    
 
Chemical Shift Molecules Name 
[0.86 .. 0.92] (2R)-2amino-4-methylpentanoic acid 
[0.92 .. 0.94] (2R)-2amino-4-methylpentanoic acid 
[0.94 .. 0.99] Leucine-CH3   -   Isoleucine 
[1.30 .. 1.36] Lactate 
[1.45 .. 1.51] Alanine 
[1.67 .. 1.70] Unidentified 
[1.70 .. 1.74] Lysine-C5-CH2 
[1.74 .. 1.79] Unidentified 
[1.89 .. 1.95] Acetate   -   Gamma-Aminobutyric acid  
[1.95 .. 1.97] 2-Hydroxy-3-methylbutyric acid 
[1.97 .. 1.99] 4-Acetamidobutanoic acid 
[1.99 .. 2.01] Methylglutaric acid 
[2.01 .. 2.04] N-Acetyl-Laspartic acid  
[2.09 .. 2.12] Glutamic acid   -  N-Acetylaspartylglutamate  
[2.12 .. 2.17] Glutamic acid – Glutamine 
[2.17 .. 2.23] Glutamic acid – Glutamine 
[2.23 .. 2.26] Unidentified 
[2.26 .. 2.32] Gamma-Aminobutyric acid  
[2.32 .. 2.37] Pyruvate-CH3  and Glutamate-C3-CH2 
[2.37 .. 2.42] Glutamate-C3-CH2 - Succinate-CH2's 
[2.42 .. 2.47] Glutamine 
[2.47 .. 2.49] Unidentified 
[2.62 .. 2.67] Methionine  -  Hypotaurine 
[2.67 .. 2.72] Citrate-CH2A / CH2B 
[2.72 .. 2.77] Citrate 
[2.79 .. 2.81] Aspartate 
[2.81 .. 2.87] Aspartate 
[2.92 .. 2.97] 6-Methyladenine 
[2.97 .. 2.99] Gamma-Aminobutyric acid 
[2.99 .. 3.05] Lysine - Ornithine  
[3.05 .. 3.11] Ornithine-CS  
[3.11 .. 3.15] Glucuronate- C2-CH 
[3.15 .. 3.17] 9-Methyluric acid 
[3.17 .. 3.19] Unidentified 
[3.19 .. 3.21] Choline 
[3.21 .. 3.26] Phosphocholine  - Gamma-phophorylcholine 
[3.26 .. 3.31] Taurine  -  Myo-Inositol 
[3.31 .. 3.35] Cystine-C3/C6-CH2 




[3.44 .. 3.50] Unidentified 
[3.50 .. 3.54] Glycine 
[3.54 .. 3.57] Myo-Inositol 
[3.57 .. 3.62] Myo-Inositol 
[3.62 .. 3.66] Myo-Inositol 
[3.71 .. 3.77] Glutamic acid – Glutamine 
[3.77 .. 3.81] Glutamic acid – Glutamine 
[3.81 .. 3.87] Unidentified 
[3.87 .. 3.93] Glycerophosphocholine  
[3.93 .. 3.95] Creatine 
[4.05 .. 4.10] Myo-inositol 
[4.10 .. 4.16] Lactate 
[4.16 .. 4.21] Phosphorocholine 
[4.21 .. 4.24] Unidentified 
[4.35 .. 4.41] N-Acetyl-L-aspartic acid  
[5.88 .. 5.93] Uridine 
[6.09 .. 6.14] Inosine acid 
[6.49 .. 6.53] Fumarate 
[6.78 .. 6.81] Tyrosine   
[6.81 .. 6.84] p-Aminobenzoic acid  
[6.84 .. 6.86] 4-Hydroxybenzoic acid 
[6.86 .. 6.88] p-Hydroxyphenylacetic acid 
[7.07 .. 7.12] Tyrosine   
[7.17 .. 7.23] Tyrosine   
[7.30 .. 7.35] Phenylalanine 
[7.47 .. 7.52] Phenylalanine 
[7.65 .. 7.70] Nicotinate 
[7.70 .. 7.72] Nicotinate – Xanthine 
[7.72 .. 7.78] Hippurate-C4-CH 
[7.85 .. 7.91] Uridine 
[7.99 .. 8.01] Uridine 
[8.23 .. 8.29] Hypoxanthine 
[8.29 .. 8.31] Inosine 
[8.69 .. 8.74] Nicotinamide adenine dinucleotide  
[8.92 .. 8.97] Nicotinate  
 
Table 52. Chemical buckets and name of the metabolites detected and relative to the NPC liver 









Observations/variables table: Workbook = Liver_Original.xlsm / Sheet = Liver.1 / Range = Liver.1!$A$1:$EM$66 / 65 rows and 143 columns
Cluster rows
Clustering criterion: Determinant(W)
Stop conditions: Iterations = 500 / Convergence = 0.00001





Seed (random numbers): 4444044
Run again:
Summary statistics:
Variable Observations Obs. with missing dataObs. without missing data Minimum Maximum Mean Std. deviation
[0.77 .. 0.80] 65 0 65 0.000 0.027 0.004 0.004
[0.80 .. 0.82] 65 0 65 0.000 0.035 0.005 0.006
[0.82 .. 0.84] 65 0 65 0.001 0.040 0.007 0.007
[0.84 .. 0.86] 65 0 65 0.002 0.043 0.009 0.008
[0.86 .. 0.92] 65 0 65 0.013 0.097 0.038 0.016
[0.92 .. 0.94] 65 0 65 0.006 0.034 0.015 0.005
[0.94 .. 0.99] 65 0 65 0.025 0.178 0.073 0.031
[0.99 .. 1.05] 65 0 65 0.010 0.096 0.035 0.019
[1.05 .. 1.08] 65 0 65 0.003 0.038 0.013 0.006
[1.13 .. 1.15] 65 0 65 0.001 0.049 0.006 0.008
[1.15 .. 1.17] 65 0 65 0.001 0.050 0.006 0.009
[1.17 .. 1.19] 65 0 65 0.002 0.025 0.007 0.004
[1.19 .. 1.22] 65 0 65 0.004 0.034 0.012 0.006
[1.22 .. 1.24] 65 0 65 0.003 0.021 0.008 0.004
[1.24 .. 1.26] 65 0 65 0.004 0.026 0.010 0.005
[1.26 .. 1.30] 65 0 65 0.011 0.074 0.024 0.012
[1.30 .. 1.36] 65 0 65 0.039 0.254 0.117 0.043
[1.45 .. 1.51] 65 0 65 0.022 0.181 0.068 0.028
[1.67 .. 1.70] 65 0 65 0.004 0.029 0.011 0.005
[1.70 .. 1.74] 65 0 65 0.011 0.074 0.029 0.012
[1.74 .. 1.79] 65 0 65 0.005 0.047 0.016 0.007
[1.89 .. 1.95] 65 0 65 0.009 0.074 0.029 0.013
[1.95 .. 1.97] 65 0 65 0.002 0.022 0.007 0.003
[1.97 .. 1.99] 65 0 65 0.002 0.020 0.006 0.003
[1.99 .. 2.01] 65 0 65 0.003 0.027 0.010 0.005
[2.01 .. 2.04] 65 0 65 0.004 0.033 0.012 0.006
[2.09 .. 2.12] 65 0 65 0.005 0.099 0.016 0.014
[2.12 .. 2.17] 65 0 65 0.014 0.084 0.039 0.016
[2.17 .. 2.23] 65 0 65 0.007 0.055 0.022 0.010
[2.23 .. 2.26] 65 0 65 0.001 0.061 0.009 0.009
[2.26 .. 2.32] 65 0 65 0.003 0.039 0.014 0.007
[2.32 .. 2.37] 65 0 65 0.004 0.059 0.023 0.012
[2.37 .. 2.42] 65 0 65 0.002 0.031 0.010 0.006
[2.42 .. 2.47] 65 0 65 0.001 0.028 0.008 0.005
[2.47 .. 2.49] 65 0 65 0.000 0.008 0.002 0.002
[2.51 .. 2.53] 65 0 65 0.000 0.008 0.002 0.002
[2.53 .. 2.59] 65 0 65 0.003 0.046 0.017 0.010
[2.59 .. 2.62] 65 0 65 0.000 0.012 0.001 0.002
[2.62 .. 2.67] 65 0 65 0.000 0.023 0.008 0.006
[2.67 .. 2.72] 65 0 65 0.000 0.016 0.004 0.004
[2.72 .. 2.77] 65 0 65 0.000 0.013 0.002 0.003
[2.79 .. 2.81] 65 0 65 0.000 0.012 0.003 0.003
[2.81 .. 2.87] 65 0 65 0.000 0.015 0.004 0.004
[2.87 .. 2.90] 65 0 65 0.000 0.006 0.001 0.001
[2.90 .. 2.92] 65 0 65 0.000 0.005 0.001 0.001
[2.92 .. 2.97] 65 0 65 0.000 0.035 0.008 0.007
[2.97 .. 2.99] 65 0 65 0.000 0.019 0.006 0.004
[2.99 .. 3.05] 65 0 65 0.007 0.063 0.025 0.012
[3.05 .. 3.11] 65 0 65 0.000 0.028 0.008 0.007
[3.11 .. 3.15] 65 0 65 0.000 0.017 0.004 0.004
[3.15 .. 3.17] 65 0 65 0.000 0.008 0.002 0.002
[3.17 .. 3.19] 65 0 65 0.000 0.011 0.003 0.003
[3.19 .. 3.21] 65 0 65 0.004 0.053 0.016 0.008
[3.21 .. 3.26] 65 0 65 0.038 0.202 0.105 0.038
[3.26 .. 3.31] 65 0 65 0.035 0.227 0.122 0.046
[3.31 .. 3.35] 65 0 65 0.000 0.015 0.006 0.004
[3.35 .. 3.37] 65 0 65 0.002 0.051 0.017 0.017
[3.37 .. 3.39] 65 0 65 0.004 0.030 0.013 0.006
[3.39 .. 3.44] 65 0 65 0.050 0.369 0.174 0.070
[3.44 .. 3.50] 65 0 65 0.045 0.355 0.162 0.067
[3.50 .. 3.54] 65 0 65 0.013 0.087 0.040 0.016
[3.54 .. 3.57] 65 0 65 0.019 0.133 0.064 0.024
[3.57 .. 3.62] 65 0 65 0.011 0.197 0.086 0.046
[3.62 .. 3.66] 65 0 65 0.008 0.157 0.069 0.039
[3.66 .. 3.69] 65 0 65 0.007 0.098 0.045 0.023
[3.69 .. 3.71] 65 0 65 0.012 0.119 0.058 0.025







Table 53. Statistics Related to the NPC LDD, with the values of the means and standard 





[3.77 .. 3.81] 65 0 65 0.035 0.354 0.156 0.064
[3.81 .. 3.87] 65 0 65 0.084 0.432 0.214 0.091
[3.87 .. 3.93] 65 0 65 0.040 0.312 0.159 0.061
[3.93 .. 3.95] 65 0 65 0.005 0.072 0.037 0.017
[3.95 .. 3.99] 65 0 65 0.010 0.135 0.062 0.030
[3.99 .. 4.05] 65 0 65 0.008 0.064 0.033 0.013
[4.05 .. 4.10] 65 0 65 0.006 0.028 0.014 0.005
[4.10 .. 4.16] 65 0 65 0.012 0.063 0.031 0.010
[4.16 .. 4.21] 65 0 65 0.003 0.025 0.011 0.004
[4.21 .. 4.24] 65 0 65 0.001 0.012 0.005 0.002
[4.24 .. 4.27] 65 0 65 0.002 0.015 0.006 0.002
[4.27 .. 4.30] 65 0 65 0.003 0.020 0.008 0.003
[4.30 .. 4.35] 65 0 65 0.002 0.018 0.008 0.003
[4.35 .. 4.41] 65 0 65 0.001 0.016 0.005 0.003
[4.41 .. 4.47] 65 0 65 0.001 0.020 0.006 0.003
[4.47 .. 4.53] 65 0 65 0.000 0.011 0.002 0.003
[4.55 .. 4.61] 65 0 65 0.000 0.019 0.003 0.004
[4.61 .. 4.63] 65 0 65 0.000 0.007 0.001 0.001
[4.63 .. 4.69] 65 0 65 0.012 0.078 0.034 0.016
[4.89 .. 4.95] 65 0 65 0.000 0.073 0.002 0.009
[5.17 .. 5.20] 65 0 65 0.000 0.006 0.002 0.001
[5.20 .. 5.22] 65 0 65 0.000 0.003 0.000 0.000
[5.22 .. 5.28] 65 0 65 0.008 0.101 0.047 0.020
[5.38 .. 5.44] 65 0 65 0.000 0.133 0.044 0.035
[5.88 .. 5.93] 65 0 65 0.000 0.004 0.001 0.001
[6.09 .. 6.14] 65 0 65 0.000 0.003 0.000 0.000
[6.49 .. 6.53] 65 0 65 0.000 0.001 0.000 0.000
[6.78 .. 6.81] 65 0 65 0.000 0.003 0.001 0.001
[6.81 .. 6.84] 65 0 65 0.000 0.002 0.000 0.000
[6.84 .. 6.86] 65 0 65 0.000 0.001 0.000 0.000
[6.86 .. 6.88] 65 0 65 0.000 0.003 0.000 0.000
[6.88 .. 6.93] 65 0 65 0.001 0.076 0.005 0.009
[7.04 .. 7.07] 65 0 65 0.000 0.030 0.001 0.004
[7.07 .. 7.12] 65 0 65 0.000 0.031 0.004 0.006
[7.12 .. 7.15] 65 0 65 0.000 0.004 0.001 0.001
[7.15 .. 7.17] 65 0 65 0.000 0.006 0.001 0.001
[7.17 .. 7.23] 65 0 65 0.003 0.016 0.007 0.003
[7.23 .. 7.28] 65 0 65 0.001 0.075 0.003 0.009
[7.28 .. 7.30] 65 0 65 0.000 0.004 0.001 0.001
[7.30 .. 7.35] 65 0 65 0.002 0.030 0.007 0.004
[7.35 .. 7.41] 65 0 65 0.002 0.185 0.007 0.023
[7.41 .. 7.47] 65 0 65 0.002 0.055 0.009 0.010
[7.47 .. 7.52] 65 0 65 0.000 0.052 0.002 0.007
[7.52 .. 7.58] 65 0 65 0.000 0.081 0.004 0.010
[7.58 .. 7.62] 65 0 65 0.001 0.016 0.003 0.002
[7.62 .. 7.65] 65 0 65 0.000 0.019 0.001 0.002
[7.65 .. 7.70] 65 0 65 0.000 0.027 0.001 0.003
[7.70 .. 7.72] 65 0 65 0.000 0.007 0.001 0.001
[7.72 .. 7.78] 65 0 65 0.000 0.031 0.002 0.004
[7.78 .. 7.83] 65 0 65 0.000 0.007 0.001 0.002
[7.83 .. 7.85] 65 0 65 0.000 0.003 0.001 0.001
[7.85 .. 7.91] 65 0 65 0.001 0.045 0.006 0.005
[7.91 .. 7.94] 65 0 65 0.000 0.039 0.001 0.005
[7.94 .. 7.99] 65 0 65 0.001 0.010 0.004 0.002
[7.99 .. 8.01] 65 0 65 0.000 0.002 0.001 0.000
[8.01 .. 8.04] 65 0 65 0.000 0.002 0.001 0.000
[8.04 .. 8.08] 65 0 65 0.000 0.006 0.002 0.001
[8.08 .. 8.12] 65 0 65 0.000 0.012 0.001 0.001
[8.12 .. 8.15] 65 0 65 0.000 0.014 0.001 0.002
[8.15 .. 8.17] 65 0 65 0.000 0.003 0.001 0.001
[8.17 .. 8.23] 65 0 65 0.002 0.017 0.008 0.003
[8.23 .. 8.29] 65 0 65 0.002 0.019 0.006 0.002
[8.29 .. 8.31] 65 0 65 0.000 0.002 0.001 0.000
[8.31 .. 8.33] 65 0 65 0.000 0.002 0.001 0.000
[8.33 .. 8.36] 65 0 65 0.001 0.012 0.002 0.002
[8.36 .. 8.39] 65 0 65 0.000 0.005 0.001 0.001
[8.39 .. 8.44] 65 0 65 0.000 0.078 0.003 0.010
[8.44 .. 8.47] 65 0 65 0.000 0.007 0.001 0.001
[8.47 .. 8.53] 65 0 65 0.001 0.084 0.003 0.011
[8.69 .. 8.74] 65 0 65 0.001 0.026 0.003 0.003
[8.74 .. 8.77] 65 0 65 0.000 0.003 0.001 0.000
[8.77 .. 8.80] 65 0 65 0.000 0.002 0.001 0.000
[8.80 .. 8.86] 65 0 65 0.000 0.005 0.001 0.001
[8.86 .. 8.90] 65 0 65 0.000 0.003 0.001 0.001
[8.90 .. 8.92] 65 0 65 0.000 0.002 0.001 0.000








Samp+RC:R[5]C[17]leTime Genotype [0.77 .. 0.80] [0.80 .. 0.82] [0.82 .. 0.84] [0.84 .. 0.86] [0.86 .. 0.92] [0.92 .. 0.94] [0.94 .. 0.99] [0.99 .. 1.05] [1.05 .. 1.08] [1.13 .. 1.15] [1.15 .. 1.17] [1.17 .. 1.19] [1.19 .. 1.22] [1.22 .. 1.24] [1.24 .. 1.26] [1.26 .. 1.30] [1.30 .. 1.36] [1.45 .. 1.51] [1.67 .. 1.70] [1.70 .. 1.74] [1.74 .. 1.79] [1.89 .. 1.95] [1.95 .. 1.97] [1.97 .. 1.99] [1.99 .. 2.01] [2.01 .. 2.04] [2.09 .. 2.12] 
1 9 WT/HET 0.0017 0.0015 0.0026 0.0038 0.0195 0.0071 0.0288 0.0111 0.0044 0.0017 0.002 0.0033 0.0061 0.0044 0.0054 0.0129 0.0658 0.0334 0.005 0.0116 0.0071 0.0121 0.0038 0.003 0.0047 0.0059 0.0062
2 9 WT/HET 0.0014 0.002 0.0032 0.005 0.0344 0.0115 0.044 0.0157 0.0057 0.0013 0.0021 0.0034 0.0087 0.0059 0.0075 0.019 0.094 0.0469 0.0055 0.0142 0.0066 0.0163 0.0037 0.0036 0.0058 0.0079 0.0097
3 9 NPC 0.0017 0.0021 0.0032 0.005 0.0303 0.0131 0.0739 0.029 0.0098 0.0019 0.0027 0.0043 0.0091 0.0062 0.007 0.0184 0.1281 0.0735 0.0096 0.0272 0.0133 0.0281 0.0062 0.005 0.0085 0.0112 0.0144
4 9 NPC 0.001 0.0012 0.0024 0.0046 0.0283 0.0085 0.0349 0.0113 0.0033 0.0008 0.0013 0.0022 0.0062 0.0046 0.0067 0.0166 0.0782 0.0334 0.0036 0.0105 0.0049 0.0102 0.003 0.0026 0.0038 0.0063 0.0065
5 11 WT/HET 0.0017 0.0015 0.0025 0.0039 0.0173 0.0073 0.0315 0.0134 0.0055 0.0019 0.002 0.0031 0.006 0.0039 0.0044 0.0114 0.0531 0.0284 0.0059 0.0148 0.008 0.0147 0.0033 0.0028 0.004 0.0046 0.0051
6 11 WT/HET 0.0035 0.0037 0.0047 0.0058 0.0283 0.0109 0.045 0.0194 0.0076 0.0028 0.003 0.0043 0.0079 0.0053 0.0063 0.0163 0.1031 0.0463 0.0077 0.0186 0.0103 0.0207 0.0044 0.004 0.0058 0.007 0.008
7 11 NPC 0.0058 0.0057 0.0073 0.0099 0.0485 0.0198 0.0991 0.0453 0.0186 0.0056 0.0065 0.0094 0.0174 0.0118 0.0128 0.0296 0.1374 0.0946 0.0168 0.0433 0.0243 0.0471 0.0106 0.0094 0.014 0.0171 0.0187
8 11 NPC 0.007 0.0059 0.0076 0.0094 0.0448 0.0186 0.0924 0.0402 0.0168 0.0054 0.0061 0.0083 0.0157 0.0099 0.0104 0.0205 0.1366 0.1018 0.0172 0.0408 0.0252 0.0403 0.0122 0.0114 0.0158 0.019 0.0226
9 11 WT/HET 0.0026 0.0023 0.0033 0.0046 0.0285 0.0106 0.0477 0.019 0.0072 0.0025 0.0028 0.0043 0.0081 0.0056 0.0072 0.0206 0.103 0.0513 0.0074 0.0183 0.0098 0.0191 0.0045 0.0037 0.0062 0.008 0.009
10 9 WT/HET 0.0019 0.0021 0.0028 0.0049 0.0299 0.0098 0.0404 0.015 0.0058 0.002 0.0024 0.0034 0.0075 0.0057 0.0073 0.0186 0.0664 0.0335 0.0058 0.0141 0.0079 0.0148 0.0043 0.0035 0.0054 0.0068 0.0061
11 9 WT/HET 0.0025 0.0024 0.0034 0.005 0.0292 0.0097 0.0368 0.0148 0.0062 0.0025 0.0032 0.0044 0.0084 0.0062 0.0081 0.0232 0.1065 0.0339 0.0066 0.0142 0.0086 0.0147 0.0038 0.0038 0.0061 0.0081 0.0072
12 9 WT/HET 0.0041 0.0043 0.0057 0.0072 0.0405 0.0154 0.0638 0.0245 0.0092 0.003 0.0035 0.0052 0.011 0.0075 0.0084 0.0196 0.1625 0.0796 0.0101 0.0249 0.0141 0.0272 0.0072 0.0066 0.0095 0.0125 0.0138
13 9 WT/HET 0.0054 0.0051 0.0061 0.0067 0.0328 0.0137 0.0638 0.0286 0.0117 0.0043 0.0047 0.0066 0.0113 0.0068 0.007 0.017 0.1597 0.0796 0.0115 0.027 0.0167 0.0331 0.0067 0.0056 0.0088 0.0109 0.0133
14 9 WT/HET 0.0038 0.0035 0.0047 0.0054 0.0272 0.0118 0.0606 0.0252 0.0098 0.0025 0.003 0.0045 0.009 0.0051 0.0056 0.0135 0.1109 0.0679 0.0095 0.0252 0.0139 0.028 0.0059 0.0048 0.0076 0.0096 0.0118
15 11 NPC 0.0002 0.0004 0.0011 0.0024 0.0166 0.0069 0.0301 0.0104 0.003 0.0006 0.0005 0.0015 0.0043 0.0033 0.0048 0.0125 0.0455 0.0216 0.0038 0.0106 0.0052 0.0088 0.0018 0.0019 0.0031 0.0051 0.0087
16 11 NPC 0.0025 0.003 0.0044 0.006 0.0385 0.0152 0.0989 0.0439 0.016 0.003 0.0037 0.0058 0.0116 0.0085 0.0105 0.0264 0.1116 0.0728 0.0115 0.0361 0.0185 0.034 0.0085 0.0069 0.0105 0.0132 0.0141
17 11 NPC 0.0175 0.0348 0.037 0.0427 0.0602 0.0141 0.0678 0.0928 0.0116 0.0357 0.037 0.0152 0.0181 0.0099 0.0087 0.017 0.1142 0.0798 0.0104 0.0269 0.0162 0.0282 0.0094 0.0099 0.0174 0.0236 0.0298
18 11 NPC 0.0062 0.01 0.012 0.0155 0.0457 0.0156 0.0982 0.0578 0.0155 0.0166 0.0174 0.0086 0.0145 0.0098 0.0124 0.0342 0.1324 0.0831 0.0123 0.0361 0.0176 0.0375 0.0089 0.0084 0.0144 0.0186 0.0223
19 11 NPC 0.0061 0.0113 0.0127 0.0163 0.0443 0.0152 0.0986 0.0599 0.0146 0.0101 0.0109 0.0081 0.0126 0.0083 0.0101 0.0257 0.0995 0.0741 0.0094 0.0315 0.0121 0.0604 0.0037 0.0025 0.0047 0.0103 0.0989
21 3 WT/HET 0.0061 0.0053 0.0068 0.0089 0.0445 0.0197 0.0723 0.0333 0.0157 0.0063 0.0063 0.0088 0.0159 0.0109 0.0125 0.028 0.1111 0.0629 0.0178 0.0324 0.0248 0.0315 0.0079 0.0075 0.0118 0.015 0.0141
22 3 WT/HET 0.0025 0.0027 0.0038 0.0053 0.036 0.0112 0.0435 0.0168 0.0066 0.0023 0.0028 0.0043 0.0093 0.0067 0.0092 0.0237 0.0982 0.0479 0.0065 0.016 0.0089 0.0164 0.004 0.0038 0.0059 0.0089 0.0123
23 6 WT/HET 0.006 0.0054 0.0073 0.0086 0.049 0.0164 0.0601 0.0264 0.012 0.0054 0.006 0.0081 0.0168 0.0105 0.0124 0.0311 0.1033 0.0524 0.0111 0.0239 0.0159 0.025 0.0075 0.0072 0.0105 0.0137 0.0159
24 6 WT/HET 0.0055 0.0052 0.0069 0.0089 0.0457 0.0169 0.0689 0.0312 0.0143 0.0061 0.0069 0.0107 0.0207 0.0148 0.017 0.0398 0.1188 0.0589 0.0135 0.033 0.0185 0.0393 0.0079 0.0075 0.0117 0.0141 0.0144
25 9 WT/HET 0.0021 0.0023 0.003 0.0048 0.029 0.0127 0.0657 0.0276 0.0093 0.0017 0.0023 0.0034 0.0082 0.0055 0.0065 0.0186 0.0958 0.063 0.0076 0.0224 0.0107 0.0216 0.0046 0.0036 0.0062 0.0088 0.0109
26 9 WT/HET 0.0058 0.0057 0.0073 0.0086 0.0406 0.0158 0.0661 0.0316 0.0143 0.0057 0.0065 0.009 0.0169 0.0106 0.0112 0.0248 0.1111 0.0562 0.0136 0.034 0.0193 0.0364 0.0074 0.0067 0.0093 0.0113 0.012
27 9 WT/HET 0.0034 0.0035 0.0047 0.0062 0.0339 0.0125 0.0576 0.0249 0.01 0.0033 0.0041 0.0059 0.0124 0.0084 0.0095 0.0238 0.1071 0.0515 0.0099 0.0267 0.0142 0.0256 0.0055 0.0047 0.0072 0.0085 0.0094
28 9 WT/HET 0.003 0.0032 0.0042 0.0054 0.0294 0.0115 0.0534 0.0226 0.0088 0.0027 0.003 0.0049 0.0106 0.0065 0.0071 0.0175 0.0762 0.0508 0.009 0.0233 0.0122 0.0243 0.0049 0.0042 0.0069 0.0093 0.0118
29 9 NPC 0.0056 0.0053 0.0072 0.0109 0.0574 0.0227 0.1217 0.0533 0.0206 0.0058 0.0067 0.0101 0.0209 0.0139 0.0159 0.0384 0.1275 0.0885 0.0206 0.0556 0.0304 0.0529 0.013 0.0114 0.0177 0.0213 0.0237
30 11 NPC 0.0023 0.0026 0.0045 0.0069 0.0443 0.0156 0.0825 0.0326 0.0119 0.0027 0.0033 0.0048 0.0116 0.0088 0.0111 0.0273 0.0962 0.0583 0.0107 0.0306 0.0163 0.0275 0.0087 0.0076 0.0112 0.0149 0.0167
31 11 NPC 0.0008 0.0012 0.0025 0.0049 0.038 0.0159 0.1002 0.0402 0.0133 0.0013 0.0018 0.0037 0.0088 0.0064 0.0077 0.0191 0.0923 0.0645 0.0109 0.0345 0.0156 0.0276 0.0071 0.0061 0.0099 0.0127 0.0146
32 11 WT/HET 0.0016 0.0017 0.0028 0.0047 0.0358 0.0105 0.0462 0.0178 0.0067 0.0023 0.003 0.0044 0.0097 0.0071 0.0102 0.0311 0.1247 0.0713 0.0068 0.0163 0.0091 0.017 0.0033 0.0034 0.0062 0.0091 0.0091
33 3 WT/HET 0.0018 0.0019 0.0031 0.0051 0.0297 0.0125 0.0661 0.0255 0.0089 0.0017 0.0021 0.0037 0.0086 0.0058 0.0065 0.0156 0.0777 0.0573 0.008 0.0247 0.0112 0.0231 0.0049 0.0038 0.0065 0.0094 0.012
34 3 NPC 0.001 0.0012 0.0021 0.0047 0.0287 0.0097 0.047 0.0154 0.0047 0.0009 0.0016 0.0033 0.0078 0.0057 0.0078 0.0171 0.0774 0.0449 0.0051 0.0158 0.0071 0.0181 0.0039 0.0033 0.0053 0.0081 0.0154
35 6 NPC 0.001 0.0015 0.0024 0.0038 0.0204 0.008 0.0361 0.0144 0.0056 0.0019 0.0027 0.0037 0.0085 0.005 0.0058 0.0134 0.0794 0.0458 0.0071 0.0167 0.0098 0.0155 0.0036 0.003 0.0048 0.0065 0.0081
37 6 WT/HET 0.0034 0.0038 0.0049 0.0061 0.033 0.0139 0.0598 0.0245 0.0096 0.0028 0.0034 0.0047 0.0098 0.0067 0.0078 0.022 0.1009 0.0511 0.0097 0.0215 0.0124 0.021 0.0047 0.0041 0.0069 0.0088 0.0095
38 9 NPC 0.004 0.0046 0.0062 0.008 0.0478 0.0194 0.1154 0.0498 0.0185 0.0044 0.005 0.007 0.0131 0.0094 0.0113 0.0289 0.1805 0.0917 0.0161 0.0447 0.0235 0.0395 0.0109 0.0091 0.014 0.0173 0.0202
39 9 NPC 0.0025 0.0025 0.0036 0.0052 0.0271 0.0124 0.0698 0.027 0.0093 0.0015 0.0021 0.0029 0.0068 0.005 0.0057 0.0145 0.0752 0.0505 0.0089 0.0253 0.0125 0.0216 0.0052 0.0044 0.0067 0.0082 0.0091
40 9 WT/HET 0.0048 0.005 0.0063 0.0075 0.0417 0.0142 0.0513 0.0221 0.009 0.0039 0.0044 0.0065 0.0119 0.0089 0.0113 0.0323 0.1355 0.0546 0.0088 0.0194 0.0118 0.0212 0.0052 0.0046 0.0074 0.0094 0.0101
41 9 WT/HET 0.0017 0.0018 0.002 0.0027 0.0131 0.0057 0.0252 0.0236 0.0269 0.0041 0.0032 0.0034 0.0051 0.0036 0.004 0.0106 0.039 0.1805 0.0086 0.021 0.0234 0.0115 0.0029 0.002 0.0029 0.0039 0.0055
42 9 WT/HET 0.0265 0.0348 0.0396 0.0432 0.0919 0.0273 0.0905 0.0818 0.0214 0.0486 0.0501 0.0247 0.0337 0.0201 0.0209 0.0419 0.2157 0.1102 0.019 0.0362 0.0251 0.0439 0.0122 0.0128 0.0205 0.0243 0.0306
43 9 WT/HET 0.0087 0.0136 0.0153 0.0173 0.0441 0.0155 0.069 0.0477 0.0119 0.0087 0.0098 0.0097 0.0153 0.0093 0.0098 0.0238 0.1556 0.0783 0.0098 0.0239 0.0118 0.0482 0.005 0.0048 0.01 0.015 0.0641
44 6 WT/HET 0.0074 0.0112 0.0131 0.0155 0.0421 0.0128 0.0458 0.0343 0.0099 0.0171 0.0182 0.0104 0.0183 0.0108 0.0116 0.0262 0.0932 0.0398 0.0115 0.0285 0.0144 0.0331 0.0051 0.0051 0.008 0.0104 0.0096
45 6 WT/HET 0.0038 0.0042 0.0053 0.006 0.0285 0.0138 0.0648 0.0281 0.0103 0.003 0.0031 0.0046 0.0084 0.0056 0.006 0.0147 0.1001 0.0565 0.0104 0.0246 0.0148 0.0237 0.0055 0.0047 0.0078 0.0098 0.0112
46 3 WT/HET 0.0065 0.0064 0.0079 0.0088 0.0395 0.0173 0.0829 0.0361 0.0145 0.0045 0.0052 0.0072 0.0133 0.0091 0.0103 0.0228 0.1536 0.0813 0.0135 0.0326 0.0191 0.0365 0.0079 0.0071 0.011 0.014 0.0175
47 3 WT/HET 0.0043 0.0049 0.0062 0.0069 0.035 0.0148 0.0777 0.0322 0.0118 0.0029 0.0033 0.0049 0.0099 0.0068 0.0078 0.0167 0.1717 0.0744 0.0105 0.0286 0.0145 0.0335 0.0061 0.0048 0.0082 0.0109 0.0134
48 6 WT/HET 0.0034 0.0035 0.0047 0.0057 0.029 0.0107 0.0477 0.0216 0.009 0.0029 0.0037 0.0055 0.0101 0.0069 0.0086 0.0228 0.0883 0.0424 0.0075 0.0178 0.0099 0.0206 0.0044 0.0043 0.0065 0.0081 0.0094
49 6 WT/HET 0.0038 0.004 0.0052 0.0062 0.0317 0.0132 0.0631 0.0266 0.0101 0.0028 0.0034 0.005 0.0093 0.0055 0.0065 0.017 0.157 0.0643 0.0088 0.0225 0.012 0.0235 0.0049 0.0045 0.0071 0.0093 0.0107
50 9 NPC 0.0033 0.0035 0.0049 0.007 0.0384 0.0194 0.1328 0.0572 0.02 0.0034 0.0039 0.006 0.0116 0.0083 0.0096 0.02 0.1018 0.0882 0.0169 0.0496 0.0252 0.0416 0.0112 0.0094 0.0151 0.0182 0.0214
51 9 NPC 0.0008 0.0012 0.0023 0.0038 0.0234 0.0103 0.0719 0.0305 0.0103 0.001 0.0015 0.0032 0.0069 0.0047 0.0059 0.0155 0.0835 0.0589 0.0081 0.0259 0.0121 0.023 0.005 0.0042 0.0073 0.0096 0.0113
52 11 NPC 0.0011 0.0014 0.0022 0.0034 0.0229 0.01 0.0717 0.0305 0.0098 0.0011 0.0014 0.0031 0.0068 0.005 0.0062 0.014 0.0819 0.0514 0.0074 0.0251 0.0119 0.0211 0.0048 0.004 0.0068 0.0093 0.0116
53 11 NPC 0.0027 0.0033 0.0047 0.0065 0.0361 0.0144 0.0851 0.0385 0.0144 0.0038 0.0046 0.0068 0.0154 0.0148 0.0171 0.0343 0.1214 0.0711 0.0111 0.0318 0.0167 0.0278 0.0077 0.0065 0.0108 0.0136 0.0177
54 11 NPC 0.0027 0.0032 0.0042 0.0061 0.0363 0.0169 0.1154 0.0505 0.0173 0.0027 0.0034 0.0053 0.0105 0.0079 0.0096 0.0218 0.1116 0.0883 0.0149 0.0437 0.0216 0.0363 0.0094 0.0084 0.0133 0.0164 0.0185
55 3 NPC 0.0126 0.0212 0.024 0.0298 0.0523 0.0188 0.1283 0.0956 0.0224 0.0339 0.0356 0.0135 0.0198 0.0117 0.0113 0.0207 0.134 0.1001 0.0158 0.0479 0.0251 0.0451 0.012 0.0109 0.0185 0.0218 0.0272
56 3 WT/HET 0.0168 0.0161 0.0199 0.0214 0.0969 0.034 0.1779 0.089 0.038 0.0134 0.014 0.0195 0.0314 0.0211 0.0252 0.0585 0.2094 0.1398 0.0289 0.0741 0.0473 0.0735 0.0219 0.0198 0.027 0.0326 0.0354
57 6 WT/HET 0.0078 0.0077 0.0102 0.0115 0.0603 0.0224 0.1067 0.0495 0.0205 0.0072 0.0081 0.0109 0.0205 0.0137 0.0165 0.0419 0.1963 0.1001 0.0165 0.0413 0.0241 0.042 0.0108 0.0095 0.0152 0.0195 0.0237
58 9 WT/HET 0.0044 0.0046 0.0062 0.0069 0.0365 0.0147 0.076 0.0338 0.0133 0.0036 0.0041 0.0057 0.011 0.0073 0.0085 0.0209 0.123 0.0672 0.0105 0.0281 0.0152 0.0302 0.0064 0.0056 0.0094 0.0123 0.0154
59 9 WT/HET 0.0036 0.0041 0.0061 0.0087 0.0569 0.0199 0.09 0.0407 0.016 0.0055 0.0067 0.0099 0.0208 0.0169 0.023 0.0655 0.1617 0.0851 0.0131 0.0333 0.0176 0.0323 0.0084 0.0082 0.0144 0.0193 0.0188
60 9 WT/HET 0.0017 0.0021 0.0029 0.0035 0.0174 0.0073 0.0372 0.0169 0.0063 0.0013 0.0018 0.0023 0.005 0.0035 0.0043 0.0108 0.0587 0.0341 0.0048 0.0134 0.0071 0.0116 0.0028 0.0023 0.0038 0.0052 0.0062
61 9 WT/HET 0.0053 0.0053 0.007 0.008 0.0396 0.0161 0.0908 0.0433 0.0173 0.0048 0.006 0.0085 0.0153 0.0102 0.0128 0.0303 0.1546 0.0895 0.0135 0.036 0.0202 0.0359 0.0091 0.0083 0.0131 0.0165 0.0187
62 9 WT/HET 0.0078 0.0078 0.0106 0.0125 0.0634 0.0221 0.1113 0.0531 0.0231 0.0085 0.0094 0.0134 0.0242 0.0176 0.0213 0.0497 0.1784 0.1006 0.0171 0.0431 0.0255 0.047 0.0119 0.0111 0.0172 0.0215 0.0244
63 11 WT/HET 0.0028 0.003 0.004 0.005 0.0278 0.011 0.0626 0.027 0.0099 0.0024 0.0026 0.0042 0.0083 0.0054 0.0062 0.0162 0.0887 0.0466 0.007 0.0206 0.01 0.0194 0.0045 0.0033 0.0058 0.0074 0.0082
64 11 WT/HET 0.0029 0.0032 0.0044 0.0061 0.0325 0.0107 0.0438 0.0172 0.0061 0.0019 0.0022 0.003 0.0076 0.0051 0.0068 0.0175 0.0882 0.039 0.0056 0.0152 0.0074 0.0155 0.0034 0.0035 0.0051 0.0071 0.0084
65 11 WT/HET 0.0064 0.0069 0.0094 0.0117 0.0745 0.0259 0.1181 0.0547 0.022 0.0079 0.0093 0.0134 0.0258 0.0199 0.0262 0.0735 0.2539 0.117 0.0174 0.0441 0.0238 0.0453 0.011 0.0106 0.0184 0.0247 0.0265
66 11 NPC 0.0016 0.0024 0.0035 0.0049 0.0314 0.0148 0.0984 0.042 0.0144 0.0018 0.0029 0.0047 0.0098 0.0068 0.008 0.0181 0.0859 0.0671 0.0106 0.035 0.0163 0.0311 0.0073 0.0062 0.0094 0.0116 0.0124






[2.12 .. 2.17] [2.17 .. 2.23] [2.23 .. 2.26] [2.26 .. 2.32] [2.32 .. 2.37] [2.37 .. 2.42] [2.42 .. 2.47] [2.47 .. 2.49] [2.51 .. 2.53] [2.53 .. 2.59] [2.59 .. 2.62] [2.62 .. 2.67] [2.67 .. 2.72] [2.72 .. 2.77] [2.79 .. 2.81] [2.81 .. 2.87] [2.87 .. 2.90] [2.90 .. 2.92] [2.92 .. 2.97] [2.97 .. 2.99] [2.99 .. 3.05] [3.05 .. 3.11] [3.11 .. 3.15] [3.15 .. 3.17] [3.17 .. 3.19] [3.19 .. 3.21] [3.21 .. 3.26] [3.26 .. 3.31] [3.31 .. 3.35] [3.35 .. 3.37] 
0.0182 0.0095 0.0025 0.0061 0.0092 0.0052 0.0063 0.0017 0.0012 0.0097 0.0002 0.0048 0.0031 0.0018 0.0015 0.0015 0.0006 0.0001 0.0056 0.0029 0.0216 0.0043 0.0013 0.0005 0.0018 0.0115 0.0648 0.0816 0.0028 0.0443
0.0292 0.0147 0.0019 0.0052 0.0164 0.0076 0.0047 0.0005 0.0008 0.0127 0 0.0006 0 0 0 0 0 0 0.003 0.0033 0.0093 0 0 0 0 0.01 0.1154 0.1519 0.0008 0.0412
0.0449 0.0179 0.0049 0.0137 0.026 0.0093 0.0131 0.0033 0.0029 0.0157 0 0.0124 0.0059 0.0005 0.0042 0.0041 0 0 0.0062 0.0067 0.0414 0.0113 0.005 0.0031 0.0042 0.0208 0.1367 0.1562 0.0076 0.0087
0.0217 0.008 0.0006 0.0032 0.0088 0.0023 0.0039 0.0002 0 0.0031 0 0 0 0 0.0004 0 0 0 0 0 0.0204 0 0 0 0 0.0047 0.0598 0.0905 0 0.0375
0.014 0.0076 0.0029 0.0063 0.0057 0.0039 0.0038 0.001 0.001 0.0049 0 0.0028 0.0016 0 0.001 0.0007 0.0003 0 0.0034 0.0029 0.0112 0.0044 0.0029 0.0016 0.0025 0.0108 0.0417 0.0434 0.004 0.0453
0.0283 0.0178 0.0048 0.0093 0.0105 0.0068 0.0078 0.0019 0.0024 0.0145 0.0001 0.0044 0.0025 0.0006 0.0011 0.0016 0.0003 0.0001 0.0066 0.0059 0.0165 0.0051 0.0027 0.0016 0.0026 0.0148 0.0966 0.0881 0.005 0.0065
0.0446 0.0291 0.0115 0.0231 0.0324 0.0165 0.0106 0.004 0.0065 0.0254 0.0037 0.019 0.012 0.009 0.0075 0.0132 0.0034 0.0024 0.0116 0.0101 0.0396 0.0187 0.0135 0.0066 0.0066 0.0186 0.1034 0.1343 0.012 0.0108
0.0534 0.0358 0.0118 0.0246 0.0412 0.0228 0.0142 0.0044 0.0061 0.0392 0.0054 0.0198 0.0126 0.0117 0.0081 0.0133 0.0063 0.0045 0.0299 0.0155 0.0441 0.0238 0.0134 0.0073 0.0094 0.0238 0.1349 0.1723 0.012 0.0477
0.028 0.0138 0.0042 0.0086 0.0115 0.006 0.0086 0.0021 0.0013 0.0108 0 0.0043 0.002 0.0001 0.0014 0.0016 0 0 0.0049 0.0037 0.0159 0.0047 0.0015 0.001 0.0018 0.012 0.0883 0.083 0.0031 0.0056
0.0167 0.0078 0.0029 0.007 0.0057 0.0025 0.0038 0.0008 0.0007 0.005 0 0.002 0.0005 0 0.0012 0.0004 0.0003 0 0.002 0.003 0.0118 0.0032 0.0003 0.0004 0.0013 0.0111 0.0639 0.0437 0.0021 0.0421
0.0218 0.0138 0.0039 0.0074 0.0107 0.0049 0.0046 0.0013 0.0018 0.0145 0.0003 0.0033 0.0014 0.0017 0.0018 0.0012 0.0006 0.0002 0.0081 0.005 0.0122 0.0045 0.0014 0.0009 0.0018 0.0092 0.0836 0.1013 0.0035 0.0422
0.0432 0.0256 0.0051 0.0114 0.0189 0.0095 0.0105 0.0025 0.0029 0.03 0.0002 0.0053 0.0021 0.0024 0.0014 0.0012 0.001 0.0011 0.022 0.0112 0.0267 0.01 0.0048 0.0034 0.0059 0.0212 0.161 0.2242 0.0078 0.0435
0.0396 0.0267 0.0101 0.0145 0.0196 0.0113 0.0122 0.0029 0.004 0.0288 0.0017 0.0095 0.0052 0.0042 0.0033 0.0074 0.0018 0.0023 0.0172 0.0101 0.0283 0.012 0.0072 0.0039 0.005 0.0168 0.1494 0.2127 0.0081 0.0085
0.0352 0.0216 0.0062 0.0117 0.022 0.0097 0.0059 0.0013 0.0029 0.024 0.0004 0.008 0.0048 0.002 0.0024 0.003 0.0006 0.0013 0.0156 0.0082 0.0224 0.0096 0.0064 0.0036 0.0048 0.0155 0.1052 0.1522 0.0055 0.0076
0.0172 0.0071 0.0026 0.0044 0.0102 0.003 0.002 0.0001 0 0.0034 0 0.0002 0 0 0 0 0 0 0 0 0.0068 0.0016 0 0 0 0.004 0.0382 0.0482 0 0.038
0.0351 0.0165 0.0119 0.0156 0.0252 0.0101 0.0058 0.0011 0.0015 0.0095 0 0.0131 0.0068 0.0012 0.0064 0.0046 0 0 0.0004 0.0029 0.0285 0.0116 0.0033 0.0021 0.0021 0.0165 0.085 0.0747 0.0056 0.0069
0.0441 0.0222 0.0089 0.0146 0.0231 0.0121 0.0103 0.0032 0.0043 0.0222 0.0017 0.0125 0.009 0.0059 0.0048 0.0066 0.0024 0.0008 0.0078 0.0071 0.0376 0.0145 0.0072 0.0033 0.0048 0.0216 0.0995 0.1375 0.0097 0.046
0.04+RC:R[7]C[7]620.0232 0.0182 0.0182 0.0328 0.014 0.0094 0.0022 0.0031 0.0192 0.0089 0.0149 0.0084 0.0033 0.0071 0.0072 0.0012 0.0001 0.0067 0.0063 0.0339 0.0144 0.0058 0.0032 0.0036 0.0154 0.0978 0.1232 0.0085 0.0079
0.0836 0.0411 0.0614 0.0283 0.032 0.0155 0.0131 0.004 0.0032 0.0173 0.0062 0.017 0.0084 0.0039 0.0059 0.0069 0.001 0 0.0045 0.0044 0.0286 0.0117 0.0045 0.003 0.0033 0.0163 0.0808 0.0911 0.0072 0.0082
0.0334 0.0257 0.0093 0.0182 0.0194 0.0112 0.0102 0.0034 0.0033 0.022 0.0023 0.0074 0.0051 0.0047 0.0035 0.0046 0.0024 0.0018 0.0138 0.0075 0.0215 0.0179 0.0048 0.0021 0.0031 0.015 0.1404 0.1527 0.0056 0.0414
0.027 0.0151 0.0041 0.0078 0.0179 0.0071 0.0036 0.0003 0.001 0.0122 0 0.0014 0.0003 0 0.0006 0 0 0 0.0053 0.0036 0.0106 0 0 0 0 0.0107 0.1199 0.1283 0.0012 0.043
0.0421 0.0255 0.0074 0.0147 0.0236 0.0131 0.0146 0.0048 0.0045 0.0258 0.0025 0.0078 0.0057 0.0044 0.004 0.0061 0.0029 0.0018 0.0149 0.0095 0.0217 0.0099 0.0054 0.0032 0.005 0.0189 0.1022 0.1185 0.0069 0.0445
0.0395 0.0247 0.0091 0.0145 0.0222 0.0119 0.0094 0.0031 0.0037 0.021 0.0015 0.0085 0.0057 0.0037 0.0043 0.006 0.0013 0.001 0.0097 0.0068 0.0185 0.0083 0.0084 0.0028 0.0039 0.0115 0.1073 0.1393 0.0066 0.0079
0.034 0.0169 0.004 0.0095 0.022 0.0069 0.002 0 0.0009 0.0156 0 0.003 0.0002 0 0.0002 0 0 0 0.0047 0.0037 0.0154 0.002 0 0 0 0.0086 0.1036 0.1311 0.0025 0.003
0.0303 0.0199 0.0086 0.0148 0.0173 0.0101 0.0086 0.0028 0.0032 0.0141 0.0009 0.0072 0.0054 0.0042 0.003 0.0056 0.0011 0.0008 0.0068 0.0057 0.0222 0.008 0.0067 0.0026 0.0035 0.0167 0.0793 0.0907 0.0057 0.0067
0.026 0.0148 0.0073 0.0112 0.0124 0.0076 0.0074 0.0017 0.002 0.0112 0 0.0049 0.0031 0.0015 0.0015 0.0027 0.0001 0 0.0043 0.0041 0.0184 0.0072 0.0053 0.0024 0.0037 0.0161 0.0848 0.097 0.0052 0.0082
0.0261 0.03+RCRC:R[7]C[7]260.0056 0.0109 0.0219 0.0111 0.0067 0.0009 0.0013 0.0104 0 0.0051 0.0027 0.0004 0.0017 0.0027 0 0 0.0035 0.0031 0.0169 0.0044 0.0021 0.0009 0.0014 0.0094 0.0868 0.1283 0.0036 0.0047
0.0515 0.0296 0.0148 0.0283 0.0467 0.0236 0.0129 0.0042 0.0052 0.0229 0.0038 0.0218 0.0149 0.0096 0.0091 0.0131 0.003 0.0015 0.0094 0.0089 0.0477 0.0235 0.0168 0.0079 0.0102 0.0317 0.1749 0.2269 0.0127 0.0137
0.0404 0.02 0.0054 0.0131 0.0273 0.0129 0.0087 0.002 0.0016 0.0144 0 0.0062 0.0047 0.0008 0.0041 0.0014 0 0 0 0.002 0.0267 0.0083 0 0 0.0007 0.0126 0.0941 0.1254 0.0045 0.0377
0.0374 0.0146 0.0051 0.0121 0.0253 0.009 0.0051 0.0007 0 0.0082 0 0.0067 0.0037 0 0.0036 0 0 0 0 0.0012 0.0275 0.0082 0.001 0.0013 0.0013 0.0149 0.0769 0.1075 0.0039 0.005
0.0244 0.0139 0.0039 0.0083 0.0158 0.0067 0.0041 0.0002 0.0014 0.0106 0 0.0037 0.0014 0 0.002 0 0 0 0.0006 0.0019 0.0127 0.0004 0 0 0 0.0105 0.0943 0.1457 0.0016 0.0037
0.034 0.0145 0.0035 0.0086 0.0254 0.0084 0.0026 0 0.0012 0.0108 0 0.0053 0.0021 0 0.0019 0 0 0 0 0.0024 0.0161 0.0016 0 0 0 0.0097 0.1054 0.1351 0.0025 0.0035
0.0313 0.0157 0.0041 0.007 0.0206 0.0082 0.0046 0.0001 0.001 0.0114 0 0.0031 0.0014 0 0.0022 0 0 0 0 0.002 0.0113 0 0 0 0 0.0053 0.0948 0.1918 0.0025 0.0424
0.0202 0.0075 0.003 0.0063 0.0165 0.0078 0.0063 0.0007 0.0001 0.0031 0.0118 0.0052 0.0019 0 0.0004 0 0 0 0 0.0005 0.0326 0.0022 0 0 0.0003 0.0208 0.0857 0.103 0.0016 0.0046
0.0334 0.0169 0.0046 0.0086 0.0084 0.0029 0.0082 0.0018 0.0013 0.0129 0 0.0015 0 0 0 0 0 0 0.0041 0.0048 0.0141 0.0023 0 0 0 0.0118 0.1033 0.1064 0.0017 0.0037
0.0618 0.0326 0.0105 0.0194 0.0329 0.0151 0.0167 0.005 0.0056 0.0305 0.0021 0.0146 0.0088 0.0035 0.0059 0.0091 0.0022 0.0024 0.0121 0.0111 0.0417 0.018 0.0089 0.0051 0.0056 0.0233 0.1411 0.1367 0.0126 0.0097
0.0278 0.013 0.0044 0.0095 0.0112 0.0035 0.0032 0.0002 0.0003 0.0068 0 0.0036 0.0007 0 0 0 0 0 0 0.0025 0.0176 0.0035 0 0 0 0.0077 0.0647 0.0664 0.0012 0.0032
0.0301 0.0176 0.0059 0.0092 0.0105 0.0043 0.0057 0.0009 0.0015 0.0124 0 0.001 0 0 0.0001 0 0 0 0.0033 0.004 0.0109 0 0 0 0 0.0103 0.0912 0.0913 0.0002 0.0025
0.0227 0.0349 0.0149 0.0111 0.0069 0.0109 0.0208 0.0054 0.0019 0.0064 0.0007 0.0024 0.0016 0.0004 0.0003 0.0007 0 0.0002 0.004 0.0032 0.0077 0.0022 0 0.0005 0.0007 0.0048 0.0381 0.0348 0.0011 0.0041
0.0809 0.0496 0.0102 0.0184 0.0205 0.0123 0.0279 0.008 0.0031 0.0462 0.0013 0.0034 0.0009 0.0011 0.0008 0 0.0011 0.0022 0.0349 0.0187 0.0273 0.0051 0.0006 0.0011 0.0054 0.0246 0.1597 0.1945 0.0022 0.0408
0.067 0.0382 0.0421 0.0181 0.0199 0.0095 0.0112 0.0028 0.0033 0.0263 0.0002 0.0072 0.0028 0.0002 0.0014 0.0007 0 0 0.0117 0.0087 0.0291 0.0055 0.0018 0.0017 0.0026 0.024 0.1026 0.085 0.0057 0.0066
0.0187 0.0118 0.0045 0.0067 0.0039 0.0044 0.0051 0.0006 0.0006 0.0036 0 0.002 0 0 0 0 0 0 0 0.0009 0.0308 0.0025 0.0023 0 0.0004 0.0109 0.0504 0.0633 0.0014 0.0505
0.0334 0.0217 0.007 0.0105 0.0186 0.0069 0.0033 0.0004 0.002 0.0198 0 0.0053 0.0025 0 0.0015 0.0009 0 0.0004 0.011 0.0074 0.0216 0.01 0.0038 0.0025 0.0038 0.0146 0.0921 0.1002 0.0057 0.007
0.0475 0.0308 0.0096 0.0168 0.0293 0.0121 0.0082 0.0024 0.0035 0.0276 0.0008 0.0086 0.0047 0.0015 0.0029 0.0041 0.0012 0.0012 0.0153 0.0107 0.0277 0.0107 0.0054 0.003 0.004 0.0161 0.1432 0.1646 0.008 0.0073
0.0421 0.0251 0.007 0.0108 0.0229 0.0072 0.0037 0.0002 0.0028 0.0237 0 0.0044 0.0018 0 0.0011 0 0 0 0.0087 0.0079 0.0245 0.0051 0 0.0007 0.0014 0.015 0.1542 0.1649 0.006 0.0053
0.0287 0.0162 0.0075 0.0082 0.0145 0.0052 0.0045 0.0011 0.0017 0.0145 0 0.0033 0.0011 0.0002 0.002 0.0019 0 0.0003 0.0081 0.0047 0.0138 0.0038 0.0007 0.0007 0.0014 0.0112 0.0759 0.078 0.0028 0.0055
0.0345 0.0222 0.012 0.0086 0.0175 0.0059 0.0039 0.0008 0.002 0.019 0 0.0033 0.0013 0 0.0003 0 0 0 0.0083 0.0068 0.0189 0.005 0.0011 0.001 0.0018 0.0146 0.1285 0.1376 0.0072 0.0077
0.0518 0.0235 0.0112 0.0231 0.0409 0.016 0.0099 0.0031 0.0036 0.0191 0.0016 0.0181 0.0116 0.0039 0.0082 0.0094 0.0021 0.001 0.0086 0.0085 0.0456 0.0204 0.0099 0.0063 0.0066 0.0195 0.0982 0.1102 0.0114 0.0101
0.0257 0.011 0.0043 0.01 0.0207 0.0097 0.0053 0.0003 0.0007 0.006 0 0.0139 0.003 0 0.0026 0.0049 0 0 0.001 0.0017 0.0257 0.0062 0.0002 0.0004 0.0012 0.0098 0.0801 0.1014 0.0038 0.0056
0.0308 0.0134 0.0059 0.009 0.0245 0.0081 0.0034 0.0004 0.0006 0.0094 0 0.0066 0.0033 0 0.0027 0.0005 0 0 0 0.002 0.0197 0.0055 0 0.0005 0.0002 0.0093 0.0734 0.0812 0.0036 0.005
0.043 0.0237 0.0102 0.0147 0.0326 0.0145 0.0097 0.0026 0.0031 0.0177 0.0012 0.012 0.0079 0.0023 0.0054 0.0053 0.0006 0 0.0043 0.0052 0.0361 0.0115 0.0051 0.0035 0.004 0.0156 0.0933 0.1191 0.0086 0.0079
0.0464 0.0227 0.0099 0.0191 0.035 0.0141 0.0085 0.0021 0.0032 0.0189 0.0009 0.0152 0.0096 0.0029 0.0071 0.0073 0.0009 0.0008 0.008 0.0073 0.0392 0.0163 0.0072 0.0045 0.0048 0.0187 0.0951 0.1013 0.0086 0.0086
0.0559 0.0249 0.0102 0.0222 0.0321 0.0148 0.0153 0.0046 0.0033 0.0177 0.0021 0.0163 0.0106 0.0031 0.0071 0.0078 0.0015 0.0002 0.0051 0.0061 0.0442 0.0201 0.0093 0.0058 0.0062 0.0246 0.0948 0.0993 0.0111 0.0095
0.0754 0.0545 0.0197 0.0388 0.0585 0.0311 0.0166 0.0057 0.008 0.0437 0.0057 0.0233 0.0155 0.0131 0.0122 0.0151 0.0062 0.0042 0.026 0.0193 0.0626 0.0281 0.0131 0.0071 0.0109 0.0527 0.1746 0.2072 0.0151 0.0457
0.066 0.0398 0.0113 0.0224 0.042 0.0171 0.0141 0.0043 0.0059 0.039 0.0019 0.0124 0.0073 0.0042 0.0062 0.0087 0.0024 0.0021 0.0222 0.0148 0.0387 0.0153 0.0086 0.0052 0.0075 0.0264 0.2016 0.2053 0.0123 0.0104
0.0454 0.024 0.0058 0.0134 0.0288 0.0106 0.0083 0.0019 0.003 0.0224 0 0.0068 0.003 0 0.0027 0.0027 0.0004 0.0003 0.0113 0.008 0.0246 0.0085 0.004 0.0025 0.0037 0.0214 0.1359 0.1358 0.007 0.0069
0.0462 0.0276 0.0087 0.0179 0.0299 0.0125 0.0058 0.0011 0.0025 0.0196 0 0.0071 0.0034 0.0015 0.0055 0.0055 0 0 0.0071 0.006 0.0229 0.0054 0 0.0001 0.0006 0.0194 0.0983 0.1124 0.0047 0.0043
0.0192 0.0122 0.0028 0.0057 0.0109 0.004 0.0006 0 0.0006 0.0094 0 0.001 0 0 0 0 0 0 0.001 0.0019 0.008 0 0 0 0 0.0078 0.0601 0.0689 0.0007 0.0022
0.0431 0.0252 0.0095 0.0204 0.0391 0.0168 0.0069 0.0026 0.0046 0.0194 0.0014 0.0124 0.0083 0.0044 0.0062 0.0078 0.0022 0.0014 0.0084 0.0085 0.0354 0.0152 0.0093 0.0053 0.0065 0.0306 0.1264 0.1082 0.0104 0.0096
0.0521 0.0319 0.0131 0.0257 0.0431 0.023 0.0167 0.0041 0.0051 0.0211 0.0028 0.0165 0.0111 0.0079 0.0088 0.0141 0.0028 0.0018 0.0099 0.0091 0.0402 0.0178 0.0084 0.005 0.0064 0.0223 0.141 0.1462 0.011 0.009
0.0275 0.0137 0.0029 0.0066 0.0116 0.0045 0.0038 0.0005 0.0006 0.0106 0 0.0018 0.0004 0 0 0 0 0 0.0008 0.002 0.0125 0.0014 0 0 0 0.0083 0.0749 0.0748 0.0014 0.0025
0.0296 0.0166 0.0021 0.0059 0.01 0.0027 0.0037 0.0002 0.0017 0.013 0 0 0 0 0 0 0 0 0.0008 0.0036 0.0079 0 0 0 0 0.0082 0.101 0.119 0 0.0361
0.0639 0.0402 0.0137 0.0231 0.0497 0.02 0.0063 0.0015 0.0046 0.0322 0 0.0101 0.0058 0.0032 0.0072 0.0082 0.001 0.0004 0.0167 0.0117 0.0378 0.0133 0.0063 0.0044 0.006 0.0296 0.1987 0.1982 0.0112 0.0105
0.0396 0.0144 0.0071 0.0128 0.0177 0.0057 0.0087 0.0017 0.0006 0.0093 0 0.0062 0.0031 0 0.0027 0.0014 0 0 0.0029 0.0036 0.0302 0.0099 0.0021 0.0019 0.0023 0.0155 0.0888 0.0888 0.0055 0.0067





[3.37 .. 3.39] [3.39 .. 3.44] [3.44 .. 3.50] [3.50 .. 3.54] [3.54 .. 3.57] [3.57 .. 3.62] [3.62 .. 3.66] [3.66 .. 3.69] [3.69 .. 3.71] [3.71 .. 3.77] [3.77 .. 3.81] [3.81 .. 3.87] [3.87 .. 3.93] [3.93 .. 3.95] [3.95 .. 3.99] [3.99 .. 4.05] [4.05 .. 4.10] [4.10 .. 4.16] [4.16 .. 4.21] [4.21 .. 4.24] [4.24 .. 4.27] [4.27 .. 4.30] [4.30 .. 4.35] [4.35 .. 4.41] [4.41 .. 4.47] [4.47 .. 4.53] [4.55 .. 4.61] [4.61 .. 4.63] [4.63 .. 4.69] [4.89 .. 4.95] 
0.0058 0.0868 0.0697 0.0182 0.0275 0.0384 0.0293 0.0203 0.0256 0.082 0.066 0.0838 0.0694 0.0222 0.0237 0.0154 0.0073 0.0164 0.0062 0.0022 0.003 0.005 0.0053 0.0027 0.0034 0.0016 0.0015 0 0.0149 0
0.0104 0.2153 0.1919 0.0422 0.0729 0.1698 0.1367 0.0844 0.0915 0.2808 0.2292 0.3204 0.2493 0.0629 0.1119 0.0642 0.0201 0.0316 0.0145 0.0059 0.006 0.0093 0.0099 0.0073 0.0073 0.0044 0.0037 0 0.0545 0.0009
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0.0004 0 0.0285 0.0149 0.0006 0.0001 0 0.0007 0.0005 0.0002 0.0005 0.0024 0.0002 0.0009 0.0005 0.0012 0.0038 0.0017 0.001 0.0037 0.0021 0.0024 0.001 0.0014 0.0021 0.0003 0.0007 0.0006 0.0009 0.0002
0.0018 0 0.0473 0.016 0.0007 0.0001 0.0001 0.0013 0.001 0.0009 0.0008 0.0051 0.0014 0.0039 0.002 0.0036 0.0077 0.0043 0.0018 0.0077 0.0053 0.0053 0.0024 0.0037 0.0052 0.0011 0.0024 0.0011 0.0022 0.0022
0.0028 0.0006 0.0662 0.0544 0.0004 0 0.0005 0.0008 0.0006 0.0009 0.0006 0.0039 0.0009 0.0045 0.002 0.0006 0.0061 0.0024 0.0009 0.0059 0.0037 0.0071 0.0014 0.0024 0.0028 0.0003 0.0018 0.0012 0.0015 0.001
0.0006 0 0.0257 0 0 0 0.0004 0.0012 0.0008 0.0008 0.0006 0.0042 0.001 0.0039 0.001 0.0007 0.0062 0.0025 0.0012 0.0065 0.0038 0.0047 0.0017 0.0025 0.0035 0.0007 0.0014 0.0007 0.0015 0.0015
0.0003 0 0.0216 0.0384 0 0 0 0 0 0 0 0.0013 0 0.0003 0.0003 0.0009 0.0026 0.0012 0.0003 0.0027 0.0016 0.0017 0.0001 0 0.0005 0 0 0 0.0002 0
0.0014 0 0.03 0.0107 0 0 0 0 0 0 0 0.0059 0 0.0027 0.0003 0.0003 0.0088 0.0018 0.0009 0.0095 0.0053 0.009 0.0003 0.0017 0.0016 0.0002 0.0002 0.0001 0.001 0
0.0015 0.0002 0.0251 0.0243 0.0003 0.0001 0 0.0002 0.0005 0.0005 0.0003 0.0049 0.0004 0.0016 0.0009 0.003 0.008 0.0023 0.0012 0.0063 0.0039 0.0048 0.0009 0.0019 0.0021 0 0.001 0.0002 0.0013 0.0008
0.0028 0.0002 0.0429 0.0586 0.0009 0 0.0006 0.0001 0.0003 0.0002 0.0005 0.0064 0.0002 0.0031 0.0007 0.0002 0.0087 0.0019 0.0009 0.0091 0.0058 0.0112 0.0088 0.0054 0.0019 0.0004 0.0003 0.0001 0.001 0.0014
0.0019 0 0.0312 0.0351 0.0007 0 0 0 0 0 0 0.0051 0 0.0018 0 0.0001 0.007 0.0009 0.0005 0.0081 0.0039 0.0078 0.0024 0.0017 0.0012 0 0 0 0.0004 0
0.0023 0.0001 0.0532 0.1113 0.0022 0.0016 0 0.0007 0.0002 0.0003 0.0005 0.0028 0.0011 0.0022 0.0007 0.002 0.0045 0.0018 0.0006 0.0044 0.003 0.0038 0.0005 0.0007 0.0018 0.0001 0.0005 0 0.0002 0
0.0013 0 0.0502 0.0581 0.0017 0.0008 0 0.0001 0.0004 0.0003 0.0002 0.0022 0 0.0007 0.0006 0.0015 0.0039 0.0011 0.0002 0.0035 0.0023 0.0027 0.0004 0.0003 0.0019 0.0003 0.0003 0.0001 0.0004 0.0001
0.0009 0 0.0285 0.0054 0.0023 0.002 0.0004 0.0015 0.0012 0.0009 0.0007 0.0039 0.001 0.0024 0.0013 0.0023 0.0057 0.0031 0.0009 0.0062 0.0036 0.0037 0.0017 0.002 0.0034 0.0006 0.001 0.0008 0.002 0.001
0.0029 0.0008 0.0508 0.0414 0.0006 0 0 0.0007 0.0001 0.0004 0.0005 0.0037 0.001 0.0032 0.0007 0.0006 0.0054 0.0015 0.001 0.0061 0.0038 0.0055 0.0011 0.0023 0.003 0.0006 0.0007 0.0003 0.0012 0.0008
0.0009 0 0.0485 0.0402 0.0014 0 0 0.0003 0 0 0 0.0027 0 0.0025 0.0003 0.0001 0.0044 0.0011 0.0005 0.006 0.0037 0.0055 0.0007 0.0022 0.0025 0.0003 0.0004 0.0002 0.0007 0.0004
0.001 0.0001 0.0273 0.0036 0 0 0 0.0008 0.0006 0.0004 0.0005 0.0034 0.0007 0.0034 0.0008 0.0009 0.0057 0.0025 0.0014 0.0064 0.0043 0.0048 0.0019 0.003 0.0027 0.0003 0.0006 0.0004 0.0012 0.001
0.0011 0 0.0369 0.022 0 0 0 0 0 0.0001 0.0001 0.003 0.0016 0.0039 0.0017 0.0008 0.0061 0.0023 0.0014 0.0061 0.0045 0.0078 0.0019 0.0045 0.0026 0.0017 0.0018 0.0009 0.0036 0.0032
0.0018 0 0.0369 0.0423 0.0008 0 0 0.0007 0.0004 0.0003 0.0002 0.0033 0.0007 0.0042 0.0023 0.002 0.0083 0.0024 0.001 0.0063 0.0042 0.0105 0.0027 0.0063 0.0036 0.0041 0.0029 0.0022 0.0057 0.0053
0.0031 0.0007 0.06 0.1071 0.0008 0 0.0002 0.0006 0.0006 0.0005 0.0002 0.0072 0.0008 0.0054 0.0012 0.0011 0.0111 0.0033 0.0017 0.0133 0.0075 0.0093 0.0024 0.0034 0.0023 0.0005 0.0007 0.0006 0.0015 0.0013
0.0029 0 0.0495 0.0891 0.0014 0 0 0 0.0001 0 0.0001 0.0042 0 0.0001 0.0006 0.003 0.0069 0.0018 0.0007 0.0077 0.0044 0.0063 0.0011 0.0011 0.0014 0.0005 0.0002 0.0002 0.0004 0
0.0007 0 0.0436 0.0794 0.0002 0 0 0 0 0 0 0.0057 0 0.0029 0.0005 0.0003 0.0081 0.0016 0.0007 0.0099 0.0058 0.0084 0.0007 0.002 0.0016 0.0004 0 0.0002 0.0007 0
0.0019 0 0.0532 0.0669 0.0023 0 0.0007 0 0 0 0 0.0019 0 0.0016 0.0001 0 0.0032 0.0011 0.0003 0.0039 0.0016 0.0028 0 0.0006 0.0014 0 0.0001 0 0.0002 0
0.002 0 0.0639 0.1265 0.0014 0 0 0 0.0001 0 0 0.004 0 0.0027 0.0004 0.0003 0.0062 0.0014 0.0006 0.0063 0.0032 0.0048 0.0003 0.0014 0.0013 0.0002 0 0.0002 0.0008 0.0004
0.0016 0 0.058 0.1326 0.0017 0 0 0 0 0 0 0.0019 0.0037 0.0063 0.001 0.0019 0.0061 0.0016 0.0008 0.004 0.0018 0.0144 0.0011 0.0015 0.0012 0.0001 0.001 0.0006 0.0006 0.0006
0.0013 0 0.0303 0.0173 0.0002 0 0 0 0.0003 0.0003 0.0029 0.076 0.0021 0.0084 0.0009 0.0005 0.0081 0.0751 0.0043 0.0297 0.1852 0.0493 0.0142 0.0808 0.0157 0.005 0.0042 0.0039 0.009 0.0038
0.0025 0 0.0727 0.0976 0.0005 0 0 0.0004 0.0003 0.0002 0.0003 0.0029 0.0003 0.0026 0.0005 0.0007 0.0054 0.0019 0.0011 0.0055 0.0032 0.0045 0.0009 0.0015 0.0018 0.0006 0.0005 0.0001 0.0008 0.0008
0.0029 0.0006 0.0638 0.0556 0.0015 0 0 0.0006 0.0004 0.0004 0.0004 0.0072 0.0003 0.0043 0.001 0.0008 0.0109 0.0026 0.0015 0.011 0.0057 0.0079 0.0003 0.0015 0.0017 0.0005 0.0004 0.0001 0.0011 0.0007
0.0009 0 0.0325 0.0223 0 0 0 0 0 0 0 0.0037 0.0001 0.0019 0.0004 0.0004 0.0062 0.0018 0.0005 0.0064 0.004 0.0055 0.0013 0.0013 0.0015 0.0002 0.0006 0.0002 0.0007 0.0001
0.0025 0 0.0578 0.0421 0.0008 0 0 0.0007 0.0004 0.0004 0.0003 0.0026 0.0004 0.0022 0.0006 0.0005 0.0038 0.0015 0.0006 0.0041 0.0021 0.003 0.0006 0.0006 0.0016 0 0.0004 0 0.0003 0
0.001 0 0.0264 0.0309 0.0008 0.0001 0 0 0 0 0 0.0009 0.0177 0.0252 0.0005 0.0001 0.0031 0.001 0.0007 0.0026 0.0018 0.0421 0.0023 0.0014 0.0014 0.0007 0.0011 0.0003 0.0011 0.0013
0.0054 0 0.0905 0.0788 0 0.0029 0 0.0025 0.0014 0.0013 0.001 0.0049 0.0025 0.0049 0.0028 0.0047 0.0087 0.0057 0.0023 0.0074 0.0053 0.0055 0.0036 0.0032 0.0051 0.0012 0.0025 0.0012 0.0022 0.0022
0.003 0 0.0508 0.0288 0.0015 0 0 0.0013 0.0007 0.0006 0.0004 0.0044 0.0007 0.0034 0.0008 0.0006 0.0066 0.0026 0.0011 0.0066 0.0041 0.0059 0.0018 0.0021 0.0032 0.0005 0.0012 0.0007 0.001 0.0015
0.0007 0 0.0275 0.0195 0 0 0 0.0001 0.0001 0.0001 0.0001 0.0018 0.0007 0.0033 0.003 0.0028 0.0054 0.0029 0.0012 0.0049 0.0038 0.0071 0.0055 0.0076 0.0074 0.0018 0.0048 0.0027 0.0087 0.0065
0.0017 0.0001 0.0391 0.0173 0 0 0 0.0007 0.0003 0.0002 0.0004 0.0034 0.0002 0.0027 0.001 0.001 0.0063 0.0022 0.0013 0.006 0.0033 0.0043 0.0006 0.0019 0.002 0.0004 0.0013 0.0003 0.0014 0.0014
0.0047 0 0.0808 0.077 0.0023 0 0.0004 0.0014 0.0003 0.0006 0.0006 0.0047 0.0009 0.0043 0.0011 0.001 0.0074 0.0027 0.0011 0.0074 0.0045 0.0066 0.0012 0.002 0.0026 0.0003 0.0009 0.0002 0.0015 0.0007
0.0041 0 0.0915 0.0795 0.0017 0 0 0.0008 0.0003 0.0002 0.0002 0.0046 0.0003 0.0038 0.0011 0.0007 0.0075 0.0027 0.001 0.0079 0.0048 0.0063 0.0013 0.0023 0.0031 0.0005 0.0015 0.0004 0.0023 0.0009
0.0019 0 0.0363 0.0193 0.0015 0 0 0.0005 0.0001 0.0003 0.0002 0.0029 0.0003 0.0021 0.0004 0.0004 0.0046 0.001 0.0007 0.0043 0.0025 0.0031 0.0005 0.0011 0.0015 0.0001 0 0.0001 0.0008 0.0002
0.0064 0.0025 0.0685 0.0356 0.0003 0 0 0.0002 0.0001 0 0.0001 0.003 0 0.0024 0.0007 0.0003 0.0058 0.0013 0.0009 0.0053 0.0035 0.0041 0.0004 0.0006 0.0015 0 0.0004 0.0002 0.0005 0
0.0019 0.0001 0.0398 0.052 0.001 0 0 0.0006 0.0004 0.0002 0.0002 0.0085 0.0007 0.0051 0.0011 0.0012 0.012 0.0029 0.0016 0.0137 0.0068 0.0096 0 0.0022 0.0013 0.0003 0.0006 0.0003 0.0012 0.0003
0.0021 0 0.0383 0.0411 0.0003 0 0 0 0 0 0 0.0052 0.0016 0.0306 0.0029 0.0011 0.0075 0.0023 0.0017 0.0077 0.0076 0.0131 0.0518 0.0108 0.0099 0.0191 0.0268 0.0072 0.0311 0.0064
0.0012 0 0.0464 0.078 0.0011 0 0 0.0001 0.0002 0 0 0.0044 0 0.0021 0.0006 0.0003 0.0065 0.0017 0.0005 0.0073 0.0038 0.0065 0.0007 0.0012 0.0011 0.0001 0.0002 0.0003 0.0012 0.0001
0.0023 0.0003 0.0517 0.0872 0.001 0 0.0001 0.0002 0.0001 0 0.0001 0.0051 0.0004 0.0036 0.0005 0.0006 0.0081 0.0019 0.001 0.0083 0.0049 0.007 0.0013 0.0019 0.0013 0 0.0003 0.0005 0.0014 0.0006
0.0019 0 0.0289 0.0092 0.0017 0 0 0.0003 0.0003 0.0003 0.0005 0.0073 0.0003 0.0045 0.0006 0.0009 0.011 0.0026 0.0015 0.0119 0.0066 0.0093 0.0005 0.0025 0.0012 0.0002 0.0008 0.0004 0.0011 0.0007
0.0007 0 0.0293 0.0084 0 0 0 0.0005 0.0005 0.0003 0.0002 0.008 0.0002 0.0049 0.0007 0.0008 0.0117 0.0026 0.0013 0.0124 0.0069 0.0095 0.001 0.0023 0.0019 0 0.0004 0.0003 0.0016 0.0002
0.0033 0.0003 0.057 0.0047 0.0044 0 0.0001 0.003 0.0018 0.0013 0.0015 0.0111 0.0017 0.0041 0.0024 0.006 0.0163 0.005 0.0025 0.0162 0.0091 0.0122 0.0023 0.0038 0.0039 0.0007 0.0017 0.0007 0.0023 0.0013
0.0049 0.0007 0.0924 0.0498 0.0031 0 0 0.0019 0.0006 0.0007 0.0007 0.0067 0.0008 0.005 0.0015 0.0011 0.0096 0.0027 0.0016 0.0098 0.0052 0.0075 0.0012 0.003 0.0035 0.0008 0.0015 0.0003 0.0019 0.0013
0.0026 0 0.0544 0.0213 0.0021 0 0.0001 0.0013 0.0004 0.0003 0.0005 0.0049 0.0005 0.0037 0.0009 0.0009 0.0077 0.0026 0.0013 0.0076 0.0045 0.0059 0.0015 0.0021 0.0028 0.0008 0.0012 0.0006 0.0016 0.0011
0.0016 0 0.0347 0.0132 0.0025 0 0 0.0006 0.0003 0 0.0001 0.0046 0 0.0021 0.0003 0.0002 0.0064 0.0016 0.0006 0.0072 0.0036 0.0064 0.0006 0.0017 0.0021 0.0002 0.0006 0.0002 0.0011 0
0.0015 0 0.035 0.0193 0.0017 0 0 0.0003 0 0 0 0.0015 0.0035 0.007 0.0004 0.0002 0.003 0.0013 0.0005 0.0035 0.0016 0.0124 0.0022 0.0011 0.0015 0.0004 0.0003 0.0001 0.0005 0
0.0016 0.0004 0.0419 0.0027 0.0024 0 0.0012 0.0015 0.0006 0.0007 0.0007 0.0061 0.0011 0.0046 0.0012 0.001 0.0084 0.0031 0.0016 0.0091 0.0053 0.007 0.0015 0.0027 0.0029 0.0003 0.0011 0.0006 0.0022 0.0014
0.0038 0.0006 0.053 0.0131 0.0042 0 0.0014 0.0018 0.0008 0.0009 0.0009 0.0075 0.001 0.0073 0.0037 0.0025 0.0137 0.0034 0.0016 0.0112 0.0076 0.0162 0.0022 0.0078 0.0045 0.0052 0.004 0.0029 0.0058 0.0059
0.0006 0 0.0366 0.0141 0.0006 0 0 0.0003 0.0001 0 0 0.0032 0.0001 0.0022 0.0003 0.0002 0.0052 0.0012 0.0006 0.0057 0.0033 0.0058 0.0008 0.0015 0.0018 0.0003 0.0011 0.0003 0.0011 0
0.0025 0 0.0605 0.0649 0.0009 0 0 0.0008 0.0003 0 0 0.0018 0 0.0008 0.0009 0.0017 0.0043 0.0014 0.001 0.0043 0.0028 0.0029 0.0009 0.0008 0.002 0.0005 0.0005 0.0001 0.0001 0.0004
0.006 0.0009 0.1008 0.0543 0.0038 0 0 0.0012 0.0003 0.0001 0.0002 0.0059 0.0003 0.0044 0.001 0.0006 0.0099 0.0029 0.0016 0.0105 0.0052 0.0078 0.0012 0.0026 0.0032 0.0006 0.001 0.0006 0.0016 0.0009
0.0017 0 0.0519 0.0674 0 0 0 0.0002 0.0002 0.0002 0.0002 0.0057 0 0.0031 0.0007 0.0005 0.0095 0.0025 0.0013 0.0102 0.0064 0.0084 0.0015 0.0026 0.0018 0.0007 0.0014 0.0005 0.0018 0.0012





Table 54. NPC LDD Dataset encompassing the 65 rows and 143 features peaks values. 
  
[7.83 .. 7.85] [7.85 .. 7.91] [7.91 .. 7.94] [7.94 .. 7.99] [7.99 .. 8.01] [8.01 .. 8.04] [8.04 .. 8.08] [8.08 .. 8.12] [8.12 .. 8.15] [8.15 .. 8.17] [8.17 .. 8.23] [8.23 .. 8.29] [8.29 .. 8.31] [8.31 .. 8.33] [8.33 .. 8.36] [8.36 .. 8.39] [8.39 .. 8.44] [8.44 .. 8.47] [8.47 .. 8.53] [8.69 .. 8.74] [8.74 .. 8.77] [8.77 .. 8.80] [8.80 .. 8.86] [8.86 .. 8.90] [8.90 .. 8.92] [8.92 .. 8.97] 
0.0001 0.0015 0.0002 0.0014 0.0001 0.0003 0.0015 0.0007 0.0002 0.0004 0.005 0.0043 0.0004 0.0004 0.0022 0.0005 0.0009 0.0011 0.001 0.0016 0 0.0003 0.0008 0.0007 0.0003 0.0011
0.0002 0.0036 0.0002 0.0025 0.0005 0.0004 0.0025 0.0007 0.0002 0.0001 0.0084 0.0068 0.0007 0.0007 0.0028 0.0012 0.0016 0.0011 0.0013 0.0026 0.0009 0.0007 0.0009 0.0006 0.0005 0.0023
0.0009 0.0071 0.001 0.004 0.0007 0.0004 0.0009 0.0008 0.0009 0.0008 0.0086 0.0058 0.0006 0.0005 0.0024 0.0014 0.0015 0.0013 0.0015 0.003 0.0006 0.0006 0.0017 0.001 0.0007 0.0022
0 0.0006 0.0001 0.0009 0.0001 0.0001 0.002 0.0004 0 0.0003 0.004 0.0047 0.0004 0.0004 0.0025 0.0009 0.0007 0.0023 0.0015 0.001 0.0005 0.0002 0.0009 0.0008 0 0.0017
0.0003 0.0016 0.0006 0.0033 0.0007 0.0017 0.0014 0.0014 0.0006 0.0008 0.0068 0.0035 0.0009 0.0005 0.0016 0.0015 0.0017 0.0015 0.0028 0.0033 0.0006 0.0005 0.0013 0.0011 0.0009 0.0022
0.0004 0.004 0.0006 0.0032 0.0005 0.0006 0.0008 0.0008 0.0004 0.0007 0.0065 0.0047 0.0006 0.0006 0.0018 0.0011 0.0012 0.0011 0.0024 0.0029 0.0007 0.0006 0.0014 0.001 0.0005 0.0022
0.0007 0.0031 0.0038 0.0014 0.0004 0.0004 0.0009 0.0008 0.0008 0.0008 0.0097 0.0037 0.0003 0.0003 0.0012 0.0007 0.0012 0.0028 0.0016 0.0021 0.0005 0.0003 0.0012 0.0004 0.0002 0.0018
0.0002 0.0027 0.0002 0.0031 0.0006 0.0007 0.0039 0.0005 0.001 0.001 0.0086 0.0047 0.0002 0.0005 0.0024 0.0009 0.001 0.0032 0.0005 0.0021 0.0004 0.0001 0.0004 0.0007 0.0005 0.001
0.0002 0.0045 0.0007 0.0029 0.0008 0.0007 0.0011 0.0004 0.0004 0.0004 0.0062 0.0048 0.0005 0.0005 0.0015 0.0011 0.0012 0.0005 0.0014 0.0025 0.0005 0.0005 0.0011 0.0007 0.0004 0.0023
0.0008 0.0025 0.0009 0.0029 0.0006 0.0007 0.0026 0.0009 0.0009 0.0011 0.0059 0.0049 0.0007 0.0007 0.002 0.0015 0.0019 0.001 0.0014 0.0026 0.001 0.0009 0.0017 0.0011 0.0005 0.0024
0.0004 0.0028 0.0002 0.0024 0.0004 0.0007 0.0028 0.0008 0.0005 0.0007 0.0063 0.0049 0.0007 0.0004 0.0023 0.0009 0.0011 0.002 0.0013 0.0023 0.0007 0.0007 0.0013 0.0006 0.0007 0.0021
0.0011 0.0062 0.0015 0.0069 0.0019 0.002 0.005 0.0019 0.0015 0.0019 0.0174 0.0108 0.0009 0.0012 0.0056 0.0019 0.0033 0.0035 0.0036 0.0065 0.0016 0.0015 0.0029 0.0021 0.0015 0.0052
0.0006 0.0054 0.0013 0.0056 0.0007 0.0006 0.0013 0.0008 0.001 0.0009 0.0113 0.0067 0.0003 0.0006 0.0023 0.0009 0.0025 0.0014 0.002 0.0031 0.0009 0.0008 0.0015 0.0012 0.0007 0.0031
0.0008 0.0057 0.0008 0.0039 0.0009 0.0011 0.0018 0.0012 0.0014 0.0011 0.0112 0.0062 0.0007 0.0006 0.0025 0.0011 0.0017 0.0015 0.0023 0.0039 0.0008 0.0008 0.0016 0.0013 0.0007 0.0028
0 0.0005 0 0.0009 0.0002 0.0004 0.0013 0.0001 0.0002 0.0002 0.0023 0.0024 0.0002 0.0001 0.0009 0.0003 0.0005 0.0007 0.0006 0.0011 0.0004 0.0006 0.0005 0.0002 0.0003 0.0006
0.0002 0.0043 0.0004 0.0033 0.0003 0.0004 0.0007 0.0001 0.0003 0.0004 0.0044 0.0035 0.0007 0.0004 0.0009 0.0009 0.0009 0.0005 0.0006 0.0015 0 0.0001 0.0007 0.0004 0.0004 0.0019
0.0004 0.0029 0.0003 0.0034 0.0002 0.0007 0.003 0.0009 0.0007 0.0005 0.0083 0.0054 0.0009 0.0005 0.002 0.0015 0.0011 0.0005 0.001 0.0026 0.0007 0.0004 0.0012 0.0006 0.0003 0.0023
0.0014 0.0113 0.0003 0.0022 0.0002 0.0002 0.0005 0.0005 0.0002 0.0003 0.005 0.0035 0.0003 0 0.0009 0.0011 0.0007 0.0005 0.0011 0.0013 0.0005 0.0001 0.0004 0.0004 0.0001 0.0011
0.0003 0.0061 0 0.0014 0.0001 0.0002 0 0 0 0 0.0047 0.0036 0.0003 0.0002 0.0006 0.0004 0.0004 0.0004 0.0006 0.0016 0.0001 0.0003 0 0.0002 0.0003 0.0009
0 0.003 0.0001 0.0027 0.0003 0.0003 0.0023 0.0004 0 0.0002 0.0083 0.0061 0.0002 0.0004 0.0034 0.001 0.0009 0.0021 0.0009 0.003 0.0004 0.0004 0.0007 0.0004 0.0001 0.0018
0 0.0028 0.0001 0.0023 0.0005 0.0002 0.0019 0.0004 0.0002 0 0.0076 0.0062 0.0006 0.0005 0.0028 0.001 0.0012 0.0021 0.0018 0.003 0.0006 0.0004 0.0013 0.0009 0.0004 0.0025
0.0004 0.0044 0.0008 0.004 0.0008 0.0008 0.0031 0.0016 0.0011 0.0011 0.0091 0.0083 0.0006 0.0008 0.0049 0.0008 0.0017 0.0024 0.0018 0.0044 0.0008 0.0006 0.002 0.0011 0.0008 0.0035
0.0005 0.0049 0.0008 0.0042 0.0006 0.0007 0.0009 0.0012 0.0005 0.0006 0.0114 0.0057 0.0004 0.0004 0.0021 0.0009 0.0012 0.0043 0.0016 0.0033 0.0006 0.0006 0.0013 0.0009 0.0007 0.003
0 0.0055 0.0004 0.0033 0.0006 0.0004 0.0007 0.0003 0.0003 0.0004 0.007 0.0054 0.0005 0.0007 0.0018 0.0007 0.0012 0.0007 0.0021 0.0028 0.0006 0.0005 0.0011 0.0011 0.0005 0.0025
0.0003 0.0043 0.0012 0.0041 0.0007 0.0005 0.0012 0.0009 0.0007 0.0006 0.0098 0.0049 0.0005 0.0007 0.0017 0.0009 0.0013 0.0032 0.0021 0.0032 0.0003 0.0005 0.0014 0.0012 0.0006 0.0028
0.0012 0.0051 0.0014 0.0045 0.0008 0.0006 0.001 0.0012 0.0006 0.0011 0.0106 0.0062 0.0008 0.0008 0.0019 0.0011 0.0027 0.0018 0.0031 0.0032 0.0008 0.0011 0.0026 0.0015 0.0008 0.0033
0.0027 0.0071 0.002 0.0059 0.0008 0.0008 0.0009 0.0009 0.0007 0.0006 0.0116 0.0072 0.0008 0.0007 0.0021 0.0012 0.0043 0.0018 0.003 0.0035 0.0008 0.0012 0.0045 0.0009 0.0005 0.0025
0.0007 0.0071 0.0015 0.0052 0.0006 0.0004 0.0017 0.001 0.001 0.0009 0.0101 0.0057 0.0007 0.0006 0.0016 0.0009 0.0015 0.0015 0.0026 0.0031 0.0004 0.0007 0.0009 0.0012 0.0004 0.0028
0 0.0017 0.0001 0.0027 0 0.0001 0.0034 0.0006 0.0001 0 0.0063 0.0043 0.0005 0.0004 0.0016 0.0011 0.0005 0.0005 0.0007 0.0016 0.0002 0.0002 0.0005 0.0006 0.0003 0.0018
0.0002 0.0045 0.0009 0.0038 0.0008 0.0004 0.0007 0 0.0005 0.0002 0.0063 0.0042 0.0005 0.0004 0.001 0.0012 0.001 0.0005 0.0015 0.0015 0.0006 0.0007 0.0007 0.0005 0.0004 0.0019
0 0.0034 0.0002 0.0021 0.0002 0.0001 0.0003 0.0006 0 0 0.0075 0.0045 0.0008 0.0002 0.001 0.0004 0.001 0.0003 0.0006 0.0018 0.0005 0.0002 0.0007 0.0002 0 0.0021
0 0.0057 0.0001 0.0031 0.0005 0.0003 0.0005 0.0005 0.0005 0.0002 0.0072 0.0042 0.0004 0.0003 0.0011 0.001 0.0012 0.0009 0.0015 0.0019 0.0009 0.0004 0.001 0.0007 0.0002 0.0015
0.0003 0.0028 0 0.0023 0 0 0.0025 0 0 0 0.0054 0.0053 0.0003 0 0.0023 0.0009 0.0013 0.0009 0.0011 0.002 0.0002 0 0.0011 0.0003 0.0001 0.0011
0.001 0.0446 0.0394 0.0098 0.0012 0.0014 0.0017 0.0013 0.001 0.0021 0.011 0.0047 0.0009 0.0017 0.0043 0.0048 0.0778 0.0067 0.084 0.0061 0.0014 0.0014 0.0023 0.0017 0.0008 0.003
0.0001 0.0056 0.0007 0.0029 0.0005 0.0008 0.0012 0.0007 0.0004 0.0007 0.0056 0.0056 0.0008 0.0006 0.003 0.0011 0.0014 0.0006 0.0015 0.0026 0.0009 0.0006 0.0009 0.0011 0.0007 0.0024
0.0003 0.0075 0.0007 0.0036 0.0003 0.0008 0.001 0.0004 0.0005 0.0009 0.0054 0.0048 0.0006 0.0004 0.0024 0.0012 0.0014 0.0008 0.0013 0.0022 0.0005 0.0005 0.0007 0.0006 0.0005 0.0017
0 0.004 0.0002 0.0019 0.0003 0.0003 0.0006 0.0004 0.0003 0.0001 0.0043 0.0045 0.0009 0.0001 0.0019 0.001 0.0011 0.0008 0.0019 0.0018 0.0007 0.0006 0.0014 0.0009 0.0002 0.0017
0 0.0041 0 0.002 0.0007 0.0003 0.0009 0.0004 0.0003 0.0003 0.0048 0.0052 0.0005 0.0003 0.0022 0.001 0.001 0.0006 0.0016 0.002 0.0007 0.0005 0.0017 0.001 0.0005 0.0023
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Figure 30. Plot of the 10 most important features (69, 68, 70, 67, 58, 59, 60, 55, 54, 17) for 
NPC disease-associated liver dysfunction. They correspond to the following biomolecules 
glutamate, glutamine, taurine, lactate, glycerophosphocholine, myo-Inositol, alanine, leucine, 
isoleucine, etc., considered as potential biomarkers in the NPC LDD diagnosis. 
 
3.5. Contour Plot of NPC Liver Dysfunction Disease (NPC LDD) Dataset 
 
 
Figure 31. Contour plot showing most important features (69, 68, 70, 67, 58, 59, 60, 55, 54, 
17, 18, 7) for NPC disease- associated liver dysfunction diagnosis. They correspond to the 
following biomolecules glutamate, glutamine, taurine, lactate, glycerophosphocholine, myo-
Inositol, alanine, leucine, isoleucine, etc., considered as potential biomarkers in the liver 
dysfunction and associated disease diagnosis. 






























Liver Contour Plot & Some Main Features
 
 






























3.6. Scale Data Plot of NPC Liver Dysfunction Disease (NPC LDD) Dataset 
 
 
Figure 32.  Scale data plot showing significant changes of intensity for the main features 69, 
68, 70, 67, 58, 59, 60, 55, 54, 17, 18, 7 – They correspond to the following potential 
biomolecules glutamate, glutamine, taurine, lactate, glycerophosphocholine, myo-Inositol, 
alanine, leucine, isoleucine, etc.,  in the NPC disease-associated liver dysfunction. 
 
3.7. Scale Data Plot of NPC Liver Dysfunction Disease (NPC LDD) Dataset 
 
 
Figure 33. Scale data image showing significant changes of intensity for the major features 69, 
68, 70, 67, 58, 59, 60, 55, 54, 17, 18, 7 – They correspond to the following biomolecules 
glutamate, glutamine, taurine, lactate, glycerophosphocholine, myo-Inositol, alanine, leucine, 
isoleucine, etc., considered as potential biomarkers in the liver dysfunction and associated 
disease diagnosis. 
  
Liver Scale Data Plot - Main Features Highlight
 
 
















Liver Scale Data Plot - Main Features Highlight










3.8. Contour Plot of NPC Liver Dysfunction Disease (NPC LDD) Dataset 
 
Figure 34. Contour plot showing significant changes of intensity for major features 69, 68, 70, 
67, 58, 59, 60, 55, 54, 17, 18, 7 –They correspond to the following biomolecules glutamate, 
glutamine, taurine, lactate, glycerophosphocholine, myo-Inositol, alanine, leucine, isoleucine, 
etc., considered as potential biomarkers in the liver dysfunction and associated disease 
diagnosis. 
3.9. Boxplot of NPC Liver Dysfunction Disease (NPC LDD) Dataset 
 
 
Figure 35. Zoomed boxplot showing features numbers 48-76 and presenting the features 69, 
67, 59, 70, 68, 60, 55, 54, 63, 64, 66, 65, 90, 91 as the most important in the NPC-associated 
liver dysfunction. They correspond to the following potential biomarkers glutamate, glutamine, 
taurine, lactate, glycerophosphocholine, myo-Inositol, gamma-phosphorylcholine, leucine, 
isoleucine, alanine, etc., considered as most important ones in the NPC LDD diagnosis 
according to the boxplot technique. 
  
Liver Contour Plot - Main Featurers Highlight
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Figure 36. Filled contour plot showing a 3D representation of the NPC-associated liver 
dysfunction dataset with more intense peaks representing the most important ones. 
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